Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use

ABSTRACT

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer&#39;s disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I 
                         
wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , R 2 , R 7 , X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer&#39;s Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

RELATED APPLICATIONS

This application is a divisional patent application of and claims apriority benefit to U.S. patent application Ser. No. 13/047,693, filedMar. 14, 2011 and granted as U.S. Pat. No. 8,497,264, which in turnclaims the benefit of U.S. Provisional Application No. 61/314,024, filedMarch 15, 2010, both specifications of which are hereby incorporatedherein by reference in their entireties.

FIELD OF THE INVENTION

The invention relates generally to pharmaceutically active compounds,pharmaceutical compositions and methods of use thereof, to treatBeta-Secretase mediated diseases and conditions, including, withoutlimitation, Alzheimer's disease, plaque formation on the brain andrelated disorders.

BACKGROUND OF THE INVENTION

Alzheimer's disease (AD) affects greater than 12 million aging peopleworldwide. AD accounts for the majority of dementia clinically diagnosedafter the age of 60. AD is generally characterized by the progressivedecline of memory, reasoning, judgement and orientation. As the diseaseprogresses, motor, sensory, and vocal abilities are affected until thereis global impairment of multiple cognitive functions. The loss ofcognitive function occurs gradually, typically leading to a diminishedcognition of self, family and friends. Patients with severe cognitiveimpairment and/or diagnosed as end-stage AD are generally bedridden,incontinent, and dependent on custodial care. The AD patient eventuallydies in about nine to ten years, on average, after initial diagnosis.Due to the incapacitating, generally humiliating and ultimately fataleffects of AD, there is a need to effectively treat AD upon diagnosis.

AD is characterized by two major physiological changes in the brain. Thefirst change, beta amyloid plaque formation, supports the “amyloidcascade hypothesis” which conveys the thought that AD is caused by theformation of characteristic beta amyloid peptide (A-beta), or A-betafragments thereof, deposits in the brain (commonly referred to as betaamyloid “plaques” or “plaque deposits”) and in cerebral blood vessels(beta amyloid angiopathy). A wealth of evidence suggests thatbeta-amyloid and accompanying amyloid plaque formation is central to thepathophysiology of AD and is likely to play an early role in thisintractable neurodegenerative disorder. The second change in AD is theformation of intraneuronal tangles, consisting of an aggregate form ofthe protein tau. Besides being found in patients with AD, intraneuronaltangles are also found in other dementia-inducing disorders. Joachim etal., Alz. Dis. Assoc. Dis., 6:7-34 (1992).

Several lines of evidence indicate that progressive cerebral depositionof A-beta plays a seminal role in the pathogenisis of AD and can precedecognitive symptoms by years or even decades. Selkoe, Neuron, 6:487(1991). Release of A-beta from neuronal cells grown in culture and thepresence of A-beta in cerebrospinal fluid (CSF) of both normalindividuals and AD patients has been demonstrated. Seubert et al.,Nature, 359:325-327 (1992). Autopsies of AD patients have revealed largenumbers of lesions comprising these 2 factors in areas of the humanbrain believed to be important for memory and cognition.

Smaller numbers of these lesions in a more restricted anatomicaldistribution are found in the brains of most aged humans who do not haveclinical AD. Amyloid containing plaques and vascular amyloid angiopathywere also found in the brains of individuals with Down's Syndrome,Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type(HCHWA-D), and other neurodegenerative disorders.

It has been hypothesized that A-beta formation is a causative precursoror factor in the development of AD. More specifically, deposition ofA-beta in areas of the brain responsible for cognitive factors isbelieved to be a major factor in the development of AD. Beta amyloidplaques are primarily composed of amyloid beta peptide (A-beta peptide).A-beta peptide is derived from the proteolytic cleavage of a largetransmembrane amyloid precursor protein (APP), and is a peptide rangingin about 39-42 amino acid residues. A-beta 42 (42 amino acids long) isthought to be the major component of these plaque deposits in the brainsof Alzheimer's Disease patients. Citron, Trends in PharmacologicalSciences, 25(2):92-97 (2004).

Similar plaques appear in some variants of Lewy body dementia and ininclusion body myositis, a muscle disease. Aβ also forms aggregatescoating cerebral blood vessels in cerebral amyloid angiopathy. Theseplaques are composed of a tangle of regularly ordered fibrillaraggregates called amyloid fibers, a protein fold shared by otherpeptides such as prions associated with protein misfolding diseases.Research on laboratory rats suggest that the two-molecule, soluble formof the peptide is a causative agent in the development of Alzheimer'sand that the two-molecule form is the smallest synaptotoxic species ofsoluble amyloid beta oligomer. Shankar, G. M., Nature Medicine (Jun. 22,2008) online doi 10:1038 nm 1782.

Several aspartyl proteases are thought to be involved in the processingor cleavage of APP, resulting in the formation of A-beta peptide. Betasecretase (BACE, also commonly referred to as memapsin) is thought tofirst cleave APP to generate two fragments: (1) a first N-terminusfragment (beta APP) and (2) a second C-99 fragment, which issubsequently cleaved by gamma secretase to generate the A-beta peptide.APP has also found to be cleaved by alpha-secretase to producealpha-sAPP, a secreted form of APP that does not result in beta-amyloidplaque formation. This alternate pathway precludes the formation ofA-beta peptide. A description of the proteolytic processing fragments ofAPP is found, for example, in U.S. Pat. Nos. 5,441,870, 5,712,130 and5,942,400.

BACE is an aspartyl protease enzyme comprising 501 amino acids andresponsible for processing APP at the beta-secretase specific cleavagesite. BACE is present in two forms, BACE 1 and BACE 2, designated assuch depending upon the specific cleavage site of APP. Beta secretase isdescribed in Sinha et al., Nature, 402:537-554 (1999) (p510) and PCTapplication WO 2000/17369. It has been proposed that A-beta peptideaccumulates as a result of APP processing by BACE. Moreover, in vivoprocessing of APP at the beta secretase cleavage site is thought to be arate-limiting step in A-beta production. Sabbagh, M. et al., Alz. Dis.Rev. 3:1-19 (1997). Thus, inhibition of the BACE enzyme activity isdesirable for the treatment of AD.

Studies have shown that the inhibition of BACE may be linked to thetreatment of AD. The BACE enzyme is essential for the generation ofbeta-amyloid or A-beta. BACE knockout mice do not produce beta-amyloidand are free from Alzheimer's associated pathologies including neuronalloss and certain memory deficits. Cole, S. L., Vasser, R., MolecularDegeneration 2:22, 2007. When crossed with transgenic mice that overexpress APP, the progeny of BACE deficient mice show reduced amounts ofA-beta in brain extracts as compares with control animals (Luo et al.,Nature Neuroscience, 4:231-232 (2001)). The fact that BACE initiates theformation of beta-amyloid, and the observation that BACE levels areelevated in this disease provide direct and compelling reasons todevelop therapies directed at BACE inhibition thus reducing beta-amyloidand its associated toxicities. To this end, inhibition of beta secretaseactivity and a corresponding reduction of A-beta in the brain shouldprovide a therapeutic method for treating AD and other beta amyloid orplaque related disorders.

Several approaches have been taken to potentially treat AD andplaque-related disorders. One approach has been to attempt to reduce theformation of plaque on the brain, by inhibiting or reducing the activityof BACE. For example, each of the following PCT publications: WO09/091,016, WO 08/108,378, WO 09/134,617, WO 05/097767, WO 08/092,785,WO 06/138265, WO 08/103,351, WO 06/138230, WO 08/200,445, WO 06/111370,WO 07/287,692, WO 05/058311, EP 01942105, WO 08/133,273, WO 08/133,274,WO 07/049,532, US20070027199, WO 07/038,271, US20070072925,US20070203116, WO 08/118,379, WO 06/076284, US20070004786, WO 06/083760,WO 07/011,810, WO 07/011,833, WO11/009,943 and WO 08/054,698, describeinhibitors of BACE, useful for treating AD and other beta-secretasemediated disorders.

BRIEF DESCRIPTION OF THE INVENTION

The present invention provides a new class of compounds useful for themodulation of beta secretase activity. To that end, the compounds of theinvention are useful for the regulation or reduction of the formation ofA-beta peptide and, consequently, the regulation and/or reduction ofbeta amyloid plaque formation on the brain. Accordingly, the compoundsare useful for the treatment of Alzheimer's disease and other betasecretase and/or plaque mediated disorders. For example, the compoundsare useful for the prophylaxis and/or treatment, acute and/or chronic,of AD and other diseases or conditions involving the deposition oraccumulation of beta amyloid peptide, and formation of plaque, on thebrain.

The compounds provided by the invention, including stereoisomers,tautomers, solvates, pharmaceutically acceptable salts, derivatives orprodrugs thereof, are generally defined by Formula I

wherein A¹, A², A³, A⁴, A⁵, A⁶, R², R⁷, X, Y and Z of Formula I aredescribed below. The invention also provides procedures for makingcompounds of sub-Formulas thereof, as well as intermediates useful insuch procedures.

The invention further provides pharmaceutical compositions, whichcomprise one or more compounds of the invention, methods for thetreatment of beta secretase mediated diseases, such as AD, using thecompounds and compositions of the invention. For example, and in oneembodiment, the invention provides a pharmaceutical compositioncomprising an effective dosage amount of a compound of Formula I inassociation with at least one pharmaceutically acceptable excipient.

The foregoing merely summarizes certain aspects of the invention and isnot intended, nor should it be construed, as limiting the invention inany way. All patents and other publications recited herein are herebyincorporated by reference in their entirety.

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable saltsthereof, are generally defined by the compound of Formula I:

or a stereoisomer, tautomer, hydrate, solvate or pharmaceuticallyacceptable salt thereof, wherein

A¹ is CR⁶ or N;

A² is CR⁵ or N;

A³ is CR⁴ or N;

A⁴ is CR³ or N;

A⁵ is CR¹ or N;

A⁶ is CR⁸ or N, provided that no more than one of A¹, A², A³, A⁴, A⁵ andA⁶ is N;

each of R¹, R⁴, R⁵ and R⁸, independently, is H, F, Cl, Br, CF₃, OCF₃,C₁₋₆-alkyl, CN, OH, —OC₁₋₆-alkyl, —S(O)_(o)C₁₋₆-alkyl, —NHC₁₋₆-alkyl or—C(O)C₁₋₆-alkyl, wherein the C₁₋₆-alkyl and C₁₋₆-alkyl portion of—OC₁₋₆-alkyl, —S(O)_(o)C₁₋₆-alkyl, —NHC₁₋₆-alkyl and —C(O)C₁₋₆-alkyl areoptionally substituted with 1-3 substituents of F, oxo or OH;

each of R² and R⁷, independently, is F, Cl, Br, I, haloalkyl,haloalkoxyl, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,—Si(CH₃)₃ or a ring selected from the group consisting of phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,diazolyl, triazolyl, tetrazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl,dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein theC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl and ring areoptionally substituted, independently, with 1-3 substituents of R⁹;

each of R³ and R⁶, independently, is H, halo, haloalkyl, haloalkoxyl,C₁₋₆-alkyl, CN, OH, OC₁₋₆-alkyl, S(O)_(o)C₁₋₆-alkyl, NHC₁₋₆-alkyl orC(O)C₁₋₆-alkyl;

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl;

X is —CR¹⁰R¹⁰—, —O— or —S—, wherein each R¹⁰, independently, is H, halo,haloalkyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl or a ringselected from the group consisting of morpholinyl, piperidinyl,piperizinyl, tetrahydrofuranyl, furanyl, thienyl, phenyl, pyrdinyl,pyrimidinyl, pyridazinyl, pyrazinyl, pyranyl, dihydropyranyl,tetrahydropyranyl, pyrrolyl, dihydropyrrolyl, tetrahydropyrrolyl andoxetanyl;

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CR¹⁰R¹⁰—, then Y is —O— or —S—; and

Z is CH₂, CHF, CF₂, CH(CH₃), C(CH₃)₂ or CH(CF₃).

In another embodiment of the present invention, the compounds, andsolvates, tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, are defined by Formula II

wherein

A¹ is CR⁶ or N;

A² is CR⁵ or N;

A³ is CR⁴ or N;

A⁴ is CR³ or N;

A⁵ is CR¹ or N;

A⁶ is CR⁸ or N, provided that no more than one of A¹, A², A³, A⁴, A⁵ andA⁶ is N;

each of R¹, R⁴, R⁵ and R⁸, independently, is H, F, Cl, Br, CF₃, OCF₃,C₁₋₆-alkyl, CN, OH, —OC₁₋₆-alkyl, —S(O)_(o)C₁₋₆-alkyl, —NHC₁₋₆-alkyl or—C(O)C₁₋₆-alkyl, wherein the C₁₋₆-alkyl and C₁₋₆-alkyl portion of—OC₁₋₆-alkyl, —S(O)_(o)C₁₋₆-alkyl, —NHC₁₋₆-alkyl and —C(O)C₁₋₆-alkyl areoptionally substituted with 1-3 substituents of F, oxo or OH;

R² is Cl, Br, C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, CN, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrazolyl,isoxazolyl, thiazolyl, pyranyl, dihydropyranyl, tetrahydropyranyl,furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl, azetidinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl,2-oxo-7-aza-[3,5]-spironon-7-yl, cyclopentyl, cyclohexyl or —Si(CH₃)₃,wherein the C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrazolyl,isoxazolyl, thiazolyl, pyranyl, dihydropyranyl, tetrahydropyranyl,furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl, azetidinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl,2-oxo-7-aza-[3,5]-spironon-7-yl, cyclopentyl and cyclohexyl areoptionally substituted, independently, with 1-3 substituents of R⁹;

each of R³ and R⁶, independently, is H, halo, haloalkyl, haloalkoxyl,C₁₋₆-alkyl, CN, OH, OC₁₋₆-alkyl, S(O)_(o)C₁₋₆-alkyl, NHC₁₋₆-alkyl orC(O)C₁₋₆-alkyl;

R⁷ is C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, CN, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrazolyl,isoxazolyl, thiazolyl, pyranyl, dihydropyranyl, tetrahydropyranyl,furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl, azetidinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl,2-oxo-7-aza-[3,5]-spironon-7-yl or cyclohexyl, wherein the C₁₋₆-alkyl,C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl,—N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl, phenyl, pyridyl, pyrimidyl,pyrazinyl, pyridazinyl, pyrazolyl, isoxazolyl, thiazolyl, pyranyl,dihydropyranyl, tetrahydropyranyl, furanyl, dihydrofuranyl,tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl andcyclohexyl are optionally substituted, independently, with 1-3substituents of R⁹;

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl;

X is —CH₂—, O or S; and

Y is —O—, S or —CH₂—, provided that (1) when X is either —O— or —S—,then Y is —CH₂— or (2) when X is —CH₂—, then Y is —O— or —S—.

In another embodiment of the present invention, the compounds, andsolvates, tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, are defined by Formula I-A

wherein each of A¹, A³, A⁴, R¹, R², R⁵, R⁷, R⁸, X, Y and Z is as definedabove with respect to Formula I.

In another embodiment of the present invention, the compounds, andsolvates, tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, are defined by Formula I-A wherein

A¹ is CR⁶;

A³ is CR⁴ or N;

A⁴ is CR³ or N, provided that no more than one of A³ and A⁴ is N;

each of R¹, R³, R⁴, R⁵, R⁶ and R⁸, independently, is H, F, Cl, CF₃,OCF₃, methyl, ethyl, CN, OH, OCH₃, SCH₃, NHCH₃ or C(O)CH₃;

one of R² and R⁷, independently, is F, Cl, Br, I, haloalkyl,haloalkoxyl, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,—Si(CH₃)₃ or a ring selected from the group consisting of phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,diazolyl, triazolyl, tetrazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl,dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein theC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl and ring areoptionally substituted, independently, with 1-3 substituents of R⁹;

-   -   the other of R² and R⁷, independently, is C₁₋₆-alkyl, C₂₋₄        alkenyl, C₂₋₄alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl,        —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl or —NH-benzyl, phenyl,        pyridyl, pyrimidyl or thienyl, wherein the C₁₋₆-alkyl,        C₂₋₄alkenyl, C₂₋₄alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl,        —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl, phenyl,        pyridyl, pyrimidinyl and thienyl are optionally substituted,        independently, with 1-3 substituents of R⁹;

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl;

X is —CH₂—, —O— or —S—;

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—; and

Z is CH₂, CF₂ or CH(CH₃).

In another embodiment of the present invention, the compounds, andsolvates, tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, are defined by Formula I-A, wherein

A¹ is CR⁶;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided that no more than one of A³ and A⁴ is N; and

each of R¹, R³, R⁴, R⁵, R⁶ and R⁸, independently, is H, F, CF₃, methylor CN.

In another embodiment of the present invention, the compounds, andsolvates, tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, are defined by Formula II-A

wherein A¹ is CH or CF;

A² is CH or CF;

A³ is CH, CF or N;

A⁴ is CH, CF or N;

A⁵ is CH;

A⁶ is CH or CF, provided that no more than one of A³ and A⁴ is N;

each of R² and R⁷, independently, is F, Cl, Br, I, haloalkyl,haloalkoxyl, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,—Si(CH₃)₃ or a ring selected from the group consisting of phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,diazolyl, triazolyl, tetrazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl,dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein theC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl and ring areoptionally substituted, independently, with 1-3 substituents of R⁹;

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl; and

X is —O— or —S—.

In another embodiment of the present invention, the compounds, andsolvates, tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, are defined by Formula II-A, wherein

A¹ is CH or CF;

A² is CH;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided that no more than one of A³ and A⁴ is N;

A⁵ is CH;

A⁶ is CH;

R² is C₃₋₆-alkyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, dihydropyranyl,tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl or8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, wherein the C₃₋₆-alkyl, C₂₋₄alkynyl,—OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl and 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, areoptionally substituted, independently, with 1-3 substituents of R⁹;

R⁷ is C₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl orpyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl,pyrazinyl and pyridazinyl are optionally substituted, independently,with 1-3 substituents of R⁹; and

each R⁹, independently, is F, CF₃, CN, CH₃, —OCH₃, —SCH₃, —NHCH₃,oxetanyl or C₂₋₃alkynyl.

In another embodiment of the present invention, the compounds, andsolvates, tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, are defined by Formula II-A, wherein

each of A¹, A², A⁵ and A⁶, independently, is CH;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided that no more than one of A³ and A⁴ is N;

R² is F, Cl, Br, I, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN,—OC₁₋₆alkyl, —SC₁₋₆alkyl, 3-methyl-3-oxetanyl-ethynyl,3-methyl-3-oxetanyl-methoxyl, 3,3-dimethyl-butyn-1-yl,3-methyl-3-butyn-1-yl, 2,2-dimethyl-3-cyano-propoxyl,2-fluoro-2-methylpropoxyl, or a ring selected from the group consistingof phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, dihydro-2H-pyran-4-yl,dihydro-2H-pyran-3-yl, tetrahydropyran-4-yl, dihydrofuranyl,tetrahydrofuranyl, pyrrolidin-1-yl, piperidin-1-yl, morpholinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl and2-oxo-7-aza-[3,5]-spironon-7-yl, wherein the C₁₋₆-alkyl, C₂₋₄alkenyl,C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, 3-methyl-3-oxetanyl-ethynyl,3-methyl-3-oxetanyl-methoxyl, 3,3-dimethyl-butyn-1-yl,3-methyl-3-butyn-1-yl, 2,2-dimethyl-3-cyano-propoxyl,2-fluoro-2-methyl-propoxyl and ring are optionally substituted,independently, with 1-3 substituents of R⁹;

R⁷ is a ring selected from the group consisting of phenyl, pyridyl,pyrimidyl, pyridazinyl, pyrazinyl, triazinyl and thienyl, said ringoptionally substituted, independently, with 1-3 substituents of R⁹; and

X is —O— or —S—.

In another embodiment of the present invention, the compounds, andsolvates, tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, are defined by Formula II-B

wherein A¹ is CH or CF;

A² is CH or CF;

A³ is CH, CF or N;

A⁴ is CH, CF or N;

A⁵ is CH;

A⁶ is CH or CF, provided that no more than one of A³ and A⁴ is N;

each of R² and R⁷, independently, is F, Cl, Br, I, haloalkyl,haloalkoxyl, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,—Si(CH₃)₃ or a ring selected from the group consisting of phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,diazolyl, triazolyl, tetrazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl,dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein theC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl and ring areoptionally substituted, independently, with 1-3 substituents of R⁹;

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl; and

Y is —O— or —S—.

In another embodiment of the present invention, the compounds, andsolvates, tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, are defined by Formula II-B, wherein

A¹ is CH or CF;

A² is CH;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided that no more than one of A³ and A⁴ is N;

A⁵ is CH;

A⁶ is CH;

R² is C₃₋₆-alkyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, dihydropyranyl,tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl or8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, wherein the C₃₋₆-alkyl, C₂₋₄alkynyl,—OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl and 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, areoptionally substituted, independently, with 1-3 substituents of R⁹;

R⁷ is C₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl orpyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl,pyrazinyl and pyridazinyl are optionally substituted, independently,with 1-3 substituents of R⁹; and

each R⁹, independently, is F, CF₃, CN, CH₃, —OCH₃, —SCH₃, —NHCH₃,oxetanyl or C₂₋₃alkynyl.

In another embodiment of the present invention, the compounds, andsolvates, tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, are defined by Formula II-B, wherein

each of A¹, A², A⁵ and A⁶, independently, is CH;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided that no more than one of A³ and A⁴ is N;

R² is F, Cl, Br, I, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN,—OC₁₋₆alkyl, —SC₁₋₆alkyl, 3-methyl-3-oxetanyl-ethynyl,3-methyl-3-oxetanyl-methoxyl, 3,3-dimethyl-butyn-1-yl,3-methyl-3-butyn-1-yl, 2,2-dimethyl-3-cyano-propoxyl,2-fluoro-2-methylpropoxyl, or a ring selected from the group consistingof phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, dihydro-2H-pyran-4-yl,dihydro-2H-pyran-3-yl, tetrahydropyran-4-yl, dihydrofuranyl,tetrahydrofuranyl, pyrrolidin-1-yl, piperidin-1-yl, morpholinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl and2-oxo-7-aza-[3,5]-spironon-7-yl, wherein the C₁₋₆-alkyl, C₂₋₄alkenyl,C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, 3-methyl-3-oxetanyl-ethynyl,3-methyl-3-oxetanyl-methoxyl, 3,3-dimethyl-butyn-1-yl,3-methyl-3-butyn-1-yl, 2,2-dimethyl-3-cyano-propoxyl,2-fluoro-2-methyl-propoxyl and ring are optionally substituted,independently, with 1-3 substituents of R⁹;

R⁷ is a ring selected from the group consisting of phenyl, pyridyl,pyrimidyl, pyridazinyl, pyrazinyl, triazinyl and thienyl, said ringoptionally substituted, independently, with 1-3 substituents of R⁹; and

Y is —O— or —S—.

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable salts,are generally defined by Formula I-A-1, wherein

each of R¹, R⁵ and R⁸, independently, is H;

A¹ is CH, CF or N;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided that no more than one of A¹, A³ and A⁴ is N;

R² is C₃₋₆-alkyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, dihydropyranyl,tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl or8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, wherein the C₃₋₆-alkyl, C₂₋₄alkynyl,—OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl and 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, areoptionally substituted, independently, with 1-3 substituents of R⁹;

R⁷ is C₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl orpyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl,pyrazinyl and pyridazinyl are optionally substituted, independently,with 1-3 substituents of R⁹;

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl or oxetanyl;

X is —CH₂—, —O— or —S—; and

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—.

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable salts,are generally defined by Formula I-A-1, wherein

each of R¹, R⁵ and R⁸, independently, is H;

A¹ is CH;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided that no more than one of A³ and A⁴ is N;

R² is 2-fluoro-4-pyridyl, 2-methyl-4-pyridyl, 5-fluoro-3-pyridyl,4-pyridyl, 2-fluoro-2-methylpropoxyl, 3-fluoro-pyrrolidin-1-yl,4,4-difluoro-1-piperidinyl, 3-methyl-3-oxetanyl-ethyn-1-yl,3,3-dimethyl-butyn-1-yl, 4-methylphenyl, 4-fluorophenyl,5,6-dihydro-2H-pyran-3-yl, 3,6-dihydro-2H-pyran-4-yl,3,4-difluorophenyl, 2,2-dimethylpropoxyl, 2,2-dimethyl-2-cyano-propoxyl,3,3-difluoro-1-pyrrolidinyl or 4-morpholinyl;

R⁷ is 2-fluoro-3-pyridyl, 3-pyridyl, 5-fluoro-3-pyridyl,2,5-difluorophenyl or 3-fluorophenyl;

X is —CH₂—, —O— or —S—; and

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—.

In another embodiment of the invention, the compounds, includingstereoisomers, and pharmaceutically acceptable salts, are generallydefined by Formula I-A-1, wherein

each of R¹, R⁵ and R⁸, independently, is H;

A¹ is CH;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided that no more than one of A³ and A⁴ is N;

R² is a ring selected from the group consisting of pyridine,pyrrolidine, piperidine, phenyl, dihydropyran, and morpholine or R² is—O—C₁₋₆alkyl, C₁₋₆alkynyl, wherein the ring, —O—C₁₋₆allyl andC₁₋₆alkynyl are optionally substituted independently with 1-5substituents of R⁹;

R⁷ is a ring selected from the group consisting of pyridine and phenyl,wherein the ring is optionally substituted independently with 1-3substituents of R⁹;

each R⁹ is, independently, F, Cl, Br, C₁₋₆alkyl, C₁₋₆alkenyl,C₁₋₆alkynyl, —OC₁₋₆alkyl, CN, CF₃, —OCF₃ or spiro-oxetanyl;

X is —CH₂—, —O— or —S—; and

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—.

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable salts,are generally defined by Formula I-A-2

wherein each of R¹, R⁵, R⁶ and R⁸, independently, is H;

A³ is CH or CF;

R² is C₃₋₆-alkyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, dihydropyranyl,tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl or8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, wherein the C₃₋₆-alkyl, C₂₋₄alkynyl,—OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl and 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, areoptionally substituted, independently, with 1-3 substituents of R⁹;

R⁷ is C₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl orpyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl,pyrazinyl and pyridazinyl are optionally substituted, independently,with 1-3 substituents of R⁹;

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl;

X is —CH₂—, —O— or —S—; and

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—.

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable salts,are generally defined by Formula I-A-3

wherein each of R¹, R⁵, R⁶ and R⁸, independently, is H;

A⁴ is CH or CF;

R² is C₃₋₆-alkyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, dihydropyranyl,tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl or8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, wherein the C₃₋₆-alkyl, C₂₋₄alkynyl,—OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl and 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, areoptionally substituted, independently, with 1-3 substituents of R⁹;

R⁷ is C₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl orpyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl,pyrazinyl and pyridazinyl are optionally substituted, independently,with 1-3 substituents of R⁹;

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl;

X is —CH₂—, —O— or —S—; and

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—.

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable salts,are generally defined by Formula I-A-4, wherein

wherein each of R¹, R⁵ and R⁸, independently, is H;

A¹ is CH or CF;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided no more than one of A³ and A⁴ is N;

R² is C₃₋₆-alkyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, dihydropyranyl,tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl or8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, wherein the C₃₋₆-alkyl, C₂₋₄alkynyl,—OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl and 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, areoptionally substituted, independently, with 1-3 substituents of R⁹;

R⁷ is C₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl orpyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl,pyrazinyl and pyridazinyl are optionally substituted, independently,with 1-3 substituents of R⁹; and

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl.

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable salts,are generally defined by Formula I-A-5, wherein

wherein each of R¹, R⁵ and R⁸, independently, is H;

A¹ is CH or CF;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided no more than one of A³ and A⁴ is N;

R² is C₃₋₆-alkyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, dihydropyranyl,tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl or8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, wherein the C₃₋₆-alkyl, C₂₋₄alkynyl,—OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl and 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, areoptionally substituted, independently, with 1-3 substituents of R⁹;

R⁷ is C₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl orpyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl,pyrazinyl and pyridazinyl are optionally substituted, independently,with 1-3 substituents of R⁹; and

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl.

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable salts,are generally defined by Formula I-A-6, wherein

wherein each of R¹, R⁵ and R⁸, independently, is H;

A¹ is CH or CF;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided no more than one of A³ and A⁴ is N;

R² is C₃₋₆-alkyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, dihydropyranyl,tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl or8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, wherein the C₃₋₆-alkyl, C₂₋₄alkynyl,—OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl and 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, areoptionally substituted, independently, with 1-3 substituents of R⁹;

R⁷ is C₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl orpyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl,pyrazinyl and pyridazinyl are optionally substituted, independently,with 1-3 substituents of R⁹; and

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl.

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable salts,are generally defined by Formula I-A-7, wherein

wherein each of R¹, R⁵ and R⁸, independently, is H;

A¹ is CH or CF;

A³ is CH, CF or N;

A⁴ is CH, CF or N, provided no more than one of A³ and A⁴ is N;

R² is C₃₋₆-alkyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, dihydropyranyl,tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl or8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, wherein the C₃₋₆-alkyl, C₂₋₄alkynyl,—OC₁₋₆alkyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl and 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, areoptionally substituted, independently, with 1-3 substituents of R⁹;

R⁷ is C₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl orpyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl,pyrazinyl and pyridazinyl are optionally substituted, independently,with 1-3 substituents of R⁹; and

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl.

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable saltsthereof, are generally defined by the compound of Formula I-B:

wherein

A⁴ is CH, CF or N;

R⁴ is H or F;

one of R² and R⁷, independently, is F, Cl, Br, I, haloalkyl,haloalkoxyl, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,—Si(CH₃)₃ or a ring selected from the group consisting of phenyl,pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,diazolyl, triazolyl, tetrazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl,dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein theC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl and ring areoptionally substituted, independently, with 1-3 substituents of R⁹;

the other of R² and R⁷, independently, is C₁₋₆-alkyl, C₂₋₄alkenyl,C₂₋₄alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂,—NH-phenyl or —NH-benzyl, phenyl, pyridyl, pyrimidyl or thienyl, whereinthe C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl, phenyl, pyridyl,pyrimidinyl and thienyl are optionally substituted, independently, with1-3 substituents of R⁹;

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl;

X is —CH₂—, —O— or —S—;

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—; and

Z is CH₂, CF₂ or CH(CH₃).

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable saltsthereof, are generally defined by the compound of Formula I-B, wherein

A⁴ is CH, CF or N;

R⁴ is H or F;

R² is 2-fluoro-4-pyridyl, 2-methyl-4-pyridyl, 5-fluoro-3-pyridyl,4-pyridyl, 2-fluoro-2-methylpropoxyl, 3-fluoro-pyrrolidin-1-yl,4,4-difluoro-1-piperidinyl, 3-methyl-3-oxetanyl-ethyn-1-yl,3,3-dimethyl-butyn-1-yl, 4-methylphenyl, 4-fluorophenyl,5,6-dihydro-2H-pyran-3-yl, 3,6-dihydro-2H-pyran-4-yl,3,4-difluorophenyl, 2,2-dimethylpropoxyl, 2,2-dimethyl-2-cyano-propoxyl,3,3-difluoro-1-pyrrolidinyl or 4-morpholinyl;

R⁷ is 2-fluoro-3-pyridyl, 3-pyridyl, 5-fluoro-3-pyridyl,2,5-difluorophenyl or 3-fluorophenyl;

X is —CH₂—, —O— or —S—;

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—; and

Z is —CH₂ or CH(CH₃).

In another embodiment of the invention, the compounds, includingstereoisomers, tautomers, solvates, pharmaceutically acceptable saltsthereof, are generally defined by the compound of Formula I-B, wherein

A⁴ is CH, CF or N;

R⁴ is H or F;

R² is a ring selected from the group consisting of pyridine,pyrrolidine, piperidine, phenyl, dihydropyran and morpholine or R² is—O—C₁₋₆allyl, C₁₋₆alkynyl, wherein the ring, —O—C₁₋₆alkyl andC₁₋₆alkynyl are optionally substituted independently with 1-5substituents of R⁹;

R⁷ is a ring selected from the group consisting of pyridine and phenyl,wherein the ring is optionally substituted independently with 1-3substituents of R⁹;

each R⁹ is, independently, F, Cl, Br, C₁₋₆alkyl, C₁₋₆alkenyl,C₁₋₆alkynyl, —OC₁₋₆alkyl, CN, CF3, —OCF₃ or spiro-oxetanyl;

X is —CH₂—, —O— or —S—;

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—; and

Z is —CH₂ or CH(CH₃).

In another embodiment of the invention, the compounds of the inventioninclude compounds wherein X is O or S when Y and Z are each —CH₂—, inconjunction with any of the above or below embodiments.

In another embodiment of the invention, the compounds of the inventioninclude compounds wherein Y is O or S when X and Z are each —CH₂—, inconjunction with any of the above or below embodiments.

In another embodiment of the invention, the compounds of the inventioninclude compounds wherein X is O, and Y and Z are each CH₂, inconjunction with any of the above or below embodiments.

In another embodiment of the invention, the compounds of the inventioninclude compounds wherein X is S, and Y and Z are each CH₂, inconjunction with any of the above or below embodiments.

In another embodiment of the invention, the compounds of the inventioninclude compounds wherein X and Z are each —CH₂— and Y is O, inconjunction with any of the above or below embodiments.

In another embodiment of the invention, the compounds of the inventioninclude compounds wherein X and Z are each —CH₂— and Y is S, inconjunction with any of the above or below embodiments.

In another embodiment of the invention, the compounds of the inventioninclude compounds wherein Z is CH₂, CHF, CF₂, CH(CH₃), C(CH₃)₂ orCH(CF₃), in conjunction with any of the above or below embodiments.

In another embodiment of the invention, the compounds of the inventioninclude compounds wherein Z is CH₂, CF₂ or C(HCH₃), in conjunction withany of the above or below embodiments.

In another embodiment of the invention, the compounds of the inventioninclude compounds wherein Z is CH₂ or C(CH₃), in conjunction with any ofthe above or below embodiments.

In another embodiment of the invention, the compounds of the inventioninclude compounds wherein Z is CH₂, in conjunction with any of the aboveor below embodiments.

The present invention contemplates that the various differentembodiments below of each individual variable A¹, A², A³, A⁴, A⁵, A⁶,R², R⁷, X, Y and Z, as described below, may be applied “in conjunctionwith any of the other {above and below} embodiments” to create variousembodiments of general Formulas I and II, and each sub-formula thereof,described hereinabove, which are not literally described herein.

In another embodiment, the invention includes compounds wherein A¹ isCH, CF or N, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A¹ isCH, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A¹ isCF, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A¹ is N,in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A² isCH, CF or N, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A² isCH, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A² isCF, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A² is N,in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A³ isCH, CF or N, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A³ isCH, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A³ isCF, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A³ is N,in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁴ isCH, CF or N, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁴ isCH, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁴ isCF, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁴ is N,in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁵ isCH, CR¹ wherein R¹ is F, Br or

or A⁵ is N, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁵ isCH, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁵ isCR¹ wherein R¹ is F, Br or

in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁵ is N,in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁶ isCH, CF or N, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁶ isCH, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁶ isCF, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein A⁶ is N,in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein R² isCl, Br, C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, CN, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrazolyl,isoxazolyl, thiazolyl, pyranyl, dihydropyranyl, tetrahydropyranyl,furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl, azetidinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl,2-oxo-7-aza-[3,5]-spironon-7-yl, cyclopentyl, cyclohexyl or —Si(CH₃)₃,wherein the C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrazolyl,isoxazolyl, thiazolyl, pyranyl, dihydropyranyl, tetrahydropyranyl,furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl, azetidinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl,2-oxo-7-aza-[3,5]-spironon-7-yl, cyclopentyl and cyclohexyl areoptionally substituted, independently, with 1-3 substituents of R⁹, inconjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein R² is F,Cl, Br, I, haloalkyl, haloalkoxyl, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl,—NH-benzyl, —Si(CH₃)₃ or a ring selected from the group consisting ofphenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,diazolyl, triazolyl, tetrazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl,dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein theC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl and ring areoptionally substituted, independently, with 1-3 substituents of R⁹, inconjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein R² isC₃₋₆-alkyl, C₂₋₄alkynyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl,pyrazinyl, pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl or 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, whereinthe C₃₋₆-alkyl, C₂₋₄alkynyl, —SC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl,pyrazinyl, pyridazinyl, dihydropyranyl, tetrahydropyranyl, pyrrolidinyl,piperidinyl, morpholinyl and 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl areoptionally substituted, independently, with 1-3 substituents of R⁹, inconjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein R² isC₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl, dihydropyranyl,tetrahydropyranyl, pyrrolidinyl or piperidinyl, wherein the C₂₋₄alkynyl,—OC₁₋₆alkyl, pyridyl, pyrimidyl, dihydropyranyl, tetrahydropyranyl,pyrrolidinyl and piperidinyl are optionally substituted, independently,with 1-3 substituents of R⁹, in conjunction with any of the above orbelow embodiments.

In another embodiment, the invention includes compounds wherein R² is F,Cl, Br, I, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN, —OC₁₋₆alkyl,—SC₁₋₆alkyl, 3-methyl-3-oxetanyl-ethynyl, 3-methyl-3-oxetanyl-methoxyl,3,3-dimethyl-butyn-1-yl, 3-methyl-3-butyn-1-yl,2,2-dimethyl-3-cyano-propoxyl, 2-fluoro-2-methyl-propoxyl, or a ringselected from the group consisting of phenyl, 2-pyridyl, 3-pyridyl,4-pyridyl, dihydro-2H-pyran-4-yl, dihydro-2H-pyran-3-yl,tetrahydropyran-4-yl, dihydrofuranyl, tetrahydrofuranyl,pyrrolidin-1-yl, piperidin-1-yl, morpholinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl and2-oxo-7-aza-[3,5]-spironon-7-yl, wherein the C₁₋₆-alkyl, C₂₋₄alkenyl,C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, 3-methyl-3-oxetanyl-ethynyl,3-methyl-3-oxetanyl-methoxyl, 3,3-dimethyl-butyn-1-yl,3-methyl-3-butyn-1-yl, 2,2-dimethyl-3-cyano-propoxyl,2-fluoro-2-methyl-propoxyl and ring are optionally substituted,independently, with 1-3 substituents of R⁹, in conjunction with any ofthe above or below embodiments.

In another embodiment, the invention includes compounds wherein R² is2-fluoro-4-pyridyl, 2-methyl-4-pyridyl, 5-fluoro-3-pyridyl, 4-pyridyl,2-fluoro-2-methylpropoxyl, 3-fluoro-pyrrolidin-1-yl,4,4-difluoro-1-piperidinyl, 3-methyl-3-oxetanyl-ethyn-1-yl,3,3-dimethyl-butyn-1-yl, 4-methylphenyl, 4-fluorophenyl,5,6-dihydro-2H-pyran-3-yl, 3,6-dihydro-2H-pyran-4-yl,3,4-difluorophenyl, 2,2-dimethylpropoxyl, 2,2-dimethyl-2-cyano-propoxyl,3,3-difluoro-1-pyrrolidinyl or 4-morpholinyl, in conjunction with any ofthe above or below embodiments.

In another embodiment, the invention includes compounds wherein R² is aring selected from the group consisting of pyridine, pyrrolidine,piperidine, phenyl, dihydropyran and morpholine or R² is —O—C₁₋₆alkyl,C₁₋₆alkynyl, wherein the ring, —O—C₁₋₆alkyl and C₁₋₆alkynyl areoptionally substituted independently with 1-5 substituents of R⁹, inconjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein R⁷ is F,Cl, Br, I, haloalkyl, haloalkoxyl, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl,—NH-benzyl, —Si(CH₃)₃ or a ring selected from the group consisting ofphenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,diazolyl, triazolyl, tetrazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl,dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein theC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl and ring areoptionally substituted, independently, with 1-3 substituents of R⁹, inconjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein R⁷ isC₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, pyridyl, pyrimidyl, pyrazinyl orpyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, pyridyl, pyrimidyl,pyrazinyl and pyridazinyl are optionally substituted, independently,with 1-3 substituents of R⁹, in conjunction with any of the above orbelow embodiments.

In another embodiment, the invention includes compounds wherein R⁷ isC₂₋₄alkynyl, —OC₁₋₆alkyl, phenyl, 3-pyridyl, 5-pyrimidyl, pyrazinyl or2-pyridazinyl, wherein the C₂₋₄alkynyl, —OC₁₋₆alkyl, 3-pyridyl,5-pyrimidyl, pyrazinyl and 2-pyridazinyl are optionally substituted,independently, with 1-3 substituents of R⁹, in conjunction with any ofthe above or below embodiments.

In another embodiment, the invention includes compounds wherein R⁷ is aring selected from the group consisting of phenyl, pyridyl, pyrimidyl,pyrazinyl, pyridazinyl, pyrazolyl, isoxazolyl, thiazolyl, pyranyl,dihydropyranyl, tetrahydropyranyl, furanyl, dihydrofuranyl,tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl andmorpholinyl, said ring optionally substituted, independently, with 1-3substituents of R, in conjunction with any of the above or belowembodiments.

In another embodiment, the invention includes compounds wherein R⁷ is aring selected from phenyl, 3-pyridyl, 5-pyrimidyl or 2-pyridazinyl, saidring optionally substituted, independently, with 1-5 substituents of R⁹,in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein R⁷ isphenyl, 3-pyridyl, 5-pyrimidyl or 2-pyridazinyl, each of which isoptionally substituted with 1-5 substituents of F, Cl, Br, I, CN, CF₃,C₂F₅, haloalkoxyl, C₁₋₆-alkyl, CN, OH, OC₁₋₆-alkyl, SC₁₋₆-alkyl,oxetanyl or C₂₋₃alkynyl, in conjunction with any of the above or belowembodiments.

In another embodiment, the invention includes compounds wherein R⁷ is3-pyridyl, 2-fluoro-3-pyridyl, 2,5-difluorophenyl,3,3-dimethyl-1-butynyl, 3-cyanophenyl, 5-fluoro-3-pyridyl,3,4-difluorophenyl, in conjunction with any of the above or belowembodiments.

In another embodiment, the invention includes compounds wherein R⁷ is2-fluoro-3-pyridyl, 3-pyridyl, 5-fluoro-3-pyridyl, 2,5-difluorophenyl or3-fluorophenyl, in conjunction with any of the above or belowembodiments.

In another embodiment, the invention includes compounds wherein R⁷ is aring selected from the group consisting of pyridine and phenyl, whereinthe ring is optionally substituted independently with 1-3 substituentsof R⁹, in conjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein

R² is halo, haloalkyl, haloalkoxyl, C₁₋₆-alkyl, C₂₋₆alkenyl,C₂₋₆alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, wherein the C₁₋₆-alkyl,C₂₋₄alkenyl, C₂₋₄alkynyl and C₃₋₈-cycloalkyl are optionally substituted,independently, with 1-3 substituents of R⁹;

each of R¹, R⁴, R⁵ and R⁸, independently, is H, F, methyl, CN or OH;

each of R³ and R⁶, independently, is H, F, Cl, CF₃, methyl, CN, OH,OCH₃, SCH₃ or NHCH₃;

R⁷ is a ring selected from the group consisting of phenyl, pyridyl,pyrimidyl, pyridazinyl, pyrazinyl, triazinyl and thienyl, said ringoptionally substituted, independently, with 1-3 substituents of R⁹;

each R⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl, spiro-oxetanyl ordioxolyl, is optionally substituted independently with 1-5 substituentsof F, Cl, CN, NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl,propyl, propoxyl, isopropyl, isopropoxyl, cyclopropyl,cyclopropylmethoxyl, butyl, butoxyl, isobutoxyl, tert-butoxyl, isobutyl,sec-butyl, tert-butyl, C₁₋₃alkylamino-, C₁₋₃dialkylamino,C₁₋₃thioalkoxyl, or oxetanyl;

X is —CH₂—, —O— or —S—;

Y is —O—, —S— or —CH₂—, provided that (1) when X is —O— or —S—, then Yis —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—; and

Z is CH₂.

In another embodiment, the invention includes compounds wherein each R⁸,independently, is F, Cl, CF₃, OCF₃, methyl, CN, OH, OCH₃, SCH₃, NHCH₃,oxetanyl or C₂₋₃alkynyl, in conjunction with any of the above or belowembodiments.

In another embodiment, the invention includes compounds wherein each R⁹,independently, is F, methyl, CN, OH, spiro-oxetanyl or C₂₋₃alkynyl, inconjunction with any of the above or below embodiments.

In another embodiment, the invention includes compounds wherein each R⁹,independently, is F, CF₃, CN, CH₃, —OCH₃, —SCH₃, —NHCH₃, spiro-oxetanylor C₂₋₃alkynyl, in conjunction with any of the above or belowembodiments.

In another embodiment, the invention includes compounds wherein each R⁹is, independently, F, Cl, Br, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl,—OC₁₋₆alkyl, CN, CF₃, —OCF₃ or spiro-oxetanyl, in conjunction with anyof the above or below embodiments.

In another embodiment, the invention provides the compound of Formula I,or a pharmaceutically acceptable salt thereof, selected from list theindividual compounds described in Table 1 herein.

In another embodiment, the invention provides the compound of Formula I,or a stereoisomer or pharmaceutically acceptable salt thereof, selectedfrom

-   (5S)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(3,4-difluorophenyl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(3,3-difluoro-1-pyrrolidinyl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(4,4-difluoro-1-piperidinyl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(2,2-dimethylpropoxy)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (3S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(2-fluoro-4-pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine;-   (3S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine;-   (3R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3R)-3-fluoro-1-pyrrolidinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine;-   (3R)-2′-(4,4-difluoro-1-piperidinyl)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine;-   (5S)-3-(3,3-dimethyl-1-butyn-1-yl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-7-(2-fluoro-3-pyridinyl)-3-(4-methylphenyl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(4-fluorophenyl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7-(2-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(2-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-3-(3,4-difluorophenyl)-7-(5-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(3,4-difluorophenyl)-7-(3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(2,2-dimethylpropoxy)-7-(3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(2,2-dimethylpropoxy)-7-(5-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(3,3-difluoro-1-pyrrolidinyl)-7-(5-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   3-(((5S)-5′-amino-7-(3-fluorophenyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-3-yl)oxy)-2,2-dimethylpropanenitrile;-   (3R)-2′-(2-fluoro-3-pyridinyl)-7′-(2-fluoro-4-pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine;-   (3R)-2′-(3,6-dihydro-2H-pyran-4-yl)-7′-(2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine;-   (3S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine;-   (3S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3-methyl-3-oxetanyl)ethynyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine;-   (3S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine;-   (3S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine;-   (5S)-3-(2-fluoro-4-pyridinyl)-7-(5-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(5-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-3-(3,3-dimethyl-1-butyn-1-yl)-7-(2-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-7-(2-fluoro-3-pyridinyl)-3-(5-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (4S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′-(3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3-methyl-3-oxetanyl)ethynyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(4-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3R)-3-fluoro-1-pyrrolidinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-2′-(4,4-difluoro-1-piperidinyl)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine;-   (4S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2-amine;-   (4S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2-amine;-   (5S)-7-(2,5-difluorophenyl)-3-(2-fluoro-4-pyridinyl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(2,2-dimethylpropoxy)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-1-fluoro-3-(2-fluoro-4-pyridinyl)-7-(5-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-1-fluoro-3-(2-fluoro-4-pyridinyl)-7-(3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(2-methyl-4-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-3-(2,2-dimethylpropoxy)-1-fluoro-7-(2-fluoro-3-pyridinyl)-6′H-Spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;-   (5S)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine;-   (5S)-7-(2-fluoro-3-pyridinyl)-3-((3-methyl-3-oxetanyl)ethynyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine;    and-   (5S)-3-(3,3-dimethyl-1-butyn-1-yl)-7-(2-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine.

All of the possible embodiments described herein for various of the Rgroups of the compounds of Formula I may be applied, as appropriate, tocompounds of Formulas II, III and IV and any sub-formulas thereof.

In another embodiment, the invention provides each of the Examplarycompounds, and stereoisomers, tautomers, solvates, pharmaceuticallyacceptable salts, derivatives or prodrugs thereof, and relatedintermediates, described herein.

In another embodiment, the invention provides the exemplified compoundsdescribed herein, and pharmaceutically acceptable salt forms of eachthereof.

DEFINITIONS

The following definitions should assist in understanding the inventiondescribed herein.

The term “comprising” is meant to be open ended, i.e., all encompassingand non-limiting. It may be used herein synonymously with “having.”Comprising is intended to include each and every indicated or recitedcomponent or element(s) while not excluding any other components orelements.

The term “C_(α-β)alkyl”, when used either alone or within other termssuch as “haloalkyl” and “alkylamino”, embraces linear or branchedradicals having α to β number of carbon atoms (such as C₁-C₁₀; C₁-C₆; orC₁-C₄). Unless otherwise specified, one or more carbon atoms of the“alkyl” radical may be substituted, such as with a cycloalkyl moiety.Examples of “alkyl” radicals include methyl, cyclopropylmethyl,cyclobutylmethyl, cyclopentylmethyl, ethyl, cyclopropylethyl,cyclobutylethyl, cyclopentylethyl, n-propyl, isopropyl, n-butyl,cyclopropylbutyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl,hexyl and the like.

The term “C_(α-β)alkenyl”, when used alone or in combination, embraceslinear or branched radicals having at least one carbon-carbon doublebond in a moiety having a number of carbon atoms in the range from α andβ. Included within alkenyl radicals are “lower alkenyl” radicals havingtwo to about six carbon atoms and, for example, those radicals havingtwo to about four carbon atoms. Examples of alkenyl radicals include,without limitation, ethenyl, propenyl, allyl, propenyl, butenyl and4-methylbutenyl. The terms “alkenyl” and “lower alkenyl”, embraceradicals having “cis” and “trans” orientations, or alternatively, “E”and “Z” orientations, as appreciated by those of ordinary skill in theart.

The term “C_(α-β)alkynyl”, when used alone or in combination, denoteslinear or branched radicals having at least one carbon-carbon triplebond in a moiety having a number of carbon atoms in the range from α andβ. Examples of alkynyl radicals include “lower alkynyl” radicals havingtwo to about six carbon atoms and, for example, lower alkynyl radicalshaving two to about four carbon atoms. Examples of such radicalsinclude, without limitation, ethynyl, propynyl (propargyl), butynyl, andthe like.

The term “C_(α-β)-alkyl”, “C_(α-β)-alkenyl” and “C_(α-β)-alkynyl”, whenused with other terms such as “wherein 1, 2 or 3 carbon atoms of saidC_(α-β)-alkyl, C_(α-β)-alkenyl or C_(2α-β)-alkynyl is optionallyreplaced with a heteroatom selected from O, S, S(O), S(O)₂ and N”embraces linear or branched radicals wherein one or more of the carbonatoms may be replaced with a heteroatom. Examples of such “alkyl”radicals include O-methyl, —O-ethyl, —CH₂—O—CH₃, —CH₂CH₂—O—CH₃, —NH—CH₂,—CH₂CH₂—N(CH₃)—CH₃, —S—(CH₂)₃CH₂, —CH₂CH₂—S—CH₃ and the like.Accordingly, such radicals also include radicals encompassed by —OR⁷where R⁷ may be defined as a C_(α-β)-alkyl. Examples of such “alkenyl”radicals include —NH—CH₂CH═CH₂, —S—CH₂CH₂CH═CHCH₃ and the like. Similarexamples exist for such “alkynyl” radicals, as appreciated by thoseskilled in the art.

The term “C_(α-β)alkoxyl” when used alone or in combination, embraceslinear or branched oxygen-containing alkyl radicals each having α to βnumber of carbon atoms (such as C₁-C₁₀). The terms “alkoxy” and“alkoxyl”, when used alone or in combination, embraces linear orbranched oxygen-containing radicals each having alkyl and substitutedalkyl portions of one or more carbon atoms. Examples of such radicalsinclude methoxy, ethoxy, propoxy, butoxy and tert-butoxy. Alkoxyradicals may be further substituted with one or more halo atoms, such asfluoro, chloro or bromo, to provide “haloalkoxyl” radicals or with othersubstitution. Examples of such radicals include fluoromethoxy,chloromethoxy, trifluoromethoxy (—OCF₃), trifluoroethoxy, fluoroethoxy,fluoropropoxy and cyclopropylmethoxy.

The term “aryl”, when used alone or in combination, means a carbocyclicaromatic moiety containing one, two or even three rings wherein suchrings may be attached together in a fused manner. Every ring of an“aryl” multi-ring system need not be aromatic, and the ring(s) fused tothe aromatic ring may be partially or fully unsaturated and include oneor more heteroatoms selected from nitrogen, oxygen and sulfur. Thus, theterm “aryl” embraces aromatic radicals such as phenyl, naphthyl,indenyl, tetrahydronaphthyl, dihydrobenzafuranyl, anthracenyl, indanyl,benzodioxazinyl, and the like. The “aryl” group may be substituted, suchas with 1 to 5 substituents including lower alkyl, hydroxyl, halo,haloalkyl, nitro, cyano, alkoxy and lower alkylamino, and the like.Phenyl substituted with —O—CH₂—O— or —O—CH₂—CH₂—O— forms an arylbenzodioxolyl substituent.

The term “carbocyclic”, also referred to herein as “cycloalkyl” or, whenused alone or in combination, means a partially or fully saturated ringmoiety containing one (“monocyclic”), two (“bicyclic”) or even three(“tricyclic”) rings wherein such rings may be attached together in afused manner and formed from carbon atoms. The term “C_(α-β)cycloalkyl”means cycloalkyl radicals each having α to β number of carbon atoms.Examples of saturated carbocyclic radicals include saturated 3 to6-membered monocyclic groups such as cyclopropane, cyclobutane,cyclopentane and cyclohexane. Carbocycilc may be substituted asdescribed herein.

The terms “ring” and “ring system” refer to a ring comprising thedelineated number of atoms, the atoms being carbon or, where indicated,a heteroatom such as nitrogen, oxygen or sulfur. Where the number ofatoms is not delineated, such as a “monocyclic ring system” or a“bicyclic ring system”, the numbers of atoms are 3-8 for a monocyclicand 6-12 for a bicyclic ring. The ring itself, as well as anysubstitutents thereon, may be attached at any atom that allows a stablecompound to be formed. The term “nonaromatic” ring or ring system refersto the fact that at least one, but not necessarily all, rings in abicyclic or tricyclic ring system is nonaromatic.

The terms “partially or fully saturated or unsaturated” and “saturatedor partially or fully unsaturated” with respect to each individual ring,refer to the ring either as fully aromatic (fully unsaturated),partially aromatic (or partially saturated) or fully saturated(containing no double or triple bonds therein). If not specified assuch, then it is contemplated that each ring (monocyclic) in a ringsystem (if bicyclic or tricyclic) may either be fully aromatic,partially aromatic or fully saturated, and optionally substituted withup to 5 substituents. This includes carbocyclics, heterocyclics, aryland heteroaryl rings.

Thus, the term “a 3-8 membered monocyclic or 6-12 membered bicyclic ringsystem, said ring system formed of carbon atoms optionally including 1-3heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, saidheteroatoms selected from O, N, or S, wherein said ring system isoptionally substituted” refers to a single ring of 3-, 4-, 5-, 6-, 7- or8-atom membered or a 6-, 7-, 8-, 9-, 10-, 11 or 12-atom memberedbicyclic ring system comprising the delineated number of atoms, theatoms being carbon or, where indicated, a heteroatom such as nitrogen(N), oxygen (O) or sulfur (S). Where the number of atoms is notdelineated, such as a “monocyclic ring system” or a “bicyclic ringsystem”, the numbers of atoms are 3-8 for a monocyclic and 6-12 for abicyclic ring. The ring or ring system may contain substitutentsthereon, attached at any atom that allows a stable compound to beformed. A bicyclic ring is intended to include fused ring sytems as wellas spiro-fused rings. This phrase encompasses carbocyclics,heterocyclics, aryl and heteroaryl rings.

The phrase “a saturated or partially or fully unsaturated” whenreferring to a 3-8 membered monocyclic or a 6-12 membered bicyclic ringsystem is intended to include both aromatic and non-aromatic rings. Thenon-aromatic rings may be partially or fully saturated in nature.

The term “cycloalkenyl”, when used alone or in combination, means apartially or fully saturated cycloalkyl containing one, two or eventhree rings in a structure having at least one carbon-carbon double bondin the structure. Examples of cycloalkenyl groups include C₃-C₆ rings,such as compounds including, without limitation, cyclopropene,cyclobutene, cyclopentene and cyclohexene. The term also includescarbocyclic groups having two or more carbon-carbon double bonds such as“cycloalkyldienyl” compounds. Examples of cycloalkyldienyl groupsinclude, without limitation, cyclopentadiene and cycloheptadiene.

The term “halo”, when used alone or in combination, means halogens suchas fluorine (F), chlorine (Cl), bromine (Br) or iodine (I) atoms.

The term “haloalkyl”, when used alone or in combination, embracesradicals wherein any one or more of the alkyl carbon atoms issubstituted with halo as defined above. For example, this term includesmonohaloalkyl, dihaloalkyl and polyhaloalkyl radicals such as aperhaloalkyl. A monohaloalkyl radical, for example, may have either aniodo, bromo, chloro or fluoro atom within the radical. Dihalo andpolyhaloalkyl radicals may have two or more of the same halo atoms or acombination of different halo radicals. Examples of haloalkyl radicalsinclude fluoromethyl, difluoromethyl, trifluoromethyl (—CF₃),chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl,heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl,difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.“Perfluoroalkyl”, as used herein, refers to alkyl radicals having allhydrogen atoms replaced with fluoro atoms. Examples includetrifluoromethyl and pentafluoroethyl.

The term “heteroaryl”, as used herein, either alone or in combination,means a fully unsaturated (aromatic) ring moiety formed from carbonatoms and having one or more heteroatoms selected from nitrogen, oxygenand sulfur. The ring moiety or ring system may contain one(“monocyclic”), two (“bicyclic”) or even three (“tricyclic”) ringswherein such rings are attached together in a fused manner. Every ringof a “heteroaryl” ring system need not be aromatic, and the ring(s)fused thereto (to the heteroaromatic ring) may be partially or fullysaturated and optionally include one or more heteroatoms selected fromnitrogen, oxygen and sulfur. The term “heteroaryl” does not includerings having ring members of —O—O—, —O—S— or —S—S—.

Examples of unsaturated heteroaryl radicals, include unsaturated 5- to6-membered heteromonocyclyl groups containing 1 to 4 nitrogen atoms,including for example, pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl,3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl[e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl] andtetrazole; unsaturated 7- to 10-membered heterobicyclyl groupscontaining 1 to 4 nitrogen atoms, including for example, quinolinyl,isoquinolinyl, quinazolinyl, isoquinazolinyl, aza-quinazolinyl, and thelike; unsaturated 5- to 6-membered heteromonocyclic group containing anoxygen atom, for example, pyranyl, 2-furyl, 3-furyl, benzofuryl, etc.;unsaturated 5 to 6-membered heteromonocyclic group containing a sulfuratom, for example, 2-thienyl, 3-thienyl, benzothienyl, etc.; unsaturated5- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atomsand 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl,oxadiazolyl [e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl,1,2,5-oxadiazolyl]; unsaturated 5 to 6-membered heteromonocyclic groupcontaining 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example,thiazolyl, isothiazolyl, thiadiazolyl [e.g., 1,2,4-thiadiazolyl,1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl].

The term “heterocyclic”, when used alone or in combination, means apartially or fully saturated ring moiety containing one, two or eventhree rings wherein such rings may be attached together in a fusedmanner, formed from carbon atoms and including one or more heteroatomsselected from N, O or S. Examples of saturated heterocyclic radicalsinclude saturated 3 to 6-membered heteromonocyclic groups containing 1to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl,pyrrolinyl, piperazinyl]; saturated 3 to 6-membered heteromonocyclicgroup containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g.morpholinyl]; saturated 3 to 6-membered heteromonocyclic groupcontaining 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g.,thiazolidinyl]. Examples of partially saturated heterocyclyl radicalsinclude dihydrothienyl, dihydropyranyl, dihydrofuryl anddihydrothiazolyl.

The term “heterocycle” also embraces radicals where heterocyclicradicals are fused/condensed with aryl radicals: unsaturated condensedheterocyclic group containing 1 to 5 nitrogen atoms, for example,indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl,indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g.,tetrazolo[1,5-b]pyridazinyl]; unsaturated condensed heterocyclic groupcontaining 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g.benzoxazolyl, benzoxadiazolyl]; unsaturated condensed heterocyclic groupcontaining 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g.,benzothiazolyl, benzothiadiazolyl]; and saturated, partially unsaturatedand unsaturated condensed heterocyclic group containing 1 to 2 oxygen orsulfur atoms [e.g. benzofuryl, benzothienyl,2,3-dihydro-benzo[1,4]dioxinyl and dihydrobenzofuryl]. Examples ofheterocyclic radicals include five to ten membered fused or unfusedradicals.

Examples of partially saturated and fully saturated heterocyclylsinclude, without limitation, pyrrolidinyl, imidazolidinyl, piperidinyl,pyrrolinyl, pyrazolidinyl, piperazinyl, morpholinyl, tetrahydropyranyl,thiazolidinyl, dihydrothienyl, 2,3-dihydro-benzo[1,4]dioxanyl,indolinyl, isoindolinyl, dihydrobenzothienyl, dihydrobenzofuryl,isochromanyl, chromanyl, 1,2-dihydroquinolyl,1,2,3,4-tetrahydro-isoquinolyl, 1,2,3,4-tetrahydro-quinolyl,2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl,5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl,3,4-dihydro-2H-benzo[1,4]oxazinyl, benzo[1,4]dioxanyl,2,3-dihydro-1H-1λ′-benzo[d]isothiazol-6-yl, dihydropyranyl, dihydrofuryland dihydrothiazolyl, and the like.

The term “alkylamino” includes “N-alkylamino” where amino radicals areindependently substituted with one alkyl radical. Preferred alkylaminoradicals are “lower alkylamino” radicals having one to six carbon atoms.Even more preferred are lower alkylamino radicals having one to threecarbon atoms. Examples of such lower alkylamino radicals includeN-methylamino, and N-ethylamino, N-propylamino, N-isopropylamino and thelike.

The term “dialkylamino” includes “N,N-dialkylamino” where amino radicalsare independently substituted with two alkyl radicals. Preferredalkylamino radicals are “lower alkylamino” radicals having one to sixcarbon atoms. Even more preferred are lower alkylamino radicals havingone to three carbon atoms. Examples of such lower alkylamino radicalsinclude N,N-dimethylamino, N,N-diethylamino, and the like.

The term “carbonyl”, whether used alone or with other terms, such as“aminocarbonyl”, denotes —(C═O)—. “Carbonyl” is also used hereinsynonymously with the term “oxo”.

The term “aminocarbonyl” denotes an amide group of the formula—C(═O)NH₂.

The term “alkylthio” or “thioalkoxy” embraces radicals containing alinear or branched alkyl radical, of one to ten carbon atoms, attachedto a divalent sulfur atom. An example of “alkylthio” or “thioalkoxy” ismethylthio, (CH₃S—).

The term “compounds of the invention” are intended to encompasscompounds of Formula I, which in turn encompasses compounds of FormulaII, as well as compounds of any sub-formulas thereof, such as FormulasI-A, I-A-1, I-A-2, I-A-3, I-A-4, I-A-5, I-A-6, I-A-7, I-B, II-A andII-B.

The term “pharmaceutically-acceptable” when used with reference to acompound of Formulas I-II, and sub-formulas thereof, is intended torefer to a form of the compound that is safe for administration. Forexample, a salt form, a solvate, a hydrate, a prodrug or derivative formof a compound of Formulas I-II, which has been approved for mammalianuse, via oral ingestion or other routes of administration, by agoverning body or regulatory agency, such as the Food and DrugAdministration (FDA) of the United States, is pharmaceuticallyacceptable.

Included in the compounds of Formulas I-II, Formulas I-II, andsub-formulas thereof, are the pharmaceutically acceptable salt forms ofthe free-base compounds. The term “pharmaceutically-acceptable salts”embraces salts commonly used to form alkali metal salts and to formaddition salts of free acids or free bases. As appreciated by those ofordinary skill in the art, salts may be formed from ionic associations,charge-charge interactions, covalent bonding, complexation,coordination, etc. The nature of the salt is not critical, provided thatit is pharmaceutically acceptable.

Suitable pharmaceutically acceptable acid addition salts of compounds ofFormulas I-II, and sub-formulas thereof, may be prepared from aninorganic acid or from an organic acid. Examples of such inorganic acidsare hydrochloric, hydrobromic, hydroiodic, hydrofluoric, nitric,carbonic, sulfuric and phosphoric acid. Appropriate organic acids may beselected from aliphatic, cycloaliphatic, aromatic, arylaliphatic,heterocyclic, carboxylic and sulfonic classes of organic acids, examplesof which include, without limitation, formic, acetic, adipic, butyric,propionic, succinic, glycolic, gluconic, lactic, malic, tartaric,citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic,glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic,mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic,ethanedisulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic,toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, camphoric,camphorsulfonic, digluconic, cyclopentanepropionic, dodecylsulfonic,glucoheptanoic, glycerophosphonic, heptanoic, hexanoic,2-hydroxy-ethanesulfonic, nicotinic, 2-naphthalenesulfonic, oxalic,palmoic, pectinic, persulfuric, 2-phenylpropionic, picric, pivalicpropionic, succinic, thiocyanic, undecanoic, stearic, algenic,β-hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitablepharmaceutically-acceptable base addition salts of compounds of FormulasI-II include metallic salts, such as salts made from aluminum, calcium,lithium, magnesium, potassium, sodium and zinc, or salts made fromorganic bases including, without limitation, primary, secondary andtertiary amines, substituted amines including cyclic amines, such ascaffeine, arginine, diethylamine, N-ethyl piperidine, histidine,glucamine, isopropylamine, lysine, morpholine, N-ethyl morpholine,piperazine, piperidine, triethylamine, disopropylethylamine andtrimethylamine. All of these salts may be prepared by conventional meansfrom the corresponding compound of the invention by reacting, forexample, the appropriate acid or base with the compound of FormulasI-IV.

Also, the basic nitrogen-containing groups can be quaternized with suchagents as lower alkyl halides, such as methyl, ethyl, propyl, and butylchloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl,dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl,myristyl and stearyl chlorides, bromides and iodides, aralkyl halideslike benzyl and phenethyl bromides, and others. Water or oil-soluble ordispersible products are thereby obtained.

Additional examples of such salts can be found in Berge et al., J.Pharm. Sci., 66:1 (1977). Conventional methods may be used to form thesalts. For example, a phosphate salt of a compound of the invention maybe made by combining the desired compound free base in a desiredsolvent, or combination of solvents, with phosphoric acid in a desiredstoichiometric amount, at a desired temperature, typically under heat(depending upon the boiling point of the solvent). The salt can beprecipitated upon cooling (slow or fast) and may crystallize (i.e., ifcrystalline in nature), as appreciated by those of ordinary skill in theart. Multiple counter-ions may form the salts of the compounds of theinvention. Thus, hemi-, mono-, di, tri- and poly-salt forms of thecompounds of the present invention are also contemplated herein. Forexample, the salt may be a mono-ionic salt, di-ionic salt or tri-ionicsalt, such as mono- or di-hydrochloride salt, bis-methansulfonate saltor a monofumarate salt. Similarly, hemi-, mono-, di, tri- andpoly-hydrated forms of the compounds, salts and derivatives thereof, arealso contemplated herein.

The term “derivative” is intended to encompass any salt of a compound ofthis invention, any ester of a compound of this invention, or any othercompound, which upon administration to a patient is capable of providing(directly or indirectly) a compound of this invention, or a metaboliteor residue thereof, characterized by the ability to the ability tomodulate an enzyme.

The term “pharmaceutically-acceptable derivative” as used herein,denotes a derivative which is pharmaceutically acceptable.

The term “prodrug”, as used herein, denotes a compound which uponadministration to a subject or patient is capable of providing (directlyor indirectly) a compound of this invention. Examples of prodrugs wouldinclude esterified or hydroxylated compounds where the ester or hydroxylgroups would cleave in vivo, such as in the gut, to produce a compoundaccording to Formula I-II. A “pharmaceutically-acceptable prodrug” asused herein, denotes a prodrug which is pharmaceutically acceptable.Pharmaceutically acceptable modifications to the compounds of FormulaI-IV are readily appreciated by those of ordinary skill in the art.

The compound(s) of Formulas I-II, and sub-formulas thereof, may be usedto treat a subject by administering the compound(s) as a pharmaceuticalcomposition. To this end, the compound(s) can be combined with one ormore excipients, including without limitation, carriers, diluents oradjuvants to form a suitable composition, which is described in moredetail herein.

The term “excipient”, as used herein, denotes any pharmaceuticallyacceptable additive, carrier, adjuvant, or other suitable ingredient,other than the active pharmaceutical ingredient (API), which istypically included for formulation and/or administration purposes.“Diluent” and “adjuvant” are defined hereinafter.

The terms “treat”, “treating,” “treatment,” and “therapy” as used hereinrefer to therapy, including without limitation, curative therapy,prophylactic therapy, and preventative therapy. Prophylactic treatmentgenerally constitutes either preventing the onset of disordersaltogether or delaying the onset of a pre-clinically evident stage ofdisorders in individuals.

The phrase “effective dosage amount” is intended to quantify the amountof each agent, which will achieve the goal of improvement in disorderseverity and the frequency of incidence over treatment of each agent byitself, while avoiding adverse side effects typically associated withalternative therapies. Accordingly, this term is not limited to a singledose, but may comprise multiple dosages required to bring about atherapeutic or prophylactic response in the subject. For example,“effective dosage amount” is not limited to a single capsule or tablet,but may include more than one capsule or tablet, which is the doseprescribed by a qualified physician or medical care giver to thesubject.

The term “leaving group” (also denoted as “LG”) generally refers togroups that are displaceable by a nucleophile. Such leaving groups areknown in the art. Examples of leaving groups include, but are notlimited to, halides (e.g., I, Br, F, Cl), sulfonates (e.g., mesylate,tosylate), sulfides (e.g., SCH₃), N-hydroxsuccinimide,N-hydroxybenzotriazole, and the like. Nucleophiles are species that arecapable of attacking a molecule at the point of attachment of theleaving group causing displacement of the leaving group. Nucleophilesare known in the art. Examples of nucleophilic groups include, but arenot limited to, amines, thiols, alcohols, Grignard reagents, anionicspecies (e.g., alkoxides, amides, carbanions) and the like.

General Synthetic Procedures

The present invention further comprises procedures for the preparationof compounds of Formulas I-II, and sub-formulas thereof. The compoundsof Formulas I-II can be synthesized according to the proceduresdescribed in the following Schemes 1 and 2, wherein the substituents areas defined for Formulas I-II above, except where further noted. Thesynthetic methods described below are merely exemplary, and thecompounds of the invention may also be synthesized by alternate routesutilizing alternative synthetic strategies, as appreciated by persons ofordinary skill in the art.

The following list of abbreviations used throughout the specificationrepresent the following and should assist in understanding theinvention:

-   ACN, MeCN—acetonitrile-   Aq., aq.—aqueous-   Ar—argon (gas)-   BOP—benzotriazol-1-yl-oxy Hexafluorophosphate-   BuLi—Butyllithium-   Cs₂CO₃—cesium carbonate-   CHCl₃—chloroform-   CH₂Cl₂, DCM—dichloromethane, methylene chloride-   Cu(1)I—copper(1) iodide-   DCC—dicyclohexylcarbodiimide-   DCE—dichloroethane-   DIBAL—diisobutylaluminumhydride-   DIC—1,3-diisopropylcarbodiimide-   DIEA, DIPEA—diisopropylethylamine-   DIPA—diisopropylamine-   DME—dimethoxyethane-   DMF—dimethylformamide-   DMAP—4-dimethylaminopyridine-   DMS—dimethylsulfide-   DMSO—dimethylsulfoxide-   EDC, EDCI—1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-   Et₂O—diethyl ether-   EtOAc—ethyl acetate-   FBS—fetal bovine serum-   G, gm—gram-   h, hr—hour-   H₂—hydrogen-   H₂O—water-   HATU—O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate-   HBr—hydrobromic acid-   HCl—hydrochloric acid-   HOBt—1-hydroxybenzotriazole hydrate-   HOAc—acetic acid-   HPLC—high pressure liquid chromatography-   IPA, IpOH—isopropyl alcohol-   K₂CO₃—potassium carbonate-   KI—potassium iodide-   LG—leaving group-   LDA—Lithium diisopropylamide-   LiOH—lithium hydroxide-   MgSO₄—magnesium sulfate-   MS—mass spectrum-   MeOH—methanol-   N₂—nitrogen-   NaCNBH₃—sodium cyanoborohydride-   Na₂CO₃—sodium carbonate-   NaHCO₃—sodium bicarbonate-   NaH—sodium hydride-   NaI—sodium iodide-   NaBH₄—sodium borohydride-   NaOH—sodium hydroxide-   Na₂SO₄—sodium sulfate-   NH₄Cl—ammonium chloride-   NH₄OH—ammonium hydroxide-   P(t-bu)₃—tri(tert-butyl)phosphine-   PBS—phosphate buffered saline-   Pd/C—palladium on carbon-   Pd(PPh₃)₄—palladium(0)triphenylphosphine tetrakis-   Pd(dppf)Cl₂—palladium(1,1-bisdiphenylphosphinoferrocene) II chloride-   Pd(PhCN)₂Cl₂—palladium di-cyanophenyl dichloride-   Pd(OAc)₂—palladium acetate-   Pd₂(dba)₃—tris(dibenzylideneacetone)dipalladium-   PyBop —benzotriazol-1-yl-oxy-tripyrrolidino-phosphonium    hexafluorophosphate-   RT, rt—room temperature-   RBF, rbf—round bottom flask-   TLC, tlc—thin layer chromatography-   TBAF—Tetrabutylammonium flouride-   TBTU—O-benzotriazol-1-yl-N,N,N,N′-tetramethyluronium    tetrafluoroborate-   TEA, Et₃N—triethylamine-   TFA—trifluoroacetic acid-   THF—tetrahydrofuran-   UV—ultraviolet light

Scheme 1 describes an exemplary method for preparing compounds 6 ofFormulas I-IV, wherein X is S, Y is CH₂, A¹ is CR⁶ and R¹, R⁴, R⁵, R⁶and R⁸ are each H, respectively. As shown, a bromo-benzoic acid 1 can becoupled to a bromo-phenol 2 using a copper reagent in conjunction with asuitable base, such cesium carbonate, under suitable conditions. Thecoupled ether 3 can then be treated with an acid, such as sulfuric acid,to effect ring closure to the corresponding bromo-xanthene 4. The ketoneof xanthene 4 can be converted to the corresponding spiro amino-thiazine5 as shown under suitable conditions, such as using vinyl magnesiumchloride and thiourea in the presence of an acid, such as HCl.Bromo-intermediate 5 (where R² is a desired group, such as methoxy) canbe converted to desired compounds 6 via coupling at the site of thebromide, such as by a Suzuki or Suzuki-like aromatic-halogen exchange,which reaction generally employs a boronic acid moiety, a palladiumcatalyst reagent and a base.

Alternatively, the ketone intermediate 4 may be functionalized with thedesired R⁷ group via a Suzuki or Suzuki-like coupling reaction, asdiscussed further herein, to provide intermediate 5-A. The ketone ofintermediate 5-A may then be converted to the corresponding aminodihydrothiazine product 6 using the conditions discussed above.

The boronic ester intermediates 7 may be prepared by methods describedin the following references: (1) PCT Int. Patent Appl. No. WO2005073189, titled “Preparation of fused heteroaryl derivatives as p38kinase inhibitors” or (2) PCT Int. Patent Appl. No. WO 2006094187,titled “Preparation of phthalazine, aza- and diaza-phthalazine compoundsas protein kinase, especially p38 kinase, inhibitors for treatinginflammation and related conditions”. Also, desired boronic acids may bepurchased commercially in catalogs, or specially made by the vendor orby persons skilled in the art.

The Suzuki method is a reaction using a borane reagent, such as aboronic acid 7 or ester such as a dioxaborolane (not shown), and asuitable leaving group containing reagent, such as the Br-xanthene 5 (Bris a suitable halogen leaving group “LG”). As appreciated to one ofordinary skill in the art, Suzuki reactions also utilize a palladiumcatalyst. Suitable palladium catalysts include, without limitation,Pd(PPh₃)₄, Pd(OAc)₂ or Pd(dppf)Cl₂. Where LG is a halide, the halide maybe an iodide, a bromide or even a chloride. Chloro-pyridyl rings (whereA¹=N) undergo Suzuki reactions in the presence of Pd catalysts. OtherLGs are also suitable. For example, Suzuki couplings are known to occurwith a sulfonate, such as trifluoromethanesulfonate, as the leavinggroup. The Suzuki reaction conditions may vary. For example, Suzukireactions are generally run in the presence of a suitable base such as acarbonate base, bicarbonate or an acetate base, in a suitable solventsuch as toluene, acetonitrile, DMF or an aqueous-organic solventcombination or a biphasic system of solvents. Further, the reaction mayrequire heat depending upon the particular bromide 5 and/or boronic acidor ester 7, as appreciated by those skilled in the art. In addition,where the bromide is an aromatic moiety, such as phenyl, the reactionmay be complete in a short period of time with heat.

Other coupling methods are known. For example metal catalized couplingchemistry, such Stille, Kumada, Negishi coupling methods, and the like,may be employed to the xanthene cores 5 to prepare desired cyclicproducts 6. In addition, for compounds wherein X is S, the free aminogroup may need to be protected for effective coupling reactions toinstall either R² or R⁷ groups, and later deprotected to afford thefinal desired compounds 6, as appreciated by persons of ordinary skillin the art.

Desired compounds 13 of Formula I, and sub-formulas of II, III and IV,wherein the R² group is —OR⁸ may be made as generally described inScheme 2. As shown, bromo-methoxy intermediate 9 can be O-d-methylateusing known reagents, such as borontribromide to afford the alcoholproduct 10. The bromide of alcohol 10 can be coupled as described abovein scheme 1 to provide the desired R⁷ group intermediate 11. The alcoholof intermediate 11 can be functionalized as desired, such as byalkylation as shown, by reaction with an alkyl halide in the presence ofa suitable base, such as cesium carbonate as shown, in suitable solventsto afford the finally desired product 13.

“LG” in this instance is a “leaving group” which may be a halide such asan iodide, bromide, chloride or fluoride. LG may also be a non-halidemoiety such as an alkylsulfonate or other known groups which generallyform an electrophilic species (E⁺). Coupling reactions generally occurmore readily in one or a combination of solvents and a base. Suitablesolvents include, without limitation, generally non-nucleophilic,anhydrous solvents such as toluene, CH₂Cl₂, THF, DMF,N,N-dimethylacetamide and the like. The solvent may range in polarity,as appreciated by those skilled in the art. Suitable bases include, forexample, tertiary amine bases such as DIEA, TEA, carbonate bases such asNa₂CO₃, K₂CO₃, Cs₂CO₃, hydrides such as NaH, KH and the like, alkoxidessuch as NaOCH₃, and the like. The base itself may also serve as asolvent. These coupling reactions are generally fast and conversionoccurs typically in ambient conditions. However, depending upon theparticular substrate, such reactions may require heat, as appreciated bythose skilled in the art.

EXAMPLES

The Examples, described herein below, represent various exemplarystarting materials, intermediates and compounds of Formulas I-II, whichshould assist in a better understanding and appreciation of the scope ofthe present invention and of the various methods which may be used tosynthesize compounds of Formulas I-II. Starting materials andintermediates used in the Examples herein may also be prepared using theprocedures described in co-pending U.S. patent application Ser. No.12/558,426, filed Sep. 11, 2009, which specification and disclosure ishereby incorporated herein by reference in its entirety. It should beappreciated that the general methods above and specific examples beloware illustrative only, for the purpose of assistance and ofunderstanding the present invention, and should not be construed aslimiting the scope of the present invention in any manner.

Chromatography:

Unless otherwise indicated, crude product-containing residues werepurified by passing the crude material orconcentrate through an ISCObrand silica gel column (pre-packed or individually packed with SiO₂)and eluting the product off the column with a solvent gradient asindicated. For example a description of (330 g SiO₂, 0-40% EtOAc/Hexane)means the product was obtained by elution from the column packed with330 gms of silica, with a suitable solvent gradient, such as 0% to 40%EtOAc in hexanes.

Preparative HPLC Method:

Unless otherwise indicated, the compounds described herein were purifiedvia reverse phase HPLC using one of the following instruments: Shimadzu,varian, Gilson; utilizing one of the following two HPLC columns: (a) aPhenomenex Luna or (b) a Gemini column (5 micron or 10 micron, C18,150×50 mm)

A typical run through the instrument included: eluting at 45 ml/min witha linear gradient of 10% (v/v) to 100% MeCN (0.1% v/v TFA) in water(0.1% TFA) over 10 minutes; conditions can be varied to achieve optimalseparations.

Proton NMR Spectra:

Unless otherwise indicated, all ¹H NMR spectra were run on a Brukerseries 300 MHz instrument or a Bruker series 400 MHz instrument. Whereso characterized, all observed protons are reported as parts-per-million(ppm) downfield from tetramethylsilane (TMS) or other internal referencein the appropriate solvent indicated.

Mass Spectra (MS)

Unless otherwise indicated, all mass spectral data for startingmaterials, intermediates and/or exemplary compounds are reported asmass/charge (m/z), having an (M+H⁺) molecular ion. The molecular ionreported was obtained by electrospray detection method (commonlyreferred to as an ESI MS) utilizing a PE SCIEX API 150EX MS instrumentor an Agilent 1100 series LC/MSD system. Compounds having an isotopicatom, such as bromine and the like, are generally reported according tothe detected isotopic pattern, as appreciated by those skilled in theart.

The compounds disclosed and described herein have been named usingeither (1) the naming convention provided with Chem-Draw Ultra 8.0software, available in Chem Office, or (2) by the ISIS database software(Advanced Chemistry Design Labs or ACD software).

Example 1 Procedure A

Synthesis of Intermediate 1

Step 1: A RBF equipped with a reflux condenser was charged with2-bromo-5-methoxy benzoic acid (430 g, 1.8614 mol), 4-bromo phenol (322g, 1.8614 mol), potassium carbonate (514.5 g, 3.7 228 mol) andCuOTf-toluene complex (24.08 g, 0.04653 mol). EtOAc (9.0 ml 0.09679 mol,0.052) and toluene (1.3 L) were carefully added portion wise. Afterstirring at RT for 10 min, the mixture was heated to 50° C. for 30 minand then to 110° C. for 20 hrs. The reaction mixture was cooled to RTand diluted with water and acidified with 2N HCl. The reaction mixturewas extracted with EtOAc (3.0×2 L) and filtered through a pad of celite.The combined extracts were dried over sodium sulfate and concentrated toprovide 590 g of a brown solid that was carried on without furtherpurification.Step 2: Sulfuric acid (1.6 L) was added to2-(4-bromophenoxy)-5-methoxybenzoic acid (530 g, 1.6401mol) at RT. Theresulting dark mixture was heated to 60° C. for 1 hour. The brownsolution was cooled to RT and poured onto ice while stirring. Theresulting tan precipitate was collected by filtration, washedsequentially with water (2 L), 1N NaOH (2.0 L) and ethanol (800 mL). Thederived solid was suspended in 2 L of acetone and stiffed vigorously for1 hour. The mixture was filtered and dried under a vacuum to afford 1.3kg of 2-bromo-7-methoxy-9H-xanthen-9-one as a white solid.

Example 2 Procedure B

Synthesis of Intermediate 2

Step 1: A mixture of 2,5-dibromobenzoic acid (1244 g, 4.44 mol),5-hydroxy-2-chloropyridine (663.3 g, 5.12 mol) and cesium carbonate(2893.3 g, 8.88 mol) was stirred for 20 minutes under a nitrogenatmosphere. To this slurry were added copper (I)trifloromethanesulfonate toluene complex (59.7 g, 0.115 mol), toluene (9L) and EtOAc (39 mL). The resulting suspension was heated to 105° C. andstirred for 2 h before being cooled to RT. The toluene was decanted, andwater (8 L) and EtOAc (8 L) were added. The resulting mixture wasstirred until the solid was completely dissolved. The EtOAc layer wasseparated and the pH of the aqueous layer was adjusted to pH 2˜3 with 6NHCl. The aqueous layer was extracted with EtOAc (3×5 L). The combinedorganic layers were dried over Na₂SO₄, filtered and concentrated to give1.28 Kg of 5-bromo-2-(6-chloropyridin-3-yloxy)benzoic acid as brownsolid. This material was used in next step without further purification.Step 2: A mixture of compound 5-bromo-2-(6-chloropyridin-3-yloxy)benzoicacid (1.28 Kg, 4.44 mol), DEA (461 mL, 4.44 mol), HOBT (600 g, 4.44mol), DIPEA (1.547 L, 8.88 mol) in anhydrous DCM (8 L) was cooled to 0°C. and EDCI (851.2 g, 4.44 mol, 1 eq) was added. The mixture was stirredat 0° C. for 30 minutes and then at RT overnight. The reaction mixturewas washed with an aqueous, saturated solution of NaHCO₃, brine andwater. The organic phase was separated, dried over MgSO₄ andconcentrated under reduced pressure. The resulting crude mixture waspurified by silica gel chromatography (5 to 20% ethyl acetate in hexane)to afford 950 g of5-bromo-2-(6-chloropyridin-3-yloxy)-N,N-diethylbenzamide as a yellowoil.Step 3: 5-Bromo-2-(6-chloropyridin-3-yloxy)-N,N-diethylbenzamide (457.5g, 1.23 mol, 1 eq) was dissolved in anhydrous THF (3 L) and cooled to−78° C. To this solution was added a solution of LDA (2M inheptane/THF/ethyl benzene, 2.25 L, 4.5 mol, 3.65 eq) maintaining thetemperature below −70° C. After the addition was complete, the solutionwas stirred for additional 30 min at −78° C. The acetone-dry ice bathwas removed and the reaction was quenched with a saturated aqueoussolution of NH₄Cl (1 L), maintaining the temperature below 10° C.Another batch of5-bromo-2-(6-chloropyridin-3-yloxy)-N,N-diethylbenzamide (457.5 g) wasprocessed using the same protocol. The crude reaction mixtures from bothreactions were combined and the layers were separated. The aqueous layerwas extracted with ethyl acetate (3×5 L). The combined organic layerswere dried and passed through a pad of silica gel. The filtrate wasevaporated, and the residue was triturated with DCM to give 70 g of7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-one. The mother liquor wasevaporated and the solid thus obtained was purified by recrystallizationusing DCM/hexanes to give 180 g of7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-one.

Example 3 Procedure C

Synthesis of Intermediate 3

Step 1: A 3-neck 12 L flask equipped with an overhead stirrer,thermometer, condenser and nitrogen inlet was charged with NaH (186.1 g,4.653 mol) and DMF (1500 mL). The slurry was cooled to 0° C. and asolution of 4-iodophenol (488.6 g, 2.221 mol) in DMF (1500 mL) andadded. The temperature of the reaction mixture was maintained below25-30° C. during this addition. After complete addition, the coolingbath was promptly removed and the mixture continued to stir at RT for 1h. 5-Bromo-2-chloronicotinic acid (500 g, 2.115 mol) was then added tothe slurry portion wise. The reaction mixture was heated to 115° C.overnight. The dark brown reaction mixture was cooled to 20° C. anddiluted with water (2 L). The reaction mixture was acidified using HOAc(845 ml). The black homogenous solution (pH=5) was allowed to stir for 1h at RT and poured slowly onto ice-water (20 L). The slurry was filteredat RT, washed with water (2×2 L) and dried in air to give 765 g of5-Bromo-2-(4-iodophenoxy)-nicotinic acid as light orange solid.Step 2: A 5 L 3-neck flask equipped with an overhead stirrer, athermometer and nitrogen inlet was charged with PPA (4 Kg, 1942 mL)(115% H₃PO₄) and heated to 115-120° C.5-Bromo-2-(4-iodophenoxy)nicotinic acid (400 g, 952 mmol) was chargedportion wise to the hot PPA. The viscous mixture was then allowed tostir overnight (16-18 h) at 115-120° C. The dark viscous mixture wascooled to 60-65° C. and poured slowly onto a mixture of ice (3000 g) andwater (2000 mL) under mechanical stirring. The light brown slurry wasallowed to stir overnight and filtered at RT. The wet cake was washedwith water (2×1000 mL) followed by IPA (1500 mL) and hexane (2×1000 mL).The solid was dried to obtain 326.4 g of3-Bromo-7-iodo-5H-chromeno[2,3-b]pyridine-5-one as a grey solid.

Example 4 Procedure D

Synthesis of Intermediate 4

Step 1: A dry 100 L glass jacketed reactor equipped with an additionfunnel, reflux condenser, solids addition system and temperature probewas charged with 2,5-dibromobenzoic acid (2685 g, 9.6 mol) and copper(I) triflate toluene complex (2:1, 50.0 g, 0.2 mol). Toluene (30 L) andEtOAc (20 mL) were then charged, followed by 2-methoxy-4-fluorophenol(1500 g, 10.6 mol). With vigorous stirring cesium carbonate (6258 g,19.2 mol) was added in portions. The mixture was heated to 90° C. for 4hours. The mixture was cooled to 35° C. and water (15 L) was added.After 15 minutes of stirring the phases were separated and the aqueousphase was washed with toluene (7.5 L). With stirring, EtOAc (15.0 L) wasadded to the aqueous phase, followed by 6 M HCl (5.6 L) keeping theinternal temperature below 30° C. The layers were separated and theorganics were dried over magnesium sulfate. Filtration through a pad ofcelite and concentration provided a solid that was reslurried in 915 mLof EtAOc and 9.2 L of heptanes. Stirring was continued for 1 hour beforethe solids were filtered and washed with heptanes. Drying provided 2560g of 5-bromo-2-(2-fluoro-4-methoxyphenoxy)benzoic acid as a creamcolored solid.Step 2: A dry 100 L glass jacketed reactor equipped with an additionfunnel, reflux condenser and temperature probe was charged with5-bromo-2-(2-fluoro-4-methoxyphenoxy)benzoic acid (2340 g, 6.9 mol). TFA(11.7 L) was carefully added followed by TFAA (1144 mL). Borontrifluoride diethyl etherate (85 mL, 0.68 mol) was then carefully added.Stirring was continued to 4 hours at which point the reaction wastransferred to another 100 L glass reactor containing 35.1 L of watercooled to 0° C. The resulting slurry was allowed to warm to RT and stirfor 1 hour. The solids were filtered and washed with water (4.7 L) and 3N NaOH (2×3.5 L) and water (7 L). The solids were transferred into a 22L reactor and acetone (4.7 L) was added. The solids were slurried for1.5 hour and the filtered, washing well with acetone (4.7 L). Anadditional slurry with acetone (6.4 L@45° C.) provided 1310 g of7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-one as an off white solid.

Example 5 Procedure E

Synthesis of Intermediate 5

Step 1: A solution of i-Pr₂NH (828 mL, 5.85 mol) in anhydrous THF (1.3L) was cooled to −10° C. n-BuLi (1.6 M in hexanes, 3660 mL, 5.85 mol)was added and the solution was stirred for 10 min at 0° C. The reactionmixture was cooled to −78° C. and a solution of2-chloro-6-fluoropyridine (700 g, 5.32 mol) in anhydrous THF (1.3 L) wasslowly added keeping the internal temperature below −60° C. After theaddition was complete, the reaction mixture was stirred for anadditional hour and then a solution of triisopropyl borate (1221 mL,5.32 mol) in anhydrous THF (620 mL) was added drop wise keeping theinternal temperature below −60° C. After the addition, the reactionmixture was warmed to RT and stirred over night. Water (3 L) was addedand the mixture was stirred vigorously. The reaction mixture wasconcentrated under reduced pressure. The residue was treated with a coldaqueous solution of NaOH (10 M, 1610 mL, 16.0 mol) and 50% H₂O₂ (392 mL,6.92 mol) and stirred over night (Note: the internal temperatureincreased slowly from 5 to 60° C.). The reaction mixture was quenchedwith ice and 4N HCl until pH of the mixture was ˜5. EtOAc (5 L) wasadded and stirred well. After phase separation, the aqueous layer wasextracted with EtOAc (1.5 L×2). The combined organic layers were washedwith brine, dried over anhydrous Na₂SO₄, and concentrated under reducedpressure to provide 6-chloro-2-fluoropyridin-3-ol as an off white solid.Step 2: A solution of 6-chloro-2-fluoropyridin-3-ol (1.4 Kg, 9.49 mol)was dissolved in acetone (13 L), and treated with K₂CO₃ (1574 g, 11.39mol, 1.2 eq) and MOMC1 (840 g, 10.44 mol, 1.1 eq). The mixture washeated at 60° C. for 2 hrs. After cooling to RT, the reaction mixturewas filtered to remove inorganic salts. The filtrate was concentratedunder reduced pressure. The residue was purified by flash columnchromatography (0-10% EtOAc/hexanes), affording6-chloro-2-fluoro-3-(methoxymethoxy)pyridine (1496 g) as a colorless oilin 80% yield over two steps.Step 3: A solution of i-Pr₂NH (1100 mL, 7.72 mol) in anhydrous THF (3.5L) was cooled to −10° C. n-BuLi (2.5 M in hexanes, 3087 mL, 7.72 mol)was added drop wise and the solution was stirred for 10 min at 0° C. Thereaction mixture was cooled to −78° C. and a solution of6-chloro-2-fluoro-3-(methoxymethoxy)pyridine (1344 g, 7.02 mol) inanhydrous THF (2 L) was added slowly, keeping the internal temperaturebelow −60° C. The resulting solution was stirred at −75° C. for 1 hr. Asolution of 5-bromo-2-fluorobenzaldehyde (1430 g, 7.02 mol) in THF (1.7L) was added drowise. After the addition was complete, the reactionmixture was stirred at −75° C. for 30 min. The reaction mixture waswarmed to RT and quenched with saturated aqueous NH₄Cl solution (3 L).EtOAc (5 L) was added and the mixture was stirred vigorously. Afterphase separation, the aqueous layer was extracted with EtOAc (3 L×2).The combined organics were washed with brine and dried over anhydrousNa₂SO₄. The solvent was removed under reduced pressure and the residuewas purified by column chromatography (0-10% EtOAc/hexanes) to provide2128 g of(5-bromo-2-fluorophenyl)(6-chloro-2-fluoro-3-(methoxymethoxy)pyridin-4-yl)methanolas a light yellow solid.Step 4: A solution of KBr (65.1 g, 0.55 mol) in water (5.9 L) was addedto a solution of(5-bromo-2-fluorophenyl)(6-chloro-2-fluoro-3-(methoxymethoxy)pyridin-4-yl)methanol(2157 g, 5.47 mol) in DCM (5.9 L). The resulting biphasic mixture wascooled to 5° C. TEMPO (8.6 g, 0.055 mol) was added and the reactionmixture was stirred for 5 min. A solution of NaHCO₃ (106 g, 1.26 mol,0.23 eq) in bleach (6170 mL, 6.01 mol, 1.1 eq) was added slowly keepingthe internal temperature below 10° C. After the addition was completed,the organic phase was separated. The aqueous layer was extracted withDCM (4 L×2). The combined organic layers were washed with 5% aqueoussolution of sodium metabisulfite (6 L×1), brine (3 L×1) and dried overanhydrous Na₂SO₄. The solution was concentrated under reduced pressureto give 2200 g of(5-bromo-2-fluorophenyl)(6-chloro-2-fluoro-3-(methoxymethoxy)pyridin-4-yl)methanoneas a yellow solid.Step 5: To a solution of(5-bromo-2-fluorophenyl)(6-chloro-2-fluoro-3-(methoxymethoxy)pyridin-4-yl)methanone(1200 g, 3.06 mol) in THF (4.8 L) was added 6 N aqueous HCl solution(1600 mL, 9.17 mol) and the reaction mixture was heated to 60° C. for 5hours. The reaction mixture was cooled to RT, and then water (3 L) andEtOAc (3 L) were added. After the phases were separated, the aqueouslayer was extracted with EtOAc (3 L×2). The combined organic layers waswashed with brine (2 L×1) and dried over Na₂SO₄. The solution wasconcentrated under reduced pressure. The residue was dissolved in hotMTBE (˜700 mL). The solution was triturated with hexanes until a solidbegan to precipitate. The slurry was cooled to RT overnight. The solidwas filtered, washed with hexanes (500 mL×2), and dried to give 821 g of(5-bromo-2-fluorophenyl)(6-chloro-2-fluoro-3-hydroxypyridin-4-yl)methanoneas a yellow solid.Step 6: A solution of(5-bromo-2-fluorophenyl)(6-chloro-2-fluoro-3-hydroxypyridin-4-yl)methanone(730 g, 2.10 mol) in dioxane (6 L) was treated with Cs₂CO₃ (1024 g, 3.14mol). The reaction mixture was heated to 100° C. for 5 hours and thencooled to RT. Water (9 L) was added and the mixture was stirredvigorously. The resulting solids were filtered, washed with water (1L×2), hexanes (1 L×1), and EtOAc (700 mL) to provide 602 g of7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-one as a lightyellow solid.

Example 6 Procedure F

Synthesis of Intermediate 6

Step 1: A RBF equipped with a reflux condenser was charged with4-bromophenol (15.5 g, 89.4 mmol), 2,5-diiodobenzoic acid (25.700 g,68.7 mmol), EtOAc (0.337 ml, 3.44 mmol), and toluene (100 mL). Cs₂CO₃(44.8 g, 137 mmol) was carefully added portion-wise. After stirring atRT for 1 min, the mixture was heated to 50° C. for 40 min and thenheated to 100° C. for 20 hrs. The reaction mixture was allowed to coolto RT. The mixture was filtered through Celite and the solids werewashed with EtOAc. The filtrate was diluted with water (200 mL),acidified with 2N HCl (300 mL), and extracted with EtOAc (4×500 mL). Theorganic extract was washed with brine and dried over sodium sulfate. Theorganic fraction was concentrated under reduced pressure to afford crude2-(4-bromophenoxy)-5-iodobenzoic acid (31.1 g) as a tan oil thatsolidified upon standing.Step 2: H₂SO₄ (73.3 ml, 1375 mmol) was added to2-(4-bromophenoxy)-5-iodobenzoic acid (28.800 g, 68.7 mmol) at rt. Theresulting dark mixture was heated to 60° C. for 45 minutes. The brownsolution was poured slowly onto ice-water (1 L) with stirring. Theresulting tan precipitant was collected by filtration, washed with watera 1 N solution of NaOH, again with water, and dried under reducedpressure to afford 2-bromo-7-iodo-9H-xanthen-9-one (23.4 g) as a tansolid that was used without further purification.

Example 7 Procedure G

Synthesis of Intermediate 7

A solution of n-butyllithium (2.7N in heptanes; 165 mL, 445 mmol) in THF(300 mL) was cooled to −78° C. and treated with2,2,6,6-tetramethylpiperidine (77 mL, 456 mmol). The reaction mixturewas allowed to stir for 30 minutes. A solution of5-chloro-2-fluoropyridine (50.0 g, 380 mmol) in THF (200 mL) was addeddrop wise over 30 minutes. After stirring for an additional 30 minutes,the reaction mixture was quenched by bubbling CO₂ through the reactionmixture for 10 minutes. The reaction mixture was allowed to warm to RT,and CO₂ was bubbled through for an additional 30 minutes. The reactionmixture was then concentrated under reduced pressure and dissolved inDMF (400 mL). 4-Bromo-3-fluorophenol (72.6 g, 380 mmol) was added,followed by potassium carbonate (68.3 g, 494 mmol). The reaction mixturewas heated to 120° C. overnight. The reaction mixture was diluted withEtOAc and washed with 4N HCl. The organic layer was separated, washedwith water and dried over MgSO₄. The solvent was removed under reducedpressure. The crude residue was dissolved in Eaton's Reagent (700 mL,54.0 g, 380 mmol) and the reaction mixture was heated to 120° C.overnight. The reaction mixture was poured onto a mixture of ice andMeOH. The resulting solid was filtered off and washed with water. Thesolid was suspended in a mixture of MeOH (100 mL) and cyclopropyl methylether (200 mL) and filtered off. The grey solid was washed with hexanesand dried yielding7-bromo-3-chloro-8-fluoro-5H-chromeno[2,3-b]pyridin-5-one (53.76 g, 164mmol, 43.0% yield) as a ˜4:1 mixture of isomers.

Example 8 Procedure H

Synthesis of Intermediate 8

Step 1: A flask was charged with 2,4-dibromophenol (50.4 g, 200 mmol),potassium carbonate (69.1 g, 500 mmol) and acetone (500 mL). Thesuspension was stirred at RT for 30 minutes and then treated dropwisewith chloromethyl ethyl ether (19 mL, 213 mmol). After 3 h at RT themixture was filtered and the filtrate was partitioned between EtOAc andwater. The organic phase was separated, washed with water, aqueoussaturated NaHCO₃ and brine. The organic phase was dried over MgSO₄ andthe solvent was removed under reduced pressure to afford 54.2 g2,4-dibromo-1-(methoxymethoxy)benzene, which was used in the next stepwithout further purification.Step 2: A solution of 2,4-dibromo-1-(methoxymethoxy)benzene (40.5 g, 137mmol) in Et₂O (140 mL) was cooled to −78° C. and treated with n-BuLi(2.5M in hexanes; 60.2 mL, 151 mmol) under nitrogen atmosphere. After 30minutes a solution of diethyl oxalate (27.9 mL, 205 mmol) in Et₂O (20mL) was added dropwise. The reaction mixture was stirred for 45 minutesat that temperature then quenched cold with saturated ammonium chloridesolution. The mixture was partitioned between Et₂O and water. Theorganic phase was separated, washed with water, brine, then dried overMgSO₄. The solvent was removed under reduced pressure to afford 49 g ofethyl 2-(5-bromo-2-(methoxymethoxy)phenyl)-2-oxoacetate, which was usedin the next step without further purification.Step 3: A flask was charged with (S)-2-methylpropane-2-sulfinamide(0.764 g, 6.31 mmol) and neopentylzinc(II) iodide (0.5 M in THF, 10.0mL, 5.00 mmol) was added under nitrogen atmosphere. The mixture wasstirred at RT for 15 minutes and ethyl2-(5-bromo-2-(methoxymethoxy)phenyl)-2-oxoacetate (1.00 g, 3.15 mmol)was added in one portion. The reaction mixture was quenched withsaturated aqueous ammonium chloride after 8 h. The reaction waspartitioned between EtOAc and water. The organic phase was separated,washed with NH₄Cl, water and brine. The organic phase was dried overMgSO₄ and the solvent was removed under reduced pressure. The crudematerial was purified by silica gel chromatography (10-30% EtOAc/hexane)to provide 0.675 g (S)-ethyl2-(5-bromo-2-(methoxymethoxy)phenyl)-2-(tert-butylsulfinylimino)acetate.

Example 9 Procedure I

Synthesis of Intermediates 9, 10, 10A and 10B

Step 1: A 500-mL RBF was charged with7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-one (12.3789 g, 39.9 mmol),trimethylsulfonium iodide (8.95 g, 43.9 mmol), and DMSO (199 mL). Theresulting slurry was stirred vigorously for 5 minutes leading to a tanslurry before potassium 2-methylpropan-2-olate (4.92 g, 43.9 mmol) wasadded in one portion. The resulting reddish orange solution wasmaintained at rt for 2 hours at which time azidotrimethylsilane (10.49mL, 80 mmol) was added in one portion. The heterogeneous mixture becamehomogeneous after 2-3 hours. The solution was maintained at RT overnightbefore being diluted with EtOAc and transferred to a separatory funnelcontaining saturated NaHCO₃ (500 mL). The layers were separated and theaqueous layer was extracted with EtOAc (3×250 mL). The combined organiclayers were sequentially washed with water and brine and dried oversodium sulfate. The solution was concentrated in vacuo to provide anorange oil that was evaporated from DCM (3×250 mL) to provide5-azido-7-bromo-3-chloro-5-((trimethylsilyloxy)methyl)-5H-chromeno[2,3-c]pyridinewhich was carried on without further purification. A solution of thederived foam in THF (250 mL) was cooled to 0° C. and LAH (2M in THF)(39.9 mL, 80 mmol) was. The reaction was maintained at 0° C. for 2 hoursthen allowed to warm to RT for 30 minutes. The reaction was diluted with150 mL of THF and quenched by the addition of sodium sulfate decahydrate(38.5 g, 120 mmol). After the addition was complete the slurry wasstirred at RT for 1.5 hours before being filtered through a pad ofcelite. The filter pad was washed with THF. The filtrate wasconcentrated under vacuum to give a brown foam. The foam wasconcentrated from DCM twise and left under vacuum overnight. The solidwas taken up in DCM (75 mL) and heated to boiling for 1 minute. Themixture was cooled to RT, and then placed in the fridge for 1 hour. Thesolid was filtered, washed with DCM (50 mL) and dried to provide(5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)methanol (8.94g) as a light orange solid.Step 2: A 4-neck 3000-mL RBF with a mechanical stirrer was charged with(5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)methanol (29.43g, 86 mmol), tetrabutylammonium hydrogen sulfate (5.85 g, 17.23 mmol),THF (431 mL), and bromoacetonitrile (30.0 mL, 431 mmol) to give a clear,brown solution. The resulting solution was stirred vigorously for 5 min,then a 2N aq. solution of NaOH (431 mL, 862 mmol) was added in oneportion. The mixture was stirred overnight and concentrated undervacuum. The remaining material was partitioned between EtOAc (500 mL)and water (500 mL). The layers were separated and the aqueous layer wasextracted with EtOAc (2×250 mL). The combined organic layers were washedwith brine and dried over magnesium sulfate. The solvent was removedunder reduced pressure. The residue was taken up in DCM and filteredthrough a short pad of silica gel. The filtrate was concentrated andpurified by silica gel chromatography (0.5% MeOH/DCM) to provide2-((5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)methoxy)acetonitrile.Step 3: A flask was charged with2-((5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)methoxy)acetonitrile(21 g, 55.2 mmol), dioxane (460 mL) and HCl (4M in dioxane) (55.2 mL,221 mmol) under nitrogen atmosphere. The reaction mixture was heated to100° C. overnight. The mixture was cooled to RT and filtered. The filtercake was washed sequentially with dioxane and ether. The collectedmaterial was dried to give 15.72 g of a cream-colored solid, which wasdissolved in DCM (100 mL) and saturated aqueous sodium bicarbonate (750mL). The mixture was extracted with DCM (2×250 mL) and EtOAc (2×250 mL).The combined organic extracts were dried over sodium sulfate andconcentrated to give7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(Intermediate 1, 14.63 g) as an off-white solid.Step 4:7-Bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-aminewas chromatographed using supercritical CO₂ (additives 25% MeOH with0.2% DEA) on a Chiralpak AD-H column (50×150 mm, 5 μm) eluting at a flowrate 300 ml/min (100 bar pressure, 40° C. column temperature). The firstpeak (retention time=1.6 min) provided(R)-7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(example 9B; intermediate 10A; >99% ee), and the second peak (retentiontime=2.4 min) provided(S)-7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(example 9A; intermediate 10B; >99% ee).

Example 10 Procedure J

Synthesis of Intermediates 11, 11A and 11B

Step 1: To a suspension of3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-one (20.00 g, 49.8 mmol) andtrimethylsulfonium iodide (11.17 g, 54.7 mmol) in 250 mL DMSO undernitrogen atmosphere was added lithium tert-butoxide [1N in heptane (54.7mL, 54.7 mmol)] drop wise over 40 minutes. After stirring for anadditional 30 minutes, trimethylsilylazide (13.21 mL, 100 mmol) wasadded. After stirring for an additional hour, the reaction mixture wasconcentrated under reduced pressure. The remaining solution was dilutedwith water. The resulting solid was filtered off and washed with water.The solid was dissolved in 2-MeTHF, dried over MgSO₄ and concentrated.The crude residue was dissolved in 200 mL THF, cooled to 0° C. andtreated with LAH (1.888 g, 49.8 mmol). After stirring for 30 minutes,the cooling bath was removed, and the reaction mixture was allowed tostir for an additional 30 minutes. The reaction mixture was then cooledto 0° C. and quenched with sodium sulfate decahydrate (32.1 g, 100mmol). The reaction mixture was vigorously stirred for one hour,filtered through a plug of celite and concentrated. Purification of thecrude residue by column chromatography [0-80% (95:5 EtOAc/MeOH)/DCM]gave (5-amino-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)methanol(8.80 g, 20.32 mmol, 40.8% yield).Step 2: A solution of(5-amino-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)methanol (10.00g, 23.09 mmol) and bromoacetonitrile (12.06 mL, 173 mmol) in 25 mL THFwas heated to 40° C. Lithium tert-butoxide [1N in THF (173 mL, 173mmol)] was added drop wise via addition funnel over 5 hours. Aftercompleted addition, the reaction mixture was concentrated. The residuewas purified by column chromatography [0-80% (95:5 EtOAc/MeOH)/heptane]to yield2-((5-amino-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)methoxy)acetonitrile(5.58 g, 11.82 mmol, 51.2% yield).Step 3: A solution of2-((5-amino-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)methoxy)acetonitrile(5.58 g, 11.82 mmol) in 100 mL 2-MeTHF under nitrogen atmosphere wastreated with trimethylaluminum [2N in heptane (7.98 mL, 15.96 mmol)].After stirring for 10 minutes at RT, the reaction mixture was heated to80° C. for 90 minutes. The reaction mixture was cooled to RT andquenched with MeOH. The reaction mixture was treated with saturatedRochelle's salt solution and vigorously stirred for an additional hour.The organic layer was separated, washed with brine, dried over MgSO₄ andconcentrated under reduced pressure. Purification of the crude residueby column chromatography [0-80% (90:10:1 DCM/MeOH/NH₄OH)/DCM] gave3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(Intermediate 2, 2.97 g).Step 4: Intermediates(R)-3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(11A) and(S)-3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(11B) were obtained form racemic3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amineusing similar chiral separation conditions as described herein forintermediate 10.

Example 11 Procedure K

Synthesis of Intermediate 12

Step 1: A solution of7-bromo-3-chloro-8-fluoro-5H-chromeno[2,3-b]pyridin-5-one (10.00 g, 30.4mmol) and trimethylsulfonium iodide (6.83 g, 33.5 mmol) in 150 mL DMSOunder argon atmosphere was treated with potassium tert-butoxide (3.76 g,33.5 mmol) at rt. After 75 minutes, trimethylsilylazide (8.08 mL, 60.9mmol) was added, and the reaction mixture was allowed to stir overnight.The reaction mixture was then diluted with EtOAc and washed with water.The suspension was filtered, and the filtrate was dried over MgSO₄ andconcentrated under reduced pressure. The crude residue was taken up in100 mL THF and cooled to 0° C. LAH (1.155 g, 30.4 mmol) was added, andthe reaction mixture was allowed to stir for 30 minutes. The ice bathwas removed, and the reaction mixture was allowed to stir for anadditional 30 minutes. The reaction mixture was then cooled back to 0°C. and quenched with sodium sulfate decahydrate (9.81 g, 30.4 mmol).After stirring for one hour, the reaction mixture was filtered throughcelite and concentrated under reduced pressure. Purification of thecrude residue by column chromatography [0-80% (95:5 EtOAc/MeOH)/DCM]gave(5-amino-7-bromo-3-chloro-8-fluoro-5H-chromeno[2,3-b]pyridin-5-yl)methanol(2.83 g, 7.87 mmol, 25.9% yield).Step 2: A solution of(5-amino-7-bromo-3-chloro-8-fluoro-5H-chromeno[2,3-b]pyridin-5-yl)methanol(2.83 g, 7.87 mmol) and bromoacetonitrile (5.48 mL, 79 mmol) in 16 mLTHF was heated to 40° C. and treated drop wise with lithiumtert-butoxide [1N in THF (79 mL, 79 mmol)] over a time period of 4hours. After completed addition the reaction mixture was concentratedunder reduced pressure. Purification of the crude residue by columnchromatography [0-40% (95:5 EtOAc/MeOH)/DCM] gave2-((5-amino-7-bromo-3-chloro-8-fluoro-5H-chromeno[2,3-b]pyridin-5-yl)methoxy)acetonitrile(1.362 g, 3.42 mmol, 43.4% yield).Step 3: To a solution of2-((5-amino-7-bromo-3-chloro-8-fluoro-5H-chromeno[2,3-b]pyridin-5-yl)methoxy)acetonitrile(1.363 g, 3.42 mmol) in 10 mL 2-MeTHF under nitrogen atmosphere wasadded trimethylaluminum [2N in heptane (3.42 mL, 6.84 mmol)]. Afterstirring for 10 minutes, the reaction mixture was heated to 80° C.overnight. The reaction mixture was then allowed to cool to RT, andquenched with MeOH. Saturated Rochelle's salt solution was added, andthe reaction mixture was vigorously stirred for an additional hour. Theorganic layer was separated, washed with brine, dried over MgSO₄ andconcentrated under reduced pressure. Purification of the crude residueby column chromatography [0-80% (90:10:1 DCM/MeOH/NH4OH)/DCM] gave7-bromo-3-chloro-8-fluoro-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.422 g, 1.059 mmol, 31.0% yield).

Example 12 Procedure L

Synthesis of Intermediates 13, 13A and 13B

Step 1: To a suspension of 7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-one(25.00 g, 77 mmol) and trimethylsulfonium iodide (23.68 g, 116 mmol) inDMSO (130 mL)/THF (130 mL) was added drop wise potassium tert-butoxide(1M in THF) (116 mL, 116 mmol). After 15 min at RT trimethylsilyl azide(20.54 mL, 155 mmol) was added. The reaction mixture was stirred foradditional 40 minutes and then quenched by addition of 100 ml ofsaturated aqueous sodium bicarbonate. After stirring for 10 minutesEtOAc (100 ml) and water (100 ml were added and the layers wereseparated. The organic layer was washed with water (3×100 ml), brine(100 ml) and dried over MgSO₄. The solvent was removed under reducedpressure to obtain a yellow residue which was dissolved in 250 ml THF.The solution was cooled to 0° C. and LAH (1 M in THF, 108 mL, 108 mmol)was added drop wise. After 5 minutes at 0° C. the reaction mixture wasallowed to warm to RT. The reaction mixture was cooled again to 0° C.and sodium sulfate decahydrate (21.98 g, 155 mmol) was added portionwise. The mixture was stirred for 5 minutes and diluted with 100 mlEtOAc. The reaction mixture was filtered through a pad of Celite and thefilter cake was washed with EtOAc (100 ml). The filtrate wasconcentrated under reduced pressure to obtain a yellow foam which wasre-crystallized from DCM to afford(9-amino-7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-yl)methanol as a whitesolid.Step 2: A solution of(9-amino-7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-yl)methanol (9.83 g,27.8 mmol) in THF (46.3 mL) was sequentially treated with lithiumt-butoxide (1 M in THF) (30.5 mL, 30.5 mmol) and 2-bromoacetonitrile(2.90 mL, 41.6 mmol) at RT. After 2.5 hours reaction time, additional0.5 equivalent lithium t-butoxide and 2-bromoacetonitrile (1.5 mL) wereadded. After 4 hours reaction time, an additional 0.25 equivalentlithium t-butoxide and bromoacetonitrile (0.75 mL) were added. After 5hours reaction time another 0.25 equivalent of lithium t-butoxide andbromoacetonitrile (0.75 mL) were added to the mixture. Water (100 ml)was added and solvents were removed under reduced pressure. The aqueousresidue was filtered, the solid was washed twice with water, dried underreduced pressure and re-suspended in ethanol. The solid was filteredoff, washed with ethanol and dried under reduced pressure to afford2-((9-amino-7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-yl)methoxy)acetonitrile.Step 3: To a solution of2-((9-amino-7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-yl)methoxy)acetonitrile(7.72 g, 19.63 mmol) in DCE (115 mL) was added trimethylaluminum (2M intoluene) (19.63 mL, 39.3 mmol) at RT. The reaction mixture was stirredfor 10 min at RT and then heated to 75° C. for 1 hour. The reactionmixture was cooled to RT and quenched with sodium sulfate decahydrate.The reaction mixture was vigorously stirred for 30 minutes, diluted withEtOAc and stirred overnight. The mixture was filtered through a pad ofcelite and filter cake was washed with EtOAc. The solvent was removedunder reduced pressure to obtain an oily residue which crystallized togive7′-bromo-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(7.49 g, 19.05 mmol, 97% yield) as a cream-colored solid.Step 4: Intermediates(R)-7′-bromo-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(13A) and(S)-7′-bromo-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(13B) were obtained from racemic product,7′-bromo-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(Intermediate 13) using similar chiral separation conditions asdescribed herein for intermediate 10.

Example 13 Procedure M

Synthesis of Intermediate 14

Step 1: To a solution of vinylmagnesium chloride (6.86 mL, 10.97 mmol)at −78° C. under nitrogen atmosphere was added drop wise a solution of2-bromo-7-iodo-9H-xanthen-9-one (2.00 g, 4.99 mmol) in THF (30 mL). Thereaction mixture was allowed to slowly warm to −10° C., then thereaction was quenched with saturated NH₄Cl. The mixture was extractedwith EtOAc followed by a solvent mixture of CHCl₃:i-PrOH (3:1). Thecombined organic layers were dried over Na₂SO₄ and concentrated underreduced pressure. The crude material was purified by filtration oversilica gel (10% EtOAc/hexane) to give 2.14 g of2-bromo-7-iodo-9-vinyl-9H-xanthen-9-ol as a white solid.Step 2: To a solution of 2-bromo-7-iodo-9-vinyl-9H-xanthen-9-ol (0.50 g,1.16 mmol) and thiourea (0.18 g, 2.33 mmol) in acetic acid (2.00 mL) wasadded TFA (4.00 mL). The reaction mixture was stirred at RT overnight.The reaction mixture was concentrated under reduced pressure andextracted with EtOAc, followed by a solvent mixture of CHCl₃:i-PrOH(3:1). The combined organic layers were dried over Na₂SO₄ andconcentrated in vacuo. The residue was purified by chromatography(10%-100% EtOAc/hexane) to provide 0.36 g of2′-bromo-7′-iodo-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-amine asa light yellow solid.

Example 14 Procedure N

Synthesis of Intermediates 15, 15A and 15B

Step 1: A suspension of7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-one (20 g, 60.9mmol), (R)-2-methyl-2-propanesulfinamide (14.76 g, 122 mmol), andtitanium (IV) ethoxide (25.2 mL, 122 mmol) in THF (250 mL) was heated to70° C. for 24 h. Additional (R)-2-methyl-2-propanesulfinamide (1.0equiv) and titanium (IV) ethoxide (1.0 equiv) were added and thereaction mixture was heated for additional 24 h. Additional(R)-2-methyl-2-propanesulfinamide (1.0 equiv) and titanium (IV) ethoxide(1.0 equiv) were added and the reaction mixture was heated foradditional 8 h. The reaction mixture was quenched with brine (150 mL).The resulting suspension was filtered through celite, and the filtercake was washed with EtOAc. The filtrate was washed with brine, driedover Na₂SO₄ and concentrated under reduced pressure. The residue waspurified by chromatography (100% hexanes) to afford racemicN-(7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-ylidene)-2-methylpropane-2-sulfinamideas an orange solid (15 g, 34.7 mmol, 57.1% yield).Step 2: A solution of (2-tert-butoxy-2-oxoethyl)zinc(II) chloride (0.5Min Et₂O; 116 mL, 57.9 mmol) was cooled to 0° C. and a solution of(Z)—N-(7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-ylidene)-2-methylpropane-2-sulfinamide(10 g, 23.16 mmol) in THF (100 mL) was added drop wise. The resultingmixture was stirred at for 1 hour 0° C. The reaction mixture was dilutedwith EtOAc and washed with aqueous saturated solution of NH₄Cl, followedby brine. The organic layer was dried over Na₂SO₄, and concentratedunder reduced pressure. The obtained residue was purified bychromatography (0-20% EtOAc/hexanes) to afford tert-butyl2-(7-bromo-3-chloro-5-(1,1-dimethylethylsulfinamido)-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)acetate(7.5 g, 13.69 mmol, 59.1% yield) as a yellow solid.Step 3: A solution of tert-butyl2-(7-bromo-3-chloro-5-(1,1-dimethylethylsulfinamido)-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)acetate(7.5 g, 13.69 mmol) in dry THF (25 mL) was cooled to −78° C. anddiisobutylaluminum hydride (54.8 mL, 54.8 mmol) was added drop wise. Themixture was warmed to 0° C. and kept at this temperature for 1 h. Thereaction mixture was quenched with a aqueous, saturated solution ofRochelle's salt and vigorously stirred for 15 h. The organic layer wasseparated and the aqueous phase was extracted with EtOAc. The combinedorganic layers were washed with brine and dried over Na₂SO₄. Thesolution was concentrated under reduced pressure. The residue waspurified by chromatography (0-30% EtOAc/hexanes) to affordN-(7-bromo-3-chloro-1-fluoro-5-(2-hydroxyethyl)-5H-chromeno[2,3-c]pyridin-5-yl)-2-methylpropane-2-sulfinamide(5.8 g, 89% yield) as a light yellow solid.Step 4: To a solution ofN-(7-bromo-3-chloro-1-fluoro-5-(2-hydroxyethyl)-5H-chromeno[2,3-c]pyridin-5-yl)-2-methylpropane-2-sulfinamide(5.8 g, 12.14 mmol) in dry MeOH (100 mL) at −20° C. was added a mixtureof MeOH (80 mL)/acetylchloride (20 ml). The resulting reaction mixturewas stirred at −20° C. for 30 min and then quenched with 10% aqueoussolution of Na₂CO₃. DCM was added, the organic phase was separated anddried over Na₂SO₄. The solution concentrated under reduced pressure andthe residue was purified by chromatography (0-50% EtOAc/hexanes) toafford2-(5-amino-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol(4.0 g, 10.71 mmol, 88% yield) as a light yellow solid-foam.Step 5: To a solution of2-(5-amino-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol(4.2 g, 11.24 mmol) in MeOH (40 mL) was added potassium acetate (2.207g, 22.48 mmol) followed by the drop wise addition of cyanogen bromide(3.0 m solution in DCM; 4.50 mL, 13.49 mmol). The resulting reactionmixture was stirred at RT for 17 h. The reaction mixture wasconcentrated under reduced pressure, followed by the addition of 4.0 MHCl in dioxane (15 mL). The reaction mixture was stirred at RT for 2 h.The reaction mixture was concentrated under reduced pressure, Theresidue was dissolved in DCM, washed with aqueous, saturated NaHCO₃solution and brine. The solution was dried over Na₂SO₄ and concentratedunder reduced pressure. The residue was purified by chromatography(0-100% EtOAc/hexanes) to afford7-bromo-3-chloro-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(Intermediate 11, 1.3 g, 3.26 mmol, 29.0% yield) as a yellow solid.Step 6: Intermediates(R)-7-bromo-3-chloro-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(15A) and(S)-7-bromo-3-chloro-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(15B) were obtained from racemic7-bromo-3-chloro-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amineusing similar chiral separation conditions as described herein forintermediate 10.

Example 15 Procedure O

Synthesis of Intermediate 16

Step 1: A suspension of7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-one (20 g, 60.9mmol), (R)-2-methyl-2-propanesulfinamide (14.76 g, 122 mmol), andtitanium (IV) ethoxide (25.2 mL, 122 mmol) in THF (250 mL) was heated to70° C. for 24 h. Additional (R)-2-methyl-2-propanesulfinamide (1.0equiv) and titanium (IV) ethoxide (1.0 equiv) were added and thereaction mixture was heated for additional 24 h. Additional(R)-2-methyl-2-propanesulfinamide (1.0 equiv) and titanium (IV) ethoxide(1.0 equiv) were added and the reaction mixture was heated foradditional 8 h. The reaction mixture was quenched with brine (150 mL).The resulting suspension was filtered through celite, and the filtercake was washed with EtOAc. The filtrate was washed with brine, driedover Na₂SO₄ and concentrated under reduced pressure. The residue waspurified by chromatography (100% hexanes) to afford racemicN-(7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-ylidene)-2-methylpropane-2-sulfinamideas an orange solid (15 g, 34.7 mmol, 57.1% yield).Step 2: A solution of (2-tert-butoxy-2-oxoethyl)zinc(II) chloride (0.5Min Et₂O; 116 mL, 57.9 mmol) was cooled to 0° C. and a solution of(Z)—N-(7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-ylidene)-2-methylpropane-2-sulfinamide(10 g, 23.16 mmol) in THF (100 mL) was added drop wise. The resultingmixture was stirred at for 1 hour 0° C. The reaction mixture was dilutedwith EtOAc and washed with aqueous saturated solution of NH₄Cl, followedby brine. The organic layer was dried over Na₂SO₄, and concentratedunder reduced pressure. The obtained residue was purified bychromatography (0-20% EtOAc/hexanes) to afford tert-butyl2-(7-bromo-3-chloro-5-(1,1-dimethylethylsulfinamido)-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)acetate(7.5 g, 13.69 mmol, 59.1% yield) as a yellow solid.Step 3: A solution of tert-butyl2-(7-bromo-3-chloro-5-(1,1-dimethylethylsulfinamido)-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)acetate(7.5 g, 13.69 mmol) in dry THF (25 mL) was cooled to −78° C. anddiisobutylaluminum hydride (54.8 mL, 54.8 mmol) was added drop wise. Themixture was warmed to 0° C. and kept at this temperature for 1 h. Thereaction mixture was quenched with a aqueous, saturated solution ofRochelle's salt and vigorously stirred for 15 h. The organic layer wasseparated and the aqueous phase was extracted with EtOAc. The combinedorganic layers were washed with brine and dried over Na₂SO₄. Thesolution was concentrated under reduced pressure. The residue waspurified by chromatography (0-30% EtOAc/hexanes) to affordN-(7-bromo-3-chloro-1-fluoro-5-(2-hydroxyethyl)-5H-chromeno[2,3-c]pyridin-5-yl)-2-methylpropane-2-sulfinamide(5.8 g, 89% yield) as a light yellow solid.Step 4: To a solution of2-(5-amino-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol(0.50 g, 1.338 mmol) in THF (10 mL) was added 4-nitrobenzoylisothiocyanate (0.306 g, 1.472 mmol) and the reaction mixture wasstirred at RT for 25 min. TEA (0.019 mL, 0.134 mmol) and1,3-dicyclohexylcarbodiimide (0.304 g, 1.472 mmol) were added and thereaction mixture was heated at 70° C. for 1.5 h. The reaction mixturewas allowed to warm to RT and concentrated under reduced pressure. Theresidue was dissolved in MeOH (15 mL) and potassium carbonate (0.555 g,4.01 mmol) was added. The resulting mixture was stirred at rt overnight.The reaction mixture was concentrated under reduced pressure, washedwith water and extracted with DCM. The combined organic layers weredried over Na₂SO₄ and the solvent was removed under reduced pressure.The residue was purified by chromatography (0-40% EtOAc/hexanes) toafford7-bromo-3-chloro-1-methoxy-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(0.45 g, 1.096 mmol, 82% yield) as a yellow solid.

Example 16 Procedure P

Alternative Methods for Synthesis of Intermediates 15, 15A and 15B

Step 1: To a solution of (2-tert-butoxy-2-oxoethyl)zinc(II) chloride(0.5M in Et₂O; 670 ml, 335 mmol) at 0° C. was added drop wise a solutionof 7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-one (55 g, 167mmol) in THF (30 mL). The resulting reaction mixture was stirred at 0°C. for 1 h. The reaction mixture was quenched with aqueous, saturatedNH₄Cl solution and extracted with EtOAc. The organic extracts were driedover Na₂SO₄ and concentrated under reduced pressure to afford tert-butyl2-(7-bromo-3-chloro-1-fluoro-5-hydroxy-5H-chromeno[2,3-c]pyridin-5-yl)acetate(66.0 g, 148 mmol, 89% yield) as a yellow solid.Step 2: A solution of tert-butyl2-(7-bromo-3-chloro-1-fluoro-5-hydroxy-5H-chromeno[2,3-c]pyridin-5-yl)acetate(66 g, 148 mmol) in THF (200 mL) was cooled to −78° C. followed by thedrop wise addition of diisobutylaluminum hydride (1.0 M solution in THF;180 ml, 180 mmol). The resulting reaction mixture was cooled to 0° C.and stirred for 2 h. The reaction mixture was quenched with aqueous,saturated NH₄Cl solutionand extracted with EtOAc. The combined organicswere dried over Na₂SO₄ and concentrated under reduced pressure. Theobtained residue was purified by chromatography (0-50% EtOAc/hexanes) toafford7-bromo-3-chloro-1-fluoro-5-(2-hydroxyethyl)-5H-chromeno[2,3-c]pyridin-5-ol(48 g, 128 mmol, 86% yield) as a light yellow solid.Step 3: To a solution of7-bromo-3-chloro-1-fluoro-5-(2-hydroxyethyl)-5H-chromeno[2,3-c]pyridin-5-ol(48 g, 128 mmol) in THF (58 mL) were added azidotrimethylsilane (34.0ml, 256 mmol) and boron trifluoride diethyl etherate (31.6 ml, 256mmol). The reaction mixture was heated to 60° C. for 15 h. Additionalazidotrimethylsilane (34.0 ml, 256 mmol) and boron trifluoride diethyletherate (31.6 ml, 256 mmol) were added and heating was continued for 3h. The reaction mixture was quenched with aqueous, saturated NaHCO₃solution and extracted with EtOAc. The organic phase was separated,dried over Na₂SO₄ and concentrated under reduced pressure. The residuewas purified by chromatography (0-30% EtOAc/hexanes) to afford2-(5-azido-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol(41 g, 103 mmol, 80% yield) as a pale yellow solid-foam.Step 4: To a solution of LAH (1.0 M solution in tetrahydrafuran; 90 ml,90 mmol) in THF (50 mL) at rt was added drop wise a solution of2-(5-azido-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol(24 g, 60.1 mmol) in THF (150 mL). The resulting mixture was stirred atRT for 1 h. The reaction mixture was quenched with sodiumsulfatedecahydrate and stirred for 30 min. The mixture was filtered, thefiltrate was concentrated under reduced pressure and the residue waspurified by chromatography (0-50% EtOAc/hexanes) to afford2-(5-amino-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol(16.5 g, 44.2 mmol) as a colorless oil.Step 5: To a solution of2-(5-amino-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol(13 g, 34.8 mmol) in EtOH (50 mL) was added sodium acetate (5.71 g, 69.6mmol) followed by the dropwise addition of cyanogen bromide (3.0Msolution in DCM; 13.92 ml, 41.8 mmol). The resulting mixture was stirredat RT for 5 days. The reaction mixture was concentrated under reducedpressure, washed with water extracted with DCM. The combined organiclayers were dried over Na₂SO₄, concentrated under reduced pressure andazeotropically dried with toluene. The obtained residue was dissolved inDCM and TFA (40 mL) was added to the solution. The resulting mixture wasstirred at RT for 30 min. The mixture was carefully quenched withaqueous, saturated NaHCO₃ solution and extracted with DCM. The combinedorganics were dried over Na₂SO₄ and concentrated under reduced pressure.The obtained residue was purified by chromatogrpahy (0-3% MeOH/DCM) toafford7-bromo-3-chloro-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(6.2 g, 15.55 mmol, 44.7% yield) as a light yellow solid.Step 6: Intermediates(R)-7-bromo-3-chloro-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(15A) and(S)-7-bromo-3-chloro-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(15B) were obtained from racemic7-bromo-3-chloro-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amineusing similar chiral separation conditions as described herein forintermediate 10.

Example 17 Procedure Q

Synthesis of Intermediates 17, 17A and 17B

Step 1: A suspension of7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-one (35 g, 107mmol) in dry THF (210 mL) under nitrogen atmosphere was cooled to 0° C.and a solution of methylmagnesium bromide (3.0M solution in diethylether; 107 mL, 320 mmol) in dry THF (70 mL) was added over 10 minutesvia an addition funnel. After complete addition a saturated aqueoussolution of NH₄Cl (125 mL) was added slowly to the stirring reactionmixture, keeping the internal temperature below 30° C. Water was addedand the mixture was extracted twice with EtOAc. The combined organiclayers were dried over sodium sulfate before concentrating under reducedpressure to afford7-bromo-3-chloro-1-fluoro-5-methyl-5H-chromeno[2,3-c]pyridin-5-ol (34.33g, 100 mmol).Step 2: To a solution of7-bromo-3-chloro-1-fluoro-5-methyl-5H-chromeno[2,3-c]pyridin-5-ol (50 g,145 mmol) in THF (300 mL) was added HCl in dioxane (4M, 19.95 mL, 80mmol). The reaction was heated to 50° C. for 16 hours. The reaction wascooled to RT and K₂CO₃ (30.1 g, 218 mmol) was added. The reactionmixture was stirred for 30 minutes before filtering. The filtrate wasconcentrated under reduced pressure and the resulting crude material waswashed with DCM. The solid was collected by filtration to afford7-bromo-3-chloro-1-fluoro-5-methylene-5H-chromeno[2,3-c]pyridine (33.0g, 101 mmol, 69.6% yield).Step 3: To a solution of7-bromo-3-chloro-1-fluoro-5-methylene-5H-chromeno[2,3-c]pyridine (33 g,101 mmol) in THF (450 mL) were added successively water (69.2 mL),iodine (51.3 g, 202 mmol) and silver(II) oxide (46.8 g, 202 mmol) at RT.The reaction mixture was stirred at RT for 10 minutes before addingK₂CO₃ (41.9 g, 303 mmol). After 30 minutes, the reaction mixture wasdiluted with EtOAc and filtered through a pad of celite. The filter cakewas washed with additional EtOAc. The combined filtrate was concentratedunder reduced pressure upon which a white solid precipitated. The solidwas filtered off. The filtrate was further concentrated under reducedpressure to obtain a residue which was triturated with ether to afford awhite precipitate. The solid was filtered off, combined with the firstsolid and dried under reduced pressure to afford7-bromo-3-chloro-1-fluorospiro[chromeno[2,3-c]pyridine-5,2′-oxirane](23.56 g, 68.8 mmol).Step 4: To a solution of7-bromo-3-chloro-1-fluorospiro[chromeno[2,3-c]pyridine-5,2′-oxirane](23.5 g, 68.6 mmol) in DMF (600 mL) was added azidotrimethylsilane (54.6mL, 412 mmol). The reaction mixture was stirred at RT for 6 hours.Additional azidotrimethylsilane (54.6 mL, 412 mmol) was added and thereaction was stirred at RT for 18 hours. The reaction mixture wasdiluted with EtOAc and water. The organic layer was separated, washedsequentially with a saturated aqueous LiCl solution and brine beforedrying over sodium sulfate. The solution was concentrated under reducedpressure to afford(5-azido-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)methanol(26.12 g, 67.7 mmol, 99% yield).Step 5: A solution of(5-azido-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)methanol(25.1 g, 65.1 mmol) in THF (500 mL) was cooled to −10° C. and a solutionof LAH (1.0 M in THF; 65.1 mL, 65.1 mmol) was added drop wise via anaddition funnel over a time period of 1.5 hours. Upon complete addition,the reaction mixture was stirred additional 20 min at −10° C. Thereaction mixture was quenched with the drop wise addition of saturatedaqueous potassium sodium tartarate solution (60 mL). The reaction wasdiluted with water and EtOAc. The organic layer was separated, washedwith brine and dried over sodium sulfate. The solvent was removed underreduced pressure to afford(5-amino-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)methanol(21.74 g, 60.5 mmol, 93% yield).Step 6: A 3-neck RBF was charged with(5-amino-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)methanol(20.7 g, 57.6 mmol) and THF (10 mL). The flask was equipped with twoaddition funnels which were charged with lithium tert-butoxide solution(1.0M in THF; 98 mL, 98 mmol) and a solution of bromoacetonitrile (6.82mL, 98 mmol) in THF (10 mL), respectively. The two solutions were addedsimultaneously to the stirring solution at ambient temperature over atime period of 3 hours. Upon complete addition, the addition funnelswere recharged with lithium tert-butoxide solution, 1.0 M in THF (98 mL,98 mmol) and a solution of bromoacetonitrile (6.82 mL, 98 mmol) in THF(10 mL), respectively. The two solutions were added simultaneously tothe stirring solution at ambient temperature over a time period of 3hours. The reaction was quenched with saturated aqueous ammoniumchloride solution and stirred for 16 hours. The reaction was dilutedwith water and EtOAc. The organic layer was separated and the aqueouslayer was extracted twice with EtOAc. The combined organic layers werewashed with brine and dried over sodium sulfate. The solution wasconcentrated under reduced pressure, and the resulting black solid wastriturated with ether and filtered to afford a brown precipitate. Thefiltrate was further concentrated and purified by chromatography(50-100% EtOAc/hexanes). The solids obtained through trituration andpurification by chromatography were combined to afford2-((5-amino-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)methoxy)acetonitrile(17.9 g, 44.9 mmol).Step 7: A solution of trimethylaluminum solution (2.0 M in toluene; 7.32ml, 14.64 mmol) was added drop wise to a suspension of2-((5-amino-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)methoxy)acetonitrile(3.89 g, 9.76 mmol) in DCE (14.00 ml) at RT under an atmosphere ofnitrogen. Upon complete addition, the reaction mixture was heated to 70°C. for 10 minutes. The reaction mixture was cooled to RT quenched with asaturated aqueous potassium sodium tartarate solution. The reactionmixture was vigorously stirred for one hour before diluting with EtOAcand water. The organic layer was separated, and the aqueous layer waswashed twice with additional EtOAc. The combined organic layers werewashed with brine, dried over sodium sulfate and concentrated underreduced pressure. DCM and EtOAc were added to the residue and theresulting solution was filtered. The filtrate was concentrated underreduced pressure and purified by chromatography (20-70% EtOAc/hexanes)to afford7-bromo-3-chloro-1-fluoro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(Intermediate 7, 1.539 g, 3.86 mmol, 37%).Step 8: Intermediates(R)-7-bromo-3-chloro-1-fluoro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(17B) and(S)-7-bromo-3-chloro-1-fluoro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(17A) were obtained from racemic7-bromo-3-chloro-1-fluoro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineusing similar chiral separation conditions as described herein forintermediate 10.

Example 18 Procedure R

Synthesis of Intermediates 18, 18A and 18B

Step 1: A 3-neck RBF equipped with an addition funnel and refluxcondenser was charged with zinc dust (37.9 g, 580 mmol) and diethylether (300 ml). Bromine (1.544 ml, 29.0 mmol) was added drop wise to thestirring suspension at RT. After 5 minutes, ethyl 2-bromoacetate (32.3ml, 290 mmol) was added drop wise via addition funnel over the timeperiod of 1 hour. The reaction mixture was heated to reflux for onehour. 7-Bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-one (30 g, 97 mmol)was added in one portion followed by THF (200 ml). After stirring at 40°C. for 10 minutes, the reaction mixture was cooled to RT and quenchedwith saturated aqueous ammonium chloride solution (250 mL). The reactionmixture was stirred for 1 hour before diluting with EtOAc and filteringthrough a pad of celite. The organic layer was separated, washed withbrine and dried over MgSO₄. The solution was concentrated under reducedpressure to afford ethyl2-(7-bromo-3-chloro-5-hydroxy-5H-chromeno[2,3-c]pyridin-5-yl)acetate(40.3 g) which was used in the next step without further purification.Step 2: To a solution of ethyl2-(7-bromo-3-chloro-5-hydroxy-5H-chromeno[2,3-c]pyridin-5-yl)acetate(38.5 g, 97 mmol) in toluene (400 ml) was added azidotrimethylsilane(38.4 ml, 290 mmol) followed by (diethyloxonio)trifluoroborate (24.48ml, 193 mmol) under an atmosphere of nitrogen. The reaction mixture wasstirred at RT for 16 hours. The reaction mixture was quenched with MeOH(200 mL) and diluted with EtOAc. The organic phase was separated, washedwith saturated aqueous sodium bicarbonate solution and brine. Theorganic layer was dried over magnesium sulfate and concentrated underreduced pressure to afford ethyl2-(5-azido-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)acetate(40.82 g) which was used in the next step without further purification.Step 3: A solution of ethyl2-(5-azido-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)acetate(40.82 g, 96 mmol) in THF (400 ml) was cooled to 0° C. under nitrogenatmosphere. A solution of LAH (1.0M solution in THF; 116 ml, 116 mmol)was added drop wise at 0° C. over a time period of 90 minutes. Uponcomplete addition, the reaction mixture was warmed to RT and stirred foradditional 10 minutes. The reaction mixture was quenched with sodiumsulfate decahydrate (50 g) and stirred for 20 minutes at RT. Celite wasadded to the reaction mixture and the suspension was filtered. Thefiltrate was concentrated under reduced pressure and the crude residuewas purified by chromatography [1-2% (2M ammonia in MeOH)/DCM] to afford2-(5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol (17.3g, 48.6 mmol, 50.5% yield).Step 4: To a solution of2-(5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol(0.782 g, 2.199 mmol) in THF (15.27 ml) was added benzoyl isothiocyanate(0.325 ml, 2.419 mmol) at RT. The reaction mixture was stirred for 30minutes after which the reaction was concentrated to dryness underreduced pressure. The residue was dissolved in ACN (15.27 ml) andtriethylamine (0.031 ml, 0.220 mmol) and dicyclohexylcarbodiimide (0.476g, 2.309 mmol) were added consecutively. The reaction mixture was heatedto 80° C. for 2 hours. The reaction mixture was cooled to RT andconcentrated to dryness under reduced pressure. The resulting residuewas suspended in MeOH (15.27 ml) and THF (3.05 ml). A solution of NaOH(1.0M in water; 10.67 ml, 11.0 mmol) was added and the reaction mixturewas heated to 70° C. for 3 hours. The reaction mixture was cooled to RTand concentrated under reduced pressure. The resulting residue wasdissolved in EtOAc and washed with water and brine. The organic layerwas dried over magnesium sulfate and concentrated under reducedpressure. The residue was purified chromatography [1-5% (2M ammonia inMeOH)/DCM] to afford7-bromo-3-chloro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(Intermediate 10, 0.492 g, 1.293 mmol, 58.8% yield).Step 5: Intermediates(R)-7-bromo-3-chloro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(18A) and(S)-7-bromo-3-chloro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(18B) were obtained from racemic7-bromo-3-chloro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amineusing similar chiral separation conditions as described herein forintermediate 10.

Example 19 Procedure S

Synthesis of Intermediate 19

Step 1: A solution of 7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-one(3000 mg, 9.66 mmol) in THF (70 mL) was cooled to −30° C. under nitrogenatmosphere. Isopropenylmagnesium bromide, (0.5m solution in THF; 48.3mL, 24.15 mmol) was added dropwise. The reaction mixture was stirred for30 min at −30° C. Aqueous saturated ammoniumchloride solution was added,followed by EtOAc. The organic phase was separated and dried over MgSO₄.The solvent was removed under reduced pressure to yield the product as alight-yellow solid (3.2 g). The product was taken onto the next reactionstep without further purification.Step 2: To a solution of7-bromo-3-chloro-5-(prop-1-en-2-yl)-5H-chromeno[2,3-c]pyridin-5-ol (3.2g, 9.08 mmol) in THF (80 mL) was added a solution of borane-THF complex(1.0M in THF; 72.6 mL, 72.6 mmol) at RT under nitrogen atmosphere. Thereaction mixture was allowed to stir at RT overnight. Water (10 mL) wasadded, followed by 2 M NaOH (15 mL). Then hydrogen peroxide (35 wt. %solution in H₂O; 22.25 mL, 726 mmol) was added slowly. Et₂O was added,followed by water. The organic phase was separated, washed with brineand dried over MgSO₄. The solvent was removed under reduced pressure andthe residue was purified by flash chromatography (5-30% EtOAc/hexanes).The desired product7-bromo-3-chloro-5-(1-hydroxypropan-2-yl)-5H-chromeno[2,3-c]pyridin-5-ol(2.53 g, 6.83 mmol, 75% yield) was isolated as a white solid (1:1mixture of diastereoisomers).Step 3: Azidotrimethylsilane (1.432 mL, 10.79 mmol) and borontriflourideetherate (1.368 mL, 10.79 mmol) were added sequentially to a solution of7-bromo-3-chloro-5-(1-hydroxypropan-2-yl)-5H-chromeno[2,3-c]pyridin-5-ol(2000 mg, 5.40 mmol) in THF (50 mL). The reaction mixture was heated to66° C. After 12 h reaction time, additional azidotrimethylsilane (1.432mL, 10.79 mmol) and borontriflouride etherate (1.368 mL, 10.79 mmol)were added and the reaction mixture was continued to be heated to 65° C.After 24 h reaction time, additional azidotrimethylsilane (1.432 mL,10.79 mmol) and borontriflouride etherate (1.368 mL, 10.79 mmol) wereadded and the reaction mixture was continued to be heated to 65° C.After 32 h reaction time, the reaction mixture was cooled to rt andaqueous saturated bicarbonate solution was added carefully, followed byEtOAc. The organic phase was separated and dried over MgSO₄. The solventwas removed under reduced pressure and the residue was purified by flashchromatography (10-55% EtOAc/hexanes).2-(5-azido-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)propan-1-ol(1.32 g, 85% purity) was isolated of a white solid and taken onto thenext step without further purification.Step 4: A solution of2-(5-azido-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)propan-1-ol(1300 mg, 3.29 mmol, 85% purity) in THF (10 mL) was cooled to 0° C.under nitrogen atmosphere. LAH (1.0M solution in THF; 3.61 mL, 3.61mmol) was added dropwise. A mixture of celite and Na₂SO₄*10H₂O wasadded. The reaction mixture was filtered, the solvent was removed underreduced pressure and the residue was purified by flash chromatography(10-50% EtOAc/hexanes) to afford the desired product2-(5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)propan-1-ol(0.85 g, 2.300 mmol, 70.0% yield) as a white solid.Step 5: To a suspension of2-(5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)propan-1-ol(0.85 g, 2.300 mmol) in EtOH (10 mL) was added anhydrous sodium acetate(0.377 g, 4.60 mmol) followed by the drop wise addition of cyanogenbromide (3.0M in CH₂Cl₂; 0.920 mL, 2.76 mmol). The suspension wasstirred at RT for 48 h. Additional cyanogen bromide (0.8 mL, 0.6 eq) andNaOAc (180 mg, 1.0 eq) were added. The reaction mixture was allowed tostir for 3 days at RT. The reaction mixture was concentrated underreduced pressure, washed with water and extracted with DCM. The combinedorganic layers were dried over MgSO₄ and azeotropically dried withtoluene. A white solid was obtained which was suspended in DCM (15 mL).Upon dropwise addition of TFA (2 mL) the reaction mixture turned clearand yellow. The resulting mixture was stirred at RT for 20 min. Thesolvent was removed under reduced pressure and aqueous saturated NaHCO₃solution and CH₂Cl₂ were added. The suspension was filtered and7-bromo-3-chloro-5′-methyl-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-aminewas obtained as a white solid (305 mg). The filtrate was transferredinto a separatory funnel. The organic phase was separated and dried overMgSO₄. The solvent was removed under reduced pressure and the residuewas purfied by flash chromatography to obtain additional7-bromo-3-chloro-5′-methyl-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine(300 mg).

Example 20 Procedure T

Synthesis of Intermediates 20, 20A and 20B

Step 1: To a suspension of 7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-one(20 g, 61.9 mmol) in 2-methyl-THF (300 mL) a solution of(2-tert-butoxy-2-oxoethyl)zinc(II) chloride (0.5 M in Et₂O; 186 mL, 93mmol) was added at RT. The mixture was stirred for 10 min at RT, andthen heated to 45° C. for 1 hour. The reaction mixture was cooled to RTand quenched with aqueous, saturated NH₄Cl (150 mL) and water (100 mL).The organic layer was separated, washed with brine and filtered throughthe pad of Celite. The solvent was removed under reduced pressure toyield as a yellowish solid which was dissolved in of benzene (200 mL).Azidotrimethylsilane (12.30 mL, 93 mmol) was added and the reactionmixture was cooled to 5° C. Borontrifluoride etherate (7.84 mL, 61.9mmol) was added drop wise. The reaction mixture was quenched by theaddition of MeOH (5 mL) and aqueous, saturated NaHCO₃ solution (100 ml).The organic layer was separated, washed with brine, filtered throughCelite and concentrated under reduced pressure to afford a yellowresidue, which was dissolved in THF (300 mL). The solution was cooled to0° C. and LAH (1M in THF; 93 mL, 93 mmol) was added drop wise at thistemperature. The reaction mixture was allowed to warm to RT and quenchedby the addition of sodium sulfate decahydrate (20 g). The reactionmixture was stirred for 2 hrs at RT, then filtered through celite. Thefilter cake was washed twice with EtOAc. The filtrate was concentratedunder reduced pressure and the residue was purified by chromatography[5-50% DCM/MeOH/NH₄OH (90:10:1)] in DCM to afford2-(9-amino-7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-yl)ethanol (10.99 g,29.8 mmol).Step 2: To a solution of2-(9-amino-7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-yl)ethanol (7.17 g,19.47 mmol) in THF (100 mL) was added 4-nitrobenzoyl isothiocyanate(4.26 g, 20.45 mmol). The reaction mixture was stirred for 30 min at RT.EDC (5.60 g, 29.2 mmol) and TEA (0.543 ml, 3.89 mmol) were addedsequentially and the reaction mixture was heated to 70° C. for 1 hr. Thereaction mixture was cooled to RT and water (50 ml) was added. Thereaction mixture was stirred for 1 hr, upon which a precipitate formed,which was filtered off and washed with water and MeOH. The solid wasdried to affordN-(7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthene]-2-yl)-4-nitrobenzamide(6.0 g, 11.06 mmol, 56.8% yield).Step 3: A suspension ofN-(7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthene]-2-yl)-4-nitrobenzamide(6.0 g, 11.06 mmol) in methanol (60 mL) was heated to 65° C. NaOH (2 Msolution) (48.7 ml, 97 mmol) was added and the resulting mixture washeated to 65° C. for 4 hrs. The reaction mixture was concentrated underreduced pressure, the precipitate was filtered off, washed twice withwater and dried to afford7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine(3.90 g, 9.92 mmol, 50.9% yield) as white solid.Step 4: Intermediates(R)-7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine(20A) and(S)-7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine(20B) were obtained from racemic7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amineusing similar chiral separation conditions as described herein forintermediate 10.

Example 21 Procedure U

Synthesis of Intermediate 21

A vial was charged with(S)-7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(Intermediate 1B, 1.0 g, 2.63 mmol) and DMSO (13.14 mL). Sodiummethoxide (0.710 g, 13.14 mmol) was added and the reaction mixture washeated to 80° C. for 2.5 hours. The reaction mixture was cooled to RTand quenched with aqueous, saturated ammonium chloride solution. Waterand EtOAc were added, and the organic layer was separated and theaqueous layer was extracted with EtOAc. The combined organic layers werewashed with brine, dried over sodium sulfate and concentrated underreduced pressure. The residue was purified via column chromatography(0-100% EtOAc/hexanes) to afford(S)-7-bromo-3-methoxy-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(Example 21A; 0.611 g, 1.624 mmol, 61.8% yield) as a yellow solid.

Example 22 Procedure V

Synthesis of Intermediate 22

Step 1: Bromine (0.072 ml, 1.4 mmol) was added to a suspension of zincdust (1.41 g, 21.57 mmol) in diethyl ether (25 ml) at RT. After 5minutes, ethyl 2-bromoacetate (1.202 ml, 10.8 mmol) was added drop wiseover a time period of 10 minutes and the reaction mixture was heated toreflux for 2 hours. 7-Bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-one (2g, 6.44 mmol) was added in one portion, followed by THF (25.00 ml) andthe reaction mixture was heated to reflux for 30 minutes. The reactionmixture was quenched with aqueous saturated NH₄Cl solution (20 mL) andwater (20 mL) and stirred 30 min at RT. The solution was filtered andthe organic phase was separated. The solvent was removed under educedpressure to afford ethyl2-(7-bromo-3-chloro-5-hydroxy-5H-chromeno[2,3-c]pyridin-5-yl)acetate(2.5 g, 6.27 mmol, 97% yield).Step 2: To a solution of ethyl2-(7-bromo-3-chloro-5-hydroxy-5H-chromeno[2,3-c]pyridin-5-yl)acetate (20g, 50.2 mmol) in toluene (300 ml) was added azidotrimethylsilane (19.93ml, 151 mmol(, followed by (diethyloxonio)trifluoroborate (12.72 ml, 100mmol). The mixture was stirred overnight at RT. The reaction mixture wasquenched with MeOH (200 mL) and diluted with EtOAc. The organic phasewas separated, washed with saturated aqueous sodium bicarbonate solutionand brine. The organic layer was dried over magnesium sulfate andconcentrated under reduced pressure to afford ethyl2-(5-azido-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yBacetate (21 g,49.6 mmol, 99% yield).Step 3: A solution of ethyl2-(5-azido-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)acetate (47g, 111 mmol) in THF (600 ml) was cooled to 0° C. under nitrogenatmosphere. A solution of LAH (1.0M in THF; 133 ml, 133 mmol) was addeddrop wise at 0° C. Upon complete addition, the reaction mixture waswarmed to RT and stirred for additional 10 minutes. The reaction mixturewas quenched with sodium sulfate decahydrate (50 g) and stirred for 1hour at room temperature. The suspension was filtered over celite. Thefiltrate was concentrated under reduced pressure and the crude residuewas purified by by recrystallization from cold DCM with heptane toafford2-(5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol (16g, 45.0 mmol, 40.6% yield).Step 4: A reaction mixture of2-(5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)ethanol (2.8g, 7.87 mmol) and 4-nitrobenzoyl isothiocyanate (1.639 g, 7.87 mmol) inTHF (100 mL) was stirred at RT for 1 hour. The reaction mixture was thenconcentrated under reduced pressure to affordN-(7-bromo-3-chloro-5-(2-hydroxyethyl)-5H-chromeno[2,3-c]pyridin-5-ylcarbamothioyl)-4-nitrobenzamide(5 g, 8.87 mmol).Step 5: 1-Chloro-N,N,2-trimethylprop-1-en-1-amine (2.84 ml, 21.28 mmol)was added to a solution ofN-((7-bromo-3-chloro-5-(2-hydroxyethyl)-5H-chromeno[2,3-c]pyridin-5-yl)carbamothioyl)-4-nitrobenzamide(12 g, 21.28 mmol) in DCM (200 ml). The reaction mixture was stirred atRT for 8 hours and then concentrated under reduced pressure to 50% ofits original volume. A precipitate formed upon cooling which wasfiltered off, washed with DCM and then dried under reduced pressure toaffordN-(7-bromo-3-chloro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]thiazin]-2′-yl)-4-nitrobenzamidehydrochloride (10.5 g, 18.03 mmol, 85% yield) as an off white solid.Step 6: A 2 N NaOH solution (24.47 ml, 48.9 mmol) was added to asolution ofN-(7-bromo-3-chloro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]thiazin]-2′-yl)-4-nitrobenzamidehydrochloride (9.5 g, 16.32 mmol) in MeOH (250 ml). The reaction mixturewas heated to 65° C. for 3 hours. The reaction mixture was diluted withwater (300 mL), stirred for 10 min, and then filtered. The solid waswashed with water and dried under reduced pressure to afford7-bromo-3-chloro-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]thiazin]-2′-amine(3.9 g, 9.83 mmol, 60.3% yield).

Example 23 Procedure W

Synthesis of Intermediate 23

Step 1: Bromine (0.797 ml, 15.47 mmol) was added to a suspension of zincdust (8.09 g, 124 mmol in diethyl ether (150 ml) at RT. After 5 minutes,ethyl 2-bromoacetate (6.86 ml, 61.9 mmol) was added drop wise over atime period of 20 minutes and the reaction mixture was heated to refluxfor 2 hours. 7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-one (10 g, 30.9mmol) was added in one portion, followed by THF (100 ml) and thereaction mixture was heated to reflux for 3 hours. The reaction mixturewas quenched with aqueous saturated NH₄Cl solution (100 mL) and EtOAc(100 mL) and stirred 2 hours at RT. The solution was filtered and theorganic phase was separated. The solvent was removed under educedpressure to afford ethyl2-(7-bromo-4-fluoro-9-hydroxy-2-methoxy-9H-xanthen-9-yl)acetate (12.7 g,30.9 mmol, 100% yield).Step 2: To a solution of ethyl2-(7-bromo-4-fluoro-9-hydroxy-2-methoxy-9H-xanthen-9-yl) acetate (1.0 g,2.432 mmol) in toluene (25 ml) was added azidotrimethylsilane (0.560 g,4.86 mmol). The solution was cooled to 0° C. and(diethyloxonio)trifluoroborate (0.308 ml, 2.432 mmol) was added dropwise. The mixture was stirred overnight at RT. The solution was quenchedwith MeOH (10 ml) and diluted with EtOAc. The organic phase wasseparated, washed with saturated aqueous sodium bicarbonate solution andbrine, and then concentrated to afford crude ethyl2-(9-azido-7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-yl)acetate (1 g,2.292 mmol, 94% yield).Step 3: A solution of ethyl2-(5-azido-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)acetate (13.5g, 30.9 mmol) in THF (200 ml) was cooled to 0° C. under nitrogenatmosphere. A solution of LAH (1.0M in THF; 37.1 ml, 37.1 mmol) wasadded drop wise at 0° C. After 10 min, the reaction mixture was quenchedwith sodium sulfate decahydrate (20 g) and stirred for 5 min at RT. Thesuspension was filtered. The filtrate was concentrated under reducedpressure and the crude residue was purified by column chromatography[10-100% 90/10/1 (DCM/MeOH/ammonia) in DCM] to afford2-(9-amino-7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-yl)ethanol (8.8 g,23.90 mmol).Step 4: A reaction mixture of2-(9-amino-7-bromo-4-fluoro-2-methoxy-9H-xanthen-9-yl) ethanol (8.8 g,23.90 mmol) and benzoyl isothiocyanate (3.22 ml, 23.90 mmol) in THF (200ml) was stirred at RT for 1 hour. The reaction mixture was thenconcentrated under reduced pressure to affordN-((7-bromo-4-fluoro-9-(2-hydroxyethyl)-2-methoxy-9H-xanthen-9-yl)carbamothioyl)benzamide(12.7 g, 23.90 mmol).Step 5: 1-Chloro-N,N,2-trimethylprop-1-en-1-amine (2.012 ml, 15.05 mmol)was added to a solution ofN-((7-bromo-4-fluoro-9-(2-hydroxyethyl)-2-methoxy-9H-xanthen-9-yl)carbamothioyl)-benzamide(8 g, 15.05 mmol) in DCM (3 ml). The reaction mixture was stirred at RTfor 8 hours. The reaction mixture was quenched with aqueous, saturatedsodium carbonate solution and stirred for 10 minutes. The organic layerwas separated and concentrated under reduced pressure to afford crudeN-(7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-yl)benzamide(7.7 g, 15.00 mmol, 100% yield).Step 6: A 2 N solution of lithium hydroxide (22.50 ml, 45.0 mmol) wasadded to a solution ofN-(7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-yl)benzamide(7.7 g, 15.00 mmol) in MeOH (250 ml). The reaction mixture was heated to65° C. for 3 hours. The reaction mixture was diluted with water andextracted with EtOAc. The combined organic extracts were concentratedunder reduced pressure. The residue was purified via columnchromatography [0-70% 90/10/1 (DCM/MeOH/ammonia) in DCM] to afford7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-amineas a racemic mixture (2 g, 2.443 mmol, 32% yield).

Example 24 Procedure X

Synthesis of Intermediate 24

Step 1: To a suspension of tetraethoxytitanium (3.40 g, 14.93 mmol) inTHF (16.58 ml) was added 3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-one(2.00 g, 4.98 mmol). The suspension was cooled to 0° C. and(2-ethoxy-2-oxoethyl)zinc(II) bromide (149 ml, 14.93 mmol) was addeddrop wise. The reaction mixture was allowed to warm to RT and stirred 1h. The reaction mixture was quenched with aqueous, half-saturated NaHCO₃solution (20 mL) and stirred for 30 min. The solution was filteredthrough a pad of celite and the filter cake was rinsed with EtOAc. Theorganic layer was separated and concentrated under reduced pressure toafford ethyl2-(3-bromo-5-hydroxy-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)acetate as ayellowish solid.Step 2: Azidotrimethylsilane (1.102 ml, 8.32 mmol) was added to asuspension of ethyl2-(3-bromo-5-hydroxy-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)acetate (2.33g, 4.75 mmol) in toluene (31.7 ml). The reaction mixture was cooled to0° C. and (diethyloxonio)trifluoroborate (0.753 ml, 5.94 mmol) was addedslowly. The reaction mixture was allowed to warm to RT. After 30 min,the reaction mixture was quenched with MeOH (5 mL) followed by aqueous,saturated NaHCO₃ solution (10 mL). The reaction mixture was extractedtwice with EtOAc. The combined organic phases were washed with brine anddried over sodium sulfate. The solvent was removed under reducedpressure to afford ethyl2-(5-azido-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)acetate as ayellow solid.Step 3: LAH (1M in THF; 6.12 ml, 6.12 mmol) was added slowly to a −78 Ccooled solution of ethyl2-(5-azido-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)acetate (2.10g, 4.08 mmol) in THF (40.8 ml). The reaction mixture was stirred at 78°C. for 15 min, and the reaction mixture was allowed to warm to RT andstirred for additional 30 min. The reaction mixture was cooled to 0° C.,quenched with sodium sulfate decahydrate (2.90 g, 20.38 mmol) andallowed to stir 20 min. The solution was filtered through a pad ofcelite, the filter cake was eluted with 10% MeOH/DCM and the filtratewas concentrated. The residue was purified via flash chromatography(0-25% EtOAc/CH₂Cl₂) to afford2-(5-amino-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)ethanol as ayellow solid.Step 4: A solution of2-(5-amino-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)ethanol (0.930g, 2.080 mmol) in THF (20.80 ml) was added cooled to 0° C. and solid4-nitrobenzoyl isothiocyanate (0.442 g, 2.122 mmol) was added. Thereaction mixture was stirred at 0° C. for 20 min. The reaction mixturewas concentrated under reduced pressure to yieldN-((3-bromo-5-(2-hydroxyethyl)-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)carbamothioyl)-4-nitrobenzamideas a yellow solid.Step 5: 1-Chloro-n,n,2-trimethyl-1-propenylamine (0.556 ml, 4.16 mmol)was added to a solution ofN-((3-bromo-5-(2-hydroxyethyl)-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)carbamothioyl)-4-nitrobenzamide(1.363 g, 2.080 mmol) in CH₂Cl₂ (7 ml) at 0° C. The reaction mixture wasallowed to warm to RT and stir for 2 h. The reaction mixture wasquenched with aqueous, saturated NaHCO₃ solution (5 mL), and was furtherdiluted with 10% MeOH/DCM and 5 mL water andN-(3-bromo-7-iodo-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]thiazin]-2′-yl)-4-nitrobenzamidecollected as a pink solid.Step 6: A suspension ofN-(3-bromo-7-iodo-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]thiazin]-2′-yl)-4-nitrobenzamide(0.906 g, 1.422 mmol) and lithium hydroxide hydrate (0.179 g, 4.27 mmol)in MeOH (28.4 ml) was heated to reflux for 3 hours. The solvent wasremoved under reduced pressure to afford3-bromo-7-iodo-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]thiazin]-2′-amineas a pink solid.Step 7: Aqueous, saturated NaHCO₃ solution (7.6 ml, 7.11 mmol) and bocanhydride (3.3 ml, 14.22 mmol) were added to a stirred suspension of3-bromo-7-iodo-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]thiazin]-2′-amine(694 mg, 1.422 mmol) in dioxane (7 ml). The reaction mixture was stirredfor 16 h at RT. The reaction mixture was partitioned between EtOAc (50mL) and water (20 ml). The aqueous layer was separated and extractedwith EtOAc (1×10 mL). The combined organic extracts were washed withbrine, dried over Na₂SO₄ and concentrated under reduced pressure. Theresidue was purified via flash chromatography (0-25% EtOAc/CH₂Cl₂) toafford tert-butyl(3-bromo-7-iodo-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]thiazin]-2′-yl)carbamatea yellow solid.

Example 25 Procedure Y

Synthesis of Intermediate 25

Step 1: 3-Bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-one (6.0 g, 14.93mmol) was taken up in THF (150 mL). Neat tetraethoxytitanium (9.29 mL,44.8 mmol) was added. An ether solution of(2-tert-butoxy-2-oxoethyl)zinc(II) chloride (0.5 M, 62.7 mL, 31.3 mmol)was added via cannula. The reaction was stirred at 0° C. for 30 min,then was warmed to rt and stirred 30 min. Excess organozinc reagent wasquenched at 0° C. with 250 mL of half-saturated brine. The mixture wasfiltered through Celite, rinsing the solid with EtOAc (700 mL). Theresulting filtrate's organic layer was separated and extracted furtherwith saturated brine (50 mL), then was dried over sodium sulfate andconcentrated. The crude tert-butyl2-(3-bromo-5-hydroxy-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)acetate (7.8g) was used in the next step without further purification.Step 2: In a 1-L flask, the tert-butyl2-(3-bromo-5-hydroxy-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)acetate (7.8g, 15.05 mmol) was suspended in toluene (100 mL). Neatazidotrimethylsilane (2.99 mL, 22.58 mmol) was added. The mixture wascooled to 0° C., and BF₃-etherate (2.098 mL, 16.56 mmol) was added. Themixture was allowed to warm naturally in the ice bath. After two hours,the mixture was quenched with MeOH (3 mL), then with half-saturatedaqueous NaHCO₃ (100 mL). The residue was extracted with 10% MeOH-EtOAc(3×200 mL). The organics were combined, washed with saturated brine (50mL), dried over sodium sulfate and concentrated. The crude tert-butyl2-(5-azido-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)acetate wasused in the next step without further purification (7.27 g).Step 3: In a 1-L flask, the tert-butyl2-(5-azido-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)acetate (7.27g, 13.38 mmol) was suspended in THF (100 mL) and the suspension wascooled to 0° C. A THF solution of LAH (1 M, 20.08 mL, 20.08 mmol) wasadded. After 30 min, the reaction mixture was quenched with carefuladdition of water (0.75 mL), 4 M aqueous NaOH (2.2 mL), and water (0.75mL). The mixture was filtered through Celite, rinsing with THF (60 mL),then with EtOAc (150 mL). The combined filtrate was concentrated. Theresidue was purified through silica gel (400 mL) which had beendeactivated with Et₃N (40 mL), using 100:100:1 EtOAc-hexane-Et₃N, toafford 2-(5-amino-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)ethanol(2.24 g).Step 4: In a 250-mL flask, the2-(5-amino-3-bromo-7-iodo-5H-chromeno[2,3-b]pyridin-5-yl)ethanol (2.24g, 5.01 mmol) was dissolved in THF (30 mL). Benzoyl isothiocyanate(0.607 mL, 4.51 mmol) was added. After 1 h, the mixture wasconcentrated. The residue was taken up in ACN (30 mL), and catalytic TEA(0.069 mL, 0.501 mmol) was added, followed by DCC (1.137 g, 5.51 mmol).A water-cooled condenser was affixed, and the solution was stirred in an80° C. oil bath for 2 h. The reaction was then concentrated. The residuewas used directly in the next step without further purification.Step 5: In a 150-mL resealable vessel, the crudeN-(3-bromo-7-iodo-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazine]-2′-yl)benzamidefrom the above procedure was dissolved in 1:1 THF-MeOH (12 mL). AqueousNaOH (12.04 mL, 30.1 mmol) was added. The vessel was sealed and heatedin a 90° C. oil bath. After 2 h, the reaction was concentrated to removemost of the THF and MeOH. The aqueous residue was diluted with water (35mL), and the aqueous layer was extracted with 5% MeOH-dcm (3×100 mL).The organics were combined, washed with dilute brine (35 mL), dried oversodium sulfate and concentrated. The residue was purified through silicagel (300 mL) using 3% MeOH-dcm, to afford intermediate 25(3-bromo-7-iodo-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine)(1.99 g). MS (m/z) 472/474 (M+H)⁺.

Example 26 Procedure Z

Synthesis of Intermediates 26, 26A and 26B

Step 1: In a 150-mL resealable flask, potassium carbonate (1.557 g,11.27 mmol3-bromo-7-iodo-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine(intermediate 25 1.97 g, 4.17 mmol), 2-fluoropyridin-3-ylboronic acid(0.441 g, 3.13 mmol), and PdCl₂-dppf-dcm (0.225 g, 0.275 mmol) weresuspended in dioxane (18 mL) and water (6 mL). Argon was blown throughthe vessel, which was sealed and heated in an 85° C. oil bath for 2 h.The reaction was concentrated to remove most of the dioxane. The aqueousresidue was diluted further with dilute brine (50 mL), and the aqueousphase was extracted with 10% MeOH-DCM (3×100 mL). The organics werecombined, washed with dilute brine (30 mL), dried over sodium sulfateand concentrated. The residue was purified by chromatography (4%MeOH/DCM), to afford(3-bromo-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine)(1.03 g). MS (m/z) 441/443 (M+H)⁺.Step 2: Intermediates((S)-3-bromo-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine)(intermediate 26A, 350 mg), and its enantiomer((R)-3-bromo-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine(intermediate 26 B, 500 mg) were obtained from racemic(3-bromo-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine)using similar chiral separation conditions as described herein forintermediate 10. MS (m/z) 441/443 (M+H)⁺.

Example 27 Procedure ZZ

Synthesis of Intermediate 27

Step 1: In a 350-mL resealable vessel the(S)-2′-bromo-7′-iodo-5H-spiro[oxazole-4,9′-xanthen]-2-amine (11.5 g,25.2 mmol) was taken up in AcOH (125 mL) and water (31 mL). The vesselwas sealed and heated in a 140° C. oil bath for 14 h. The reaction wasconcentrated to remove most of the AcOH. The reaction residue wasneutralized with 1M aqueous Na₂CO₃ (250 mL). The residue was filteredthrough Celite, rinsing with 5% MeOH-DCM (800 mL). The filtrate'sorganic layer was separated, dried over sodium sulfate and concentrated.The crude (S)-2′-bromo-7′-iodospiro[oxazolidine-4,9′-xanthen]-2-one wasused in the next step without further purification.Step 2: In a 350-mL resealable vessel, the(S)-2′-bromo-7′-iodospiro[oxazolidine-4,9′-xanthen]-2-one (11 g, 24.02mmol) was dissolved in 1:1 MeOH-dioxane (160 mL). Aqueous KOH (5 M, 48.0mL, 240 mmol) was added. The vessel was sealed and placed in a 105° C.oil bath. After 24 h, the reaction was concentrated to remove the MeOHand most of the dioxane. The residue was diluted with water (200 mL) andthe aqueous phase was extracted with 5% MeOH-DCM (4×200 mL). Theorganics were combined, washed with dilute brine (35 mL), dried oversodium sulfate and concentrated. The residue was purified bychromatography (1.5% MeOH/DCM) to afford(S)-(9-amino-2-bromo-7-iodo-9H-xanthen-9-yl)methanol (3.84 g, 8.89mmol).Step 3: The (S)-(9-amino-2-bromo-7-iodo-9H-xanthen-9-yl)methanol (3.84g, 8.89 mmol) was dissolved in THF (200 mL). The solution was cooled to0° C., and TEA (1.425 mL, 10.22 mmol) and 2-chloroacetyl chloride (0.707mL, 9.07 mmol) were added. The reaction was allowed to warm naturally toRT. After 14 h, the reaction was concentrated. The residue was taken upin aqueous 1 M Na₂CO₃ (50 mL) and the aqueous phase was extracted with7.5% MeOH-DCM (3×133 mL). The organics were combined, washed withaqueous 1 M Na₂CO₃ (30 mL), dried over sodium sulfate and concentrated.The residue was dissolved in THF (100 mL) and aqueous 1 M Na₂CO₃ (15 mL)was added. The reaction was concentrated. The residue was taken up in 5%MeOH-dcm (400 mL) and the organic phase was washed with dilute brine (40mL), dried over sodium sulfate and concentrated to afford crude(S)—N-(2-bromo-9-(hydroxymethyl)-7-iodo-9H-xanthen-9-yl)-2-chloroacetamide,which was used in the next step without further purification.Step 4: In a 500-mL flask(S)—N-(2-bromo-9-(hydroxymethyl)-7-iodo-9H-xanthen-9-yl)-2-chloroacetamide(4.52 g, 8.89 mmol) was dissolved in t-amyl alcohol (125 mL). Potassiumt-butoxide (2.244 g, 20.00 mmol) was added. After 14 h, the reaction wasconcentrated. The residue was taken up in dilute aqueous NH₄Cl (50 mL)and the aqueous phase was extracted with 5% MeOH-DCM (3×133 mL). Theorganics were combined, washed with dilute brine (25 mL), dried oversodium sulfate and concentrated. The material was purified throughsilica gel (500 mL) using 30% EtOAc-hexane to afford(S)-2′-bromo-7′-iodospiro[morpholine-3,9′-xanthen]-5-one (1.92 g, 4.07mmol).Step 5: In a 250-mL flask, the(S)-2′-bromo-7′-iodospiro[morpholine-3,9′-xanthen]-5-one (1.483 g, 3.14mmol) was suspended in toluene (30 mL). Lawesson's reagent (0.794 g,1.963 mmol) was added. An air-cooled condenser was affixed, and thereaction vessel was placed in a 90° C. oil bath After 7 h, the reactionwas concentrated. Without working it up, the residue was purified bychromatography (15% EtOAc/hexanes) to afford(S)-2′-bromo-7′-iodospiro[morpholine-3,9′-xanthene]-5-thione (1.25 g,2.56 mmol).Step 6: In a 350-mL resealable vessel, the(S)-2′-bromo-7′-iodospiro[morpholine-3,9′-xanthene]-5-thione (1.25 g,2.56 mmol) was dissolved in a dioxane solution of ammonia (0.5 M, 61.5mL, 30.7 mmol). After the solid had dissolved, mercury(II) chloride(1.043 g, 3.84 mmol) was added. The vessel was sealed and placed in a55° C. oil bath overnight. The reaction was filtered through Celite,rinsing with DCM (50 mL). The mixture was concentrated to remove theDCM, and Boc₂O (0.84 g, 3.84 mmol) and Et₃N (0.535 mL, 3.84 mmol) wereadded. After 1.5 h, the mixture was concentrated, and the residue waspurified by chromatography (15% EtOAc/hexanes) to afford impure(S)-tert-butyl2′-bromo-7′-iodo-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamate.Step 7: In a 150-mL resealable vessel, the (S)-tert-butyl2′-bromo-7′-iodo-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamate(1.475 g, 2.58 mmol) was dissolved in dcm (10 mL), and2,2,2-trifluoroacetic acid (1.989 mL, 25.8 mmol) was added. The vesselwas sealed and placed in a 50° C. oil bath. After 2 h, the reaction wasconcentrated and the mixture was neutralized with 0.5 M aqueous Na₂CO₃(15 mL) and the aqueous phase was extracted with 5% MeOH-dcm (3×33 mL).The organics were combined, washed with dilute brine (10 mL), dried oversodium sulfate and concentrated. The residue was purified bychromatography (5.5% MeOH/DCM) to afford(S)-2′-bromo-7′-iodo-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(151 mg, 0.321 mmol). MS (m/z) 471/473 (M+H)⁺.

Example 28

Synthesis of Intermediates 28 and 29

Step 1: The same reagents and reaction conditions in Steps 1-4 ofProcedure ZZ were used to convert(S)-2′-bromo-4′-fluoro-7′-methoxy-5H-spiro[oxazole-4,9′-xanthen]-2-amineto(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthen]-5-one.MS (m/z) 394/396 (M+H)⁺.Step 2: The same reagents and reaction conditions in Steps 5-7 ofProcedure ZZ were used to convert(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthen]-5-one to(S)-2′-bromo-4′-fluoro-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine.MS (m/z) 393/395 (M+H)⁺.

Example 29

Synthesis of Intermediates 30 and 31

Step 1: The same reagents and conditions in Steps 1-4 in Procedure ZZwere used to convert(S)-2′-bromo-7′-methoxy-5H-spiro[oxazole-4,9′-xanthen]-2-amine to(S)-2′-bromo-7′-methoxyspiro[morpholine-3,9′-xanthen]-5-one.

Step 2: The same reagents and conditions in Steps 5-7 of Procedure ZZwere used to convert(S)-2′-bromo-7′-methoxyspiro[morpholine-3,9′-xanthen]-5-one to(S)-2′-bromo-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine.MS (m/z) 375/377 (M+H)⁺.

Example 30 Method A1

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-(2-fluoropyridin-4-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial was charged with(S)-7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(546.36 mg, 1.435 mmol), 2-fluoropyridin-3-ylboronic acid (303 mg, 2.153mmol), potassium phosphate (914 mg, 4.31 mmol), andbis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II)(50.8 mg, 0.072 mmol). The vial was flushed with Argon, and then dioxane(5383 μL) and water (1794 μL) were added. The vial was sealed and heatedin a Biotage Initiator microwave reactor for 20 min at 90° C. Thereaction mixture was diluted with water and extracted with EtOAc (3×).The combined organic extracts were dried over sodium sulfate,concentrated under reduced pressure. The residue was purified bychromatography (0-100% EtOAc/Hexane) to give(S)-3-chloro-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(510.4 mg, 95% purity) as an off-white solid.Step 2: A vial was charged with(S)-3-chloro-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(104.72 mg, 0.264 mmol), 2-fluoropyridin-4-ylboronic acid (74.4 mg,0.528 mmol), potassium phosphate (168 mg, 0.792 mmol), andbis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II)(9.34 mg, 0.013 mmol). The vial was flushed with Argon, then dioxane(990 μL) and water (330 μL) were added. The vial was sealed and heatedin a Biotage Initiator microwave reactor for 30 min at 110° C. Themixture was extracted with EtOAc (3×), and the combined organic extractswere concentrated under reduced pressure. The residue was purified bychromatography (30-60% of a 90:10:1 mixture of DCM/MeOH/NH₄OH in DCM) togive(S)-7-(2-fluoropyridin-3-yl)-3-(2-fluoropyridin-4-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(90 mg) as a light-yellow solid. MS m/z=458.2 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ=8.72 (s, 1 H), 8.38 (d, J=5.3 Hz, 1 H), 8.26(td, J=1.4, 3.2 Hz, 1 H), 8.11 (ddd, J=2.0, 7.7, 10.1 Hz, 1 H),8.00-7.87 (m, 2 H), 7.75 (s, 1 H), 7.64 (td, J=1.6, 8.7 Hz, 1 H),7.57-7.47 (m, 2 H), 7.41 (d, J=8.4 Hz, 1 H), 6.29 (br. s., 2 H),4.45-4.20 (m, 2 H), 3.68-3.47 (m, 2 H).

Example 31 Method A2

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial charged with 2-fluoropyridin-3-ylboronic acid (0.078 g,0.556 mmol), PdCl₂(dppf)-CH₂Cl₂ (0.022 g, 0.026 mmol),(S)-3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine,and potassium carbonate (0.293 g, 2.118 mmol) was treated with 2.5 mLdioxane and 1 mL water. The vial was then flushed with argon, sealed andheated to 80° C. for 1 hr. The reaction mixture was diluted with EtOAc,dried over MgSO₄ and concentrated under reduced pressure to yield3-bromo-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.309 g, 0.700 mmol, 132% yield). This material was used withoutfurther purification.Step 2: A vial charged with Pd(PPh₃)₄ (0.079 g, 0.068 mmol), copper(I)iodide (0.013 g, 0.068 mmol), 18-crown-6 (0.045 g, 0.170 mmol),potassium fluoride (0.118 g, 2.040 mmol),trimethyl((3-methyloxetan-3-yl)ethynyl)silane (0.229 g, 1.360 mmol), and3-bromo-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.300 g, 0.680 mmol) was treated with 3 mL DMF, sealed under argon, andheated to 110° C. overnight. The reaction mixture was then poured ontowater (10 mL) and extracted with EtOAc (3×10 mL). The combined organiclayers were dried over MgSO₄ and concentrated under reduced pressure.Purification of the crude residue by column chromatography [0-50% (9:1DCM/MeOH)/DCM] gave(S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.079 g, 0.094 mmol, 25.46% yield).

Example 32 Method A3

Synthesis of(S)-3-(4,4-difluoropiperidin-1-yl)-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial was charged with(S)-7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(546.36 mg, 1.435 mmol), 2-fluoropyridin-3-ylboronic acid (303 mg, 2.153mmol), potassium phosphate (914 mg, 4.31 mmol), andbis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II)(50.8 mg, 0.072 mmol). The vial was flushed with Ar (g), then dioxane(5383 μL) and water (1794 μL) were added in sequence. The vial wassealed and heated in a Biotage Initiator microwave reactor for 20 min at90° C. The mixture was diluted with water and extracted with EtOAc (3×).The combined organic extracts were dried over sodium sulfate, filtered,and concentrated. The residue was purified by chromatography (0-100%EtOAc/Hexane) to give(S)-3-chloro-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(510.4 mg, 95% purity) as an off-white solid.Step 2: A vial was charged with(S)-3-chloro-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(60.4 mg, 0.152 mmol), 4,4-difluoropiperidine hydrochloride (27.7 mg,0.228 mmol), and X-Phos Precatalyst (25.2 mg, 0.030 mmol). The vial wasflushed with Ar (g), then capped with a septum. Lithiumbis(trimethylsilyl)amide (1M in THF) (533 μL, 0.533 mmol) was added inone portion at rt. After 30 min. the reaction mixture was diluted withsaturated aq. ammonium chloride solution and extracted with EtOAc (3×).The combined organic extracts were dried over sodium sulfate, filtered,and concentrated. The residue was purified by chromatography (30% of a90:10:1 mixture of DCM/MeOH/NH₄OH in DCM) to give 43 mg of an oil. Theoil was further purified by reverse-phase HPLC (15-90% CH₃CN/H₂O with0.1% TFA). Fractions containing product were combined and washed withsaturated aq. sodium bicarbonate solution. The mixture was extractedwith DCM (3×). The combined organic extracts were dried over sodiumsulfate, and concentrated to give(S)-3-(4,4-difluoropiperidin-1-yl)-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineas a white solid. MS m/z=482.1 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ=8.23 (td, J=1.5, 4.8 Hz, 1 H), 8.14 (d,J=0.4 Hz, 1 H), 8.07 (ddd, J=1.9, 7.5, 10.3 Hz, 1 H), 7.59-7.54 (m, 1H), 7.51-7.43 (m, 2 H), 7.29 (d, J=8.5 Hz, 1 H), 6.72 (s, 1 H), 6.14(br. s., 2 H), 4.27-4.14 (m, 2 H), 3.60 (t, J=5.7 Hz, 4 H), 3.47-3.38(m, 2 H), 2.09-1.96 (m, 4 H).

Example 33 Method A4

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial was charged with 2,2-dimethylpropan-1-ol (100 mg, 1.130mmol) and DMSO (1130 μL). Sodium hydride (60% in mineral oil; 45.2 mg,1.130 mmol) was added. The vial was placed in a 100° C. oil bath for 5min. the reaction mixture was cooled to room temperature and(S)-7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(86 mg, 0.226 mmol) was added in one portion. The vial was sealed andheated in a 100° C. oil bath for 2 h. The mixture was cooled to roomtemperature, then diluted with water and EtOAc. Brine was added, and thelayers were separated. The aq. layer was extracted with EtOAc (2×). Thecombined organic extracts were dried over sodium sulfate, andconcentrated. The residue was purified by chromatography (0-100%EtOAc/Hexane) to give(S)-7-bromo-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineas a light-yellow solid.Step 2: A vial was charged with(S)-7-bromo-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(51 mg, 0.118 mmol), 2-fluoropyridin-3-ylboronic acid (33.2 mg, 0.236mmol), potassium phosphate (75 mg, 0.354 mmol), andbis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II)(4.18 mg, 5.90 μmol). The vial was flushed with Ar (g), then dioxane(442 μL) and water (147 μL) were added in sequence. The vial was sealedand heated in a Biotage Initiator microwave reactor for 20 min at 90° C.The mixture was extracted with EtOAc (3×), and the combined organicextracts were concentrated. The residue was purified by chromatography(30% of a 90:10:1 mixture of DCM/MeOH/NH₄OH in DCM) to give(S)-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(46.23 mg) as an off-white solid. MS m/z=449.2 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ=8.23 (td, J=1.5, 4.8 Hz, 1 H), 8.14-8.01 (m,2 H), 7.65-7.54 (m, 1 H), 7.53-7.43 (m, 2 H), 7.31 (d, J=8.4 Hz, 1 H),6.64 (s, 1 H), 6.16 (br. s., 2 H), 4.33-4.13 (m, 2 H), 3.99-3.84 (m, 2H), 3.53-3.36 (m, 2 H), 1.02 (br. s., 9 H).

Example 34 Method A5

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-(tetrahydro-2H-pyran-4-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial was charged with(S)-7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(546.36 mg, 1.435 mmol), 2-fluoropyridin-3-ylboronic acid (303 mg, 2.153mmol), potassium phosphate (914 mg, 4.31 mmol), andbis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II)(50.8 mg, 0.072 mmol). The vial was flushed with Ar (g), then dioxane(5383 μL) and water (1794 μL) were added in sequence. The vial wassealed and heated in a Biotage Initiator microwave reactor for 20 min at90° C. The mixture was diluted with water and extracted with EtOAc (3×).The combined organic extracts were dried over sodium sulfate, filtered,and concentrated. The residue was purified by chromatography on silicagel (0-100% EtOAc/Hexane) to give(S)-3-chloro-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(510.4 mg) as an off-white solid containing ca. 5% of the bis-coupledbyproduct.Step 2: A vial was charged with and(S)-3-chloro-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(79.05 mg, 0.199 mmol), 3,6-dihydro-2H-pyran-4-ylboronic acid (76 mg,0.598 mmol),bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II)(7.05 mg, 9.96 μmol), and potassium phosphate (127 mg, 0.598 mmol).Dioxane (747 μL) and water (249 μL) were added, and the vial was sealedand heated in a Biotage Initiator microwave reactor for 30 min at 110°C. The mixture was extracted with EtOAc (3×), and the combined organicextracts were concentrated. The residue was purified by chromatographyon silica gel (0-10% MeOH/DCM) to give(S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(82.18 mg) as a yellow solid.Step 3: A 10-mL round-bottom flask was charged with(S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(82.8 mg, 0.186 mmol) and MeOH (2.5 mL). The flask was flushed with Ar(g), then 10% Pd/C (ca. 35 mg) was added. H₂ (g) was bubbled through themixture for 1 min, then the reaction mixture was stirred under an H₂ (g)atmosphere overnight. An additional portion of 10% Pd/C (21 mg) wasadded, and H₂ (g) was bubbled through for 1 min. After stirringovernight, the mixture was filtered through celite, and the filter cakewas washed with methanol. The filtrate was concentrated, and the residuewas purified by chromatography (10-40% of a 90:10:1 mixture ofDCM/MeOH/NH₄OH in DCM) to give(S)-7-(2-fluoropyridin-3-yl)-3-(tetrahydro-2H-pyran-4-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(72 mg) as an off-white solid. [M+H]+=447.2.

Example 35A Method A6

Synthesis of(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-morpholino-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Step 1: A 250 ml RBF was charged with7′-bromo-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(2.73 g, 6.94 mmol),bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)(0.492 g, 0.694 mmol) and 2-fluoropyridin-3-ylboronic acid (1.467 g,10.41 mmol). Dioxane (40 mL) and potassium carbonate (1M in water; 20.83mL, 20.83 mmol) were added and the mixture was flushed with argon andheated at 85° C. for 30 minutes. The mixture was cooled to RT, dilutedwith EtOAc and the organic layer was separated and concentrated in vacuoto give a yellow residue. After triturating with 10 ml of ethanol thesolid was filtered off, washed with EtOH (2×1 ml) and dried on airovernight to afford4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(2.11 g, 5.15 mmol).Step 2: To a suspension of4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(1.668 g, 4.07 mmol) in DCM (12 ml) was added boron tribromide (0.963mL, 10.19 mmol) at 0° C. The reaction mixture was stirred for 45 hrs at0° C. The reaction mixture was allowed to warm to RT and was stirred foradditional 2 hrs. The reaction mixture was cooled to 0° C. and quenchedby addition of saturated aqueous NaHCO₃ solution (˜10 mL). The solventwas removed in vacuo, the mixture was diluted with water and filtered.The solid was washed with water and dried under reduced pressure toafford5-amino-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-2′-ol(1.53 g, 3.87 mmol, 95% yield).Step 3: To a suspension of5-amino-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-2′-ol(1.01 g, 2.55 mmol) in DCM (12.77 mL) were added TEA (1.424 mL, 10.22mmol) andN-(5-chloropyridin-2-yl)-1,1,1-trifluoro-N-(trifluoromethylsulfonyl)methanesulfonamide(1.103 g, 2.81 mmol). After stirring for 2 hours the reaction mixturewas washed 3× with 2N NaOH solution followed by brine. The solution wasthen concentrated. The yellow residue was diluted with DCM (5 ml) andthe white precipitate was filtered, washed with DCM and dried under astream of air to afford 355 mg (26%) of pure product. The filtrate waspurified by chromatography (5-40% DCM/MeOH/NH₄OH in DCM) to afford5-amino-5′-fluoro-2′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (880 mg, 1.668 mmol, 65.3% yield) as a whitefoam. Total isolated5-amino-5′-fluoro-2′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (1235 mg, 2.342 mmol, 92% yield).Step 4: A re-sealable vial was charged with5-amino-5′-fluoro-2′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (200 mg, 0.379 mmol),chloro(2-dicyclohexylphosphino-2′,6′-di-isopropoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)1 (27.6 mg, 0.038 mmol) and 0.5 ml of THF. The mixture was stirred at RTuntil all solids were dissolved. Morpholine (66.1 μL, 0.758 mmol) andLiHMDS (1M in THF) (1138 μL, 1.138 mmol) were added and the vial wassealed and stirred at RT for 20 minutes. The reaction was quenched byaddition of water (1 ml) and diluted with EtOAc (2 ml). The organiclayer was separated, and the aqueous layer was extracted with EtOAc (2×2ml). The combined organic fractions were concentrated and purified bychromatography (10-80% DCM/MeOH/NH₄OH in DCM) to provide racemic4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-morpholino-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(97 mg, 0.209 mmol, 55.1% yield).Step 5: The final compound(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-morpholino-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-aminewas obtained from racemic4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-morpholino-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amineusing similar chiral separation conditions as described herein forintermediate 10.

Example 36A Method A7

Synthesis of(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-(2-fluoropyridin-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Step 1: A 250 ml RBF was charged with7′-bromo-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(2.73 g, 6.94 mmol),bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)(0.492 g, 0.694 mmol) and 2-fluoropyridin-3-ylboronic acid (1.467 g,10.41 mmol). Dioxane (40 mL) and potassium carbonate (1M solution)(20.83 mL, 20.83 mmol) were added and the mixture was flushed with argonand heated at 85° C. for 30 minutes. The mixture was cooled to RT,diluted with EtOAc and the organic layer was separated and concentratedin vacuo to give a yellow semisolid. After trituration with 10 ml ofEtOH the solid was filtered, washed with EtOH (2×1 ml) and dried on airovernight to afford4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(2.11 g, 5.15 mmol).Step 2: To a suspension of4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(1.668 g, 4.07 mmol) in DCM (12 ml) was added boron tribromide (0.963mL, 10.19 mmol). Stirring was continued for 45 hrs at 0° C. at whichpoint the mixture was removed from the bath and stirred for 2 hrs at RT.The reaction mixture was recooled to 0° C. and quenched by carefuladdition of saturated aqueous NaHCO₃ solution (˜10 mL). The mixturebecame colorless with a white precipitate. The solvent was removed invacuo, the mixture was diluted with water and filtered. The solid waswashed with water and dried on air for 2 hrs, then for 2 hrs in highvacuum at RT to afford5-amino-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-2′-ol(1.53 g, 3.87 mmol, 95% yield).Step 3: To a suspension of5-amino-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-2′-ol(1.01 g, 2.55 mmol) in DCM (12.77 mL) were added TEA (1.424 mL, 10.22mmol) andN-(5-chloropyridin-2-yl)-1,1,1-trifluoro-N-(trifluoromethylsulfonyl)methanesulfonamide(1.103 g, 2.81 mmol). After stirring for 2 hours the reaction mixturewas washed 3× with 2N NaOH solution followed by brine. The solution wasthen concentrated. The yellow residue was diluted with DCM (5 ml) andthe white precipitate was filtered, washed with DCM and dried under astream of air to afford 355 mg (26%) of pure product. The filtrate waspurified by chromatography (5-40% DCM/MeOH/NH4OH in DCM) to afford5-amino-5′-fluoro-2′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (880 mg, 1.668 mmol, 65.3% yield) as a whitefoam. Total isolated5-amino-5′-fluoro-2′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (1235 mg, 2.342 mmol, 92% yield).Step 4: A 10 ml resealable tube was charged with5-amino-5′-fluoro-2′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (385 mg, 0.730 mmol),2-fluoropyridin-4-ylboronic acid (165 mg, 1.168 mmol), PdCl₂(dppf)-DCMadduct (59.6 mg, 0.073 mmol), dioxane (3650 μL) and potassium carbonate(1M solution) (2190 μL, 2.190 mmol). The mixture was flushed with argon,sealed and heated at 85° C. for 1 hr. The mixture was diluted withEtOAc, organic layer was filtered through Celite and concentrated. Thebrown residue was purified by chromatography (10-80% DCM/MeOH/NH₄OH inDCM) to afford4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-(2-fluoropyridin-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(294 mg, 85% yield) as off-white solid.Step 5: The final compound(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-(2-fluoropyridin-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(36A) were obtained form racemic4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-(2-fluoropyridin-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amineusing similar chiral separation conditions as described herein forintermediate 10.

MS m/z=475.0 [M+H]⁺. Calculated for C₂₆H₁₇F₃N₄O₂: 474.13

¹H NMR (400 MHz, DMSO-d₆) δ ppm 4.24 (d, J=15.7 Hz, 1 H), 4.30 (d,J=15.7 Hz, 1 H), 6.15 (br. s., 1 H), 7.41 (d, J=8.5 Hz, 1 H), 7.46-7.56(m, 4 H), 7.59-7.69 (m, 2 H), 7.90 (dd, J=11.7, 2.0 Hz, 1 H), 8.09 (ddd,J=9.9, 7.8, 1.6 Hz, 1 H), 8.25 (d, J=4.6 Hz, 1 H), 8.33 (d, J=5.2 Hz, 1H)

Example 37A Method A8

Synthesis of(S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(37A)

Step 1: A 250 ml RB flask was charged with7′-bromo-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(2.73 g, 6.94 mmol),bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)(0.492 g, 0.694 mmol) and 2-fluoropyridin-3-ylboronic acid (1.467 g,10.41 mmol). Dioxane (40 mL) and potassium carbonate (1M solution)(20.83 mL, 20.83 mmol) were added and the mixture was flushed with argonand heated at 85° C. for 30 minutes. The mixture was cooled to RT,diluted with EtOAc and the organic layer was separated and concentratedin vacuo to give a yellow semisolid. After trituration with 10 ml ofEtOH the solid was filtered, washed with EtOH (2×1 ml) and dried on airovernight to afford4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(2.11 g, 5.15 mmol).Step 2: To a suspension of4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(1.668 g, 4.07 mmol) in DCM (12 ml) was added boron tribromide (0.963mL, 10.19 mmol). Stirring was continued for 45 hrs at 0° C. at whichpoint the mixture was removed from the bath and stirred for 2 hrs at RT.The reaction mixture was recooled to 0° C. and quenched by carefuladdition of saturated aqueous NaHCO₃ solution (˜10 mL). The mixturebecame colorless with a white precipitate. The solvent was removed invacuo, the mixture was diluted with water and filtered. The solid waswashed with water and dried on air for 2 hrs, then for 2 hrs in highvacuum at RT to afford5-amino-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-2′-ol(1.53 g, 3.87 mmol, 95% yield).Step 3: To a solution of5-amino-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-2′-ol(200 mg, 0.506 mmol) in DMF (2529 μL) cesium carbonate (330 mg, 1.012mmol), KI (25.2 mg, 0.152 mmol) and 2-fluoro-2-methylpropyltrifluoromethanesulfonate (125 mg, 0.556 mmol) were added sequentiallyand the resulting mixture was stirred overnight at RT. The mixture wasdiluted with 5 ml of water and stirred for 5 minutes. The solvents weredecanted from a precipitated gummy solid. 10 ml of water was added andthe mixture was stirred for 1 hr at RT at which point a fine precipitateformed. The solids were filtered, washed with water and dried on air for3 hr, then overnight in vacuo to afford racemic4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(175 mg, 73% yield).Step 4: The final compound(S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(37A) was obtained form racemic4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amineusing similar chiral separation conditions as described herein forintermediate 10.

MS m/z=470.0 [M+H]⁺. Calculated for C₂₅H₂₂F₃N₃O₃: 469.13

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40 (s, 3 H), 1.45 (s, 3 H), 3.40-3.45(m, 2 H), 3.90-4.09 (m, 2 H), 4.14-4.25 (m, 2 H), 6.01-6.18 (m, 2 H),6.66 (dd, J=2.9, 1.6 Hz, 1 H), 7.04 (dd, J=12.5, 2.9 Hz, 1 H), 7.44-7.51(m, 2 H), 7.57 (ddd, J=8.5, 2.2, 1.6 Hz, 1 H), 8.07 (ddd, J=10.4, 7.5,1.9 Hz, 1 H), 8.20-8.27 (m, 1 H)

Example 38 Method A9

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-methoxy-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A microwave vial was charged with(S)-7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(1.2557 g, 3.30 mmol), 2,2-dimethylpropan-1-ol (0.914 g, 10.37 mmol),18-crown-6 (0.087 g, 0.330 mmol), and potassium hydroxide (0.925 g,16.50 mmol) (freshly ground). The vial was flushed with Ar (g), thendioxane (6.60 mL) was added. The vial was sealed and placed in a 120° C.oil bath and stirred for 24 hours. The reaction mixture was diluted withwater and a small amount of brine. The aq. mixture was then extractedwith EtOAc (3×). The combined organic extracts were dried over sodiumsulfate, filtered, and concentrated. The residue was purified bychromatography (0-100% EtOAc/hexanes) to afford 0.657 g of(S)-7-bromo-3-methoxy-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineas a yellow solid.Step 2: A microwave vial was charged with(S)-7-bromo-3-methoxy-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.065 g, 0.173 mmol), 2-fluoropyridin-3-ylboronic acid (0.049 g, 0.346mmol), potassium phosphate (0.110 g, 0.518 mmol), andbis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)(6.12 mg, 8.64 μmol). The vial was flushed with Ar (g), dioxane (0.648mL) and water (0.216 mL) were added in sequence. The vial was sealed andheated in a Biotage Initiator microwave reactor for 30 min at 100° C.The reaction was diluted with ethyl acetate and washed with water. Theaqueous layer was extracted with EtOAc, and the combined organic layerswere washed with brine, dried with sodium sulfate, filtered, andconcentrated. The material was purified via column chromatography (0-10%MeOH/EtOAc) to afford 65 mg of(S)-7-(2-fluoropyridin-3-yl)-3-methoxy-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineas a light yellow solid.

Example 39 Method A10

Synthesis of(S)-5-amino-4′-fluoro-2′-(2-fluoropyridin-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol

Step 1: In a 500-mL flask,(S)-2′-bromo-4′-fluoro-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(0.676 g, 1.719 mmol) was suspended in DCM (50 mL). The suspension wascooled to 0° C., and boron tribromide (1.0 M in DCM; 5.16 mL, 5.16 mmol)was added. After 1.5 h, excess boron tribromide was quenched withsaturated aqueous NH₄Cl (18 mL) and aqueous NH₄OH (2 mL). The aqueousphase was separated and extracted further with 5% MeOH-DCM (3×50 mL).The organics were combined, washed with brine (15 mL), dried over sodiumsulfate and concentrated to afford 604 mg of(S)-5-amino-2′-bromo-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-olwhich was used in the next step without further purification.Step 2: A flask was charged with(S)-5-amino-2′-bromo-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(10 mg, 0.026 mmol) and dioxane (0.6 mL). Triethylamine (10.5 μL, 0.076mmol) and di-tert-butyl dicarbonate (0.017 g, 0.076 mmol) were added,and the solution was stirred at RT for 14 h. The material was taken upin 1 M aqueous HCl (10 mL) and the aqueous phase was extracted with DCM(3×20 mL). The organics were combined, dried over sodium sulfate andconcentrated. The material was purified by chromatography (30% ethylacetate/hexane) to afford 12 mg of (S)-tert-butyl2′-bromo-4′-fluoro-7′-hydroxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamate.Step 3: A microwave vial was charged with potassium acetate (6.14 mg,0.063 mmol),bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)(1.77 mg, 2.504 μmol), and 2-fluoropyridin-4-ylboronic acid (4.23 mg,0.030 mmol). The (S)-tert-butyl2′-bromo-4′-fluoro-7′-hydroxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamate(0.012 g, 0.025 mmol) was added as a solution in 1:1acetonitrile/dioxane (1 mL). Water (0.1 mL) was added. Argon was blownthrough the vessel, which was then sealed and heated in a 100° C. oilbath for 6 h. The mixture was cooled, diluted with brine (10 mL), andthe aqueous layer was extracted with 10% MeOH-DCM (3×20 mL). Theorganics were combined, washed with dilute brine (5 mL), dried oversodium sulfate and concentrated. The residue was purified by preparativeTLC (20% MeOH in DCM) to afford 3.8 mg of(S)-5-amino-4′-fluoro-2′-(2-fluoropyridin-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol.

Example 40 Method A11

Synthesis of(S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Step 1: In a 250-mL flask, Lawesson's reagent (0.577 g, 1.427 mmol) and(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthen]-5-one(0.978 g, 2.481 mmol) were suspended in toluene (25 mL). An air-cooledcondenser was attached, and the flask was heated in a 90° C. oil bathfor 3 h. The mixture was then cooled and concentrated to give(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthene]-5-thionewhich was used in the next step without further purification.Step 2: In a 150-mL resealable vessel, the crude(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthene]-5-thione(1.0 g, 2.437 mmol) was dissolved in a dioxane solution of ammonia (0.5M, 58.5 mL, 29.2 mmol). Mercury (II) chloride (0.993 g, 3.66 mmol) wasadded, and the vessel was sealed and heated in a 55° C. oil bathovernight. The mixture was then cooled and concentrated. The residue wasfiltered through Celite, rinsing with 10% MeOH-DCM (400 mL). Thefiltrate was concentrated, and the residue was purified through silicagel (150 mL) using 7.5% MeOH-DCM to afford 131 mg of(S)-2′-bromo-4′-fluoro-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amineStep 3: In a 100-mL flask,(S)-2′-bromo-4′-fluoro-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(0.233 g, 0.593 mmol) was dissolved in DCM (7.5 mL). The solution wascooled to 0° C., and a DCM solution of boron tribromide (1 M, 1.78 mL,1.78 mmol) was added. The mixture was stirred at 0° C. for 1 h, then wasquenched with saturated aqueous NH₄Cl (18 mL) and aqueous NH₄OH (2 mL).The aqueous phase was extracted 5% MeOH-DCM (3×40 mL). The organics werecombined, washed with dilute brine (15 mL), dried over sodium sulfateand concentrated to afford 187 mg of(S)-5-amino-2′-bromo-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol.Step 4: In a microwave vial, potassium phosphate (0.307 g, 1.448 mmol),PdCl₂(AmPhos)₂ (0.026 g, 0.036 mmol),(S)-5-amino-2′-bromo-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.183 g, 0.483 mmol), and2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(0.147 g, 0.700 mmol) were suspended in dioxane (4 mL) and water (1.6mL). Argon was blown through the vessel, which was sealed and heated bymicrowave at 120° C. for 30 min. The reaction was concentrated, and theresidue was neutralized with 1/3 saturated aqueous NH₄Cl (15 mL) and theaqueous phase was extracted with 5% MeOH-DCM (3×25 mL). The organicswere combined, washed with dilute brine (7 mL), and concentrated toafford(S)-5-amino-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-olwhich was used in the next step without further purification.Step 5: In a 100-mL flask, the crude(S)-5-amino-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.185 g, 0.484 mmol) was suspended in THF (12 mL). Boc₂O (0.132 g,0.605 mmol) was added, followed by TEA (0.088 mL, 0.629 mmol). Themixture was stirred at rt overnight. The mixture was concentrated toafford (S)-tert-butyl2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′-hydroxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamatewhich was used in the next step without further purification.Step 6: In a 100-mL flask, the crude (S)-tert-butyl2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′-hydroxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamate(0.233 g, 0.483 mmol) was dissolved in DCM (10 mL). The solution wascooled to 0° C., and TEA (0.157 mL, 1.14 mmol) was added, followed by1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide(0.362 g, 1.01 mmol). After 2 h, the reaction was quenched with aqueoussodium bicarbonate (5 mL). The mixture was diluted with water (10 mL)and the aqueous phase was extracted with 3% MeOH-DCM (3×20 mL). Theorganics were combined, washed with dilute brine (7 mL), dried oversodium sulfate and concentrated. The residue was purified through silicagel (50 mL) using 30% EtOAc in hexane to afford 166 mg of(S)-5-(tert-butoxycarbonylamino)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate.Step 7: In a microwave vial, 2-fluoropyridin-3-ylboronic acid (0.048 g,0.338 mmol),(S)-5-(tert-butoxycarbonylamino)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (0.166 g, 0.270 mmol), and Pd(PPh₃)₄ (0.031 g,0.027 mmol) were suspended in DMF (3 mL). Aqueous sodium carbonate (1 M,0.810 mL, 0.810 mmol) was added. Argon was blown through the vessel,which was sealed and heated in an 85° C. oil bath for 2.5 h. Thereaction was cooled and concentrated. The residue was taken up in water(15 mL) and the aqueous phase was extracted with 3% MeOH-DCM (3×25 mL).The organics were combined, washed with dilute brine (7 mL), dried oversodium sulfate and concentrated. The residue was transferred to amicrowave vial in DCM (3 mL), and TFA (0.520 mL, 6.75 mmol) was added.The vial was sealed and heated in a 65° C. oil bath for 1.5 h. Themixture was cooled and concentrated, and the residue was neutralizedwith 0.5 M aqueous Na₂CO₃ (15 mL) and the aqueous phase was extractedwith 5% MeOH-DCM (3×25 mL). The organics were combined, washed withdilute brine (7 mL), dried over sodium sulfate and concentrated. Theresidue was purified through silica gel (50 mL) using 8% MeOH-DCM toafford 72 mg of(S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine.m/z=462.0[M+H]⁺.

¹H NMR (400 MHz, CDCl₃) δ ppm; 8.18 (d, 1 H, J=5.0 Hz), 7.89 (m, 1 H),7.52 (m, 2 H), 7.35 (d, 1 H, J=8.4 Hz), 7.28 (m, 1 H), 7.16 (dd, 1 H,J=11.7, 2.0 Hz), 7.10 (s, 1 H), 6.10 (s, 1 H), 4.33 (m, 4 H), 3.93 (t, 2H, J=5.5 Hz), 3.59 (d, 2 H, J=5.7 Hz), 2.50 (m, 2 H).

Example 41 Method A12

Synthesis of(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-((3-methyloxetan-3-yl)ethynyl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Step 1: In a 1-L flask, the(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthen]-5-one(3.16 g, 8.02 mmol) was suspended in toluene (75 mL). Lawesson's reagent(1.864 g, 4.61 mmol) was added. An air-cooled condenser was affixed, andthe mixture was heated in a 90° C. oil bath for 2 h. The mixture wascooled and concentrated to afford crude(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthene]-5-thionewhich was used in the next step without further purification.Step 2: In a 350-mL resealable vessel, the(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthene]-5-thione(3.0 g, 7.31 mmol) was dissolved in a dioxane solution of ammonia (0.5M, 175 mL, 88 mmol). Mercury (II) chloride (2.98 g, 10.97 mmol) wasadded, and the vessel was sealed and heated in a 55° C. oil bathovernight. The reaction was cooled and then filtered through Celite,rinsing with 10% MeOH-DCM. The filtrate was concentrated, and theresidue was transferred to a resealable vessel with 50 mL of dioxane. Asolution of ammonia in dioxane (0.5 M, 100 mL, 50 mmol) was added,followed by mercury (II) chloride (2.0 g, 7.36 mmol). The vessel wassealed and heated in a 60° C. oil bath for 14 h. The mixture was cooledand filtered through Celite, rinsing with 10% MeOH-DCM. The filtrate wasconcentrated, and the residue was purified through silica gel (300 mL)using 7.5% MeOH-DCM to afford 1.33 g of(S)-2′-bromo-4′-fluoro-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amineStep 3: In a 50-mL flask, the(S)-2′-bromo-4′-fluoro-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(0.340 g, 0.864 mmol) was taken up in DCM (15 mL). The suspension wascooled to 0° C., and a DCM solution of boron tribromide (2.59 mL, 2.59mmol) was added. After 1 h, the reaction was quenched with 18 mL ofsaturated aqueous NH₄Cl and 2 mL of aqueous NH₄OH. The mixture wasdiluted further with water (10 mL), and the aqueous phase was extractedwith 5% MeOH-DCM (3×50 mL). The organics were combined, washed withdilute brine (15 mL), dried over sodium sulfate and concentrated toafford 241 mg of(S)-5-amino-2′-bromo-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-olwhich was used in the next step without further purification.Step 4: A microwave vial was charged with tetrabutylammonium fluoridetrihydrate (0.301 g, 0.952 mmol), Pd(PPh₃)₄ (0.073 g, 0.063 mmol), andcopper(I) iodide (12.3 mg, 0.065 mmol). The(S)-5-amino-2′-bromo-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.241 g, 0.64 mmol) was added as a solution in THF (2.7 mL). Argon wasblown through the vessel, andtrimethyl((3-methyloxetan-3-yl)ethynyl)silane (0.161 g, 0.951 mmol) wasadded. The vessel was sealed and heated in an 80° C. oil bath for 1.5 h.The mixture was cooled and concentrated, diluted with water (15 mL), andthe aqueous phase was extracted with 5% MeOH-DCM (3×25 mL). The organicswere combined, washed with dilute brine (7 mL), dried over sodiumsulfate and concentrated to afford(S)-5-amino-4′-fluoro-2′-((3-methyloxetan-3-yl)ethynyl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol,which was used in the next step without further purification.Step 5: In a 50-mL flask, the crude(S)-5-amino-4′-fluoro-2′-((3-methyloxetan-3-yl)ethynyl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.251 g, 0.636 mmol) was dissolved in THF (12 mL). Boc₂O (0.303 g, 1.39mmol) and triethylamine (0.204 mL, 1.47 mmol) were added. After 14 h,the reaction mixture was concentrated to afford (S)-tert-butyl4′-fluoro-7′-hydroxy-2′-((3-methyloxetan-3-yl)ethynyl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamatewhich was used in the next step without further purification.Step 6: In a 50-mL flask, the crude (S)-tert-butyl4′-fluoro-7′-hydroxy-2′-((3-methyloxetan-3-yl)ethynyl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamate(0.315 g, 0.637 mmol) was dissolved in DCM (12 mL). The solution wascooled to 0° C., and triethylamine (0.175 mL, 1.26 mmol) and1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide(0.400 g, 1.12 mmol) were added. After 2.5 h, the reaction was quenchedwith dilute aqueous NaHCO₃ (15 mL) and the aqueous phase was extractedwith 3% MeOH-DCM (3×20 mL). The organics were combined, dried oversodium sulfate and concentrated. The residue was purified through silicagel (60 mL) using 25% ethyl acetate in hexane to afford 230 mg of(S)-5-(tert-butoxycarbonylamino)-4′-fluoro-2′-((3-methyloxetan-3-yl)ethynyl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7-yltrifluoromethanesulfonateStep 7: In a microwave vial, 2-fluoropyridin-3-ylboronic acid (0.065 g,0.459 mmol), Pd(PPh₃)₄ (0.042 g, 0.037 mmol) and(S)-5-(tert-butoxycarbonylamino)-4′-fluoro-2′-((3-methyloxetan-3-yl)ethynyl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (0.230 g, 0.367 mmol) were taken up in DMF (3mL). Aqueous sodium carbonate (1.0 M, 1.10 mL, 1.10 mmol) was added.Argon was blown through the vessel which was then sealed and heated inan 85° C. oil bath for 4 h. The reaction was cooled and concentrated,and the residue was diluted with water (15 mL) and the aqueous phase wasextracted with 3% MeOH-DCM (3×25 mL). The organics were combined, washedwith dilute brine (7 mL), dried over sodium sulfate and concentrated.The residue was purified through silica gel (33 mL) which had beendeactivated with Et₃N (3.3 mL), using 33% EtOAc in hexane. The resultingresidue was transferred to a microwave vessel in DCM (3 mL), and TFA(0.283 mL, 3.67 mmol) was added. The vessel was sealed and heated in a60° C. oil bath for 1.5 h. The reaction was cooled and concentrated, andthe residue was neutralized with 0.5 M aqueous Na₂CO₃ (15 mL). Theaqueous phase was extracted with 5% MeOH-DCM (3×25 mL). The organicswere combined, washed with dilute brine (7 mL) and dried over sodiumsulfate. The residue was purified through silica gel (33 mL) using 7.5%MeOH-DCM to afford 27 mg of(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-((3-methyloxetan-3-yl)ethynyl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine.m/z=474.0[M+H]⁺.

¹H NMR (400 MHz, CDCl₃) δ ppm; 8.19 (d, 1 H, J=4.9 Hz), 7.89 (m, 2 H),7.52 (m, 2 H), 7.34 (d, 1 H, J=8.4 Hz), 7.28 (m, 1 H), 7.16 (m, 2 H),4.92 (d, 2 H, J=5.3 Hz), 4.48 (d, 2 H, J=5.3 Hz), 4.33 (d, 2 H, J=2.5Hz), 3.57 (d, 2 H, J=2.7 Hz), 1.71 (s, 3 H).

Example 42 Method A13

Synthesis of(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-(tetrahydro-2H-pyran-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

In a microwave vial,(S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(0.040 g, 0.087 mmol) and Pd/C (10%, 0.055 g, 0.052 mmol) were suspendedin EtOH (1.5 mL). A balloon full of hydrogen (˜1 L) was emptied into thevessel, venting through a needle, and the vessel was sealed. After 2days, the mixture was filtered through Celite, rinsing with 5% MeOH-DCM.The filtrate was concentrated, and the residue was purified bychromatography (7.5% MeOH/DCM) to afford 29 mg of(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-(tetrahydro-2H-pyran-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Example 43 Method A14

Synthesis of(S)—N-(7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazine]-5′-yl)formamide

Step 1: A vial was charged with neopentyl alcohol (0.579 g, 6.57 mmol)and DMF (6.57 mL). Sodium hydride (60% in mineral oil; 0.263 g, 6.57mmol) was added and the reaction was stirred for 10 minutes at roomtemperature. The vial was heated to 100° C. for 5 min. The vial wascooled to rt.(S)-7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.500 g, 1.314 mmol) was added in one portion. The vial was sealed andheated to 100° C. three hours. The mixture was diluted with ethylacetate and water. A small amount of brine was added and the layers wereseparated. The aq. layer was extracted twice with ethyl acetate. Thecombined organic extracts were dried over sodium sulfate, filtered, andconcentrated. The residue was purified by chromatography (0-100%EtOAc/Hexanes) to give 175 mg of(S)—N-(7-bromo-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazine]-5′-yl)formamideas a light yellow solid.Step 2: A microwave vial was charged with(S)—N-(7-bromo-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazine]-5′-yl)formamide(0.075 g, 0.163 mmol), 2-fluoropyridin-3-ylboronic acid (0.046 g, 0.326mmol), potassium phosphate (0.104 g, 0.489 mmol), andbis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)(5.77 mg, 8.15 μmol). The vial was flushed with Ar (g), then dioxane(0.611 mL) and water (0.204 mL) were added in sequence. The vial wassealed and heated in a Biotage Initiator microwave reactor for 30 min at100° C. The reaction was diluted with EtOAc and washed with water. Theaqueous layer was extracted with EtOAc, and the combined organic layerswere washed with brine, dried with sodium sulfate, filtered, andconcentrated. The material was purified via column chromatography (0-10%MeOH:DCM w/1% NH₄OH) to afford 32 mg of(S)—N-(7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazine]-5′-yl)formamideas an off-white solid.

Example 44 Method A15

Synthesis of(S)-7-(4,4-difluoropiperidin-1-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial was charged with 2,2-dimethylpropan-1-ol (100 mg, 1.130mmol) and DMSO (1130 μL) to give a clear solution. Sodium hydride (60%in mineral oil; 45.2 mg, 1.130 mmol) was added and the vial was placedin a 100° C. oil bath for 5 min, then was removed from the heat andcooled to RT.(S)-7-bromo-3-chloro-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(Intermediate 1B, 86 mg, 0.226 mmol) was added to give an orangesolution. The vial was sealed and heated in a 100° C. oil bath for 2 h.The mixture was cooled to room temperature, then diluted with water andEtOAc. Brine was added and the layers were separated. The aq. layer wasextracted with EtOAc (2×). The combined organic extracts were dried oversodium sulfate, filtered, and concentrated. The residue was purified bychromatography on silica gel (0-100% EtOAc/Hexane) to give(S)-7-bromo-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineas a light-yellow solid.Step 2: A vial was charged with(S)-7-bromo-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(74.0 mg, 0.171 mmol) 4,4-difluoropiperidine hydrochloride (31.1 mg,0.257 mmol), andchloro(2-dicyclohexylphosphino-2′,4′,6′-tri-1-propyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II)methyl-t-butylether adduct (12.02 mg, 0.017 mmol). The vial was flushedwith Argon and sealed. Lithium bis(trimethylsilyl)amide (1M in THF) (599μL, 0.599 mmol) was added in one portion. The resulting mixture wassonicated for 1 min, then stirred for 30 min at rt. The reaction mixturewas diluted with saturated aq ammonium chloride solution and extractedwith EtOAc (3×). The combined organic extracts were dried over sodiumsulfate, filtered, and concentrated. The residue was purified bychromatography (0-10% MeOH/DCM) to give(S)-7-(4,4-difluoropiperidin-1-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineas an off-white solid. [M+H]⁺=473.2.

¹H NMR (400 MHz, DMSO-d₆) δ=8.01 (d, J=0.5 Hz, 1 H), 7.10-6.95 (m, 2 H),6.83 (d, J=2.8 Hz, 1 H), 6.57 (d, J=0.4 Hz, 1 H), 6.16 (br. s., 2 H),4.28-4.11 (m, 2 H), 3.98-3.80 (m, 2 H), 3.47-3.27 (m, 2 H), 3.25-3.12(m, 4 H), 2.21-1.98 (m, 4 H), 0.99 (s, 9 H)

Example 45 Method A16

Synthesis of(S)-7′-(4,4-difluoropiperidin-1-yl)-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

A vial was charged with(S)-7′-bromo-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(200 mg, 0.509 mmol),chloro(2-dicyclohexylphosphino-2′,6′-di-i-propoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II)methyl-t-butylether adduct (18.53 mg, 0.025 mmol),4,4-difluoropiperidine hydrochloride (160 mg, 1.017 mmol) and 1 ml ofTHF. The mixture was cooled to 0° C. and LHMDS (1M in THF; 2035 μL,2.035 mmol) was added. The vial was sealed and stirred at roomtemperature for 2 hr. At this point morechloro(2-dicyclohexylphosphino-2′,6′-di-i-propoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II)methyl-t-butylether adduct (18.53 mg, 0.025 mmol), (18.53 mg, 0.025mmol) was added followed by LHMDS solution (1 ml) and stirring wascontinued for another hour. The mixture was quenched by addition of 2 mlof water and extracted with ethyl acetate. The combined organic layerswere concentrated and purified by chromatography (5-50% DCM/MeOH/NH4OH(90:10:1) to afford(S)-7′-(4,4-difluoropiperidin-1-yl)-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(130 mg, 0.300 mmol, 59.0% yield) as yellowish foam.

Example 46 Method A17

Synthesis of(S)-7′-(4,4-difluoropiperidin-1-yl)-4′-fluoro-2′-((3-methyloxetan-3-yl)methoxy)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Step 1: A vial was charged with(S)-7′-bromo-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(200 mg, 0.509 mmol),chloro(2-dicyclohexylphosphino-2′,6′-di-i-propoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II)methyl-t-butylether adduct (18.53 mg, 0.025 mmol),4,4-difluoropiperidine hydrochloride (160 mg, 1.017 mmol) and 1 ml ofTHF. The mixture was cooled to 0° C. and LHMDS (1M in THF) (2035 μL,2.035 mmol) was added, and the vial was sealed and stirred at RT for 2hr. At this point morechloro(2-dicyclohexylphosphino-2′,6′-di-i-propoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II) methyl-t-butylether adduct (18.53 mg, 0.025 mmol), (18.53mg, 0.025 mmol) was added followed by LHMDS solution (1 ml) and stirringcontinued for another hour. The mixture was quenched by addition of 2 mlof water and extracted with EtOAc. The combined organic fractions wereconcentrated and purified by chromatography [5-50% DCM/MeOH/NH₄OH(90:10:1)] to afford(S)-7′-(4,4-difluoropiperidin-1-yl)-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amineas yellowish foam.Step 2: To a solution of(S)-7′-(4,4-difluoropiperidin-1-yl)-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(130 mg, 0.300 mmol) in DCM (3 ml) boron tribromide (0.085 ml, 0.900mmol) was added dropwise at room temperature and the mixture was stirredfor 3 hrs at RT. The reaction was quenched by addition of MeOH (˜1 ml),stirred for 10 min, then neutralized by addition of 25% NH₄OH. Thehomogeneous mixture was concentrated in vacuo and extracted with EtOAc.The organic layer was washed with brine and concentrated in vacuo togive after trituration with DCM off white solid. The solid wasredissolved in 3 ml of DMF, cesium carbonate (195 mg, 0.600 mmol) andpotassium iodide (14.94 mg, 0.090 mmol) were added and then3-bromomethyll-3-methyloxetane (0.054 ml, 0.330 mmol) was addeddropwise. The mixture was stirred at RT for 4 hrs. The mixture wasdiluted with water (10 ml) and extracted with EtOAc. The combinedorganic layers was washed twice with water, then with brine andconcentrated in vacuo. The residue was purified by chromatography[10-80% DCM/MeOH/NH4OH (90:10:1) in DCM] to afford(S)-7′-(4,4-difluoropiperidin-1-yl)-4′-fluoro-2′-((3-methyloxetan-3-yl)methoxy)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Example 47 Method A18

Synthesisof(R)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-((3-methyloxetan-3-yl)ethynyl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine(Example 47B) and(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′((3-methyloxetan-3-yl)ethynyl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine(Example 47A)

Step 1: A 50 ml RB flask was charged with7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine(806 mg, 2.050 mmol), 2-fluoropyridin-3-ylboronic acid (433 mg, 3.07mmol), PdCl₂(Cy₂PC₆H₄NMe₂)₂ (72.6 mg, 0.102 mmol), then dioxane (10 ml)and potassium carbonate (1M solution in water; 6.15 ml, 6.15 mmol). Themixture was stirred at 85° C. for 1 hr. The reaction mixture was cooledto RT, diluted with EtOAc and organic layer was separated andconcentrated in vacuo. The residue was treated with 3 ml of EtOH andprecipitated solid was filtered off, washed with ethanol and dried onair to afford 514 mg (61%) of pure desired product. The filtrate wasconcentrated and purified by chromatography [5-80% DCM./MeOH/NH₄OH(90:10:1) in DCM] to afford additional 300 mg (35%) of the product.Step 2: To a suspension of4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-methoxy-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine(2.178 g, 5.32 mmol) in DCM (43 mL) boron tribromide (1.509 mL, 15.96mmol) was added dropwise at RT. The mixture was stirred 2 hrs at RT, themixture was cooled to 0° C. and quenched by addition of 5 ml of methanoldropwise. The resulting white suspension was stirred for 20 min at 0°C., then sat. aq. NaHCO₃ (˜5 ml) was added followed by addition of 25%aq. ammonia (˜15 ml). The mixture was stirred for 30 min, then DCM wasremoved in a stream of nitrogen. The mixture was diluted with water (10ml) and 25% ammonia (10 ml) and filtered. The white solid was washedwith water twice, then dried for 3 hrs on air, then in vacuo overnightto give2-amino-4′-fluoro-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2′-ol(2.08 g, 5.26 mmol, 99% yield).Step 3: To a suspension of2-amino-4′-fluoro-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2′-ol(1.91 g, 4.83 mmol) in DCM (24.16 ml) TEA (1.347 ml, 9.66 mmol) andN-(5-chloropyridin-2-yl)-1,1,1-trifluoro-N-((trifluoromethyl)sulfonyl)methanesulfonamide(2.087 g, 5.31 mmol) were added at RT. The mixture was stirred for 1 hrat RT and the mixture became homogeneous. The reaction mixture waswashed twice with 2N NaOH solution, brine, filtered through the pad ofcelite and concentrated to leave2-amino-5′-fluoro-2′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-7′-yltrifluoromethanesulfonate (2.04 g, 3.87 mmol, 80% yield) as a creamysolid which was used without further purification.Step 4: A sealable tube was charged with2-amino-5′-fluoro-2′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-7′-yltrifluoromethanesulfonate (500 mg, 0.948 mmol),tetrakis(triphenylphosphine)palladium (0) (219 mg, 0.190 mmol),copper(I) iodide (72.2 mg, 0.379 mmol), DMF (4.5 mL),trimethyl((3-methyloxetan-3-yl)ethynyl)silane (479 mg, 2.84 mmol) andDIPA (1.3 ml, 9.48 mmol). The vial was sealed and stirred at 90° C. for18 hrs. The mixture was diluted with EtOAc (10 ml) and washed twice withwater (5 ml) and brine. The organic layer was concentrated and purifiedby chromatography (30-50% DCM/MeOH/NH₄OH in DCM) to afford racemic4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-((3-methyloxetan-3-yl)ethynyl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine(117 mg, 0.247 mmol, 26.1% yield).Step 5: The final compounds(R)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-((3-methyloxetan-3-yl)ethynyl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amineand(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-((3-methyloxetan-3-yl)ethynyl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-aminewere obtained from racemic4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-((3-methyloxetan-3-yl)ethynyl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amineusing similar chiral separation conditions as described herein forintermediate 10.

Example 48 Method A19

Synthesis of(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

A 250 ml RB flask was charged with(S)-7′-bromo-4′-fluoro-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(1.0 g, 2.54 mmol), PdCl₂(Cy₂C₆H₄NMe₂)₂ (0.126 g, 0.178 mmol) and2-fluoropyridin-3-ylboronic acid (0.538 g, 3.81 mmol). Dioxane (12.72mL) and potassium carbonate (1M solution) (7.63 mL, 7.63 mmol) wereadded, and the mixture was flushed with argon and heated to 85° C. for30 min. The mixture was cooled to RT and diluted with EtOAc. The organiclayer was separated and concentrated under reduced pressure to give ayellow foam. The residue was purified by chromatography (5-50% ofEtOAc/MeOH/NH₄OH 90:10:1 in EtOAc) to afford(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(0.82 g, 2.003 mmol, 79% yield).

Example 49 Method A20

Synthesis of(S)-3-(difluoromethoxy)-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1:(S)-7-bromo-3-methoxy-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.611 g, 1.624 mmol) was dissolved in HOAc (6.14 mL, 107 mmol).Hydrobromic acid (48% aq.; 6.06 mL, 53.6 mmol) was added and thereaction was stirred at 100° C. for two hours. The reaction was dilutedwith water, slowly neutralized to pH 7 with 6N NaOH, and stirredovernight, during which a light pink solid crashed out of solution. Thesolution was filtered, and the solid was air dried to afford(S)-5′-amino-7-bromo-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-3-ol(0.554 g, 1.530 mmol, 94% yield) as an off-white solid. [M+H]⁺=363.9Step 2: A flask was charged with(S)-5′-amino-7-bromo-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-3-ol(0.250 g, 0.690 mmol), cesium fluoride (9.17 mg, 0.069 mmol), andacetonitrile (6.90 mL). Trimethylsilyl2,2-difluoro-2-(fluorosulfonyl)acetate (0.272 mL, 1.381 mmol) was addedslowly and the reaction was stirred for 15 minutes. The reaction wasdiluted with EtOAc and washed with water. The aqueous layer wasextracted with EtOAc, and the combined organic layers were washed withbrine, dried with sodium sulfate, filtered, and concentrated. Thematerial was purified via column chromatography (0-10% MeOH/DCM), toafford(S)-7-bromo-3-(difluoromethoxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.056 g, 0.136 mmol, 19.68% yield) as a light yellow solid.[M+H]⁺=411.9Step 3: A microwave vial was charged with(S)-7-bromo-3-(difluoromethoxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.056 g, 0.136 mmol). 2-fluoropyridin-3-ylboronic acid (0.038 g, 0.272mmol), potassium phosphate (0.087 g, 0.408 mmol), andbis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)(4.81 mg, 6.79 μmol) were added. The vial was flushed with Ar (g), thendioxane (0.509 mL) and water (0.170 mL) were added in sequence. The vialwas sealed and heated in a Biotage Initiator microwave reactor for 30min at 100° C. The reaction was diluted with EtOAc and washed withwater. The aqueous layer was extracted with EtOAc, and the combinedorganic layers were washed with brine, dried with sodium sulfate,filtered, and concentrated. The material was purified via columnchromatography (0-10% MeOH/DCM) to afford(S)-3-(difluoromethoxy)-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.042 g, 0.098 mmol) as a light yellow solid. [M+H]⁺=429.0

Example 50 Method A21

Synthesis of(S)-7-(3,4-difluorophenyl)-3-methoxy-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

A microwave vial was charged with(S)-7-bromo-3-methoxy-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.075 g, 0.199 mmol). 3,4-difluorophenylboronic acid (0.063 g, 0.399mmol), potassium phosphate (0.127 g, 0.598 mmol), andbis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)(7.06 mg, 9.97 μmol) were added. The vial was flushed with Ar (g), thendioxane (0.748 mL) and water (0.249 mL) were added in sequence. The vialwas sealed and heated in a Biotage Initiator microwave reactor for 30min at 100° C. The reaction was diluted with ethyl acetate and washedwith water. The aqueous layer was extracted with ethyl acetate, and thecombined organic layers were washed with brine, dried with sodiumsulfate, filtered, and concentrated. The material was purified viacolumn chromatography (0-100% EtOAc/Hexanes) to afford(S)-7-(3,4-difluorophenyl)-3-methoxy-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.073 g, 0.178 mmol, 89% yield) as an off-white solid. [M+H]+=410.4

Example 51 Method A22

Synthesis of(S)-7-(2,5-difluorophenyl)-3-(2-fluoropyridin-4-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

A vial was charged with 2,5-difluorophenylboronic acid (0.035 g, 0.222mmol), PdCl₂(dppf)-CH₂Cl₂ adduct (8.65 mg, 10.59 μmol),(S)-3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.100 g, 0.212 mmol), and potassium phosphate (0.450 g, 2.118 mmol).Dioxane (2 mL) and water (1 mL) were added, the vial was flushed withargon, sealed and heated to 80° C. 1 hour. The reaction mixture wascooled to rt andbis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)(7.50 mg, 10.59 μmol) was added, followed by 2-fluoropyridin-4-ylboronicacid (0.045 g, 0.318 mmol). The reaction mixture was again capped underargon and was heated to 80° C. for and additional hour. The reactionmixture was then diluted with 2-MeTHF, dried over MgSO₄ andconcentrated. Purification of the crude residue by column chromatography[0-100% (95:5 EtOAc/MeOH)/DCM] gave(S)-7-(2,5-difluorophenyl)-3-(2-fluoropyridin-4-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.028 g, 0.059 mmol, 27.9% yield) as a light yellow solid. [M+H]+=475.0

Example 52 Method A23

Synthesis of(S)-3-(3,3-dimethylbut-1-ynyl)-7-(pyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial was charged with pyridin-3-ylboronic acid (0.027 g, 0.222mmol), PdCl₂(dppf)-CH₂Cl₂-adduct (8.65 mg, 10.59 μmol),(S)-3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.100 g, 0.212 mmol), and potassium carbonate (0.117 g, 0.847 mmol).Dioxane (5 mL) and water (0.5 mL) were added. The vial was flushed withargon, and heated to 100° C. for 1 hour. An additional portion ofpyridin-3-ylboronic acid (0.027 g, 0.222 mmol) was added, and thereaction mixture was heated to 100° C. for an additional hour. Thereaction mixture was diluted with 2-MeTHF, dried over MgSO₄ andconcentrated under reduced pressure. The crude residue was used withoutpurification.Step 2: The crude residue from step 1 was dissolved in 2 mL DMF, treatedwith 3,3-dimethyl-1-butyne (0.130 mL, 1.059 mmol), cesium carbonate(0.345 g, 1.059 mmol), and tBu-XPhos palladacycle (7.27 mg, 10.59 μmol).The reaction mixture was capped under argon, and was heated to 90° C.for 2 hours. The reaction mixture was then diluted with 2-MeTHF andwashed with water. The organics were dried over MgSO₄ and concentrated.Purification of the crude residue by column chromatography [0-100% (95:5EtOAc/MeOH)/DCM] gave(S)-3-(3,3-dimethylbut-1-ynyl)-7-(pyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.018 g, 0.042 mmol, 20.02% yield) as a grey solid. [M+H]+=425.0

Example 53 Method A24

Synthesis of(S)-3,7-bis(3,3-dimethylbut-1-ynyl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial was charged with(S)-3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.520 g, 1.102 mmol), DIPA (0.785 mL, 5.51 mmol), Pd(PPh₃)₄ (0.127 g,0.110 mmol), copper(I) iodide (0.021 g, 0.110 mmol), and3,3-dimethyl-1-butyne (0.203 mL, 1.652 mmol) DMF (3 ml) was added, thevial was sealed under argon, and was heated to 90° C. for 60 minutes.The reaction mixture was diluted with 2-MeTHF then washed with water.The organics were dried over MgSO₄ and concentrated. Purification of thecrude residue by column chromatography gave(S)-3,7-bis(3,3-dimethylbut-1-ynyl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.180 g, 0.421 mmol) as a white solid. [M+H]+=428.0

Example 54 Method A25

Synthesis of(S)-7-(3,3-dimethylbut-1-ynyl)-3-(2-fluoropyridin-4-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial was charged with(S)-3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine,diisopropylamine (0.785 mL, 5.51 mmol), Pd(PPh₃)₄ (0.127 g, 0.110 mmol),copper(I) iodide (0.021 g, 0.110 mmol), and 3,3-dimethyl-1-butyne (0.203mL, 1.652 mmol). DMF (3 mL) were added, the vial was sealed under argonand heated to 90° C. for 60 minutes. The reaction mixture was dilutedwith 2-MeTHF then washed with water. The organics were dried over MgSO4and concentrated. Purification of the crude residue by columnchromatography gave(S)-3-bromo-7-(3,3-dimethylbut-1-ynyl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.120 g, 0.281 mmol, 25.6% yield) as a white solid.Step 2: A vial was charged with(S)-3-bromo-7-(3,3-dimethylbut-1-ynyl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.060 g, 0.141 mmol), 2-fluoropyridin-4-ylboronic acid (0.050 g, 0.352mmol), potassium phosphate (0.299 g, 1.407 mmol) andbis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)(4.98 mg, 7.04 μmol) Dioxane (2 mL) and water (0.5 mL) were added, thevial was sealed under argon and heated to 80° C. for 1 hour. Thereaction mixture was then diluted with 2-MeTHF, dried over MgSO4 andconcentrated. Purification of the crude residue by column chromatography[0-100% (95:5 EtOAc/MeOH)/DCM] gave(S)-7-(3,3-dimethylbut-1-ynyl)-3-(2-fluoropyridin-4-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.029 g, 0.066 mmol, 46.6% yield) as a yellow solid. [M+H]⁺⁼443.0

Example 55 Method A26

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial charged with a solution of(S)-3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.880 g, 1.864 mmol), 2-fluoropyridin-3-ylboronic acid (0.276 g, 1.957mmol), PdCl₂(dppf)-CH₂Cl₂-adduct (0.038 g, 0.047 mmol), and potassiumcarbonate (1.031 g, 7.46 mmol). Dioxane (10 mL) and water (5 mL) wereadded, and the vial was flushed with argon and heated to 100° C. for 90minutes. Pd₂(dba)₃ (0.171 g, 0.186 mmol),di-tert-butyl(2′,4′,6′-triisopropyl-3,4,5,6-tetramethylbiphenyl-2-yl)phosphine(0.224 g, 0.466 mmol), and potassium hydroxide (1.046 g, 18.64 mmol)were added to the reaction mixture. The vial was sealed and heated to120° C. for an additional 3 hours. The reaction mixture was thenneutralized to pH 7 with 1N HCl, and was diluted with 2-MeTHF. Theorganics were dried over MgSO4 and concentrated. Purification of thecrude residue by column chromatography [0-100% (90:10:1DCM/MeOH/NH₄OH)/DCM] gave(S)-5′-amino-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-3-ol(0.133 g, 0.352 mmol).Step 2: A solution of(S)-5′-amino-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-3-ol(0.133 g, 0.352 mmol), potassium carbonate (0.194 g, 1.406 mmol), andneopentyl iodide (0.093 mL, 0.703 mmol) in 1.5 mL DMF was heated to 115°C. overnight. The reaction mixture was then diluted with 2-MeTHF andwashed with water. The organics were dried over MgSO₄ and concentrated.Purification of the crude residue by column chromatography [0-100% (9:1EtOAc/MeOH)/DCM] gave(S)-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.025 g, 0.056 mmol, 15.86% yield). MS m/z=449.20 [M+H]⁺. Calculatedfor C₂₅H₂₅FN₄O₃: 448.49.

¹H NMR (400 MHz, MeCN) δ ppm 1.05 (s, 9 H) 3.48 (s, 2 H) 3.72 (s, 2 H)4.21-4.31 (m, 2 H) 7.26-7.30 (m, 2 H) 7.35-7.39 (m, 1 H) 7.48-7.50 (m, 1H) 7.55-7.58 (m, 1 H) 7.91 (d, J=4.0 Hz, 1 H) 7.96-8.01 (m, 1 H)8.16-8.19 (m, 1 H)

Example 56 Method A27

Synthesis of(3′R,6′S)-3-chloro-6′-cyclohexyl-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(Example 56B) and racemic(3′S,6′S)-3-chloro-6′-cyclohexyl-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(Example 56A)

Steps 1 and 2: Synthesis of (E)-(2-nitrovinyl)cyclohexaneStep 1: 10 M aqueous NaOH (8.31 mL, 83 mmol) was added dropwise viaaddition funnel to a solution of nitromethane (4.46 mL, 83 mmol) andcyclohexanecarboxaldehyde (10 mL, 83 mmol) in EtOH (20 mL) at 0° C. withvigorous stirring. The resulting white slurry was stirred 10 minutes andbecame a white solid. Acetic acid (4.76 mL, 83 mmol) was added and thereaction was partitioned between diethyl ether and water. The layerswere separated and the aqueous layer was extracted with diethyl ether.The combined organic extracts were washed with water, saturated aqueoussodium chloride, and dried over magnesium sulfate. The solution wasfiltered and concentrated in vacuo and dried under vacumm to afford1-cyclohexyl-2-nitroethanol. The product was used directly for the nextstep without further purification.Step 2: Methanesulfonyl chloride (2.83 mL, 36.4 mmol) was added viasyringe to a solution of (E)-(2-nitrovinyl)cyclohexane and hydroquinone(0.200 g, 1.819 mmol) in DCM (35 mL) at 0° C. Next, triethylamine (10.14mL, 72.7 mmol) was added dropwise and the solution was stirred 20minutes (precipitate forms) before being transferred to a separatoryfunnel with DCM and water. The layers were separated and the organicswere washed with water, 1N HCl, saturated aqueous sodium chloride, anddried over sodium sulfate. The solution was filtered and concentrated invacuo to give (E)-(2-nitrovinyl)cyclohexane. The product was useddirectly for the next step without further purification.Step 3: Potassium t-butoxide (0.517 g, 4.61 mmol) was added in oneportion to a solution of(5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)methanol(Intermediate X, 1.5 g, 4.39 mmol) in THF (30 mL) at −78° C. Afterstirring for 45 minutes, (E)-(2-nitrovinyl)cyclohexane (0.716 g, 4.61mmol) in THF (15.00 mL) was added slowly via syringe. The reaction wasstirred at −78° C. for 20 minutes and was quenched with acetic acid(0.502 mL, 8.78 mmol) at −78° C., diluted with saturated aqueousammonium chloride, water and EtOAc. After warming to RT, the layers wereseparated and the aqueous layer was extracted with EtOAc. The combinedorganic extracts were washed with water, saturated aqueous sodiumchloride, and dried over sodium sulfate. The solution was filtered andconcentrated in vacuo to give the crude material. The crude material waspurified by silica gel chromatography by eluting with 1:6 to 1:4 EtOAcin hexane, to provide7-bromo-3-chloro-5-((1-cyclohexyl-2-nitroethoxy)methyl)-5H-chromeno[2,3-c]pyridin-5-amineas a yellow oil. [M+H]⁺=496.1.Step 4: TEA (1.263 ml, 9.06 mmol) and triiodophosphine (1.243 g, 3.02mmol) were added to7-bromo-3-chloro-5-((1-cyclohexyl-2-nitroethoxy)methyl)-5H-chromeno[2,3-c]pyridin-5-amine(1.5 g, 3.02 mmol) in DCM (30.2 ml) at 0° C. The reaction was stirred 10minutes before the ice water bath was removed and the reaction wasallowed to come to RT. After 1.5 hours, the solution is cooled to 0° C.and quenched with saturated aqueous sodium bicarbonate, diluted withwater, and extracted with DCM. The combined organic extracts were washedwith 1N NaOH, water, saturated aqueous NaCl, and dried over sodiumsulfate. The solution was filtered and concentrated in vacuo to give thecrude material. The crude material was purified by silica gelchromatography by eluting with 1:4 EtOAc in hexane, to provide2-((5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)methoxy)-2-cyclohexylacetonitrile,[M+H]=462.0.Step 5: Trimethylaluminum, as a 2 M solution in toluene, (0.973 ml,1.947 mmol) was added dropwise via syringe to a solution of2-((5-amino-7-bromo-3-chloro-5H-chromeno[2,3-c]pyridin-5-yl)methoxy)-2-cyclohexylacetonitrile(0.563 g, 1.217 mmol) in DCE (12 ml) at RT. After stirring 14 hours, thereaction was cooled to 0° C. and 1 N aq. HCl (12 ml, 12 mmol) was addeddropwise via syringe (slowly at first until vigorous reaction subsided)and the mixture was stirred at 0° C. for 10 minutes and then at RTbefore being diluted with DCM. The layers were separated and the aqueouslayer was extracted with DCM. The combined organic extracts were washedwith 1 N aq. NaOH, saturated aqueous sodium chloride, and dried oversodium sulfate. The solution was filtered and concentrated in vacuo togive the crude material. The crude material was purified by silica gelchromatography by eluting with 1:20 MeOH in DCM, to provide7-bromo-3-chloro-6′-cyclohexyl-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineas a mixture of racemic diastereomers. [M+H]=462.0.Step 6: A glass microwave reaction vessel was charged with7-bromo-3-chloro-6′-cyclohexyl-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.075 g, 0.162 mmol), 2 M aqueous sodium carbonate (0.8 mL, 1.600mmol), and dioxane (1.6 mL). The vessel was capped and the solution wasdegassed by bubbling nitrogen gas through the solution for 10 minutes.Next, Pd(PPh₃)₄ (7.49 mg, 6.48 μmol) and (2-fluoropyridin-3-yl)boronicacid (0.027 g, 0.194 mmol) were added and the vessel was sealed. Thereaction mixture was stirred and heated in a Initiator microwave reactor(Personal Chemistry, Biotage AB, Inc., Upssala, Sweden) at 120° C. for20 minutes. The reaction was poured into water and the mixture wasextracted with EtOAc. The combined organic extracts were washed withwater, saturated aqueous sodium chloride, and dried over sodium sulfate.The solution was filtered and concentrated in vacuo to give the crudematerial. The crude material was purified by silica gel chromatographyby eluting with 1:20 MeOH in DCM, to provide the product as a racemicmixture of diastereomers. The diastereomers were separated byreverse-phase preparative HPLC using a Phenomenex Gemini column, 10micron, C18, 100 Å, 150×30 mm, 0.1% TFA in CH₃CN/H₂O, gradient 10% to70% over 20 min to provide racemic(3′R,6′S)-3-chloro-6′-cyclohexyl-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineand racemic(3′S,6′S)-3-chloro-6′-cyclohexyl-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineeach as a white solid after isolating the free base by partitioningbetween DCM and 1 N NaOH. [M+H]⁺=479.1 for each racemic diastereomerpair.

Example 57 Method A28

Synthesis of2′-methoxy-7′-(pyrimidin-5-yl)-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-amine

Step 1: A vial charged with Pd₂(dba)₃ (0.150 g, 0.164 mmol), XPhos(0.391 g, 0.819 mmol), 5-(tributylstannyl)pyrimidine (1.81 g, 4.92mmol), 2-bromo-7-methoxy-9H-xanthen-9-one (1.000 g, 3.28 mmol) anddioxane (10 mL). The reaction mixture was evacuated and backfilled withnitrogen. The reaction mixture was heated to 100° C. overnight. Thereaction mixture was cooled to RT and diluted with water and EtOAc. Agrey solid precipitated out, which was filtered off. The solid waswashed with EtOAc and water. The grey solid dried under reduced pressureto afford 2-methoxy-7-(pyrimidin-5-yl)-9H-xanthen-9-one) (0.600 g, 60.2%yield).Step 2: A solution of vinylmagnesium chloride (1.6M solution in THF;0.82 mL, 1.314 mmol) was added dropwise to a solution of2-methoxy-7-(pyrimidin-5-yl)-9H-xanthen-9-one (200 mg, 0.657 mmol) inTHF (10 mL) at −78° C. After 30 min, the reaction mixture was allowed towarm to −10° C. and was then quenched with saturated aqueous ammoniumchloride. The reaction was extracted with EtOAc, and the organic phasewas dried over sodium sulfate, and concentrated under reduced pressure.The residue was purified by chromatography to give2-methoxy-7-(pyrimidin-5-yl)-9-vinyl-9H-xanthen-9-ol as a pale yellowgum.Step 3: 2 N HCl (3 mL) was added to solution of2-methoxy-7-(pyrimidin-5-yl)-9-vinyl-9H-xanthen-9-ol (50 mg, 0.150 mmol)and thiourea (9.25 μL, 0.171 mmol) in HOAc (5 mL). The reaction mixturewas allowed to stir overnight at rt and concentrated under reducedpressure. The residue was treated with of TFA (4 mL). The reactionmixture was stirred overnight at rt. The reaction mixture wasconcentrated under reduced pressure and the residue was treated withaqueous, half-saturated sodium bicarbonate, extracted with EtOAc, andconcentrated under reduced pressure. The residue was purified bychromatography (DCM/MeOH 20:1 to 5:1) to give2′-methoxy-7′-(pyrimidin-5-yl)-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-amineas an off-white solid.

Example 58 Method A29

Synthesis of(S)-1-fluoro-7-(2-fluoropyridin-3-yl)-3-morpholino-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine.TFA

Step 1: A suspension of cesium carbonate (41.1 g, 126 mmol),2,6-difluoropyridine (11.01 mL, 121 mmol) and morpholine (10.00 mL, 115mmol) in ACN (100 mL) was heated to 70° C. for 12 hours in a sealedvessel. The reaction mixture was cooled to RT and filtered. The obtainedfiltrate was concentrated under reduced pressure. The crude material waspurified by silica gel chromatography (5-25% EtOAc/hexanes) to provide13.7 g, of 4-(6-fluoropyridin-2-yl)morpholine.Step 2: Chlorosuccinimide (10.29 g, 77 mmol) was added to a solution of4-(6-fluoropyridin-2-yl)morpholine (11.7 g, 64.2 mmol) in ACN (15 mL).The reaction mixture was heated to 70° C. for 30 min. Water and DCM wereadded. The organic phase was separated, washed with aqueous NaHCO₃,brine and subsequently dried over MgSO₄. The solvent was removed underreduced pressure and the residue was purified by silica gelchromatography (5-20% EtOAc/hexanes) to afford 3.11 g of4-(5-chloro-6-fluoropyridin-2-yl)morpholine.Step 3: A solution of 2,2,6,6-tetramethylpiperidine (1.897 mL, 11.24mmol) in THF (45 mL) was cooled to −78° C. and treated with n-BuLi (1.6Min hexanes) (6.77 mL, 10.83 mmol) under nitrogen atmosphere. Thesolution was warmed to 0° C. and stirred at that temperature for 25minutes. The solution was cooled back down to −78° C. and treated with asolution of 4-(5-chloro-6-fluoropyridin-2-yl)morpholine (2.165 g, 9.99mmol) in THF (11.25 mL) under nitrogen atmosphere. The solution wasallowed to stir at that temperature for 40 minutes and then added dropwise via cannula to a solution of (S)-ethyl2-(5-bromo-2-(methoxymethoxy)phenyl)-2-(tert-butylsulfinylimino)acetate(3.5 g, 8.33 mmol) in THF (11.25 mL) also cooled to −78° C. undernitrogen atmosphere. The reaction mixture was allowed to stir at −78° C.for additional 2 hours and then quenched with acetic acid (0.715 mL,12.49 mmol). The reaction mixture was allowed to warm to RT overnight.The solvent was removed under reduced pressure and the crude materialwas purified by silica gel chromatography (10-60% EtOAc/hexane) toafford 3.56 g (S)-ethyl2-(5-bromo-2-(methoxymethoxy)phenyl)-2-(3-chloro-2-fluoro-6-morpholinopyridin-4-yl)-2-((S)-1,1-dimethylethylsulfinamido)acetate.Step 4: A solution of (S)-ethyl2-(5-bromo-2-(methoxymethoxy)phenyl)-2-(3-chloro-2-fluoro-6-morpholinopyridin-4-yl)-2-((S)-1,1-dimethylethylsulfinamido)acetate(3.56 g, 5.59 mmol) in THF (60 mL) was cooled to 0° C. and treated dropwise with DIBAL (1M in THF) (22.36 mL, 22.36 mmol) under nitrogenatmosphere. After 1 h additional 10 mL DIBAL solution were added at RT.After 12 h at RT additional 10 mL DIBAL solution were added. After 30min aqueous saturated solution of potassium sodium tartrate was added,followed by EtOAc. The reaction mixture was allowed to stir vigorouslyfor 1 h. The organic phase was separated, washed with aqueous saturatedsolution of potassium sodium tartrate and dried over MgSO₄. The solventwas removed under reduced pressure and the crude material was purifiedby silica gel chromatography (20-100% EtOAc/hexane) to provide 1.90 g of(S)—N—((S)-1-(5-bromo-2-(methoxymethoxy)phenyl)-1-(3-chloro-2-fluoro-6-morpholinopyridin-4-yl)-2-hydroxyethyl)-2-methylpropane-2-sulfinamide.Step 5: Lithium hydroxide hydrate (0.402 g, 9.58 mmol) was added to asolution of(S)—N—((S)-1-(5-bromo-2-(methoxymethoxy)phenyl)-1-(3-chloro-2-fluoro-6-morpholinopyridin-4-yl)-2-hydroxyethyl)-2-methylpropane-2-sulfinamide(1.9 g, 3.19 mmol) in THF (25 mL) at RT, followed by bromoacetonitrile(0.445 mL, 6.39 mmol). The reaction mixture was allowed to stir at RTfor 12 h. The reaction mixture was treated with aqueous saturatedammonium chloride, and the mixture was extracted with EtOAc. The organicphase was washed with water, brine, dried over MgSO₄ and thenconcentrated under reduced pressure. The remaining residue was purifiedby silica gel chromatography (50-100% EtOAc/hexanes) to afford 1.51 g of(S)—N—((S)-1-(5-bromo-2-(methoxymethoxy)phenyl)-1-(3-chloro-2-fluoro-6-morpholinopyridin-4-yl)-2-(cyanomethoxy)ethyl)-2-methylpropane-2-sulfinamide.Step 6-7: A solution of hydrogen chloride (5-6N in iPrOH; 1.025 mL, 5.12mmol) was added to a solution of(S)—N—((S)-1-(5-bromo-2-(methoxymethoxy)phenyl)-1-(3-chloro-2-fluoro-6-morpholinopyridin-4-yl)-2-(cyanomethoxy)ethyl)-2-methylpropane-2-sulfinamide(1083 mg, 1.708 mmol) in THF (4 mL) under nitrogen atmosphere. Thereaction mixture was stirred for 10 min at RT. The solvent was removedunder reduced pressure and the residue was dissolved in DCE (2 mL). Asolution of AlMe₃ (2M in toluene; 2.56 mL, 5.12 mmol) was added dropwise and the reaction mixture was allowed to stir at 70 C for 3 h. Thereaction mixture was cooled to RT and a solution of aqueous saturatedsolution of potassium sodium tartrate was added, followed by EtOAc. Thereaction mixture was allowed to stir vigorously for 1 h. The organicphase was separated, washed with brine and dried over MgSO₄. The solventwas removed under reduced pressure and the residue was purified bysilica gel chromatography (100% EtOAc) to afford 390 mg of(S)-2-(5-amino-3-(3-chloro-2-fluoro-6-morpholinopyridin-4-yl)-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-bromophenol.Step 8: A sealable vial was charged with(S)-2-(5-amino-3-(3-chloro-2-fluoro-6-morpholinopyridin-4-yl)-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-bromophenol(234 mg, 0.482 mmol), cesium carbonate (471 mg, 1.445 mmol) and copperchloride (9.54 mg, 0.096 mmol The vial was evacuated and back-filledwith nitrogen. NMP (1.5 mL) was added and the vial was evacuated andbackfilled with nitrogen. 2,2,6,6-Tetramethyl-3,5-heptanedione (0.080mL, 0.385 mmol) was added and the reaction mixture was heated to 120° C.for 1 h. The reaction mixture was cooled to room temperature, dilutedwith EtAOc and filtered through a pad of silica gel. The solvent wasremoved under reduced pressure and the residue was purified bypreparative reversed-phase preparative HPLC using a Phenomenex Geminicolumn, 10 micron, C18, 110 Å, 100×50 mm, 0.1% TFA in CH₃CN/H₂O,gradient 10% to 100% over 20 min to obtain 68 mg of(S)-7-bromo-1-fluoro-3-morpholino-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine.TFA.Step 9: A sealable vial was charged with(S)-7-bromo-1-fluoro-3-morpholino-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(50 mg, 0.111 mmol), 2-fluoropyridin-3-ylboronic acid (31.4 mg, 0.223mmol),bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II)(7.88 mg, 0.011 mmol) and potassium phosphate (0.028 mL, 0.334 mmol).The vial was evacuated and backfilled with nitrogen (procedure wasrepeated twice). Dioxane (1.3 mL) and water (0.433 mL) were added andthe reaction mixture was purged for 1 min with nitrogen. The vial wasplaced in a preheated oil bath (100° C.) for start 2.5 h. The reactionmixture was cooled to RT and the solvent was removed under reducedpressure. The residue was purified by preparative reversed-phasepreparative HPLC using a Phenomenex Gemini column, 10 micron, C18, 110Å, 100×50 mm, 0.1% TFA in CH₃CN/H₂O, gradient 10% to 100% over 20 min toobtain 39 mg of(S)-1-fluoro-7-(2-fluoropyridin-3-yl)-3-morpholino-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine2,2,2-trifluoroacetate as a light-yellow powder. MS m/z=466.0 [M+H]⁺.Calculated for C₂₄H₂₁F₂N₅O₃.C₂HF₃O₂: 579.48 (TFA salt).

Example 59 Method A30

Synthesis of(R)-1-fluoro-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineand(S)-1-fluoro-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A solution of neopentyl alcohol (1.065 mL, 9.81 mmol) in DMSO(82 mL) was cooled to 0° C. NaH (60% in mineral oil; 0.490 g, 12.26mmol) were added in one portion, the reaction mixture was warmed to rtand stirred for 20 minutes. 2,6-Difluoropyridine (0.941 mL, 8.175 mmol)was added and the reaction mixture was stirred at overnight. Thereaction mixture was quenched with aqueous, saturated ammonium chloridesolution, diluted with water and EtOAc. The organic layer was separated,washed with brine and dried over sodium sulfate. The solvent was removedunder reduced pressure to afford 2-fluoro-6-(neopentyloxy)pyridine (1.48g, 8.08 mmol) as a colorless liquid.Step 2: N-bromosuccinimide (8.29 g, 46.6 mmol) was added to a solutionof 2-fluoro-6-(neopentyloxy)pyridine (7.11 g, 38.8 mmol) in acetonitrile(80 mL) at rt. The reaction mixture was heated to 70° C. overnight. Thereaction mixture was cooled to rt and the solvent was removed underreduced pressure. The residue was dissolved in DCM and washed withwater. The organic layer was separated, dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by flashchromatography (100% hexanes) to obtain3-bromo-2-fluoro-6-(neopentyloxy)pyridine (5.27 g, 20.11 mmol) as awhite solid.Step 3: A solution of 3-bromo-2-fluoro-6-(neopentyloxy)pyridine (5.6 g,21.36 mmol) in THF (50 mL) was cooled to −100° C. and a solution ofn-butyllithium (1.6M in hexane; 14.69 mL, 23.50 mmol) was added dropwise. The reaction mixture was allowed to stir for 10 min at −100° C.Triisopropyl borate (7.35 mL, 32.0 mmol) was added and the reactionmixture was allowed to warm to rt. Aqueous NaOH solution (5M; 29.9 mL,150 mmol) was added, followed by hydrogen peroxide (30%; 15.28 mL, 150mmol). The reaction mixture was allowed to stir for 30 min at rt. Thereaction mixture was acidified with 2N HCl and extracted with EtOAc. Theorganic phase was separated and dried over MgSO₄. The solvent wasremoved under reduced pressure, the residue was dissolved in acetone (50mL) and the solution was cooled to 0° C. K₂CO₃ (3.25 g, 23.50 mmol) wasadded, followed by chloromethyl methyl ether (1.785 mL, 23.50 mmol).After 30 min, additional K₂CO₃ (3.25 g, 23.50 mmol) and chloromethylmethyl ether (1.785 mL, 23.50 mmol) were added and the reaction mixturewas warmed to rt. After 2 h brine and diethyl ether were added. Theorganic was separated and dried over magnesium sulfate. The solvent wasremoved under reduced pressure. The residue was purified by flashchromatography (0-20% EtOAc/hexanes) to yield2-fluoro-3-(methoxymethoxy)-6-(neopentyloxy)pyridine (2.88 g, 11.84mmol).Step 4: A solution of n-butyllithium (1.6M in hexanes; 6.52 mL, 10.44mmol) was added drop wise to a solution of 2,2,6,6-tetramethylpiperidine(1.897 mL, 11.24 mmol) in THF (30 mL) at −78° C. under nitrogenatmosphere. The reaction mixture was warmed to 0° C. and stirred for 25min. The reaction mixture was cooled down again to −78° C. and asolution of 2-fluoro-3-(methoxymethoxy)-6-(neopentyloxy)pyridine (2.149g, 8.83 mmol) in THF (5 mL) was added drop wise. The reaction mixturewas kept for 1 h at 78° C., after which a solution of5-bromo-2-fluorobenzaldehyde (1.63 g, 8.03 mmol) in THF (5 mL) wasadded. The reaction mixture was allowed to warm up to rt. Aqueous,saturated NH₄Cl solution was added, followed by EtOAc. The organic phasewas separated and dried over MgSO₄. The solvent was removed underreduced pressure and the residue was dissolved in DCM (75 mL).4-Methylmorpholine 4-oxide (1.176 g, 10.04 mmol) followed bytetrapropylammonium perruthenate (0.141 g, 0.401 mmol) were added. Thereaction mixture was allowed to stir for 2 h at rt. The reaction mixturewas filtered through a pad of celite and the solvent was removed underreduced pressure. The residue was purified by flash chromatography(5-20% EtOAc/hexanes) to yield(5-bromo-2-fluorophenyl)(2-fluoro-3-(methoxymethoxy)-6-(neopentyloxy)pyridin-4-yl)methanoneas a white solid.Step 5: A solution of(5-bromo-2-fluorophenyl)(2-fluoro-3-(methoxymethoxy)-6-(neopentyloxy)pyridin-4-yl)methanone(1.89 g, 4.25 mmol) in DCM (20 mL) was cooled to −78° C. under nitrogenatmosphere. Boron tribromide (1.0M in CH₂Cl₂; 4.25 mL, 4.25 mmol) wasadded drop wise and the reaction mixture was stirred for 5 min at rt.Aqueous, saturated ammonium chloride solution was added, followed bywater and DCM. The organic phase was separated and dried over magnesiumsulfate. The solvent was removed under reduced pressure to afford ayellow solid, which was dissolved in ACN (20.00 mL). Cesium carbonate(1.386 g, 4.25 mmol) was added in one portion and the reaction mixturewas allowed to stir for 5 min. Water was added and the remaininglight-yellow solid was filtered off and dried to afford7-bromo-1-fluoro-3-(neopentyloxy)-5H-chromeno[2,3-c]pyridin-5-one (1.27g).Step 6: To a suspension of7-bromo-1-fluoro-3-(neopentyloxy)-5H-chromeno[2,3-c]pyridin-5-one (1000mg, 2.63 mmol) in THF (25 mL) at −40° C. was added drop wise((trimethylsilyl)methyl)lithium (1.0M solution in pentane; 3.95 mL, 3.95mmol). After 10 min, TFA (0.304 mL, 3.95 mmol) was added drop wise andthe reaction mixture was allowed to warm to rt Additional 1 ml of TFAwas added and the reaction mixture was allowed to stir for 1 hour at rt.An aqueous, saturated K₂CO₃ solution was added, followed by EtOAc. Theorganic phase was separated and dried over Na₂SO₄. The solvent wasremoved under reduced pressure to yield7-bromo-1-fluoro-5-methylene-3-(neopentyloxy)-5H-chromeno[2,3-c]pyridineas a yellow solid (995 mg), which was used in the next step withoutfurther purification.Step 7: To a solution of7-bromo-1-fluoro-5-methylene-3-(neopentyloxy)-5H-chromeno[2,3-c]pyridine(995 mg, 2.63 mmol) in THF (60 mL)/Water (10 mL) was added iodine (1335mg, 5.26 mmol) and silver oxide (1219 mg, 5.26 mmol). The reactionmixture was allowed to stir at rt for 20 min. K₂CO₃ (545 mg, 3.95 mmol)was added in one portion and the reaction mixture was allowed to stirfor 30 min. The reaction mixture was filtered through a pad of celite.The reaction mixture was partitioned between water and EtOAc. Theorganic phase was separated, dried over Na₂SO₄. The solvent was removedunder reduced pressure to afford7-bromo-1-fluoro-3-(neopentyloxy)spiro[chromeno[2,3-c]pyridine-5,2′-oxirane]as a yellow solid (1000 mg) which was taken onto the next step withoutfurther purification.Step 8:7-Bromo-1-fluoro-3-(neopentyloxy)spiro[chromeno[2,3-c]pyridine-5,2′-oxirane](1000 mg, 2.54 mmol) was dissolved in DMF (16 mL) andazidotrimethylsilane (2.020 mL, 15.22 mmol) was added drop wise. Thereaction mixture was allowed to stir at rt for 1 h. Water and EtOAc wereadded, the organic layer was separated and dried over MgSO₄. The solventwas removed under reduced pressure to afford an oil which was dissolvein THF (20 mL) and cooled to 0° C. Lithium aluminum hydride (1.0M inTHF; 3.27 mL, 3.27 mmol) was added drop wise. After 1 h additional 1.5mL of LiAlH₄ solution were added and the reaction mixture was allowed tostir for additional 10 min at 0° C. The reaction mixture was quenchedwith an aqueous, saturated solution of Rochelle's salt. Water and EtOAcwere added. The organic phase was separated and dried over Na₂SO₄. Thesolvent was removed under reduced pressure and the crude product wastaken onto the next step without further purification.Step 9: To a solution of(5-amino-7-bromo-3-chloro-1-fluoro-5H-chromeno[2,3-c]pyridin-5-yl)methanol(1 g, 2.78 mmol) in THF (2 mL) was added simultaneously and drop wiselithium tert-butoxide (1.0 M in THF; 4.73 mL, 4.73 mmol) and a solutionof bromoacetonitrile (0.329 mL, 4.73 mmol) in THF (2 mL) at RT.Additional lithium tert-butoxide (1.0 M in THF; 4.73 mL, 4.73 mmol) anda solution of bromoacetonitrile (0.329 mL, 4.73 mmol) in THF (2 mL) wereadded after 1 hour, 2 hours and 3 hours reaction time, respectively. Thereaction mixture was quenched with aqueous, saturated NH₄Cl solution and2M HCl. EtOAc was added and the organic phase was separated and driedover MgSO₄. The solvent was removed under reduced pressure and theresidue was taken onto the next step without further purification.Step 10:2-((5-Amino-7-bromo-1-fluoro-3-(neopentyloxy)-5H-chromeno[2,3-c]pyridin-5-yl)methoxy)-acetonitrile(1000 mg, 2.221 mmol) was dissolved in DCE (4 mL) and trimethylaluminumsolution (2M in toluene; 2.221 mL, 4.44 mmol) was added drop wise. Thereaction mixture was heated to 70° C. for 15 min. The reaction mixturewas cooled to rt. Aqueous, saturated solution of Rochelle's salt wasadded, followed by EtOAc. The organic phase was separated, washed withbrine and dried over MgSO₄. The solvent was removed under reducedpressure and the residue was purified by flash chromatography (10-100%EtOAc/hexanes) to afford7-bromo-1-fluoro-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineas a light-brown solid.Step 11: A sealable vial was charged with7-bromo-1-fluoro-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(200 mg, 0.444 mmol), 2-fluoropyridin-3-ylboronic acid (125 mg, 0.888mmol),bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II)(31.4 mg, 0.044 mmol) and potassium phosphate (283 mg, 1.332 mmol). Thevial was evacuated and backfilled with nitrogen (procedure was repeatedtwice). Dioxane (3 mL) and water (1 mL) were added and the reactionmixture was purged for 1 min with nitrogen. The vial was placed in apreheated oilbath (100° C.) for start 1.5 h. The reaction mixture wascooled to rt and water and EtOAc were added to the reaction mixture. Theorganic phase was separated and dried over MgSO₄. The solvent wasremoved under reduced pressure and the residue was purified by columnchromatography (1-10% MeOH in DCM) to obtain1-fluoro-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineas a beige solid (185 mg).Step 12: Compounds(R)-1-fluoro-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(Example 59B) and(S)-1-fluoro-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine(Example 59A) were obtained from racemic1-fluoro-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amineusing similar chiral separation conditions as described herein forintermediate 10.

Mass for both peaks m/z=467.0 [M+H]⁺. Calculated for C₂₅H₂₄F₂N₄O₃:466.18

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.03 (s, 9 H) 3.53-3.61 (m, 1 H)3.62-3.69 (m, 1 H) 3.86-3.92 (m, 1 H) 3.92-3.98 (m, 1 H) 4.28-4.41 (m, 2H) 6.58 (s, 1 H) 7.28-7.31 (m, 1 H) 7.33 (d, J=8.41 Hz, 1 H) 7.47-7.57(m, 2 H) 7.88 (t, J=9.39 Hz, 1 H) 8.19 (d, J=4.50 Hz, 1 H).

Example 60 Method A31

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-(2-fluoropyridin-4-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine

In a microwave vial, potassium phosphate (0.084 g, 0.394 mmol),PdCl₂(AmPhos)₂ (8.38 mg, 0.012 mmol), and 2-fluoropyridin-4-ylboronicacid (0.024 g, 0.171 mmol) were loaded. The(S)-3-bromo-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine(0.058 g, 0.131 mmol) was added as a solution in dioxane (2.5 mL). Water(1 mL) was added and argon gas was blown through the vessel, which wassealed and heated in a 90° C. oil bath for 1.5 h. The residue was takenup in 5% MeOH/DCM (60 mL) and the organic layer was extracted withdilute brine (2×6 mL), then was dried over sodium sulfate andconcentrated. The residue was purified by chromatography (4.5-5.5%MeOH/DCM) to afford(S)-7-(2-fluoropyridin-3-yl)-3-(2-fluoropyridin-4-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine(Example 60A; 44 mg). MS (m/z) 458 (M+H)⁺. ¹H NMR (400 MHz, CDCl₃) δppm:8.57 (d, 1 H, J=2.5 Hz), 8.32 (d, 1 H, J=5.3 Hz), 8.22 (d, 1 H, J=4.7Hz), 8.07 (d, 1 H, J=2.3 Hz), 7.88 (m, 1 H), 7.55 (m, 2 H), 7.43 (m, 2H), 7.30 (m, 1 H), 7.17 (s, 1 H), 4.39 (br, 2 H), 4.18 (m, 2 H), 2.02(m, 1 H), 1.90 (m, 1 H).

Example 61 Method A32

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine

In a microwave vial, tetrabutylammonium fluoride trihydrate (0.059 g,0.187 mmol), trimethyl((3-methyloxetan-3-yl)ethynyl)silane (0.031 g,0.187 mmol), copper(I) iodide (2.374 mg, 0.012 mmol), Pd(PPh₃)₄ (0.014g, 0.012 mmol), and(S)-3-bromo-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine(0.055 g, 0.125 mmol) were suspended in THF (1.25 mL). Argon gas wasblown through the vessel, which was sealed and heated in an 80° C. oilbath for 1.5 h. The mixture was taken up in 10% MeOH-EtOAc (60 mL) andthe organic layer was extracted with dilute brine (8 mL) then withsaturated brine (8 mL), dried over sodium sulfate and concentrated. Theresidue was purified by chromatography (5% MeOH/DCM), to afford(S)-7-(2-fluoropyridin-3-yl)-3-(3-methyloxetan-3-yl)ethynyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine(41 mg, 0.09 mmol). MS (m/z) 457 (M+H)⁺. ¹H NMR (400 MHz, CDCl₃) δ ppm:8.32 (d, 1 H, J=2.0 Hz), 8.20 (d, 1 H, J=4.9 Hz), 7.90 (m, 1 H), 7.78(s, 1 H), 7.53 (m, 2 H), 7.38 (d, 1 H, J=8.4 Hz), 7.27 (m, 1 H), 4.94(d, 2 H, J=5.3 Hz), 4.50 (d, 2 H, J=5.5 Hz), 4.44 (br, 2 H), 4.28 (m, 2H), 1.95 (m, 1 H), 1.85 (m, 1 H), 1.74 (s, 3 H).

Example 62 Method A33

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine

Step 1: In a 25-mL flask, the(R)-3-bromo-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine(0.350 g, 0.793 mmol) was suspended in1,1-dimethoxy-N,N-dimethylmethanamine (5.29 mL, 39.7 mmol). The reactionmixture was heated to 100° C. for 1 h. The reaction was concentrated,and the residue was taken up in 5% MeOH/DCM (60 mL) and the organicphase was extracted with dilute brine (2×8 mL), then was dried oversodium sulfate and concentrated. The residue was purified bychromatography (3.5% MeOH/DCM) to afford(R,E)-N′-(3-bromo-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-yl)-N,N-dimethylformimidamide(394 mg, 0.793 mmol).Step 2: In a 100-mL resealable vessel, the potassium acetate (0.234 g,2.381 mmol), PdCl₂-dppf-DCM (0.065 g, 0.079 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.242 g,0.953 mmol),(R,E)-N′-(3-bromo-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-yl)-N,N-dimethylformimidamide(0.394 g, 0.794 mmol) was suspended in THF (8 mL). Argon was blownthrough the vessel, which was then sealed and heated in an 85° C. oilbath for 14 h. The vessel was removed from the oil bath and cooled to 0°C., and aqueous NaOH (2.5 M, 1.905 mL, 4.76 mmol) was added, followed byaqueous 30% hydrogen peroxide (0.811 mL, 7.94 mmol). The ice bath wasremoved, and the mixture was stirred for 45 min. The mixture wasconcentrated to remove most of the THF. The residue was taken up in 10%MeOH/DCM (600 mL), and the organic layer was extracted with dilute brine(2×15 mL). The organic layer was dried with magnesium sulfate, filtered,and concentrated. The crude(R,E)-N′-(7-(2-fluoropyridin-3-yl)-3-hydroxy-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-yl)-N,N-dimethylformimidamidewas used in the next step without further purification.Step 3: In a 35-mL resealable vessel, cesium carbonate (0.621 g, 1.905mmol), 1-iodo-2,2-dimethylpropane (0.211 mL, 1.587 mmol), and crude(S,E)-N′-(7-(2-fluoropyridin-3-yl)-3-hydroxy-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-yl)-N,N-dimethylformimidamide(0.344 g, 0.794 mmol) were taken up in DMF (8 mL). The vessel was sealedand heated in a 100° C. oil bath. After 6 h, the reaction wasconcentrated. The residue was taken up in 10% MeOH/DCM (120 mL) and theorganic layer was extracted with water (2×10 mL). The organic layer wasdried over MgSO₄, filtered and concentrated. The residue was taken up indioxane (8 mL), and a dioxane solution of HCl (4 M, 2 mL) was added. Thevessel was sealed and heated in a 60° C. oil bath. After 1 h, thereaction was concentrated. The residue was diluted with water (30 mL)and the aqueous phase was extracted with 10% MeOH/DCM (3×50 mL). Theorganics were dried over magnesium sulfate, filtered, and concentrated.The material was purified by chromatography using 65:35:0.5:1EtOAc-hexane-MeOH-Et₃N to afford(5)-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine(4.5 mg, 0.010 mmol). MS (m/z) 449 (M+H)⁺.

Example 63 Method A34

Synthesis of(S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(pyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Step 1: In a 250-mL flask, Lawesson's reagent (0.577 g, 1.427 mmol) and(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthen]-5-one(0.978 g, 2.481 mmol) were suspended in toluene (25 mL). An air-cooledcondenser was attached, and the flask was heated in a 90° C. oil bathfor 3 h. The mixture was then cooled and concentrated to give(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthene]-5-thionewhich was used in the next step without further purification.Step 2: In a 150-mL resealable vessel, the crude(S)-2′-bromo-4′-fluoro-7′-methoxyspiro[morpholine-3,9′-xanthene]-5-thione(1.0 g, 2.437 mmol) was dissolved in a dioxane solution of ammonia (0.5M, 58.5 mL, 29.2 mmol). Mercury (II) chloride (0.993 g, 3.66 mmol) wasadded, and the vessel was sealed and heated in a 55° C. oil bathovernight. The mixture was then cooled and concentrated. The residue wasfiltered through Celite, rinsing with 10% MeOH-DCM (400 mL). Thefiltrate was concentrated, and the residue was purified through silicagel (150 mL) using 7.5% MeOH-DCM to afford 131 mg of(S)-2′-bromo-4′-fluoro-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amineStep 3: In a 500-mL flask, the(S)-2′-bromo-4′-fluoro-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(0.595 g, 1.513 mmol) was dissolved in DCM (45 mL). The orange solutionwas cooled to 0° C. and a DCM solution of boron tribromide (1.0 M, 4.54mL, 4.54 mmol) was added. After 2 h, the reaction mixture was quenchedwith 20 mL of 9:1 NH₄Cl/NH₄OH. The mixture was diluted further withwater (10 mL) and the aqueous phase was extracted with 5% MeOH-dcm (3×60mL). The organics were combined, washed with brine (20 mL), dried oversodium sulfate and concentrated to afford crude(S)-5-amino-2′-bromo-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.574 g, 1.21 mmol) which was used directly in the next step.Step 4: In a microwave vial, the potassium phosphate (0.771 g, 3.63mmol), PdCl₂(AmPhos)₂ (0.064 g, 0.091 mmol) and2-(5,6-dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(0.356 g, 1.695 mmol) were loaded. The(S)-5-amino-2′-bromo-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.459 g, 1.211 mmol) was added as a solution in dioxane (6 mL). Water(2.4 mL) was added and argon gas was blown through the vessel, which wassealed and heated by microwave at 120° C. for 30 min. The residue wastaken up in half-saturated aqueous NH₄Cl (30 mL) and the aqueous phasewas extracted with 5% MeOH/DCM (3×25 mL). The organics were combined,washed with brine (7 mL), dried over sodium sulfate and concentrated toafford crude(S)-5-amino-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-olwhich was used directly in the next step.Step 5: Crude(S)-5-amino-2′-(5,6-dihydro-2H-pyran-3-l)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.463 g, 1.211 mmol) was dissolved in DCM (35 mL). The solution wascooled to 0° C., and TEA (0.175 mL, 1.27 mmol) was added, followed byN-(5-chloropyridin-2-yl)-1,1,1-trifluoro-N-(trifluoromethylsulfonyl)methanesulfonamide(0.427 g, 1.09 mmol). The solution was allowed to warm naturally. After9 h, the reaction was quenched with 1 M aqueous NaOH (15 mL). Theaqueous layer was separated and extracted further with 5% MeOH-DCM (3×20mL). The organics were combined, washed with brine (7 mL), dried oversodium sulfate and concentrated. The residue was partially purified bychromatography (5% MeOH/DCM) to afford(S)-5-amino-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (393 mg, 0.764 mmol).Step 6: In a microwave vial, the pyridin-3-ylboronic acid (0.061 g,0.495 mmol),(S)-5-amino-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (0.196 g, 0.381 mmol), and Pd(PPh₃)₄ (0.044 g,0.038 mmol) were suspended in dmf (4.1 mL). Aqueous sodium carbonate(1.0 M, 1.143 mL, 1.143 mmol) was added. Argon was blown through thevessel, which was sealed and heated in an 85° C. oil bath (11:40). After1.5 h the reaction was concentrated. The residue was taken up in EtOAc(100 mL) and the organic layer was extracted with water (15 mL), brine(, then was dried over sodium sulfate and concentrated. The residue waspurified by chromatography (7.5% MeOH/DCM) to afford(S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(pyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(99 mg, 0.22 mmol). MS (m/z) 444 (M+H)+. ¹H NMR (400 MHz, CDCl₃) δ ppm;8.85 (s, 1 H), 8.57 (d, 1 H, J=4.5 Hz), 7.86 (d, 1 H, J=8.0 Hz), 7.50(m, 2 H), 7.36 (m, 2 H), 7.08 (dd, 1 H, J=11.7, 2.0 Hz), 6.99 (s, 1 H),6.17 (s, 1 H), 4.46 (m, 2 H), 4.33 (s, 2 H), 3.85 (t, 2 H, J=5.7 Hz),3.57 (m, 2 H), 2.33 (m, 2 H).

Example 64 Method A35

Synthesis of(R)-2′-(3,6-dihydro-2H-pyran-4-yl)-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Step 1: In a 250-mL flask, the(R)-2′-bromo-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(0.393 g, 1.047 mmol) was dissolved in dcm (10 mL). The solution wascooled to 0° C. A DCM solution of boron tribromide (1.0 M, 3.14 mL, 3.14mmol) was added. After 1.5 h, the mixture was quenched with 9:1saturated aqueous NH₄Cl/NH₄OH (10 mL). The mixture was diluted furtherwith water (10 mL) and the aqueous phase was extracted with 5% MeO/DCM(3×50 mL). The organics were combined, washed with dilute brine (10 mL),dried over sodium sulfate and concentrated to afford crude(R)-5-amino-2′-bromo-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(349 mg, 0.966 mmol), which was used directly in the next step.Step 2: In a microwave vial, potassium phosphate (0.615 g, 2.90 mmol),bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II)(0.068 g, 0.097 mmol), 2-fluoropyridin-3-ylboronic acid (0.170 g, 1.208mmol) and(R)-5-amino-2′-bromo-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.349 g, 0.966 mmol) were suspended in dioxane (8 mL). Water (2 mL) wasadded, and argon gas was blown through the vessel, which was then sealedand heated in a 100° C. oil bath for 3 h. The reaction was concentratedto remove the dioxane. The residue was diluted with aqueous NH₄Cl (15mL) and the aqueous phase was extracted with 5% MeOH/DCM (3×33 mL). Theorganics were combined, washed with dilute brine (8 mL), dried oversodium sulfate and concentrated to afford crude(S)-5-amino-2′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-olwhich was used directly in the next step.Step 3: In a 250-mL flask, the crude(S)-5-amino-2′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.365 g, 0.967 mmol) was dissolved in THF (10 mL). Boc₂o (0.232 g, 1.06mmol) was added, followed by TEA (0.148 mL, 1.06 mmol). After 1 h Thereaction was concentrated to afford crude (S)-tert-butyl2′-(2-fluoropyridin-3-yl)-7′-hydroxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamate,which was used directly in the next step.Step 4: In a 100-mL flask, crude (S)-tert-butyl2′-(2-fluoropyridin-3-yl)-7′-hydroxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamate(0.462 g, 0.968 mmol) was dissolved in DCM (10 mL). The solution wascooled to 0° C., and1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide(0.513 g, 1.43 mmol) and triethylamine (0.243 mL, 1.74 mmol) were added.After 3 h, the reaction was concentrated and material was purified bychromatography (33% EtOAc/hexanes) to afford(S)-5-(tert-butoxycarbonylamino)-2′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (0.293 g, 0.481 mmol).Step 5: In a microwave vial,2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(0.062 g, 0.297 mmol),(S)-5-(tert-butoxycarbonylamino)-2′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (0.145 g, 0.238 mmol) andtetrakis(triphenylphosphine)palladium(0) (0.027 g, 0.024 mmol) weretaken up in DMF (3 mL). Aqueous sodium carbonate (1.0 M, 0.714 mL, 0.714mmol) was added. Argon was blown through the vessel which was sealed andplaced in an 85° C. oil bath. After 3 h, the reaction was concentrated.The residue was diluted with water (15 mL) and the aqueous phase wasextracted with 3% MeOH/DCM (3×25 mL). The organics were combined, washedwith brine (7 mL), dried over sodium sulfate and concentrated. Theresidue was transferred to a microwave vial with 3 mL of DCMm and tfa(0.275 mL, 3.57 mmol) was added. The vial was sealed and the reactionwas stirred in a 65° C. oil bath for 2 h. The reaction was concentrated.The residue was neutralized with 0.5 M Na₂CO₃ (13 mL). The aqueous phasewas extracted with 5% MeOH/DCM (3×25 mL). The organics were combined,washed with dilute brine (8 mL), dried over sodium sulfate andconcentrated. The residue was purified by chromatography (7%-8%MeOH/DCM) to afford(R)-2′-(3,6-dihydro-2H-pyran-4-yl)-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(65 mg, 0.146 mmol).

MS (m/z) 444 (M+H)⁺.

¹H NMR (400 MHz, CDCl₃) δ ppm; 8.17 (d, 1 H, J=4.5 Hz), 7.89 (m, 1 H),7.52 (m, 2 H), 7.34 (m, 2 H), 7.27 (m, 2 H), 7.15 (d, 1 H, J=8.4 Hz),6.08 (s, 1 H), 4.40 (s, 2 H), 4.33 (m, 2 H), 3.94 (t, 2 H, J=5.5 Hz),3.64 (d, 1 H, J=11.5 Hz), 3.59 (d, 1 H, J=11.5 Hz), 2.53 (m, 2 H).

Example 65 Method A36

Synthesis of(R)-2′-(2-fluoropyridin-3-yl)-7′-(2-fluoropyridin-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Step 1: In a microwave vial, sodium carbonate (0.094 g, 0.885 mmol),2-fluoropyridin-4-ylboronic acid (0.048 g, 0.339 mmol), Pd(PPh₃)₄ (0.034g, 0.030 mmol), and(S)-2′-bromo-7′-iodo-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(0.139 g, 0.295 mmol) were suspended in DME (2.5 mL) and water (0.5 mL).Argon gas was blown through the vessel which was sealed and heated in an80° C. oil bath. After 6 h, the reaction mixture was diluted with brine(10 mL) and the aqueous phase was extracted with 7.5% MeOH-dcm (3×25mL). The organics were combined, washed with dilute brine (5 mL), driedover sodium sulfate and concentrated. The material was purified throughsilica gel (33 mL) using 3.5 to 4.5 to 7% MeOH-DCM to afford(R)-2′-bromo-7′-(2-fluoropyridin-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amineStep 2: In a microwave vial, the potassium phosphate (0.071 g, 0.334mmol), PdCl₂(AmPhos)₂ (7.88 mg, 0.011 mmol), 2-fluoropyridin-3-ylboronicacid (0.020 g, 0.139 mmol), and(R)-2′-bromo-7′-(2-fluoropyridin-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(0.049 g, 0.111 mmol) were suspended in dioxane (2 mL) and water (0.5mL). Argon gas was blown through the vessel, which was sealed and heatedby microwave at 120° C. for 30 min. The mixture was concentrated, andthe residue was diluted with brine (15 mL), and the aqueous phase wasextracted with 5% MeOH-dcm (3×25 mL). The organics were combined, driedover sodium sulfate and concentrated. The residue was purified bychromatography (3.5%-4.5% MeOH/DCM) to afford(R)-2′-(2-fluoropyridin-3-yl)-7′-(2-fluoropyridin-4-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(35 mg, 0.076 mmol). MS (_(m/z)) 457 (M+H)⁺.

¹H NMR (400 MHz, CDCl₃) δ ppm; 8.25 (d, 1 H, J=5.3 Hz), 8.19 (d, 1 H,J=8.2 Hz), 7.89 (m, 1 H), 7.56 (m, 4 H), 7.40 (d, 1 H, J=5.1 Hz), 7.29(m, 4 H), 7.13 (s, 1 H), 4.60 (br, 2 H), 4.34 (s, 2 H), 3.59 (m, 2 H).

Example 66 Method A37

Synthesis of(S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(5-(prop-1-ynyl)pyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

Step 1: In a 500-mL flask, the(S)-2′-bromo-4′-fluoro-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(0.676 g, 1.719 mmol) was suspended in dcm (50 mL). The suspension wascooled to 0° C., and a DCM solution of tribromoborane (1.0 M, 5.16 mL,5.16 mmol) was added. After 1.5 h, the reaction was quenched with 9:1aqueous NH₄Cl/NH₄OH (20 mL). The aqueous phase was extracted with 5%MeOH/DCM (3×50 mL). The organics were combined, washed with brine (15mL), dried over sodium sulfate and concentrated to afford crude(S)-5-amino-2′-bromo-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(604 mg, 1.593 mmol) which was used directly in the next step.Step 2: In a microwave vial, the potassium phosphate (1.014 g, 4.78mmol), PdCl₂(AmPhos)₂ (0.085 g, 0.119 mmol),(S)-5-amino-2′-bromo-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.604 g, 1.593 mmol), and2-(5,6-dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(0.485 g, 2.310 mmol) were suspended in dioxane (6.5 mL) and water (2.5mL). Argon gas was blown through the vessel, which was sealed and heatedby microwave at 120° C. for 30 min. The mixture was concentrated. Theresidue was neutralized with half-saturated aqueous NH₄Cl (35 mL). Theaqueous phase was extracted with 5% MeOH/DCM (3×35 mL). The organicswere combined, washed with dilute brine (15 mL), dried over sodiumsulfate and concentrated to afford crude(S)-5-amino-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-olwhich was used directly in the next step.Step 3: In a 250-mL flask, the crude(S)-5-amino-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-7′-ol(0.609 g, 1.593 mmol) was suspended in THF (30 mL). Boc₂O (0.564 g, 2.58mmol) was added, followed by triethylamine (0.373 mL, 2.69 mmol). Themixture was stirred at rt. After 1.5 h, the reaction was concentrated toafford crude (S)-tert-butyl2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-hydroxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamatewhich was used directly in the next step.Step 4: In a 250-mL flask, the (S)-tert-butyl2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-hydroxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-5-ylcarbamate(0.768 g, 1.592 mmol) was dissolved in DCM (25 mL). The solution wascooled to 0° C. TEA (0.533 mL, 3.85 mmol) was added, followed by1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide(1.25 g, 3.50 mmol). After 2 h, the reaction was concentrated. Withoutworking it up, the residue was purified by chromatography (25%EtOAc/hexanes) to afford(S)-5-(tert-butoxycarbonylamino)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (436 mg, 0.709 mmol).Step 5: In a microwave vial, diisopropyl5-(prop-1-ynyl)pyridin-3-ylboronate (0.109 g, 0.443 mmol),(S)-5-(tert-butoxycarbonylamino)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthene]-7′-yltrifluoromethanesulfonate (0.218 g, 0.355 mmol), and Pd(PPh₃)₄ (0.041 g,0.035 mmol) were taken up in DMF (3.7 mL). Aqueous sodium carbonate (1.0M, 1.064 mL, 1.064 mmol) was added. Argon gas was blown through thevessel, which was sealed and heated in an 85° C. oil bath for 1.5 h. Thereaction was concentrated. The residue was taken up in water (10 mL) andthe aqueous phase was extracted with 5% MeOH/DCM (3×20 mL). The organicswere combined, washed with dilute brine (5 mL), dried over sodiumsulfate and concentrated. The residue was transferred to a microwavevial in DCM (2 mL), and TFA (0.683 mL, 8.87 mmol) was added. The vesselwas sealed and heated in a 50° C. oil bath for 1.5 h. The reaction wasconcentrated, and the residue was neutralized with 0.5 M aqueous Na₂CO₃(15 mL). The aqueous phase was extracted with 5% MeOH/DCM (3×20 mL). Theorganics were combined, washed with dilute brine (6 mL), dried oversodium sulfate and concentrated. The residue was purified bychromatography (7% MeOH/DCM) to afford(S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(5-(prop-1-ynyl)pyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine(98 mg, 0.203 mmol).

MS (m/z) 482 (M+H)⁺.

Example 67 Method A38

Synthesis of(3S)-2′-(2,2-dimethylpropoxy)-7′-(2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine

Step 1: In a 25-mL flask, the2′-bromo-7′-methoxyspiro[morpholine-3,9′-xanthen]-5-one (0.094 g, 0.250mmol) was dissolved in DCM (5 mL). The solution was cooled to −78° C.,and a solution of boron tribromide (1.0 M, 0.750 mL, 0.750 mmol) in DCMwas added. The mixture was warmed to 0° C. and held at that temperaturefor 2 h. The reaction was diluted with water (20 mL) and the aqueousphase was extracted with 3% MeOH/DCM (3×25 mL). The organics werecombined, washed with dilute brine (5 mL), dried over sodium sulfate,and concentrated. The residue was purified by chromatography (70:30:1EtOAc/hexane/MeOH) toafford(R)-2′-bromo-7′-hydroxyspiro[morpholine-3,9′-xanthen]-5-one.Step 2: In a 25-ml flask,2′-bromo-7′-hydroxyspiro[morpholine-3,9′-xanthen]-5-one (0.020 g, 0.055mmol) was dissolved in DMF (1 mL). Cesium carbonate (0.043 g, 0.133mmol) was added, followed by 1-iodo-2,2-dimethylpropane (0.022 g, 0.110mmol). The reaction was heated in a 115° C. oil bath for 10 h. Thereaction was cooled to ambient temperature and concentrated. The residuewas taken up in 0.3 M aqueous HCl (15 mL) and the aqueous layer wasextracted with EtOAc (3×20 mL). The organic layers were combined, washedwith saturated brine (5 mL), dried over sodium sulfate, andconcentrated. The residue was purified by chromatography (25%EtOAc/hexane) to afford(R)-2′-bromo-7′-(neopentyloxy)spiro[morpholine-3,9′-xanthen]-5-one.Steps 3 and 4:(R)-2′-Bromo-7′-(neopentyloxy)spiro[morpholine-3,9′-xanthen]-5-one(0.0068 g, 0.016 mmol) was converted to(3R)-2′-bromo-7′-(2,2-dimethylpropoxy)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amineusing procedures analogous to that described in steps 1 and 2 in methodA12 (Example 67a).Step 5: In a microwave vessel, potassium phosphate (0.012 g, 0.056mmol),bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II)(0.985 mg, 1.391 μmol) and 2-fluoropyridin-3-ylboronic acid (5.23 mg,0.037 mmol) were loaded as solids, and(3R)-2′-bromo-7′-(2,2-dimethylpropoxy)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine(0.008 g, 0.019 mmol) was added via cannula as a solution in dioxane (1mL). Water (0.25 mL) was added to the vessel, and the mixture was purgedwith argon gas, then the vessel was sealed and heated in microwaveradiation at 135° C. for 30 min. The material was taken up in water (10mL) and the aqueous phase was extracted with DCM (3×20 mL). The organicswere combined, washed with dilute brine (5 mL), dried over sodiumsulfate, and concentrated. The material was purified by preparative TLC(13% MeOH/DCM) to afford(3S)-2′-(2,2-dimethylpropoxy)-7′-(2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine.

Example 68 Method A39

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-((R)-3-fluoropyrrolidin-1-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

Step 1: A vial was charged with 2-fluoropyridin-3-ylboronic acid (0.094g, 0.667 mmol), PdCl₂(dppf)-CH₂Cl₂-adduct (0.026 g, 0.032 mmol),(S)-3-bromo-7-iodo-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.300 g, 0.635 mmol), and potassium carbonate (0.351 g, 2.54 mmol).Dioxane (3.5 mL) and water (1.5 mL) were added. The vial was flushedwith argon, sealed and heated to 80° C. for 1 hour. The reaction mixturewas then diluted with EtOAc, dried over MgSO₄ and concentrated.Purification of the crude residue by column chromatography [0-80%(90:10:1 DCM/MeOH/NH4OH)/DCM] gave(S)-3-bromo-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.202 g, 0.458 mmol)Step 2: A vial was charged with (R)-3-fluoropyrrolidine HCl (0.021 g,0.170 mmol),(S)-3-bromo-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.050 g, 0.113 mmol) and RuPhos palladacycle (9.05 mg, 0.011 mmol). THF(1 mL) and LiHMDS (1N in THF; 0.567 mL, 0.567 mmol) were added, and thereaction mixture was allowed to stir at RT overnight. Additional RuPhospalladacycle (9.05 mg, 0.011 mmol) and LiHMDS solution (0.567 mL, 0.567mmol) were added, and the reaction mixture was heated to 45° C. for 2hours. The reaction mixture was then quenched with MeOH and concentratedunder reduced pressure. Purification of the crude residue by columnchromatography [0-100% (90:10:1 DCM/MeOH/NH4OH)/DCM] gave(S)-7-(2-fluoropyridin-3-yl)-3-((R)-3-fluoropyrrolidin-1-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine(0.018 g, 0.040 mmol, 35.3% yield).

The following compounds in Table I are additional representativeexamples of compounds of Formulas I, I-A, I-A-1 through I-A-7, I-B, II,II-A and II-B provided by the present invention. The methods andintermediates used to prepare each compound are also included in theTable, along with the mass found and biological data (average nM IC₅₀'sfor the enzyme and cell assays) where available. The names of thecompounds were generated using the naming convention of the ChemDrawUltra software, version 11 and above. Where the example is a racemicmixture, the name for that example includes both enantiomers. Individualenantiomers of examples are as indicated in the name.

TABLE I BACE 1 HEK FRET cell Ex. Observed Intermediate assay assay No.Compound Name Mass Method used (uM) (uM)  9 (5R)-7-bromo-3-chloro-6′H-380 Procedure I Intermediate 2 4.1333 10spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,(5S)-7-bromo-3-chloro- 6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine  69 (5R)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-458.1 A1 Intermediate 0.0009 0.0055pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 105,3′-[1,4]oxazin]-5′-amine, (5S)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine  9B(5R)-7-bromo-3-chloro-6′H- 380 Procedure I Intermediate 2 23.128 10spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine  9A(5S)-7-bromo-3-chloro-6′H- 380 Procedure I Intermediate 2 4.1525 10spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine  70(5R)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4- 458.2 A1 Intermediate0.0524 0.2676 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10A5,3′-[1,4]oxazin]-5′-amine  30(5S)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4- 458.2 A1 Intermediate0.0003 0.0017 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10A5,3′-[1,4]oxazin]-5′-amine  71(5S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(2-fluoro- 445.2 A1 Intermediate0.0004 0.0012 3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine  72(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro- 445.2 A1 Intermediate0.0004 0.0006 3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine  31(5S)-7-(2-fluoro-3-pyridinyl)-3-((3-methyl-3- 457.2 A2 Intermediate0.0007 0.0015 oxetanyl)ethynyl)-6′H-spiro[chromeno[2,3- 10Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine  73(5S)-3-(3,4-difluorophenyl)-7-(2-fluoro-3- 475.2 A1 Intermediate 0.00030.0027 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10b5,3′-[1,4]oxazin]-5′-amine  74(5S)-3-(3,3-difluoro-1-pyrrolidinyl)-7-(2-fluoro- 468.2 A3 Intermediate0.0004 0.0008 3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10b5,3′-[1,4]oxazin]-5′-amine  32(5S)-3-(4,4-difluoro-1-piperidinyl)-7-(2-fluoro-3- 482.1 A3 Intermediate0.0006 0.0012 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine  33(5S)-3-(2,2-dimethylpropoxy)-7-(2-fluoro-3- 449.2 A4 Intermediate 0.00040.0011 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine  75(5S)-3-(2-fluoro-4-pyridinyl)-7-(5-(1-propyn-1- 478.2 A1 Intermediate0.0005 0.0028 yl)-3-pyridinyl)-6′H-spiro[chromeno[2,3- 10Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine  76(5S)-3-(6,6-dimethyl-3,6-dihydro-2H-pyran-4- 474.2 A1 Intermediate0.0006 0.0007 yl)-7-(2-fluoro-3-pyridinyl)-6′H- 10Bspiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine  77(5S)-3-(2,2-dimethyl-3,6-dihydro-2H-pyran-4- 474.2 A1 Intermediate0.0007 0.0005 yl)-7-(2-fluoro-3-pyridinyl)-6′H- 10bspiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine  34(5S)-7-(2-fluoro-3-pyridinyl)-3-(tetrahydro-2H- 447.2 A5 Intermediate0.0007 0.0009 pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine  78(5S)-3-(2-fluoro-4-pyridinyl)-7-(5-pyrimidinyl)- 441.2 A1 Intermediate0.0005 0.0011 6′H-spiro[chromeno[2,3-c]pyridine-5,3′- 10B[1,4]oxazin]-5′-amine  79 (5S)-3-(3,4-difluorophenyl)-7-(5-pyrimidinyl)-458.2 A1 Intermediate 0.0003 0.00086′H-spiro[chromeno[2,3-c]pyridine-5,3′- 10B [1,4]oxazin]-5′-amine  80(5S)-7-(2-fluoro-3-pyridinyl)-3-((3R)-tetrahydro- 447.2 A5 Intermediate0.0039 0.0058 2H-pyran-3-yl)-6′H-spiro[chromeno[2,3- 10Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine  81(5S)-7-(2-fluoro-3-pyridinyl)-3-((3S)-tetrahydro- 447.2 A5 Intermediate0.0037 0.0041 2H-pyran-3-yl)-6′H-spiro[chromeno[2,3- 10Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine  36B(3R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(2- 475 A7 Intermediate0.1403 0.628 fluoro-4-pyridinyl)-6H-spiro[1,4-oxazine-3,9′- 13Axanthen]-5-amine  36A (3S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(2-475 A7 Intermediate 0.0004 0.0029fluoro-4-pyridinyl)-6H-spiro[1,4-oxazine-3,9′- 13A xanthen]-5-amine  35A(3S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(4- 465 A6 Intermediate0.0005 0.0019 morpholinyl)-6H-spiro[1,4-oxazine-3,9′- 13Bxanthen]-5-amine  35B (3R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(4-465 A6 Intermediate 0.211 0.0862 morpholinyl)-6H-spiro[1,4-oxazine-3,9′-13A xanthen]-5-amine  82(3R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3- 480 A8 Intermediate0.043 0.1212 methyl-3-oxetanyl)methoxy)-6H-spiro[1,4- 13Aoxazine-3,9′-xanthen]-5-amine  83(3S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3- 480 A8 Intermediate0.0004 0.0004 methyl-3-oxetanyl)methoxy)-6H-spiro[1,4- 13Boxazine-3,9′-xanthen]-5-amine  37A(3S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′- 470 A8 Intermediate0.0002 0.0013 (2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′- 13Bxanthen]-5-amine  37B (3R)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-470 A8 Intermediate 0.1096 0.0641(2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′- 13A xanthen]-5-amine 84 (3R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3R)- 467 A6Intermediate 0.0004 0.00223-fluoro-1-pyrrolidinyl)-6H-spiro[1,4-oxazine- 13A 3,9′-xanthen]-5-amine 85 (3S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3R)- 467 A6Intermediate 0.0397 0.10083-fluoro-1-pyrrolidinyl)-6H-spiro[1,4-oxazine- 13B 3,9′-xanthen]-5-amine 86 (3R)-2′-(4,4-difluoro-1-piperidinyl)-4′-fluoro-7′- 499 A6Intermediate 0.0005 0.0026(2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′- 13A xanthen]-5-amine 87 (5S)-7-(2-fluoro-3-pyridinyl)-3-((3-methyl-3- 457 A2 Intermediate0.002 0.0013 oxetanyl)ethynyl)-6′H-spiro[chromeno[2,3- 11Bb]pyridine-5,3′-[1,4]oxazin]-5′-amine  88(5R)-7-(2-fluoro-3-pyridinyl)-3-((3-methyl-3- 457 A2 Intermediate 0.33180.1975 oxetanyl)ethynyl)-6′H-spiro[chromeno[2,3- 11Ab]pyridine-5,3′-[1,4]oxazin]-5′-amine  89(5S)-3-(3,3-dimethyl-1-butyn-1-yl)-7-(2-fluoro- 443 A2 Intermediate0.0007 0.0004 3-pyridinyl)-6′H-spiro[chromeno[2,3-b]pyridine- 11B5,3′-[1,4]oxazin]-5′-amine  90 (5S)-7-(2-fluoro-3-pyridinyl)-3-(4- 453A22 Intermediate 0.0006 0.0012 methylphenyl)-6′H-spiro[chromeno[2,3- 11Bb]pyridine-5,3′-[1,4]oxazin]-5′-amine  91(5S)-3-(4-fluorophenyl)-7-(2-fluoro-3-pyridinyl)- 457 A22 Intermediate0.0005 0.0007 6′H-spiro[chromeno[2,3-b]pyridine-5,3′- 11B[1,4]oxazin]-5′-amine  68(5S)-7-(2-fluoro-3-pyridinyl)-3-((3R)-3-fluoro-1- 450 A39 Intermediate0.0014 0.0012 pyrrolidinyl)-6′H-spiro[chromeno[2,3-b]pyridine- 11B5,3′-[1,4]oxazin]-5′-amine  92(5S)-7-(5-chloro-2-fluorophenyl)-3-((3R)-3- 483 A39 Intermediate 0.00060.0019 fluoro-1-pyrrolidinyl)-6′H-spiro[chromeno[2,3- 11Bb]pyridine-5,3′-[1,4]oxazin]-5′-amine  93(5S)-7-(5-chloro-2-fluorophenyl)-3-(4- 481 A39 Intermediate 0.00070.0039 morpholinyl)-6′H-spiro[chromeno[2,3- 11Bb]pyridine-5,3′-[1,4]oxazin]-5′-amine  94(5S)-7-(5-chloro-2-fluorophenyl)-3-(8-oxa-3- 507 A39 Intermediate 0.00130.0013 azabicyclo[3.2.1]oct-3-yl)-6′H- 11Bspiro[chromeno[2,3-b]pyridine-5,3′- [1,4]oxazin]-5′-amine  95(5S)-7-(5-chloro-2-fluorophenyl)-3-((3-methyl- 490 A2 Intermediate0.0005 0.0012 3-oxetanyl)ethynyl)-6′H-spiro[chromeno[2,3- 11Bb]pyridine-5,3′-[1,4]oxazin]-5′-amine  96(5S)-3-(3,3-dimethyl-1-butyn-1-yl)-8-fluoro-7- 444 A2 Intermediate0.0012 0.0006 (5-pyrimidinyl)-6′H-spiro[chromeno[2,3- 12b]pyridine-5,3′-[1,4]oxazin]-5′-amine  97(5R)-3-(3,3-dimethyl-1-butyn-1-yl)-8-fluoro-7- 444 A2 Intermediate0.4186 0.273 (5-pyrimidinyl)-6′H-spiro[chromeno[2,3- 12b]pyridine-5,3′-[1,4]oxazin]-5′-amine  13(4R)-2′-bromo-7′-iodo-5,6-dihydrospiro[1,3- 487, Procedure M 9.9592 10thiazine-4,9′-xanthen]-2-amine, (4S)-2′-bromo- 4897′-iodo-5,6-dihydrospiro[1,3-thiazine-4,9′- xanthen]-2-amine  982′,7′-di-5-pyrimidinyl-5,6-dihydrospiro[1,3- 439 A1 Intermediate 0.25720.6346 thiazine-4,9′-xanthen]-2-amine 14  992′,7′-di-3-pyridinyl-5,6-dihydrospiro[1,3- 437 A1 Intermediate 0.08180.1184 thiazine-4,9′-xanthen]-2-amine 14 100(5R)-3,7-bis(2-fluoro-3-pyridinyl)-5′,6′- 458.1 A1 Intermediate 0.04960.184 dihydrospiro[chromeno[2,3-c]pyridine-5,4′- 18[1,3]oxazin]-2′-amine, (5S)-3,7-bis(2-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 101(5R)-1-fluoro-3,7-bis(2-fluoro-3-pyridinyl)-5′,6′- 476.1 A1 Intermediate0.0146 0.0459 dihydrospiro[chromeno[2,3-c]pyridine-5,4′- 15[1,3]oxazin]-2′-amine, (5S)-1-fluoro-3,7-bis(2-fluoro-3-pyridinyl)-5′,6′- dihydrospiro[chromeno[2,3-c]pyridine-5,4′-102 (5R)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4- 457.9 A1 Intermediate0.025 0.0366 pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3- 18c]pyridine-5,4′-[1,3]oxazin]-2′-amine, (5S)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 103(5R)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(2- 475.9 A1 Intermediate0.0022 0.0069 fluoro-4-pyridinyl)-5′,6′- 15dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine,(5S)-1-fluoro-7-(2-fluoro- 3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 104(5R)-1-fluoro-3,7-bis(2-fluoro-3-pyridinyl)-5′,6′- 475.9 A1 Intermediate1.7445 1.9035 dihydrospiro[chromeno[2,3-c]pyridine-5,4′- 15A[1,3]oxazin]-2′-amine 105(5S)-1-fluoro-3,7-bis(2-fluoro-3-pyridinyl)-5′,6′- 475.9 A1 Intermediate0.0206 0.0242 dihydrospiro[chromeno[2,3-c]pyridine-5,4′- 15B[1,3]oxazin]-2′-amine 106 (5R)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(2-475.9 A1 Intermediate 1.7387 2.639 fluoro-4-pyridinyl)-5′,6′- 15Adihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 107(5S)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(2- 475.9 A1 Intermediate0.0005 0.0018 fluoro-4-pyridinyl)-5′,6′- 15Bdihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 108(5S)-3-(3,6-dihydro-2H-pyran-4-yl)-1-fluoro-7- 463 A1 Intermediate0.0006 0.0006 (2-fluoro-3-pyridinyl)-5′,6′- 15Bdihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 109(5R)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(2-fluoro- 445.1 A1 Intermediate2.8157 0.5792 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3- 18Ac]pyridine-5,4′-[1,3]oxazin]-2′-amine 110(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7- 463 A1 Intermediate0.0005 0.0005 (2-fluoro-3-pyridinyl)-5′,6′- 15Bdihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 111(5S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(2-fluoro- 445.1 A1 Intermediate0.0018 0.0021 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3- 18Bc]pyridine-5,4′-[1,3]oxazin]-2′-amine 112(5S)-3,7-bis(5-fluoro-3-pyridinyl)-6′H- 458.4 A1 Intermediate 0.00050.0015 spiro[chromeno[2,3-c]pyridine-5,3′- 10B [1,4]oxazin]-5′-amine 113(5S)-3-(2-fluoro-4-pyridinyl)-7-(5-fluoro-3- 458.4 A1 Intermediate0.0005 0.001 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine 114(5S)-3-(3,4-difluorophenyl)-7-(5-fluoro-3- 475.2 A1 Intermediate 0.00040.0023 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine 115(5S)-3-(3,4-difluorophenyl)-7-(3-pyridinyl)-6′H- 457.2 A1 Intermediate0.0004 0.0016 spiro[chromeno[2,3-c]pyridine-5,3′- 10B[1,4]oxazin]-5′-amine 116(5S)-3-(2-fluoro-4-pyridinyl)-7-(3-pyridinyl)-6′H- 440.4 A1 Intermediate0.0006 0.0008 spiro[chromeno[2,3-c]pyridine-5,3′- 10B[1,4]oxazin]-5′-amine 117 (5S)-3-(3,4-difluorophenyl)-7-(4-fluoro-3-475.2 A1 Intermediate 0.0003 0.0016pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine 118(5S)-3-(2-fluoro-4-pyridinyl)-7-(4-fluoro-3- 458.4 A1 Intermediate0.0004 0.0006 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine  43N-((5S)-3-(2,2-dimethylpropoxy)-7-(2-fluoro-3- 477.3 A14 Intermediate0.0174 0.0012 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-yl)formamide 119(5S)-3-(2,2-dimethylpropoxy)-7-(3-pyridinyl)- 431.4 A4 Intermediate0.0006 0.0004 6′H-spiro[chromeno[2,3-c]pyridine-5,3′- 10B[1,4]oxazin]-5′-amine 120 (5S)-3-(2,2-dimethylpropoxy)-7-(5-fluoro-3-449.4 A4 Intermediate 0.0006 0.0007pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine 121(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(5-fluoro- 445.2 A1 Intermediate0.0005 0.0002 3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine 122(5S)-3-(3,3-difluoro-1-pyrrolidinyl)-7-(5-fluoro- 468.3 A3 Intermediate0.0006 0.0003 3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 10B5,3′-[1,4]oxazin]-5′-amine 123(5S)-7-(2-fluoro-3-pyridinyl)-3-methoxy-6′H- 393.3 A21 Intermediate0.0022 0.0033 spiro[chromeno[2,3-c]pyridine-5,3′- 21[1,4]oxazin]-5′-amine 124 (5S)-3-methoxy-7-(3-pyridinyl)-6′H- 375.2 A21Intermediate 0.0068 0.0051 spiro[chromeno[2,3-c]pyridine-5,3′- 21[1,4]oxazin]-5′-amine 125 (5S)-7-(2-chloro-5-fluorophenyl)-3-methoxy-426.3 A21 Intermediate 0.0022 0.01246′H-spiro[chromeno[2,3-c]pyridine-5,3′- 21 [1,4]oxazin]-5′-amine 1263-(((5S)-5′-amino-7-(3-fluorophenyl)-6′H- 459.3 A4 Intermediate 0.00040.0015 spiro[chromeno[2,3-c]pyridine-5,3′- 10B[1,4]oxazin]-3-yl)oxy)-2,2- dimethylpropanenitrile 1273-(((5S)-5′-amino-7-(5-chloro-2-fluorophenyl)- 493.2 A4 Intermediate0.0003 0.0014 6′H-spiro[chromeno[2,3-c]pyridine-5,3′- 10B[1,4]oxazin]-3-yl)oxy)-2,2- dimethylpropanenitrile 128(5S)-7-bromo-3-(4,4-difluoro-1-piperidinyl)-1- 482.9 A29 0.0173 0.1094fluoro-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine 129(5S)-3-(4,4-difluoro-1-piperidinyl)-1-fluoro-7-(2- 500 A29 0.0009 0.0049fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine  39(3S)-5-amino-5′-fluoro-7′-(2-fluoro-4-pyridinyl)- 396 A10 Intermediate0.3682 2.5925 6H-spiro[1,4-oxazine-3,9′-xanthen]-2′-ol 29  65(3R)-2′-(2-fluoro-3-pyridinyl)-7′-(2-fluoro-4- 457 A36 Intermediate0.0016 0.0182 pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]- 27 5-amine 64 (3R)-2′-(3,6-dihydro-2H-pyran-4-yl)-7′-(2- 444 A35 Intermediate0.0006 0.0052 fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′- 31xanthen]-5-amine  40 (3S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′-462 A11 Intermediate 0.0003 0.003(2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′- 28 xanthen]-5-amine130 (3R)-2′-(5,6-dihydro-2H-pyran-3-yl)-7′-(2- 444 A35 Intermediate0.0007 0.0122 fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′- 31xanthen]-5-amine  41 (3S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3-474 A12 Intermediate 0.0005 0.0019methyl-3-oxetanyl)ethynyl)-6H-spiro[1,4- 28oxazine-3,9′-xanthen]-5-amine 131(3S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′- 482 A37 Intermediate0.0007 0.0025 (5-(1-propyn-1-yl)-3-pyridinyl)-6H-spiro[1,4- 29oxazine-3,9′-xanthen]-5-amine  66(3S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′- 482 A37 Intermediate0.0005 0.0015 (5-(1-propyn-1-yl)-3-pyridinyl)-6H-spiro[1,4- 29oxazine-3,9′-xanthen]-5-amine 132(3S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′- 462 A37 Intermediate0.0003 0.0013 (2-fluoro-3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′- 29xanthen]-5-amine  42 (3S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′- 464A13 0.0004 0.0024 (tetrahydro-2H-pyran-4-yl)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine  63(3S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′- 444 A34 Intermediate0.0003 0.0005 (3-pyridinyl)-6H-spiro[1,4-oxazine-3,9′- 28xanthen]-5-amine 133 (3S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-445 A34 Intermediate 0.0003 0.0004(5-pyrimidinyl)-6H-spiro[1,4-oxazine-3,9′- 28 xanthen]-5-amine 134(3R)-2′-bromo-7′-methoxy-6H-spiro[1,4- 375/377 Procedure 7.1087 10oxazine-3,9′-xanthen]-5-amine ZZ 135(3R)-2′-bromo-7′-(2,2-dimethylpropoxy)-6H- 431/433 A38 Intermediate0.1017 0.5873 spiro[1,4-oxazine-3,9′-xanthen]-5-amine 30  67(3S)-2′-(2,2-dimethylpropoxy)-7′-(2-fluoro-3- 448 A38 Intermediate 0.0020.0155 pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]- 30 5-amine 136(4R/S)-2′-bromo-7′-methoxy-5,6- 390.9/392.9 28 Intermediate 1 23.658 10dihydrospiro[1,3-thiazine-4,9′-xanthen]-2- amine 137(4R/S)-2′-methoxy-7′-(5-pyrimidinyl)-5,6- 391 28 Intermediate 1 1.13331.1404 dihydrospiro[1,3-thiazine-4,9′-xanthen]-2- amine 138(5S)-7-(2-fluoro-3-pyridinyl)-3-phenyl-5′,6′- 439.1 A1 18B 0.0041dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 139(5S)-3-(3,3-dimethyl-1-butyn-1-yl)-7-(5-fluoro- 443 A2 18B 0.0128 0.00693-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 140(5S)-7-(5-fluoro-3-pyridinyl)-3-(3-pyridinyl)- 440 A1 18B 0.0108 0.00345′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine141 (5S)-3-(5-chloro-3-pyridinyl)-7-(2-fluoro-3- 473.9 A1 18B 0.00950.0225 pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 142(5S)-3,7-bis(5-fluoro-3-pyridinyl)-5′,6′- 458 A1 18B 0.0062 0.0042dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 143(5S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(5-fluoro- 445.1 A1 18B 0.00570.0037 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 144(5S)-7-(2-fluoro-3-pyridinyl)-3-(tetrahydro-2H- 447 A5 18B 0.0132 0.0354pyran-4-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 145(5S)-3-(2-fluoro-4-pyridinyl)-7-(5-fluoro-3- 458 A1 18B 0.005 0.004pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 146(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(5-fluoro- 445.1 A1 18B 0.00220.0015 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 147(5R)-7-(2-fluoro-3-pyridinyl)-3-(3-pyridinyl)- 440 A1 18B 0.132 0.1325′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine148 (5S)-7-(2-fluoro-3-pyridinyl)-3-(3-pyridinyl)- 440 A1 18B 0.00460.0041 5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 149 (5S)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-458 A1 18B 0.0048 0.0038 pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 150 3,7-di-3-pyridinyl-5′,6′- 422A1 18B 0.013 0.0103 dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 151 3-(3,6-dihydro-2H-pyran-4-yl)-7-(3-pyridinyl)-427.1 A1 18B 0.0073 0.00345′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine152 (5R)-7-(2-fluoro-3-pyridinyl)-3-(5-fluoro-3- 458 A1 18B 0.23840.1081 pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 153(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro- 445.1 A1 18B 0.0020.0026 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 154(5S)-3-(3,3-dimethyl-1-butyn-1-yl)-7-(2-fluoro- 443 A2 18B 0.0058 0.0053-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 155(5S)-7-(2-fluoro-3-pyridinyl)-3-(5-fluoro-3- 458 A1 18B 0.0038 0.0062pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine  44(5S)-7-(4,4-difluoro-1-piperidinyl)-3-(2,2- 473.2 A15 10B 0.0105 0.0193dimethylpropoxy)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine  48(3S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′- 410 A19 13B 0.0015 0.0156methoxy-6H-spiro[1,4-oxazine-3,9′-xanthen]-5- amine  45(3S)-7′-(4,4-difluoro-1-piperidinyl)-4′-fluoro-2′- 434.2 A16 13B 0.15780.4203 methoxy-6H-spiro[1,4-oxazine-3,9′-xanthen]-5- amine 156(4S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′- 443.8 A7 20B 0.00480.0042 (3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine157 (4R)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′- 443.8 A7 20A0.7839 0.0781 (3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 158 (4R)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-452 A8 20A 0.9406 0.393 (3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 159 (4R)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-444.2 A7 20A 0.6156 0.0713(3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine 160(4S)-4′-fluoro-2′-((3-methyl-3- 461.9 A8 20A 0.0063 0.0059oxetanyl)methoxy)-7′-(3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2- amine  20(4R)-7′-bromo-4′-fluoro-2′-methoxy-5,6- 394.2 Procedure T 15.44 10dihydrospiro[1,3-oxazine-4,9′-xanthen]-2- amine,′(4S)-7′-bromo-4′-fluoro-2′-methoxy-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2- 161(4R)-4′-fluoro-2′-((3-methyl-3- 461.9 A8 20A 2.782 0.3329oxetanyl)methoxy)-7′-(3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2- amine 162(4R)-2′-(4,4-difluoro-1-piperidinyl)-4′-fluoro-7′- 498.9 A6 20A 0.95823.0182 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 163(4S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′- 461.8 A7 20B 0.00260.006 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 164(4S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′- 444.2 A7 20B 0.00280.0027 (3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine 17A (4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3- 473.8 A18 20B0.0033 0.0026 methyl-3-oxetanyl)ethynyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2- amine  17B(4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3- 473.8 A18 20A 0.22430.4702 methyl-3-oxetanyl)ethynyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2- amine 165(4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(4- 456.8 A7 20A 0.55330.248 pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine 166(4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(4- 456.8 A7 20B 0.0060.0082 pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine167 (4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(3- 456.8 A7 20A 0.14730.1095 pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine168 (4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(3- 456.8 A7 20B 0.00350.0063 pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine169 (4R)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′- 461.8 A7 20A3.0734 3.4016 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 170(4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′- 410 A19 20 0.1016 0.2721methoxy-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine,′(4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-methoxy-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 171(4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3- 479.8 A8 20A 0.52470.2451 methyl-3-oxetanyl)methoxy)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2- amine 172(4R)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′- 461.8 A7 20A 1.19381.0675 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 173(4S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′- 461.8 A7 20B 0.00110.0029 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 174(4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′- 409.9 A19 20A 4.2221 10methoxy-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine 175(4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′- 409.9 A19 20B 0.0383 0.093methoxy-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine 176(4S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′- 452 A8 20B 0.00610.0085 (3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine177 (4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3R)- 466.8 A6 20A0.8922 2.5323 3-fluoro-1-pyrrolidinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 178(4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3R)- 466.8 A6 20B 0.0040.0101 3-fluoro-1-pyrrolidinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 179(4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(4- 464.8 A6 20A 5.18722.8172 morpholinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine 46 (3S)-7′-(4,4-difluoro-1-piperidinyl)-4′-fluoro-2′- 503.8 A17 20B0.0094 0.0321 ((3-methyl-3-oxetanyl)methoxy)-6H-spiro[1,4-oxazine-3,9′-xanthen]-5-amine 180(4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3- 479.8 A8 20B 0.00230.0032 methyl-3-oxetanyl)methoxy)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2- amine 181(4R)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′- 469.8 A8 20A 1.37111.1607 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 182(4S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′- 469.8 A8 20B 0.00250.0041 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 183(4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(2- 474.9 A7 20 0.007 0.0154fluoro-4-pyridinyl)-5,6-dihydrospiro[1,3- oxazine-4,9′-xanthen]-2-amine,′(4S)-4′-fluoro- 7′-(2-fluoro-3-pyridinyl)-2′-(2-fluoro-4-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2- amine 184(4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-(4- 464.8 A6 20 0.00480.0069 morpholinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′- xanthen]-2-amine,′(4S)-4′-fluoro-7′-(2-fluoro-3- pyridinyl)-2′-(4-morpholinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2- amine 185(4S)-2′-(4,4-difluoro-1-piperidinyl)-4′-fluoro-7′- 498.8 A6 20B 0.00440.0096 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-oxazine-4,9′-xanthen]-2-amine 186(4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′- 425.8 A19 23 9.5873 10methoxy-5,6-dihydrospiro[1,3-thiazine-4,9′- xanthen]-2-amine 187(4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′- 425.8 A19 23 0.0299 0.159methoxy-5,6-dihydrospiro[1,3-thiazine-4,9′- xanthen]-2-amine 188(5S)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4- 473.8 A1 22 0.0026 0.0111pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]thiazin]-2′-amine 189(5R)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4- 473.8 A1 22 2.3918 3.2804pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]thiazin]-2′-amine 190(4R)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′- 477.8 A7 23 0.46160.434 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2-amine 191(4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′- 425.8 A19 23 0.0873 0.3745methoxy-5,6-dihydrospiro[1,3-thiazine-4,9′- xanthen]-2-amine,′(4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-methoxy-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2-amine 192(5R)-3-chloro-7-(2-fluoro-3-pyridinyl)-5′,6′- 412.8 A1 22 3.3485 5.6113dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]thiazin]-2′-amine 193(5S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(2-fluoro- 461.2 A1 22 0.00330.0047 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]thiazin]-2′-amine 194(5R)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(2-fluoro- 461.2 A1 22 0.47340.9372 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]thiazin]-2′-amine 195(5R)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro- 461.2 A1 22 0.92181.9675 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]thiazin]-2′-amine 196(4R)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′- 478.2 A7 23 2.53090.0831 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2-amine 197(4S)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3- 495.8 A8 23 0.00250.0048 methyl-3-oxetanyl)methoxy)-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2- amine 198(4R)-4′-fluoro-7′-(2-fluoro-3-pyridinyl)-2′-((3- 495.8 A8 23 0.56330.6337 methyl-3-oxetanyl)methoxy)-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2- amine 199(5S)-3-chloro-7-(2-fluoro-3-pyridinyl)-5′,6′- 412.8 A1 22 0.0908 0.3922dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]thiazin]-2′-amine 200(4S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′- 478.2 A7 23 0.00270.0123 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2-amine 201(4S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′- 477.8 A7 23 0.00140.0097 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2-amine 202(4R)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′- 485.8 A8 23 0.86312.4276 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2-amine 204(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro- 461.2 A1 22 0.00160.0027 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]thiazin]-2′-amine 204(4S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′- 485.8 A8 23 0.00280.0112 (2-fluoro-3-pyridinyl)-5,6-dihydrospiro[1,3-thiazine-4,9′-xanthen]-2-amine  56A(5R,6′R)-3-chloro-6′-cyclohexyl-7-(2-fluoro-3- 479.1 A27  9 0.03070.1383 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine, ′(5S,6′S)-3-chloro-6′-cyclohexyl-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine 205(5S,6′S)-7-bromo-3-chloro-6′-(trifluoromethyl)- 450.0 A27  9 19.967 106′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5R,6′R)-7-bromo-3- chloro-6′-(trifluoromethyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5R,6′S)-7-bromo-3- chloro-6′-(trifluoromethyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5S,6′R)-7-bromo-3- chloro-6′-(trifluoromethyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine 206(5S,6′R)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′- 481.2 A27  9 0.33330.0687 (tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5R,6′S)-3-chloro-7-(2- fluoro-3-pyridinyl)-6′-(tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine 207(5R,6′R)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′- 481.2 A27  9 0.01150.0213 (tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5S,6′S)-3-chloro-7-(2- fluoro-3-pyridinyl)-6′-(tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine 208(5S,6′R)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′- 473.2 A27  9 0.08830.1344 phenyl-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine, ′(5R,6′S)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′-phenyl-6′H- spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine, ′(5R,6′R)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′-phenyl-6′H- spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine, ′(5S,6′S)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′-phenyl-6′H- spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine  56B(5R,6′S)-3-chloro-6′-cyclohexyl-7-(2-fluoro-3- 479.1 A27  9 1.27660.4516 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine, ′(5S,6′R)-3-chloro-6′-cyclohexyl-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine 209(5S,6′R)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′-(3- 474.0 A27  9 0.10440.6644 pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine, ′(5R,6′S)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′-(3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5S,6′S)-3-chloro-7-(2- 210(5R,6′S)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′- 411.1 A27  9 0.09080.2053 methyl-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine, ′(5R,6′R)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′-methyl-6′H- spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine, ′(5S,6′R)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′-methyl-6′H- spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine, ′(5S,6′S)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′-methyl-6′H- spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine 211 (5S,6′R)-7-bromo-3-chloro-6′-(tetrahydro-2H-466.0 A27  9 2.55 2.4526 pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine, ′(5R,6′S)-7-bromo-3-chloro-6′-(tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5R,6′R)-7-bromo-3- chloro-6′-(tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5S,6′S)-7-bromo-3- chloro-6′-(tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine 212(5S,6′R)-3-chloro-7-(2-fluoro-3-pyridinyl)-6′- 481.2 A27  9 0.02410.0327 (tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5R,6′S)-3-chloro-7-(2- fluoro-3-pyridinyl)-6′-(tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5R,6′R)-3-chloro-7-(2- fluoro-3-pyridinyl)-6′-(tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine,′(5S,6′S)-3-chloro-7-(2- fluoro-3-pyridinyl)-6′-(tetrahydro-2H-pyran-4-yl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine 213(5S)-7-(2-fluoro-3-pyridinyl)-3-(3-methyl-1- 429 A23 11B 0.0006 0.001butyn-1-yl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine  52 (5S)-3-(3,3-dimethyl-1-butyn-1-yl)-7-(3-425 A23 11B 0.0004 0.0003 pyridinyl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine  53(5S)-3,7-bis(3,3-dimethyl-1-butyn-1-yl)-6′H- 428 A24 11B 0.0054 0.0251spiro[chromeno[2,3-b]pyridine-5,3′- [1,4]oxazin]-5′-amine 214(5S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(3,3- 430 A25 11B 0.0032 0.0061dimethyl-1-butyn-1-yl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine 215(5S)-7-(2,5-difluorophenyl)-3-(tetrahydro-2H- 464 A2& 11B 0.0037 0.0032pyran-4-yl)-6′H-spiro[chromeno[2,3-b]pyridine- A135,3′-[1,4]oxazin]-5′-amine 216(5S)-7-(2,5-difluorophenyl)-3-(3-pyridinyl)-6′H- 457 A22 11B 0.00230.0028 spiro[chromeno[2,3-b]pyridine-5,3′- [1,4]oxazin]-5′-amine 217(5S)-7-(2,5-difluorophenyl)-3-(4-pyridinyl)-6′H- 457 A22 11B 0.00360.0043 spiro[chromeno[2,3-b]pyridine-5,3′- [1,4]oxazin]-5′-amine 218(5S)-7-(2,5-difluorophenyl)-3-(3,6-dihydro-2H- 462 A22 11B 0.0013 0.0026pyran-4-yl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine 219(5S)-7-(3,3-dimethyl-1-butyn-1-yl)-3-(2-fluoro- 443 A25 11B 0.00590.0248 4-pyridinyl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine 220(5S)-7-(2,5-difluorophenyl)-3-(2-fluoro-4- 475 A22 11B 0.002 0.0044pyridinyl)-6′H-spiro[chromeno[2,3-b]pyridine- 5,3′-[1,4]oxazin]-5′-amine55 (5S)-3-(2,2-dimethylpropoxy)-7-(2-fluoro-3- 449.2 A26 11B 0.00080.0004 pyridinyl)-6′H-spiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine 221(5R)-7-(2-fluoro-3-pyridinyl)-1-methoxy-3-(3- 470 A1 Int 16 0.04980.1186 pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine, ′(5S)-7-(2-fluoro-3-pyridinyl)-1-methoxy-3-(3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine222 3-((5R)-2′-amino-1-fluoro-3-(2-fluoro-4- 482 A1 Int 0.1704 1.5776pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3- 15Bc]pyridine-5,4′-[1,3]oxazin]-7-yl)benzonitrile 2233-((5S)-2′-amino-3-(5,6-dihydro-2H-pyran-3- 469.1 A1 Int 0.0008 0.0014yl)-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3- 15Bc]pyridine-5,4′-[1,3]oxazin]-7-yl)benzonitrile 2243-((5R)-2′-amino-3-(5,6-dihydro-2H-pyran-3- 469.1 A1 Int 0.5412 0.9816yl)-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3- 15Bc]pyridine-5,4′-[1,3]oxazin]-7-yl)benzonitrile 2253-((5S)-2′-amino-1-fluoro-3-(2-fluoro-4- 482 A1 Int 0.0007 0.003pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3- 15Bc]pyridine-5,4′-[1,3]oxazin]-7-yl)benzonitrile 226(5S)-1-fluoro-3-(2-fluoro-4-pyridinyl)-7-(5- 476 A1 Int 0.0014 0.0016fluoro-3-pyridinyl)-5′,6′- 15Bdihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 227(5R)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(3- 458 A1 Int 0.4894 0.1006pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3- 15Bc]pyridine-5,4′-[1,3]oxazin]-2′-amine 228(5S)-3-(3,6-dihydro-2H-pyran-4-yl)-1-fluoro-7- 463.1 A1 Int 0.00030.0007 (5-fluoro-3-pyridinyl)-5′,6′- 15Bdihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 229(5R)-3-(3,6-dihydro-2H-pyran-4-yl)-1-fluoro-7- 463.1 A1 Int 0.14890.1268 (5-fluoro-3-pyridinyl)-5′,6′- 15Bdihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 230(5S)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-phenyl- 457.1 A1 Int 0.0025′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- 15B[1,3]oxazin]-2′-amine 231 (5S)-1-fluoro-3-(5-fluoro-3-pyridinyl)-7-(3-458 A1 Int 0.0008 0.0003 pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3- 15Bc]pyridine-5,4′-[1,3]oxazin]-2′-amine 232(5R)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7- 463.1 A1 Int 0.79250.1641 (5-fluoro-3-pyridinyl)-5′,6′- 15Adihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 2333-((5R)-2′-amino-3-(3,6-dihydro-2H-pyran-4- 469.1 A1 Int 1.5787 0.1085yl)-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3- 15Ac]pyridine-5,4′-[1,3]oxazin]-7-yl)benzonitrile 2343-((5S)-2′-amino-3-(3,6-dihydro-2H-pyran-4- 469 A1 Int 0.0007 0.0007yl)-1-fluoro-5′,6′-dihydrospiro[chromeno[2,3- 15Bc]pyridine-5,4′-[1,3]oxazin]-7-yl)benzonitrile 235(5R)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-phenyl- 457 A1 Int 0.17555′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- 15A[1,3]oxazin]-2′-amine 236 (5S)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7-463.1 A1 Int 0.0008 0.0005 (5-fluoro-3-pyridinyl)-5′,6′- 15Bdihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 237(5R)-3,7-di-3-pyridinyl-5′,6′- 422 A1 Int 0.0616 0.0342dihydrospiro[chromeno[2,3-c]pyridine-5,4′- 18A [1,3]oxazin]-2′-amine,′(5S)-3,7-di-3-pyridinyl-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine238 (5R)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7- 463.1 A1 Int 0.29310.1714 (2-fluoro-3-pyridinyl)-5′,6′- 15Adihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 239(5S)-1-fluoro-3-(2-fluoro-4-pyridinyl)-7-(3- 458 A1 Int 0.035 0.0161pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3- 15Bc]pyridine-5,4′-[1,3]oxazin]-2′-amine 240(5R)-1-fluoro-3-(2-fluoro-4-pyridinyl)-7-(3- 458 A1 Int 0.1525 0.2065pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3- 15Ac]pyridine-5,4′-[1,3]oxazin]-2′-amine 241(5S)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(3- 458 A1 Int 0.0006 0.0009pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3- 15Bc]pyridine-5,4′-[1,3]oxazin]-2′-amine 242(5S)-3-chloro-1-fluoro-7-(2-fluoro-3-pyridinyl)- 415 A1 Int 0.0012 0.0166′H-spiro[chromeno[2,3-c]pyridine-5,3′- 17B [1,4]oxazin]-5′-amine 243(5S)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(3- 458 A1 Int 0.0003 0.0005pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 17B5,3′-[1,4]oxazin]-5′-amine 244(5R)-3-chloro-1-fluoro-7-(2-fluoro-3-pyridinyl)- 415 A1 Int 0.48123.1458 6′H-spiro[chromeno[2,3-c]pyridine-5,3′- 17B [1,4]oxazin]-5′-amine245 (5S)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(5- 476 A1 Int 0.00030.0003 fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3- 17Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine 246(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7- 445.1 A1 Int 0.00040.0001 (3-pyridinyl)-6′H-spiro[chromeno[2,3- 17Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine 247(5S)-3-(3,6-dihydro-2H-pyran-4-yl)-1-fluoro-7- 463.1 A1 Int 0.00060.0008 (2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3- 17Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine 248(5S)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(2- 472.1 A1 Int 0.0006 0.0007methyl-4-pyridinyl)-6′H-spiro[chromeno[2,3- 17Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine 249(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7- 463.1 A1 Int 0.00040.0004 (2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3- 17Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine 250(5S)-3-(2,2-dimethylpropoxy)-1-fluoro-7-(2- 467 A30 0.0006 0.0028fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine  50(5S)-7-(3,4-difluorophenyl)-3-methoxy-6′H- 410.4 A21 Int 21 0.03090.1065 spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine  49(5S)-3-(difluoromethoxy)-7-(2-fluoro-3- 429 A20 Int 21 0.0067 0.0115pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine- 5,3′-[1,4]oxazin]-5′-amine251 (5S)-7-bromo-3-(2,2-dimethylpropoxy)-6′H- 432.3 A4 Int 0.0196 0.0625spiro[chromeno[2,3-c]pyridine-5,3′- 10B [1,4]oxazin]-5′-amine 252(5S)-7-(3-fluorophenyl)-3-methoxy-6′H- 392.4 A21 Int 21 0.0106 0.05spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine 253(5S)-7-(5-chloro-3-pyridinyl)-3-ethoxy-6′H- 423.3 A4 Int 0.001 0.0015spiro[chromeno[2,3-c]pyridine-5,3′- 10B [1,4]oxazin]-5′-amine 254(5S)-7-(5-fluoro-3-pyridinyl)-3-(2- 435.3 A4 Int 0.0005 0.0009methylpropoxy)-6′H-spiro[chromeno[2,3- 10Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine 255(5S)-7-(2-fluoro-3-pyridinyl)-3-(2- 435.3 A4 Int 0.0005 0.001methylpropoxy)-6′H-spiro[chromeno[2,3- 10Bc]pyridine-5,3′-[1,4]oxazin]-5′-amine 256(5S)-3-ethoxy-7-(3-fluorophenyl)-6′H- 406.5 A4 Int 0.0043 0.0255spiro[chromeno[2,3-c]pyridine-5,3′- 10B [1,4]oxazin]-5′-amine 257(5S)-3-chloro-7-(5-fluoro-3-pyridinyl)-6′H- 397.2 A1 Int 0.0328 0.042spiro[chromeno[2,3-c]pyridine-5,3′- 10B [1,4]oxazin]-5′-amine 258(5S)-3-(1-methylethoxy)-7-(3-pyridinyl)-6′H- 403.5 A4 Int 1 0.00270.0042 spiro[chromeno[2,3-c]pyridine-5,3′- [1,4]oxazin]-5′-amine 259(5S)-7-(2-fluoro-3-pyridinyl)-3-(1- 421.5 A4 Int 1 0.0012 0.004methylethoxy)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine 260(5S)-3-ethoxy-7-(2-fluoro-3-pyridinyl)-6′H- 407.4 A4 Int 0.0016 0.0021spiro[chromeno[2,3-c]pyridine-5,3′- 10B [1,4]oxazin]-5′-amine 261(5R)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro- 459 A1 19 0.88953-pyridinyl)-5′-methyl-5′,6′- dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine 262 (4′S,5′S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-459 A1 19 0.0041 fluoropyridin-3-yl)-5′-methyl-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine 263(4′R,5′R)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2- 459 A1 19 0.4495fluoropyridin-3-yl)-5′-methyl-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′- [1,3]oxazin]-2′-amine  59B(5R)-3-(2,2-dimethylpropoxy)-1-fluoro-7-(2- 467 A30 0.0849 0.3696fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine 264(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro- 459 A1 19 0.00373-pyridinyl)-5′-methyl-5′,6′- dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine  17A (5S)-7-bromo-3-chloro-1-fluoro-6′H- 399.8Procedure Q 0.5711 1.5917 spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine  17B (5R)-7-bromo-3-chloro-1-fluoro-6′H- 399.8Procedure Q 5.9968 10 spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine  58 (5S)-1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(4-466 A29 0.0005 0.0007 morpholinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine 265(3R)-2′-bromo-7′-methoxy-6H-spiro[1,4- 375/377 Procedure 7.1087 10oxazine-3,9′-xanthen]-5-amine ZZ  67(3S)-2′-(2,2-dimethylpropoxy)-7′-(2-fluoro-3- 448 A38 30 0.0007 0.0131pyridinyl)-6H-spiro[1,4-oxazine-3,9′-xanthen]- 5-amine 266(5R)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4- 458 A31 26B 0.0199 0.017pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine, ′(5S)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine- 5,4′-[1,3]oxazin]-2′-amine267 (5R)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4- 458 A31 26B 6.66583.5589 pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine 268(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro- 445 A31 26B 0.01160.0217 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine  60(5S)-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4- 458 A31 26B 0.0122 0.011pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine  67a(3R)-2′-bromo-7′-(2,2-dimethylpropoxy)-6H- 431/433 A38 30 0.1017 0.5873spiro[1,4-oxazine-3,9′-xanthen]-5-amine  62(5S)-3-(2,2-dimethylpropoxy)-7-(2-fluoro-3- 449 A33 26B 0.0025 0.0048pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine  61(5S)-7-(2-fluoro-3-pyridinyl)-3-((3-methyl-3- 457 A32 26B 0.0028 0.0024oxetanyl)ethynyl)-5′,6′- dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine 269 (S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(2- 445A31 26B 0.012 0.0056 fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′- [1,3]oxazin]-2′-amine  25(5R)-3-bromo-7-iodo-5′,6′- 472/474 Procedure Y 15.959 10dihydrospiro[chromeno[2,3-b]pyridine-5,4′- [1,3]oxazin]-2′-amine,′(5S)-3-bromo-7-iodo- 5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine 270(5S)-3-(3,3-dimethyl-1-butyn-1-yl)-7-(2-fluoro- 443 A32 26B 0.00310.0049 3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine 271(5R)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro- 461 A22 24 1.040 2.5403-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]thiazin]-2′-amine 272(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro- 461 A22 24 0.004 0.0113-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]thiazin]-2′-amine

Various of the compounds in Table I above were prepared andcharacterized as follows:

Example 107

Synthesis(S)-1-fluoro-7-(2-fluoropyridin-3-yl)-3-(2-fluoropyridin-4-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The title compound was synthesized by steps analogous to those describedin method A1 above, but using intermediate 15B,2-fluoropyridin-3-ylboronic acid and 2-fluoropyridin-4-ylboronic acid.MS m/z=476.0 [M+H]⁺. Calculated for C₂₅H₁₆F₃N₅O₃: 475.13

¹H NMR (300 MHz, MeOH) δ ppm 2.33-2.49 (m, 2 H) 4.51-4.60 (m, 2 H)7.33-7.40 (m, 1 H) 7.49 (d, J=9.21 Hz, 1 H) 7.68-7.74 (m, 3 H) 7.94 (td,J=3.22, 1.50 Hz, 1 H) 8.05 (ddd, J=10.01, 7.53, 2.00 Hz, 1 H) 8.13-8.16(m, 1 H) 8.15 (br. s, 1 H) 8.23 (d, J=5.41 Hz, 1 H).

Example 110

Synthesis of(S)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The title compound was synthesized by steps analogous to those describedin method A1 above, but using intermediate 15B,2-fluoropyridin-3-ylboronic acid and2-(5,6-dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

MS m/z=463.0 [M+H]⁺. Calculated for C₂₅H₂₀F₂N₄O₃: 462.15

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.80-2.02 (m, 2 H) 2.26-2.43 (m, 2H) 3.84 (t, J=5.55 Hz, 2 H) 4.03-4.24 (m, 2 H) 4.42-4.68 (m, 3 H)6.66-6.76 (m, 1 H) 7.19-7.31 (m, 1 H) 7.36 (d, J=8.33 Hz, 1 H) 7.48-7.59(m, 2 H) 7.86 (ddd, J=9.79, 7.60, 1.90 Hz, 1 H) 8.14-8.23 (m, 1 H).

Example 111

Synthesis of (S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-(2-fluorodihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The title compound was synthesized by steps analogous to those describedin method A1 above, but using intermediate 18B,2-fluoropyridin-3-ylboronic acid and2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

MS m/z=445.1 [M+H]⁺. Calculated for C₂₅H₂₁FN₄O₃: 444.16

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.86-1.94 (m, 2 H) 3.92-3.99 (m, 2H) 4.08-4.19 (m, 2 H) 4.23-4.30 (m, 2 H) 4.35-4.41 (m, 2 H) 6.59-6.65(m, 1 H) 7.26 (s, 2 H) 7.43 (s, 1 H) 7.49-7.54 (m, 1 H) 7.54-7.58 (m, 1H) 7.86 (ddd, J=10.00, 7.40, 2.0 Hz, 1 H) 8.20 (d, J=4.69 Hz, 1 H) 8.50(s, 1 H).

Example 239

Synthesis of(S)-1-fluoro-3-(2-fluoropyridin-4-yl)-7-(pyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The title compound was synthesized by steps analogous to those describedin method A1 above, but using intermediate 15B, 3-pyridylboronic acidand 2-fluoropyridine-4-boronic acid. MS m/z=458.0 [M+H]⁺. Calculated forC₂₅H₁₇F₂N₅O₂: 457.14

¹H NMR (300 MHz, MeOH) δ ppm 2.01-2.09 (m, 2 H) 4.23 (m, 2 H) 7.50 (d,J=1.00 Hz, 1 H) 7.53-7.60 (m, 1 H) 7.67-7.79 (m, 3 H) 7.94-7.98 (m, 1 H)8.00 (s, 1 H) 8.11-8.17 (m, 1 H) 8.30-8.35 (m, 1 H) 8.53-8.59 (m, 1 H)8.82-8.86 (m, 1 H).

Example 226

Synthesis of(S)-1-fluoro-7-(5-fluoropyridin-3-yl)-3-(2-fluoropyridin-4-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The title compound was synthesized by steps analogous to those describedin method A1 above, but using intermediate 15B,5-fluoropyridin-3-ylboronic acid and 2-fluoropyridine-4-boronic acid.

MS m/z=476.0 [M+H]⁺. Calculated for C₂₅H₁₆F₃N₅O₂: 475.13

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.93-2.02 (m, 2 H) 4.12-4.21 (m, 2H) 7.41-7.47 (m, 1 H) 7.53 (br. s, 1 H) 7.57 (m, J=2.30 Hz, 3 H)7.74-7.81 (m, 2 H) 8.29-8.34 (m, 1 H) 8.46-8.50 (m, 1 H) 8.66-8.71 (m, 1H).

Example 241

Synthesis of(S)-1-fluoro-7-(2-fluoropyridin-3-yl)-3-(pyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The title compound was synthesized by steps analogous to those describedin method A1 above, but using intermediate 15B,2-fluoropyridin-3-ylboronic acid and 3-pyridylboronic acid. MS m/z=458.0[M+H]⁺. Calculated for C₂₅H₁₇F₂N₅O₂: 457.14

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.90-2.07 (m, 2 H) 4.10-4.27 (m, 2H) 7.24-7.33 (m, 1 H) 7.35-7.45 (m, 2 H) 7.51-7.63 (m, 2 H) 7.74 (s, 1H) 7.87 (ddd, J=9.76, 7.64, 1.90 Hz, 1 H) 8.21 (d, J=4.68 Hz, 1 H) 8.29(dt, J=8.04, 1.90 Hz, 1 H) 8.63 (dd, J=4.75, 1.39 Hz, 1 H) 9.20 (d,J=1.90 Hz, 1 H).

Example 249

Synthesis of(S)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A1 above, but using (Intermediate 17B),2-fluoropyridin-3-ylboronic acid and2-(5,6-dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

MS m/z=463.1 [M+H]⁺. Calculated for C₂₅H₂₀F₂N₄O₃: 462.15.

¹H NMR (300 MHz, MeOH) δ ppm 2.31-2.42 (m, 2 H) 3.57-3.69 (m, 2 H)3.80-3.86 (m, 2 H) 4.33-4.47 (m, 2 H) 4.53-4.58 (m, 2 H) 6.69-6.76 (m, 1H) 7.27 (s, 1 H) 7.35-7.46 (m, 2 H) 7.57-7.60 (m, 1 H) 7.61-7.66 (m, 1H) 8.03-8.11 (m, 1 H) 8.17-8.21 (m, 1 H)

Example 248

Synthesis of(S)-1-fluoro-7-(2-fluoropyridin-3-yl)-3-(2-methylpyridin-4-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A1 above, but using (Intermediate 17B),2-fluoropyridin-3-ylboronic acid and 2-methylpyridine-4-boronic acidpinacol ester.

MS m/z=472.1 [M+H]⁺. Calculated for C₂₅H₂₀F₂N₄O₃: 471.15.

¹H NMR (300 MHz, MeOH) δ ppm 2.63 (s, 3 H) 3.65-3.79 (m, 2 H) 4.38-4.58(m, 3 H) 7.41-7.47 (m, 3 H) 7.62-7.70 (m, 3 H) 7.81-7.87 (m, 2 H)7.90-7.94 (m, 1 H) 8.05-8.14 (m, 2 H) 8.18-8.23 (m, 1 H) 8.49-8.53 (m, 1H)

Example 129

Synthesis of(S)-3-(4,4-difluoropiperidin-1-yl)-1-fluoro-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine2,2,2-trifluoroacetate

The titled compound was synthesized by steps analogous to thosedescribed in method 29 above, but using 4,4-difluoropiperidine in step1.

MS m/z=500.0 [M+H]⁺. Calculated for C₂₅H₂₁F₄N₅O₂.C₂HF₃O₂:613.48 (TFAsalt).

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.95-2.12 (m, 4 H) 3.59-3.68 (m, 2H) 3.68-3.76 (m, 2 H) 3.88 (s, 2 H) 4.80 (m, 2 H) 6.47 (s, 1 H) 7.31(dd, J=7.43, 4.50 Hz, 1 H) 7.41 (d, J=8.61 Hz, 1 H) 7.55 (s, 1 H) 7.62(d, J=9.19 Hz, 1 H) 7.91 (t, J=8.02 Hz, 1 H) 8.02 (br. s., 1 H)8.13-8.23 (m, 1 H) 11.22 (br. s., 1 H) 12.31 (br. s., 1 H)

Example 155

Synthesis of (S)-7-(2-fluoropyridin-3-yl)-3-(5-fluorodihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A1 above, but using intermediate 18B,2-fluoropyridin-3-ylboronic acid and 5-fluoropyridin-3-ylboronic acid.MS m/z=458.0 [M+H]⁺. Calculated for C₂₅H₁₇F₂N₅O₂: 457.43

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.90-2.00 (m, 2 H) 4.12-4.21 (m, 2H) 7.29 (ddd, J=7.23, 5.04, 1.75 Hz, 1 H) 7.35 (d, J=8.33 Hz, 1 H)7.49-7.63 (m, 2 H) 7.81-7.95 (m, 2 H) 8.05-8.13 (m, 1 H) 8.21 (dt,J=4.75, 1.50 Hz, 1 H) 8.49 (d, J=2.63 Hz, 1 H) 8.64 (s, 1 H) 9.03 (t,J=1.61 Hz, 1 H)

Example 153

Synthesis of(S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A1 above, but using intermediate 18B,2-fluoropyridin-3-ylboronic acid and2-(5,6-dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

MS m/z=445.0 [M+H]⁺. Calculated for C₂₅H₂₁FN₄O₃: 444.46

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 2.33-2.42 (m, 2 H) 3.86 (s, 2 H)4.10-4.17 (m, 2 H) 4.28-4.51 (m, 2 H) 4.55-4.76 (m, 2 H) 6.62-6.68 (m, 1H) 7.26 (s, 2 H) 7.42 (s, 1 H) 7.48-7.54 (m, 1 H) 7.54-7.58 (m, 1 H)7.81-7.91 (m, 1 H) 8.17-8.22 (m, 1 H) 8.45 (s, 1 H)

Example 154

Synthesis of(S)-3-(3,3-dimethylbut-1-ynyl)-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A2 above, but using intermediate 18B,2-fluoropyridin-3-ylboronic acid and 3,3-dimethylbut-1-yne. MS m/z=443.0[M+H]⁺. Calculated for C₂₆H₂₃FN₄O₂: 442.48

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.36 (s, 9 H) 1.84-1.93 (m, 2 H)4.09-4.20 (m, 2 H) 7.27-7.31 (m, 2 H) 7.41-7.56 (m, 3 H) 7.80-7.95 (m, 1H) 8.15-8.26 (m, 1 H) 8.40-8.51 (m, 1 H)

Example 149

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-(2-fluoropyridin-4-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A1 above, but using intermediate 18B,2-fluoropyridin-3-ylboronic acid and 2-fluoropyridin-4-ylboronic acid.MS m/z=458.0 [M+H]⁺. Calculated for C₂₅H₁₇F₂N₅O₂: 457.43

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.95 (d, J=6.14 Hz, 2 H) 4.17 (d,J=4.53 Hz, 2 H) 4.29-4.49 (m, 2 H) 7.30 (s, 1 H) 7.35 (d, J=8.33 Hz, 1H) 7.51-7.60 (m, 3 H) 7.80 (d, J=5.12 Hz, 1 H) 7.88 (s, 2 H) 8.22 (d,J=4.38 Hz, 1 H) 8.31 (d, J=5.41 Hz, 1 H) 8.66 (s, 1 H)

Example 145

Synthesis of(S)-7-(5-fluoropyridin-3-yl)-3-(2-fluoropyridin-4-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A1 above, but using intermediate 18B,5-fluoropyridin-3-ylboronic acid and 2-fluoropyridin-4-ylboronic acid.MS m/z=458.0 [M+H]⁺. Calculated for C₂₅H₁₇F₂N₅O₂: 457.43

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.95 (q, J=5.07 Hz, 2 H) 4.12-4.20(m, 2 H) 7.35-7.42 (m, 1 H) 7.54-7.67 (m, 4 H) 7.81 (dt, J=5.26, 1.61Hz, 1 H) 7.87 (s, 1 H) 8.31 (d, J=5.26 Hz, 1 H) 8.46 (d, J=2.63 Hz, 1 H)8.63-8.70 (m, 2 H)

Example 146

Synthesis of(S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(5-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A1 above, but using intermediate 18B,5-fluoropyridin-3-ylboronic acid and2-(5,6-dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

MS m/z=445.1 [M+H]⁺. Calculated for C₂₅H₁₇F₂N₅O₂: 444.56

¹H NMR (300 MHz, MeOH) δ ppm 1.87-1.99 (m, 2 H) 2.28-2.48 (m, 2 H) 3.85(s, 2 H) 4.13-4.21 (m, 2 H) 4.63 (d, J=1.90 Hz, 2 H) 6.50-6.79 (m, 1 H)7.40 (s, 1 H) 7.52 (s, 1 H) 7.68 (d, J=2.63 Hz, 2 H) 7.85-7.97 (m, 1 H)8.41 (s, 1 H) 8.45 (d, J=2.63 Hz, 1 H) 8.69 (s, 1 H)

Example 86

Synthesis of(S)-2′-(4,4-difluoropiperidin-1-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

The title compound was synthesized by steps analogous to those describedin method A6 above, but using intermediate 13A,2-fluoropyridin-3-ylboronic acid and 4,4-difluoropiperidine. MSm/z=499.0 [M+H]⁺. Calculated for C₂₆H₂₂F₄N₄O₂: 498.17

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.01-2.15 (m, 4 H), 3.40 (d, J=11.2 Hz,1 H), 3.43 (d, J=11.2 Hz, 1 H), 4.19 (s, 2 H), 6.08 (br. s., 1 H), 6.65(dd, J=2.7, 1.2 Hz, 1 H), 7.31 (d, J=8.4 Hz, 1 H), 7.43-7.51 (m, 2 H),7.56 (ddd, J=8.4, 2.2, 1.6 Hz, 1 H), 8.06 (ddd, J=10.3, 7.5, 1.9 Hz, 1H), 8.23 (ddd, J=4.8, 1.5, 1.4 Hz, 1 H)

Example 178

Synthesis of(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-((R)-3-fluoropyrrolidin-1-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

The title compound was synthesized by steps analogous to those describedin method A6 above, but using intermediate 20B,2-fluoropyridin-3-ylboronic acid and (R)-3-fluoropyrrolidine. MSm/z=467.0 [M+H]⁺. Calculated for C₂₅H₂₁F₃N₄O₂: 466.16

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.10-2.31 (m, 2 H), 3.23-3.62 (m, 4 H),4.18 (m, 2 H), 5.45 (dm, J=54.9 Hz, 1 H, HCF), 5.98-6.20 (m, 2 H),6.23-6.27 (m, 2 H), 6.53 (dd, J=13.4, 2.8 Hz, 1 H), 7.30 (d, J=8.4 Hz, 2H), 7.46 (s, 2 H), 7.54 (ddd, J=8.4, 2.2, 1.5 Hz, 1 H), 8.07 (ddd,J=10.3, 7.5, 2.0 Hz, 1 H), 8.23 (ddd, J=4.8, 1.7, 1.4 Hz, 1 H)

Example 84

Synthesis of(S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine

The title compound was synthesized by steps analogous to those describedin method A6 above, but using intermediate 20B,2-fluoropyridin-3-ylboronic acid and (R)-3-fluoropyrrolidine. MSm/z=467.0 [M+H]⁺. Calculated for C₂₅H₂₁F₃N₄O₂: 466.16

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.75 (m, J=3.6 Hz, 2 H), 2.08-2.33 (m, 2H), 3.29-3.62 (m, 4 H), 3.89-4.09 (m, 2 H), 5.44 (dm, J=55.0 Hz, 1 H,HCF), 5.74 (br. s, 2 H), 6.31 (m, 1 H), 6.50 (dd, J=13.4, 2.8 Hz, 1 H),7.32 (d, J=9.0 Hz, 1 H), 7.47 (ddd, J=7.2, 4.8, 1.9 Hz, 1 H), 7.50-7.56(m, 2 H), 8.07 (ddd, J=10.3, 7.5, 1.9 Hz, 1 H), 8.22 (ddd, J=4.8, 1.6,1.4 Hz, 1 H)

Example 163

Synthesis of(S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine

The title compound was synthesized by steps analogous to those describedin method A7 above, but using intermediate 20B,2-fluoropyridin-3-ylboronic acid and2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

MS m/z=462.0 [M+H]⁺. Calculated for C₂₆H₂₁F₂N₃O₃: 461.16

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.73-1.81 (m, 2 H), 2.39-2.47 (m, 2 H),3.81-3.86 (m, 2 H), 3.94-4.02 (m, 2 H), 4.24 (d, J=2.8 Hz, 2 H), 5.82(s, 2 H), 6.23-6.27 (m, 1 H), 7.21-7.23 (m, 1 H), 7.40 (m, 2 H), 7.49(ddd, J=7.4, 4.9, 2.0 Hz, 1 H), 7.55 (m, 2 H), 8.10 (ddd, J=10.4, 7.4,2.0 Hz, 1 H), 8.25 (ddd, J=4.8, 1.9, 1.4 Hz, 1 H).

Example 173

Synthesis of(S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine

The title compound was synthesized by steps analogous to those describedin method A7 above, but using intermediate 20B,2-fluoropyridin-3-ylboronic acid and2-(5,6-dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

MS m/z=462.0 [M+H]⁺. Calculated for C₂₆H₂₁F₂N₃O₃: 461.16

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.77 (m, 2 H), 2.20-2.33 (m, 2 H), 3.74(m, 2 H), 3.91-4.05 (m, 2 H), 4.33-4.48 (m, 2 H), 5.83 (br. s., 2 H),6.27 (s, 1 H), 7.11-7.14 (m, 1 H), 7.33 (dd, J=12.2, 2.1 Hz, 1 H), 7.40(d, J=8.3 Hz, 1 H), 7.49 (ddd, J=7.4, 4.9, 1.9 Hz, 1 H), 7.53-7.56 (m, 1H), 7.58 (ddd, J=8.4, 2.2, 1.4 Hz, 1 H), 8.09 (ddd, J=10.3, 7.5, 2.0 Hz,1 H), 8.25 (ddd, J=4.8, 1.9, 1.5 Hz, 1 H)

Example 182

Synthesis of(S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine

The title compound was synthesized by steps analogous to those describedin method A8 above, but using intermediate 20B,2-fluoropyridin-3-ylboronic acid and 2-fluoro-2-methylpropyltrifluoromethanesulfonate.

MS m/z=470.0 [M+H]⁺. Calculated for C₂₅H₂₂F₃N₃O₃: 469.16

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40 (s, 3 H), 1.46 (s, 3 H), 1.77 (dd,J=6.4, 4.8 Hz, 2 H), 3.94-4.10 (m, 4 H), 5.82 (s, 2 H), 6.74 (dd, J=2.9,1.5 Hz, 1 H), 7.02 (dd, J=12.3, 2.9 Hz, 1 H), 7.37 (d, J=8.4 Hz, 1 H),7.49 (ddd, J=7.4, 4.9, 1.9 Hz, 1 H), 7.51-7.54 (m, 1 H), 7.56 (ddd,J=8.3, 2.2, 1.4 Hz, 1 H), 8.09 (ddd, J=10.4, 7.4, 2.0 Hz, 1 H), 8.24(ddd, J=4.8, 1.7, 1.4 Hz, 1 H)

Example 168

Synthesis of((S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-(pyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine

The title compound was synthesized by steps analogous to those describedin method A7 above, but using intermediate 20B,2-fluoropyridin-3-ylboronic acid and 3-pyridineboronic acid. MSm/z=457.0 [M+H]⁺. Calculated for C₂₆H₁₈F₂N₄O₂: 456.14

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.78-1.91 (m, 2 H), 4.03 (m, 2 H),5.86-6.10 (m, 2 H), 7.42-7.65 (m, 6 H), 7.76 (dd, J=11.6, 2.2 Hz, 1 H),8.07 (d, J=8.6 Hz, 1 H), 8.09-8.15 (m, 1 H), 8.26 (d, J=4.7 Hz, 1 H),8.60 (dd, J=4.7, 1.6 Hz, 1 H), 8.89 (d, J=1.9 Hz, 1 H)

Example 184

Synthesis of(S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-morpholino-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine

The title compound was synthesized by steps analogous to those describedin method A6 above, but using intermediate 20,2-fluoropyridin-3-ylboronic acid and morpholine.

MS m/z=464.8 [M+H]⁺. Calculated for C₂₅H₂₂F₂N₄O₃: 464.17

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.70-1.80 (m, 2 H), 3.07 (m, 4 H),3.71-3.78 (m, 4 H), 3.95-4.02 (m, 2 H), 5.79 (s, 2 H), 6.66-6.70 (m, 1H), 6.92 (dd, J=13.7, 2.8 Hz, 1 H), 7.32-7.37 (m, 1 H), 7.49 (ddd,J=7.4, 4.9, 1.9 Hz, 1 H), 7.53 (m, 2 H), 8.08 (ddd, J=10.3, 7.5, 1.9 Hz,1 H), 8.24 (ddd, J=4.8, 1.6, 1.4 Hz, 1 H)

Example 166

Synthesis of((S)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2′-(pyridin-4-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine

The title compound was synthesized by steps analogous to those describedin method A7 above, but using intermediate 20B,2-fluoropyridin-3-ylboronic acid and 4-pyridineboronic acid. MSm/z=456.8 [M+H]⁺. Calculated for C₂₆H₁₈F₂N₄O₂: 456.14

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.78-1.91 (m, 2 H), 4.03 (m, 2 H), 5.90(br. s., 2 H), 7.45 (d, J=8.3 Hz, 1 H), 7.50 (ddd, J=7.3, 5.0, 1.9 Hz, 1H), 7.54-7.58 (m, 1 H), 7.59-7.64 (m, 1 H), 7.66-7.71 (m, 1 H), 7.82(dd, J=11.7, 2.2 Hz, 1 H), 8.11 (ddd, J=10.3, 7.5, 1.9 Hz, 1 H), 8.25(ddd, J=4.8, 18, 1.5 Hz, 1 H), 8.63-8.69 (m, 1 H)

Example 176

Synthesis of(S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(pyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine

The title compound was synthesized by steps analogous to those describedin method A8 above, but using intermediate 20B, pyridin-3-ylboronic acidand 2-fluoro-2-methylpropyl trifluoromethanesulfonate.

MS m/z=451.8 [M+H]⁺. Calculated for C₂₅H₂₃F₂N₃O₃: 451.17

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41 (s, 3 H), 1.46 (s, 3 H), 1.78 (m, 2H), 3.92-4.11 (m, 4 H), 5.85 (br. s., 2 H), 6.74 (dd, J=2.9, 1.5 Hz, 1H), 7.02 (dd, J=12.3, 2.9 Hz, 1 H), 7.36 (d, J=8.4 Hz, 1 H), 7.50 (ddd,J=8.0, 4.7, 0.9 Hz, 1 H), 7.58 (d, J=2.3 Hz, 1 H), 7.67 (dd, J=8.4, 2.3Hz, 1 H), 7.97-8.03 (m, 1 H), 8.57 (dd, J=4.7, 1.6 Hz, 1 H), 8.83 (dd,J=2.4, 0.8 Hz, 1 H)

Example 164

Synthesis of(S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(pyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine

The title compound was synthesized by steps analogous to those describedin method A7 above, but using intermediate 20B, pyridin-3-ylboronic acidand2-(5,6-dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

MS m/z=443.8.0 [M+H]⁺. Calculated for C₂₆H₂₂FN₃O₃: 443.16

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.75-1.82 (m, 2 H), 2.23-2.31 (m, 2 H),3.72-3.77 (m, 2 H), 3.93-4.04 (m, 2 H), 4.37-4.44 (m, 2 H), 5.82-5.88(m, 2 H), 6.25-6.29 (m, 1 H), 7.10-7.13 (m, 1 H), 7.33 (dd, J=12.1, 2.2Hz, 1 H), 7.39 (d, J=8.4 Hz, 1 H), 7.51 (ddd, J=7.9, 4.8, 0.9 Hz, 1 H),7.60 (d, J=2.2 Hz, 1 H), 7.68 (dd, J=8.4, 2.3 Hz, 1 H), 8.01 (m, J=2.4,1.6 Hz, 1 H), 8.58 (dd, J=4.7, 1.6 Hz, 1 H), 8.84 (dd, J=2.4, 0.8 Hz, 1H)

Example 156

Synthesis of(S)-2′-(3,6-dihydro-2H-pyran-4-yl)-4-′-fluoro-7′-(pyridin-3-yl)-5,6-dihydrospiro[[1,3]oxazine-4,9′-xanthen]-2-amine

The title compound was synthesized by steps analogous to those describedin method A7 above, but using intermediate 20B, pyridin-3-ylboronic acidand2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

MS m/z=443.8 [M+H]⁺. Calculated for C₂₆H₂₂FN₃O₃: 443.16

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.79 (m, 2 H), 2.44 (m, 2 H), 3.84 (m, 2H), 3.94-4.08 (m, 2 H), 4.24 (m, 2 H), 5.84 (m, 2 H), 6.25 (m, 1 H),7.21 (s, 1 H), 7.35-7.44 (m, 2 H), 7.47-7.56 (m, 1 H), 7.60 (d, J=2.2Hz, 1 H), 7.68 (dd, J=8.4, 2.3 Hz, 1 H), 7.97-8.06 (m, 1 H), 8.58 (dd,J=4.7, 1.5 Hz, 1 H), 8.84 (d, J=1.7 Hz, 1 H).

Example 126

Synthesis of(S)-3-(5′-amino-7-(3-fluorophenyl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazine]-3-yloxy)-2,2-dimethylpropanenitrile

The title compound was synthesized by steps analogous to those describedin Method A4, but using Intermediate 10B,3-hydroxy-2,2-dimethylpropanenitrile, and 3-fluorophenylboronic acid. MSm/z=459.3 [M+H]⁺. Calculated for C₂₆H₂₃FN₄O₃: 458.18.

¹H NMR (400 MHz, DMSO-d₆) δ=8.13 (s, 1 H), 7.66 (dd, J=2.3, 8.5 Hz, 1H), 7.55-7.49 (m, J=5.8 Hz, 2 H), 7.48-7.40 (m, 2 H), 7.28 (d, J=8.4 Hz,1 H), 7.22-7.15 (m, 1 H), 6.71 (s, 1 H), 6.16 (s, 2 H), 4.32-4.20 (m, 5H), 3.52-3.42 (m, 2 H), 1.42 (d, J=5.4 Hz, 6 H)

Example 122

Synthesis of(S)-3-(3,3-difluoropyrrolidin-1-yl)-7-(5-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

The title compound was synthesized by steps analogous to those describedin Method A3, but using Intermediate 10B, 5-fluoropyridin-3-ylboronicacid, and 3,3-difluoropyrrolidine hydrochloride. MS m/z=468.3 [M+H]⁺.Calculated for C₂₄H₂₀FN₅O₂: 467.16.

1 H NMR (400 MHz, DMSO-d₆) δ=8.73 (t, J=1.7 Hz, 1 H), 8.56 (d, J=2.7 Hz,1 H), 8.12 (s, 1 H), 7.98 (td, J=2.3, 10.3 Hz, 1 H), 7.72 (dd, J=2.4,8.5 Hz, 1 H), 7.57 (d, J=2.2 Hz, 1 H), 7.29 (d, J=8.4 Hz, 1 H), 6.35 (s,1 H), 6.11 (br. s., 2 H), 4.25 (s, 2 H), 3.90-3.73 (m, 2 H), 3.67-3.51(m, 2 H), 3.49-3.40 (m, 2 H), 2.61-2.53 (m, 2 H)

Example 120

Synthesis of(S)-7-(5-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

The title compound was synthesized by steps analogous to those describedin Method A4, but using Intermediate 10B, neopentyl alcohol, and5-fluoropyridin-3-ylboronic acid.

MS m/z=449.4 [M+H]⁺. Calculated for C₂₅H₂₅FN₄O₃: 448.19.

¹H NMR (400 MHz, DMSO-d₆) δ=8.74 (t, J=1.8 Hz, 1 H), 8.57 (d, J=2.7 Hz,1 H), 8.10 (d, J=0.5 Hz, 1 H), 8.02-7.96 (m, 1 H), 7.74 (dd, J=2.4, 8.5Hz, 1 H), 7.58 (d, J=2.3 Hz, 1 H), 7.31 (d, J=8.5 Hz, 1 H), 6.63 (d,J=0.5 Hz, 1 H), 6.14 (s, 2 H), 4.25 (s, 2 H), 3.98-3.87 (m, 2 H),3.52-3.42 (m, 2 H), 1.00 (s, 9 H)

Example 119

Synthesis of(S)-3-(neopentyloxy)-7-(pyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

The title compound was synthesized by steps analogous to those describedin Method A4, but using Intermediate 10B, neopentyl alcohol, andpyridin-3-ylboronic acid.

MS m/z=431.4 [M+H]⁺. Calculated for C₂₅H₂₆N₄O₃: 430.20.

¹H NMR (400 MHz, DMSO-d₆) δ=8.84 (dd, J=0.7, 2.4 Hz, 1 H), 8.56 (dd,J=1.6, 4.7 Hz, 1 H), 8.09 (s, 1 H), 8.04-7.97 (m, 1 H), 7.72-7.65 (m, 1H), 7.53 (d, J=2.2 Hz, 1 H), 7.50 (ddd, J=0.8, 4.8, 7.9 Hz, 1 H), 7.30(d, J=8.4 Hz, 1 H), 6.63 (s, 1 H), 6.15 (s, 2 H), 4.24 (s, 2 H),3.98-3.87 (m, 2 H), 3.52-3.40 (m, 2 H), 1.00 (s, 9 H)

Example 114

Synthesis of(S)-3-(3,4-difluorophenyl)-7-(5-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

The title compound was synthesized by steps analogous to those describedin Method A1, but using Intermediate 10B, 5-fluoropyridin-3-ylboronicacid, and 3,4-difluorophenylboronic acid.

MS m/z=475.2 [M+H]⁺. Calculated for C₂₆H₁₇F₃N₄O₂: 474.13.

¹H NMR (400 MHz, DMSO-d₆) δ=8.75 (t, J=1.8 Hz, 1 H), 8.61 (s, 1 H), 8.58(d, J=2.6 Hz, 1 H), 8.06-7.97 (m, 2 H), 7.83 (br. s., 1 H), 7.80-7.76(m, 1 H), 7.74 (s, 1 H), 7.63 (s, 1 H), 7.56 (td, J=8.5, 10.6 Hz, 1 H),7.38 (d, J=8.4 Hz, 1 H), 6.15 (br. s., 2 H), 4.34 (br. s., 2 H), 3.58(br. s., 2 H)

Example 115

Synthesis of(S)-3-(3,4-difluorophenyl)-7-(pyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

The title compound was synthesized by steps analogous to those describedin Method A1, but using Intermediate 10B, pyridin-3-ylboronic acid, and3,4-difluorophenylboronic acid. MS m/z=457.2 [M+H]⁺. Calculated forC₂₆H₁₈F₂N₄O₂: 456.14.

¹H NMR (400 MHz, DMSO-d₆) δ=8.86 (dd, J=0.7, 2.4 Hz, 1 H), 8.62 (s, 1H), 8.58 (dd, J=1.6, 4.7 Hz, 1 H), 8.06-7.99 (m, 2 H), 7.88-7.81 (m, 1H), 7.74 (s, 1 H), 7.72 (dd, J=2.4, 8.5 Hz, 1 H), 7.61-7.53 (m, 2 H),7.53-7.49 (m, 1 H), 7.38 (d, J=8.4 Hz, 1 H), 6.16 (s, 2 H), 4.39-4.27(m, 2 H), 3.60-3.52 (m, 2 H)

Example 156

Synthesis of(S)-4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A8 above, but using intermediate 23 and obtainedfrom racemic4′-fluoro-2′-(2-fluoro-2-methylpropoxy)-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-amineusing similar chiral separation conditions as described herein forintermediate 10.

MS m/z=485.8 [M+H]⁺. Calculated for C₂₅H₂₂F₃N₃O₂S: 485.14.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41 (s, 3 H) 1.47 (s, 3 H) 1.65-1.78(m, 2 H) 2.76-2.83 (m, 2 H) 3.95-4.09 (m, 2 H) 6.32 (s, 2 H) 6.71 (dd,J=2.9, 1.6 Hz, 1 H) 7.05 (dd, J=12.3, 2.9 Hz, 1 H) 7.38 (d, J=8.4 Hz, 1H) 7.46-7.53 (m, 2 H) 7.59 (ddd, J=8.4, 2.3, 1.4 Hz, 1 H) 8.03-8.12 (m,1 H) 8.19-8.29 (m, 1 H

Example 201

Synthesis of(S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A7 above, but using intermediate 23 and2-(5,6-dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.(S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-amine(>99% ee) was obtained from racemic2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-5,6-dihydrospiro[[1,3]thiazine-4,9′-xanthen]-2-amineusing similar chiral separation conditions as described herein forintermediate 10.

MS m/z=477.8 [M+H]⁺. Calculated for C₂₆H₂₁F₂N₃O₂S: 477.13.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.68-1.80 (m, 2 H) 2.21-2.34 (m, 2 H)2.69-2.89 (m, 2 H) 3.71-3.80 (m, 2 H) 4.37-4.45 (m, 2 H) 6.26-6.31 (m, 1H) 6.33 (s, 2 H) 7.08-7.12 (m, 1 H) 7.35 (dd, J=12.2, 2.2 Hz, 1 H) 7.41(d, J=8.5 Hz, 1 H) 7.47-7.55 (m, 2 H) 7.60 (ddd, J=8.4, 2.3, 1.4 Hz, 1H) 8.10 (ddd, J=10.3, 7.4, 1.9 Hz, 1 H) 8.26 (ddd, J=4.8, 2.4 Hz, 1 H)

Example 89

Synthesis of(S)-3-(3,3-dimethylbut-1-yn-1-yl)-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

The titled compound was synthesized as described in Method A2

MS m/z=443.0 [M+H]⁺. Calculated for C₂₆H₂₃FN₄O₂: 442.48.

¹H NMR (400 MHz, MeCN) δ ppm 1.33 (s, 12 H) 3.48 (s, 2 H) 4.26 (m, 2 H)7.32 (d, J=8.0 Hz, 1 H) 7.36-7.39 (m, 1 H) 7.50-7.51 (m, 1 H) 7.56-7.60(m, 1 H) 7.65 (d, J=2.4 Hz, 1 H) 7.97-8.02 (m, 1 H) 8.17-8.19 (m, 1 H)8.22 (d, J=2.4 Hz, 1 H)

Example 91

Synthesis of(S)-3-(4-fluorophenyl)-7-(2-fluoropyridin-3-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method 22 above, but using 4-fluorophenylboronic acid.

MS m/z=457.0 [M+H]⁺. Calculated for C₂₆H₁₈F₂N₄O₂: 456.44.

¹H NMR (400 MHz, MeCN) δ ppm 3.50-3.60 (m, 2 H) 4.27-4.35 (m, 2 H)7.22-7.26 (m, 2 H) 7.35-7.40 (m, 2 H) 7.51-7.74 (m, 4 H) 7.89 (d, J=2.8Hz, 1 H) 7.95-8.05 (m, 1 H) 8.18-8.20 (m, 1 H) 8.47 (d, J=2.8 Hz, 1 H)

Example 90

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-(p-tolyl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method 22 above, but using 4-methylphenylboronic acid.

MS m/z=453.0 [M+H]⁺. Calculated for C₂₇H₂₁FN₄O₂: 452.48.

¹H NMR (400 MHz, MeCN) δ ppm 2.39 (s, 3 H) 3.54 (s, 2 H) 4.25-4.34 (m, 2H) 7.30-7.40 (m, 4 H) 7.54-7.61 (m, 4 H) 7.90 (d, J=4.0 Hz, 1 H)7.98-8.03 (m, 1 H) 8.18-8.20 (m, 1 H) 8.48 (d, J=4.0 Hz, 1 H)

Example 220

Synthesis of(S)-7-(2,5-difluorophenyl)-3-(2-fluoropyridin-4-yl)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method 22 above, but using 2,5-difluorophenylboronic acidand 2-fluoropyridine-4-boronic acid.

MS m/z=475.0 [M+H]⁺. Calculated for C₂₆H₁₇F₃N₄O₂: 474.43.

¹H NMR (400 MHz, MeCN) δ ppm 3.60 (s, 2 H) 4.34-4.45 (m, 2 H) 7.10-7.16(m, 1 H) 7.22-7.33 (m, 2 H) 7.35-7.37 (m, 2 H) 7.54-7.61 (m, 3 H) 7.05(d, J=4 Hz, 1 H) 8.30 (d, J=8 Hz, 1 H) 8.63 (d, J=4.0 Hz, 1 H)

Example 55

Synthesis of(S)-7-(2-fluoropyridin-3-yl)-3-(neopentyloxy)-2′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,3′-[1,4]oxazin]-5′-amine

The titled compound was synthesized as described in method 26 above.

MS m/z=449.20 [M+H]⁺. Calculated for C₂₅H₂₅FN₄O₃: 448.49.

¹H NMR (400 MHz, MeCN) δ ppm 1.05 (s, 9 H) 3.48 (s, 2 H) 3.72 (s, 2 H)4.21-4.31 (m, 2 H) 7.26-7.30 (m, 2 H) 7.35-7.39 (m, 1 H) 7.48-7.50 (m, 1H) 7.55-7.58 (m, 1 H) 7.91 (d, J=4.0 Hz, 1 H) 7.96-8.01 (m, 1 H)8.16-8.19 (m, 1 H)

Example 72

Synthesis of(5S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A1. MS m/z=445.2 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ=8.45 (d, J=0.5 Hz, 1 H), 8.29-8.21 (m, 1 H),8.09 (ddd, J=1.9, 7.5, 10.4 Hz, 1 H), 7.63-7.57 (m, 1 H), 7.53-7.44 (m,2 H), 7.41-7.29 (m, 3 H), 6.66-6.55 (m, 1 H), 6.19 (d, J=5.9 Hz, 2 H),4.58-4.47 (m, 2 H), 4.34-4.15 (m, 2 H), 3.81-3.69 (m, 2 H), 3.53-3.39(m, 2 H), 2.38-2.23 (m, 2 H).

Example 73

Synthesis of(5S)-3-(3,4-difluorophenyl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A1. MS m/z=475.2 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ=8.63 (s, 1 H), 8.25 (td, J=1.5, 4.8 Hz, 1H), 8.14-7.98 (m, 2 H), 7.86 (dd, J=2.5, 5.5 Hz, 1 H), 7.78 (s, 1 H),7.65-7.47 (m, 4 H), 7.38 (d, J=8.5 Hz, 1 H), 6.29 (br. s., 2 H),4.43-4.21 (m, 2 H), 3.66-3.48 (m, 2 H).

Example 74

Synthesis of(5S)-3-(3,3-difluoro-1-pyrrolidinyl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A3. MS m/z=468.2[M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ=8.23 (td, J=1.5, 4.8 Hz, 1 H), 8.13 (d,J=0.4 Hz, 1 H), 8.07 (ddd, J=2.0, 7.5, 10.4 Hz, 1 H), 7.56 (td, J=1.7,8.8 Hz, 1 H), 7.51-7.45 (m, 2 H), 7.28 (d, J=8.4 Hz, 1 H), 6.36 (s, 1H), 6.14 (br. s., 2 H), 4.27-4.13 (m, 2 H), 3.82 (sxt, J=12.9 Hz, 2 H),3.67-3.51 (m, 2 H), 3.47-3.36 (m, 2 H), 2.62-2.53 (m, 2 H).

Example 132

Synthesis of(S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A37 except that 2-fluoropyridin-3-ylboronic acid wasused in Step 5,(S)-2′-bromo-4′-fluoro-7′-methoxy-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-aminewas converted to(S)-2′-(5,6-dihydro-2H-pyran-3-yl)-4′-fluoro-7′-(2-fluoropyridin-3-yl)-2,6-dihydrospiro[[1,4]oxazine-3,9′-xanthen]-5-amine.MS (m/z) 462 (M+H)⁺.

¹H NMR (400 MHz, CDCl₃) δ ppm; 8.19 (d, 1 H, J=4.7 Hz), 7.88 (m, 1 H),7.52 (m, 2 H), 7.34 (d, 1 H, J=8.4 Hz), 7.28 (m, 1 H), 7.10 (dd, 1 H,J=11.5, 1.9 Hz), 6.99 (s, 1 H), 6.17 (s, 1 H), 4.46 (m, 2 H), 4.34 (s, 3H), 3.84 (t, 2 H, J=5.6 Hz), 3.58 (m, 2 H), 2.33 (m, 2 H).

Example 270

Synthesis of(S)-3-(3,3-dimethylbut-1-ynyl)-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine

The titled compound was synthesized by steps analogous to thosedescribed in method A32 (except that 3,3-dimethylbut-1-yne was used, anddiisopropylamine was used instead of TBAF-(H₂O)₃), Intermediate 26B wasconverted to(S)-3-(3,3-dimethylbut-1-ynyl)-7-(2-fluoropyridin-3-yl)-5′,6′-dihydrospiro[chromeno[2,3-b]pyridine-5,4′-[1,3]oxazin]-2′-amine.MS (m/z) 443 (M+H)⁺.

¹H NMR (400 MHz, CDCl₃) δ ppm; 8.29 (d, 1 H, J=2.3 Hz), 8.20 (d, 2 H,J=4.9 Hz), 7.86 (t, 1 H, J=9.6 Hz, 7.79 (d, 1 H, J=2.2 Hz), 7.52 (m, 2H), 7.37 (m, 1 H), 7.28 (m, 1 H), 4.30 (br, 2 H), 4.15 (m, 2 H), 1.94(m, 1 H), 1.88 (m, 1 H), 1.34 (s, 9H).

The present invention also provides methods for making compounds ofFormulas I-II, and sub-formulas thereof. For example, and in addition tothe methods described herein, the compounds of the invention may be madeby the methods similar to those described in the literature referencescited below.

In one embodiment of the invention, there is provided a method of makinga compound of Formula I, the method comprising the step of reacting acompound 20

wherein A¹, A², A³, A⁴, A⁵, A⁶, R², X, Y and Z of Formula I are asdefined herein, with a compound having the structure

or R⁷—B(OH)₂, wherein R⁷ is as defined herein, to make a compound ofFormula I.

In another embodiment of the invention, there is provided a method ofmaking a compound of Formula I-A, the method comprising the step ofreacting a compound 20

wherein A¹, A³, A⁴, R⁷, X, Y and Z of Formula I-A are as defined hereinand LG is Br, Cl or —OH, with a compound having the structure

R²—B(OH)₂ or R²—Br, wherein R² is as defined herein, to make a compoundof Formula I-A.

In another embodiment of the invention, there is provided a method ofmaking a compound of Formula I-B, the method comprising the step ofreacting a compound 20

wherein A⁴, R⁷, X, Y and Z of Formula I-B are as defined herein and LGis Br, Cl or —OH, with a compound having the structure

R²—B(OH)₂ or R²—Br, wherein R² is as defined herein, to make a compoundof Formula I-B.

In another embodiment of the invention, there is provided a method ofmaking a compound of Formula II, the method comprising the step ofreacting a compound 20

wherein A¹, A², A³, A⁴, A⁵, A⁶, R², X and Y of Formula II are as definedherein, with a compound having the structure

or R⁷—B(OH)₂, wherein R⁷ is as defined herein, to make a compound ofFormula II.

As can be appreciated by the skilled artisan, the above syntheticschemes and representative examples are not intended to comprise acomprehensive list of all means by which the compounds described andclaimed in this application may be synthesized. Further methods will beevident to those of ordinary skill in the art. Additionally, the varioussynthetic steps described above may be performed in an alternatesequence or order to give the desired compounds.

For example, in these procedures, the steps may be preceded, orfollowed, by additional protection/deprotection steps as necessary.Particularly, if one or more functional groups, for example carboxy,hydroxy, amino, or mercapto groups, are or need to be protected inpreparing the compounds of the invention, because they are not intendedto take part in a specific reaction or chemical transformation, variousknown conventional protecting groups may be used. For example,protecting groups typically utilized in the synthesis of natural andsynthetic compounds, including peptides, nucleic acids, derivativesthereof and sugars, having multiple reactive centers, chiral centers andother sites potentially susceptible to the reaction reagents and/orconditions, may be used.

Synthetic chemistry transformations and protecting group methodologies(protection and deprotection) useful in synthesizing the inhibitorcompounds described herein are known in the art and include, forexample, those such as described in R. Larock, Comprehensive OrganicTransformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts,Protective Groups in Organic Synthesis, 3^(rd) edition, John Wiley andSons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents forOrganic Synthesis, John Wiley and Sons (1994); A. Katritzky and A.Pozharski, Handbook of Heterocyclic Chemistry, 2^(nd) edition (2001); M.Bodanszky, A. Bodanszky, The Practice of Peptide Synthesis,Springer-Verlag, Berlin Heidelberg (1984); J. Seyden-Penne, Reductionsby the Alumino- and Borohydrides in Organic Synthesis, 2^(nd) edition,Wiley-VCH, (1997); and L. Paquette, editor, Encyclopedia of Reagents forOrganic Synthesis, John Wiley and Sons (1995).

Salts, including pharmaceutically acceptable salts, of a compound of theinvention having a salt-forming group may be prepared in a conventionalmanner or manner known to persons skilled in the art. For example, acidaddition salts of compounds of the invention may be obtained bytreatment with an acid or with a suitable anion exchange reagent. A saltwith two acid molecules (for example a dihalogenide) may also beconverted into a salt with one acid molecule per compound (for example amonohalogenide); this may be done by heating to a melt, or for exampleby heating as a solid under a high vacuum at elevated temperature, forexample from 50° C. to 170° C., one molecule of the acid being expelledper molecule of the compound.

Acid salts can usually be converted to free-base compounds, e.g. bytreating the salt with suitable basic agents, for example with alkalimetal carbonates, alkali metal hydrogen carbonates, or alkali metalhydroxides, typically potassium carbonate or sodium hydroxide. Exemplaryand suitable salts, and their preparation, are described herein in theDefinition section of the application.

All synthetic procedures described herein can be carried out under knownreaction conditions, advantageously under those described herein, eitherin the absence or in the presence (usually) of solvents or diluents. Asappreciated by those of ordinary skill in the art, the solvents shouldbe inert with respect to, and should be able to dissolve, the startingmaterials and other reagents used. Solvents should be able to partiallyor wholly solubilize the reactants in the absence or presence ofcatalysts, condensing agents or neutralizing agents, for example ionexchangers, typically cation exchangers for example in the H⁺ form. Theability of the solvent to allow and/or influence the progress or rate ofthe reaction is generally dependant on the type and properties of thesolvent(s), the reaction conditions including temperature, pressure,atmospheric conditions such as in an inert atmosphere under argon ornitrogen, and concentration, and of the reactants themselves.

Suitable solvents for conducting reactions to synthesize compounds ofthe invention include, without limitation, water; esters, includinglower alkyl-lower alkanoates, e.g., EtOAc; ethers including aliphaticethers, e.g., Et₂O and ethylene glycol dimethylether or cyclic ethers,e.g., THF; liquid aromatic hydrocarbons, including benzene, toluene andxylene; alcohols, including MeOH, EtOH, 1-propanol, IPOH, n- andt-butanol; nitriles including CH₃CN; halogenated hydrocarbons, includingCH₂Cl₂, CHCl₃ and CCl₄; acid amides including DMF; sulfoxides, includingDMSO; bases, including heterocyclic nitrogen bases, e.g. pyridine;carboxylic acids, including lower alkanecarboxylic acids, e.g., AcOH;inorganic acids including HCl, HBr, HF, H₂SO₄ and the like; carboxylicacid anhydrides, including lower alkane acid anhydrides, e.g., aceticanhydride; cyclic, linear, or branched hydrocarbons, includingcyclohexane, hexane, pentane, isopentane and the like, and mixtures ofthese solvents, such as purely organic solvent combinations, orwater-containing solvent combinations e.g., aqueous solutions. Thesesolvents and solvent mixtures may also be used in “working-up” thereaction as well as in processing the reaction and/or isolating thereaction product(s), such as in chromatography.

Purification methods are known in the art and include, for example,crystallization, chromatography (liquid and gas phase, and the like),extraction, distillation, trituration, reverse phase HPLC and the like.Reactions conditions such as temperature, duration, pressure, andatmosphere (inert gas, ambient) are known in the art and may be adjustedas appropriate for the reaction.

The invention further encompasses “intermediate” compounds, includingstructures produced from the synthetic procedures described, whetherisolated or generated in-situ and not isolated, prior to obtaining thefinally desired compound. Structures resulting from carrying out stepsfrom a transient starting material, structures resulting from divergencefrom the described method(s) at any stage, and structures formingstarting materials under the reaction conditions are all “intermediates”included in the invention. Further, structures produced by usingstarting materials in the form of a reactive derivative or salt, orproduced by a compound obtainable by means of the process according tothe invention and structures resulting from processing the compounds ofthe invention in situ are also within the scope of the invention.

The invention also provides new starting materials and/or intermediates,as well as processes for the preparation thereof. In select embodiments,such starting materials are used and reaction conditions so selected asto obtain the desired compound(s). Starting materials of the invention,are either known, commercially available, or can be synthesized inanalogy to or according to methods that are known in the art. Manystarting materials may be prepared according to known processes and, inparticular, can be prepared using processes described in the examples.In synthesizing starting materials, functional groups may be protectedwith suitable protecting groups when necessary. Protecting groups, theirintroduction and removal are described above.

Compounds of the present invention can possess, in general, one or moreasymmetric carbon atoms and are thus capable of existing in the form ofoptical isomers as well as in the form of racemic or non-racemicmixtures thereof. While shown without respect to stereochemistry inFormulas I-II, the present invention includes such optical isomers anddiastereomers, as well as the racemic and resolved, enantiomericallypure R and S stereoisomers, as well as other mixtures of R and Sstereoisomers and pharmaceutically acceptable salts thereof.

The optical isomers can be obtained by resolution of the racemicmixtures according to conventional processes, e.g., by formation ofdiastereoisomeric salts, by treatment with an optically active acid orbase. Examples of appropriate acids are tartaric, diacetyltartaric,dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and thenseparation of the mixture of diastereoisomers by crystallizationfollowed by liberation of the optically active bases from these salts. Adifferent process for separation of optical isomers involves the use ofa chiral chromatography column optimally chosen to maximize theseparation of the enantiomers. Still another available method involvessynthesis of covalent diastereoisomeric molecules by reacting compoundsof the invention with an optically pure acid in an activated form or anoptically pure isocyanate. The synthesized diastereoisomers can beseparated by conventional means such as chromatography, distillation,crystallization or sublimation, and then hydrolyzed to deliver theenantiomerically pure compound. The optically active compounds of theinvention can likewise be obtained by using optically active startingmaterials. These isomers may be in the form of a free acid, a free base,an ester or a salt. All such isomeric forms of such compounds areexpressly included in the present invention.

The compounds of the invention may also be represented in multipletautomeric forms. Tautomers often exist in equilibrium with each other,and interconvert under environmental and physiological conditions. Thecompounds of the invention may also occur in cis- or trans- or E- orZ-double bond isomeric forms. The invention expressly includes alltautomeric forms of the compounds described herein.

All crystal forms of the compounds described herein are expresslyincluded in the present invention.

The present invention also includes isotopically-labeled compounds,which are identical to those recited herein, but for the fact that oneor more atoms are replaced by an atom having an atomic mass or massnumber different from the atomic mass or mass number usually found innature. Examples of isotopes that can be incorporated into compounds ofthe invention include isotopes of hydrogen, carbon, nitrogen, oxygen,phosphorous, fluorine and chlorine, such as ²H (deuterium), ³H(tritium), ¹³C, ¹⁴C, ¹⁵N, ¹⁶O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F, and ³⁶Cl.

Compounds of the present invention that contain the aforementionedisotopes and/or other isotopes of other atoms are within the scope ofthis invention. Certain isotopically-labeled compounds of the presentinvention, for example those into which radioactive isotopes such as ³Hand ¹⁴C are incorporated, are useful in drug and/or substrate tissuedistribution assays. Deuterated (²H), Tritiated (³H) and carbon-14,i.e., ¹⁴C, isotopes are particularly preferred for their ease ofpreparation and detection. Further, substitution with heavier isotopessuch as deuterium, i.e., ²H, can afford certain therapeutic advantagesresulting from greater metabolic stability, for example increased invivo half-life or reduced dosage requirements and, hence, may bepreferred in some circumstances. Isotopically labeled compounds of thisinvention can generally be prepared by substituting a readily availableisotopically labeled reagent for a non-isotopically labeled reagent.

Biological Evaluation

The compounds of the invention may be modified by appending appropriatefunctionalities to enhance selective biological properties. Thepharmacokinetic and pharmacodynamic properties of a compound relate,directly and indirectly, to the ability of the compound to be effectivefor its intended use.

Although the pharmacological properties of the compounds of theinvention (Formulas I-II and sub-Formulas thereof) vary with structuralchange, in general, activity possessed by compounds of Formulas I-II maybe demonstrated both in vitro as well as in vivo. The followingexemplified pharmacological assays have been carried out with thecompounds according to the invention, to assess and characterize thecompound's ability to modulate BACE activity and to regulate thecleavage of amyloid beta precursor protein, thereby reducing orinhibiting the production of amyloid beta.

In Vitro Enzymatic BACE FRET (Fluorescence Resonance Energy Transfer)Assay (Enzyme Assay Data in the Example Table I)

The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSOfinal, 100 uM genapol (which is a nonionic detergent, below its CriticalMicelle Concentration). The beta secretase enzyme (0.2 nM) ispre-incubated for one hour with inhibitors, typically in about 1 uL ofDMSO according to a serial dilution, are added thereto. This assay iseffectively started by the addition of FRET substrate (50 nM) and thecombination is incubated for one hour. The FRET assay is terminated withby addition of Tris buffer, which raises the pH to neutrality, and thefluorescence is determined. The FRET substrate is a peptide withcommercially available fluorophore and quencher, on opposite sides ofthe BACE cleavage site. Proteolytic cleavage of the FRET substratereleases quenching of fluorescence (excitation 488 nm and emission 425nm).

Where available, the in-vitro BACE FRET enzyme data for each of theExamples is provided in Table I.

In Vitro BACE Cell-Based Assay

The cell-based assay measures inhibition or reduction of Aβ40 inconditioned medium of test compound treated cells expressing amyloidprecursor protein.

Cells stably expressing Amyloid Precursor Protein (APP) were plated at adensity of 40K cells/well in 96 well plates (Costar). The cells werecultivated for 24 hours at 37° C. and 5% CO₂ in DMEM supplemented with10% FBS. The test compounds were then added to cells in 10-point doseresponse concentrations with the starting concentration being either 100μM or 10 μM. The compounds were diluted from stock solutions in DMSO andthe final DMSO concentration of the test compounds on cells was 0.1%.After 24 h of incubation with the test compounds the supernatantconditioned media was collected and the Aβ40 levels were determinedusing a sandwich ELISA. The IC₅₀ of the compound was calculated from thepercent of control or percent inhibition of Aβ40 as a function of theconcentration of the test compound.

The sandwich ELISA to detect Aβ40 was performed in 96 well microtiterplates, which were pre-treated with goat anti-rabbit IgG (Pierce). Thecapture and detecting antibody pair that were used to detect Aβ40 fromcell supernatants were affinity purified pAb40 (Biosource) andbiotinylated 6E10 (Signet Labs Inc.), respectively. The optimalconcentration for the pAb40 antibody was 3 μg/ml in Superblock/TBS(Pierce) that was supplemented with 0.05% Tween 20 (Sigma). Optimalconcentration for the detection antibody 6E10-biotinylated was 0.5 μg/mlin Superblock/TBS (Pierce) that had been supplemented with 2% normalgoat serum and 2% normal mouse serum.

Cellular supernatants were incubated with the capture antibody for 3 hat 4° C., followed by 3 wash steps in TBS-tween (0.05%). The detectingantibody incubation was for 2 h at 4° C., again followed by the washsteps as described previously. The final readout of the ELISA isTime-Resolved Fluorescence (counts per minute) using Delfia reagentsStreptavidin-Europium and Enhancement solutions (Perkin Elmer) and theVictor 2 multilabel counter (Perkin Elmer).

Where available, the in-vitro BACE cell based data for each of theExamples is provided in Table I.

In Vivo Inhibition of Beta-Secretase

Several animal models, including mouse, rat, dog, and monkey, may beused to screen for inhibition of beta-secretase activity in vivofollowing administration of a test compound sample. Animals used in thisinvention can be wild type, transgenic, or gene knockout animals. Forexample, the Tg2576 mouse model, prepared and conducted as described inHsiao et al., 1996, Science 274, 99-102, and other non-transgenic orgene knockout animals are useful to analyze in vivo inhibition ofAmyloid beta peptide (Abeta) production in the presence of inhibitorytest compounds. Generally, 2 to 18 month old Tg2576 mice, gene knockoutmice or non-transgenic animals are administered test compoundsformulated in vehicles, such as cyclodextran, phosphate buffers,hydroxypropyl methylcellulose or other suitable vehicles. One totwenty-four hours following the administration of compound, animals aresacrificed, and brains as well as cerebrospinal fluid (CSF) and plasmaare removed for analysis of A-beta levels and drug or test compoundconcentrations (Dovey et al., 2001, Journal of Neurochemistry,76,173-181) Beginning at time 0, animals are administered by oralgavage, or other means of delivery such as intravenous injection, aninhibitory test compound of up to 100 mg/kg in a standard, conventionalformulation, such as 2% hydroxypropyl methylcellulose, 1% Tween80. Aseparate group of animals receive 2% hydroxypropyl methylcellulose, 1%Tween80 alone, containing no test compound, and serve as avehicle-control group. At the end of the test period, animals aresacrificed and brain tissues, plasma or cerebrospinal fluid arecollected. Brains are either homogenized in 10 volumes (w/v) of 0.2%diethylamine (DEA) in 50 mM NaCl (Best et al., 2005, Journal ofPharmacology and Experimental Therapeutics, 313, 902-908), or in 10volumes of 0.5% TritonX-100 in Tris-buffered saline (pH at about 7.6).Homogenates are centrifuged at 355,000 g, 4° C. for 30 minutes. CSF orbrain supernatants are then analyzed for the presence of A-beta peptideby specific sandwich ELISA assays based on ECL(Electrochemiluminescence) technology. For example, rat Abeta40 ismeasured using biotinylated-4G8 (Signet) as a capture antibody and Fab40(an in-house antibody specific to the C-terminal of Abeta40) as adetection antibody. For example, 4 hours after administration of 30mg/kg oral dose of the test compound in 2% hydroxypropylmethylcellulose, 1% Tween80 (pH2.2) to 200 g male Sprague Dawley rats,amyloid beta peptide levels are measured for reduction by X % and Y % incerebrospinal fluid and brain, respectively, when compared to the levelsmeasured in the vehicle-treated rats.

-   Actual vehicles used: Oral: 2% HPMC, 1% Tween80, pH 2.2    -   IV: 5% EtOH, 45% Propylene glycol in 5% Dextrose

The compounds of the invention may be shown to reduce the formationand/or deposition of amyloid beta peptide in the cerebrospinal fluid(CSF) as well as in the brain of a mouse or rat at either 3 mpk, 10 mpkor 30 mpk (mpk=mg compound per kg weight of the animal) dosingconcentrations after 4 hrs. The following examples exhibited thefollowing percent Abeta 40 reductions at 10 mpk (unless otherwise noted)in the CSF and brain of the rat, respectively.

Ex. % reduction of rat % reduction of rat No. CSF levels at 10 pmk brainlevels at 10 mpk  30 67% 62%  72 38% 27%  73 62% 42%  74 47% 26%  32 37%26%  33 61% 48%  36A 26% 25%  37A 44% 39%  84 15% 17%  86 12% 11%  8950% 41%  90  7% at 3 mpk  0% at 3 mpk  91 29%  3% 107 82% 72% 110 86%79% 111 81% 67% 114 54% 34% 115 38% 21% 119  5% at 3 mpk  6% at 3 mpk120 30% at 3 mpk 24% at 3 mpk 122 11% at 3 mpk 14% at 3 mpk 126 25%  8%129 22% 17%  65 14% 55%  64  8%  4%  40 33% 15%  41 13% 23% 132 38% 25% 63 19% 16% 145 78% 59% 146 75% 62% 149 80% 62% 153 78% 64% 154 57% 37%155 68% 53% 156 27%  8% 163 52% 28% 164 35% 12%  17A 44% 37% 166 42% 25%168 44% 18% 173 40% 14% 176 30% 13% 178 21% 14% 182 59% 30% 184 19% 12%185 53% at 30 mpk 26% at 30 mpk 201 80% at 30 mpk 65% at 30 mpk 204 80%at 30 mpk 66% at 30 mpk 220 38%  2%  55 65% 51% 226 83% 74% 239 68% 48%248 53% 39% 249 72% 59% 250 72% 72%  60 56% 25%  61 70% 55% 270 70% 52%

Indications

The compounds of the invention have been shown to modulate, andspecifically inhibit the activity of beta-secretase (Memapsin 2) enzyme,thereby reducing the A-beta peptide fragments believed to be responsiblefor Alzheimer's Disease (AD). Bapineuzamab, a monoclonal amino-terminusspecific anti-amyloid antibody is presently in Phase III clinical trialsfor the treatment of AD. Alzheimer's Research & Therapy, 1:2, 2009.Bapineuzumab targets beta amyloid protein involved in AD. It is the mostadvanced monoclonal antibody in clinical development to stop the diseaseprogression and degradation of cognitive function. The drug has fasttrack regulatory status with the USFDA (Medpedia, 2011). Hence, it mustclearly show a beneficial and lasting effect through validated biomarkerof underlying AD disease mechanism. Clinical trials in AD now measureCSF Aβ levels, brain amyloid load, CSF tau, brain volume by MRI and FDGPET scan. Each of the known genetic causes of AD is linked to A-beta.

Other conditions including dementia, Down's Syndrome to APPover-production, are all believed to be linked to the deposition ofA-beta on the brain. With methods for identifying brain amyloiddeposition, positron emission scanning (PET) and CSF measurements ofAb42, identification of AD suffering individuals needing treatment isbecoming more easy. It is firmly believed that by reducing the formationof A-beta, one can begin to pre-treat AD. Vassar et al, Journal ofNeuroscience, 29 (41):12787-12794, 2009. One published pathway fortreatment of AD is inhibition of beta-secretase. Tirrell, BloombergNews, The Boston Globe, 1-7-2010; Curr. Alzheimer's Res. 2008, Apr. 5(2):121-131; Expert Opin. Drug Discov. (200( ) 4(4):319-416.

Accordingly, compounds of the invention, and pharmaceutical compositionscomprising said compounds, are useful for, but not limited to, theprevention or treatment of beta-secretase related diseases, includingAlzheimer's disease, the leading cause of dementia. Particularly, thecompounds of the invention are useful to treat various stages of AD,including without limitation mild to moderate AD and prodromal patientspre-disposed to developing AD. The compounds of the invention have theability to modulate the activity of beta secretase enzyme, therebyregulating the production of amyloid beta (Abeta peptide) and slowing orreducing the formation and deposition of Abeta peptide in both thecerebral spinal fluid as well as in the brain, resulting in a decreaseof amyloid plaque on the brain. In one embodiment of the invention,there is provided a method of treating a disorder related to abeta-secretase enzyme in a subject, the method comprising administeringto the subject an effective dosage amount of a compound of Formulas I,I-A, I-A-1 through I-A-7, I-B, II, II-A or II-B. In another embodiment,there is provided a method of reducing production of amyloid beta, andof slowing plaque formation on the brain. In another embodiment, thereis provided a method for the treatment, prevention or amelioration of adisease or disorder characterized by the elevated beta-amyloid depositsor beta-amyloid levels in a subject, the method comprising administeringto the subject a therapeutically effective amount of a compoundaccording to any of Formulas I-II, and sub-Formulas thereof. In yetanother embodiment, the invention provides a method of treatingAlzheimer's disease, cognitive impairment including mild, moderateand/or severe, Down's Syndrome, cognitive decline, senile dementia,cerebral amyloid angiopathy or a neurodegenerative disorder.

Accordingly, the compounds of the invention would be useful in therapyas CNS agents in treating neurological disorders and related conditions.

In one embodiment, the compounds of the invention are provided for themanufacture of a medicament, or a pharmaceutical composition, for thetherapeutic and/or prophylactic treatment of diseases and disorderscharacterized by elevated levels of β-amyloid and/or β-amyloid oligomersand/or b-amyloid plaques and further deposits, including Alzheimer'sDisease. In another embodiment, the invention provides compounds, ineffective dosage amounts, for the therapeutic and/or prophylactictreatment of AD. Thus, the compounds of the invention may be used totreat prodromol patients, i.e., subjects exhibiting the biomarkersand/or hallmarks of developing AD.

Besides being useful for human treatment, these compounds are useful forveterinary treatment of companion animals, exotic animals and farmanimals, including mammals, rodents, and the like. For example, animalsincluding horses, dogs, and cats may be treated with compounds providedby the invention.

Formulations and Method of Use

Treatment of diseases and disorders herein is intended to also includetherapeutic administration of a compound of the invention, or apharmaceutical salt thereof, or a pharmaceutical composition of eitherto a subject (i.e., an animal, preferably a mammal, most preferably ahuman) which may be in need of preventative treatment, such as, forexample, for pain, inflammation and the like. Treatment also encompassesprophylactic administration of a compound of the invention, or apharmaceutical salt thereof, or a pharmaceutical composition of eitherto a subject (i.e., an animal, preferably a mammal, most preferably ahuman). Generally, the subject is initially diagnosed by a licensedphysician and/or authorized medical practitioner, and a regimen forprophylactic and/or therapeutic treatment via administration of thecompound(s) or compositions of the invention is suggested, recommendedor prescribed.

The amount of compound(s) which is/are administered and the dosageregimen for treating neurological disorders and beta-secretase mediateddiseases with the compounds and/or compositions of this inventiondepends on a variety of factors, including the age, weight, sex andmedical condition of the subject, the type of disease, the severity ofthe disease, the route and frequency of administration, and theparticular compound employed. Thus, the dosage regimen may vary widely,but can be determined routinely using standard methods. A daily dose ofabout 0.01 to 500 mg/kg, advantageously between about 0.01 and about 50mg/kg, more advantageously about 0.01 and about 30 mg/kg, and even moreadvantageously between about 0.1 and about 10 mg/kg body weight may beappropriate, and should be useful for all methods of use disclosedherein. The daily dose can be administered in one to four doses per day.

While it may be possible to administer a compound of the inventionalone, in the methods described, the compound administered normally willbe present as an active ingredient in a pharmaceutical composition.Thus, in another embodiment of the invention, there is provided apharmaceutical composition comprising a compound of this invention incombination with a pharmaceutically acceptable excipient, which includesdiluents, carriers, adjuvants and the like (collectively referred toherein as “excipient” materials) as described herein, and, if desired,other active ingredients. A pharmaceutical composition of the inventionmay comprise an “effective amount” of a compound of the invention or an“effective dosage amount” of a compound of the invention. An “effectivedosage amount” of a compound of the invention includes an amount lessthan, equal to or greater than an effective amount of the compound. Forexample, a pharmaceutical composition in which two or more unit dosages,such as in tablets, capsules and the like, are required to administer aneffective amount of the compound, or alternatively, a multi-dosepharmaceutical composition, such as powders, liquids and the like, inwhich an effective amount of the compound is administered byadministering a portion of the composition.

The compound(s) of the present invention may be administered by anysuitable route, preferably in the form of a pharmaceutical compositionadapted to such a route, and in a dose effective for the treatmentintended. The compounds and compositions of the present invention may,for example, be administered orally, mucosally, topically, rectally,pulmonarily such as by inhalation spray, or parentally includingintravascularly, intravenously, intraperitoneally, subcutaneously,intramuscularly intrasternally and infusion techniques, in dosage unitformulations containing conventional pharmaceutically acceptablecarriers, adjuvants, and vehicles.

For oral administration, the pharmaceutical composition may be in theform of, for example, a tablet, capsule, suspension or liquid. Thepharmaceutical composition is preferably made in the form of a dosageunit containing a particular amount of the active ingredient. Examplesof such dosage units are tablets or capsules. For example, these maycontain an amount of active ingredient from about 1 to 2000 mg,advantageously from about 1 to 500 mg, and typically from about 5 to 150mg. A suitable daily dose for a human or other mammal may vary widelydepending on the condition of the patient and other factors, but, onceagain, can be determined using routine methods and practices.

For therapeutic purposes, the active compounds of this invention areordinarily combined with one or more adjuvants or other “excipients”appropriate to the indicated route of administration. If orallyadministered on a per dose basis, the compounds may be admixed withlactose, sucrose, starch powder, cellulose esters of alkanoic acids,cellulose alkyl esters, talc, stearic acid, magnesium stearate,magnesium oxide, sodium and calcium salts of phosphoric and sulfuricacids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone,and/or polyvinyl alcohol, to form the final formulation. For example,the active compound(s) and excipient(s) may be tableted or encapsulatedby known and accepted methods for convenient administration. Examples ofsuitable formulations include, without limitation, pills, tablets, softand hard-shell gel capsules, troches, orally-dissolvable forms anddelayed or controlled-release formulations thereof. Particularly,capsule or tablet formulations may contain one or morecontrolled-release agents, such as hydroxypropylmethyl cellulose, as adispersion with the active compound(s).

Formulations for parenteral administration may be in the form of aqueousor non-aqueous isotonic sterile injection solutions or suspensions.These solutions and suspensions may be prepared from sterile powders orgranules using one or more of the carriers or diluents mentioned for usein the formulations for oral administration or by using other suitabledispersing or wetting agents and suspending agents. The compounds may bedissolved in water, polyethylene glycol, propylene glycol, ethanol, cornoil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodiumchloride, tragacanth gum, and/or various buffers. Other adjuvants andmodes of administration are well and widely known in the pharmaceuticalart. The active ingredient may also be administered by injection as acomposition with suitable carriers including saline, dextrose, or water,or with cyclodextrin (ie. Captisol), cosolvent solubilization (ie.propylene glycol) or micellar solubilization (ie. Tween 80).

The sterile injectable preparation may also be a sterile injectablesolution or suspension in a non-toxic parenterally acceptable diluent orsolvent, for example as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that may be employed are water,Ringer's solution, and isotonic sodium chloride solution. In addition,sterile, fixed oils are conventionally employed as a solvent orsuspending medium. For this purpose any bland fixed oil may be employed,including synthetic mono- or diglycerides. In addition, fatty acids suchas oleic acid find use in the preparation of injectables.

The active ingredient may also be administered by injection as acomposition with suitable carriers including saline, dextrose, or water.The daily parenteral dosage regimen will be from about 0.1 to about 30mg/kg of total body weight, and preferably from about 0.1 to about 10mg/kg.

For pulmonary administration, the pharmaceutical composition may beadministered in the form of an aerosol or with an inhaler including drypowder aerosol.

The pharmaceutical compositions may be subjected to conventionalpharmaceutical operations such as sterilization and/or may containconventional adjuvants, such as preservatives, stabilizers, wettingagents, emulsifiers, buffers etc. Tablets and pills can additionally beprepared with enteric coatings. Such compositions may also compriseadjuvants, such as wetting, sweetening, flavoring, and perfuming agents.Accordingly, in yet another embodiment of the present invention, thereis provided a method of manufacturing a medicament, the methodcomprising combining an amount of a compound according to Formulas I-IIwith a pharmaceutically acceptable carrier to manufacture themedicament.

In yet another embodiment, the invention provides a method ofmanufacturing a medicament for the treatment of Alzheimer's disease, themethod comprising combining an amount of a compound according toFormulas I-II with a pharmaceutically acceptable carrier to manufacturethe medicament.

COMBINATIONS

While the compounds of the invention can be dosed or administered as thesole active pharmaceutical agent, they can also be used in combinationwith one or more compounds of the invention or in conjunction with otheragents. When administered as a combination, the therapeutic agents canbe formulated as separate compositions that are administeredsimultaneously or sequentially at different times, or the therapeuticagents can be given as a single composition.

The phrase “co-therapy” (or “combination-therapy”), in defining use of acompound of the present invention and another pharmaceutical agent, isintended to embrace administration of each agent in a sequential mannerin a regimen that will provide beneficial effects of the drugcombination, and is intended as well to embrace co-administration ofthese agents in a substantially simultaneous manner, such as in a singlecapsule having a fixed ratio of these active agents or in multiple,separate capsules for each agent.

Specifically, the compounds of the present invention may be administeredin conjunction with additional therapies known to those skilled in theart in the prevention or treatment of beta-secretase, gamma-secretaseand/or other reagents known in influence the formation and/or depositionof amyloid beta, otherwise responsible for the formation of plaque onthe brain. Thus, the compounds may be co-administered simultaneously orsequentially along with the other therapeutic agent.

If formulated as a fixed dose, such combination products employ thecompounds of this invention within the accepted dosage ranges. Compoundsof Formulas I and II may also be administered sequentially with knownCNS treating agents when a combination formulation is inappropriate. Theinvention is not limited in the sequence of administration; compounds ofthe invention may be administered either prior to, simultaneous with orafter administration of the known and used CNS agent.

The foregoing description is merely illustrative of the invention and isnot intended to limit the invention to the disclosed compounds,compositions and methods. Variations and changes, which are obvious toone skilled in the art, are intended to be within the scope and natureof the invention, as defined in the appended claims. From the foregoingdescription, one skilled in the art can easily ascertain the essentialcharacteristics of this invention, and without departing from the spiritand scope thereof, can make various changes and modifications of theinvention to adapt it to various usages and conditions. All patents andother publications recited herein are hereby incorporated by referencein their entireties.

What is claimed is:
 1. A compound of Formula I:

or a stereoisomer, tautomer, hydrate, solvate or pharmaceuticallyacceptable salt thereof, wherein A¹ is CR⁶; A² is CR⁵; A³ is CR⁴; A⁴ isN; A⁵ is CR¹; A⁶ is CR⁸; each of R¹, R⁴, R⁵ and R⁸, independently, is H,F, Cl, Br, CF₃, OCF₃, C₁₋₆-alkyl, CN, OH, —OC₁₋₆-alkyl,—S(O)_(o)C₁₋₆-alkyl, —NHC₁₋₆-alkyl or —C(O)C₁₋₆-alkyl, wherein theC₁₋₆-alkyl and C₁₋₆-alkyl portion of —OC₁₋₆-alkyl, —S(O)_(o)C₁₋₆-alkyl,—NHC₁₋₆-alkyl and —C(O)C₁₋₆-alkyl are optionally substituted with 1-3substituents of F, oxo or OH; each of R² and R⁷, independently, is F,Cl, Br, I, haloalkyl, haloalkoxyl, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl,—NH-benzyl, —Si(CH₃)₃ or a ring selected from the group consisting ofphenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,diazolyl, triazolyl, tetrazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl,dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein theC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl and ring areoptionally substituted, independently, with 1-3 substituents of R⁹; R⁶is H, halo, haloalkyl, haloalkoxyl, C₁₋₆-alkyl, CN, OH, OC₁₋₆-alkyl,S(O)_(o)C₁₋₆-alkyl, NHC₁₋₆-alkyl or C(O)C₁₋₆-alkyl; each R⁹,independently, is halo, haloalkyl, haloalkoxyl, CN, OH, NO₂, NH₂,acetyl, —C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,C₃₋₆cycloalkyl, C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl,C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl,pyrrolidinyl, piperazinyl, oxetanyl or dioxolyl, wherein each of theC₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl; X is—CR¹⁰R¹⁰— or —O—, wherein each R¹⁰, independently, is H, halo,haloalkyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl or a ringselected from the group consisting of morpholinyl, piperidinyl,piperizinyl, tetrahydrofuranyl, furanyl, thienyl, phenyl, pyrdinyl,pyrimidinyl, pyridazinyl, pyrazinyl, pyranyl, dihydropyranyl,tetrahydropyranyl, pyrrolyl, dihydropyrrolyl, tetrahydropyrrolyl andoxetanyl; Y is —O—, —S— or —CH₂—, provided that (1) when X is —O—, thenY is —CH₂—, or (2) when X is —CR¹⁰R¹⁰—, then Y is —O— or —S—; and Z isCH₂, CHF, CF₂, CH(CH₃), C(CH₃)₂ or CH(CF₃).
 2. The compound of claim 1having a Formula II:

or a stereoisomer, tautomer, hydrate, solvate or pharmaceuticallyacceptable salt thereof, wherein A¹ is CR⁶; A² is CR⁵; A³ is CR⁴; A⁴ isN; A⁵ is CR¹; A⁶ is CR⁸; each of R¹, R⁴, R⁵ and R⁸, independently, is H,F, Cl, Br, CF₃, OCF₃, C₁₋₆-alkyl, CN, OH, —OC₁₋₆-alkyl,—S(O)_(o)C₁₋₆-alkyl, —NHC₁₋₆-alkyl or —C(O)C₁₋₆-alkyl, wherein theC₁₋₆-alkyl and C₁₋₆-alkyl portion of —OC₁₋₆-alkyl, —S(O)_(o)C₁₋₆-alkyl,—NHC₁₋₆-alkyl and —C(O)C₁₋₆-alkyl are optionally substituted with 1-3substituents of F, oxo or OH; R² is Cl, Br, C₁₋₆-alkyl, C₂₋₄alkenyl,C₂₋₄alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂,—NH-phenyl, —NH-benzyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, pyrazolyl, isoxazolyl, thiazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl,pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azetidinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl,2-oxo-7-aza-[3,5]-spironon-7-yl, cyclopentyl, cyclohexyl or —Si(CH₃)₃,wherein the C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl,—SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl,phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrazolyl,isoxazolyl, thiazolyl, pyranyl, dihydropyranyl, tetrahydropyranyl,furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl, azetidinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl,2-oxo-7-aza-[3,5]-spironon-7-yl, cyclopentyl and cyclohexyl areoptionally substituted, independently, with 1-3 substituents of R⁹; R⁶is H, halo, haloalkyl, haloalkoxyl, C₁₋₆-alkyl, CN, OH, OC₁₋₆-alkyl,S(O)_(o)C₁₋₆-alkyl, NHC₁₋₆-alkyl or C(O)C₁₋₆-alkyl; R⁷ is C₁₋₆-alkyl,C₂₋₄alkenyl, C₂₋₄alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl,—N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl, phenyl, pyridyl, pyrimidyl,pyrazinyl, pyridazinyl, pyrazolyl, isoxazolyl, thiazolyl, pyranyl,dihydropyranyl, tetrahydropyranyl, furanyl, dihydrofuranyl,tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopentyl or cyclohexyl, wherein the C₁₋₆-alkyl, C₂₋₄alkenyl,C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂,—NH-phenyl, —NH-benzyl, phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, pyrazolyl, isoxazolyl, thiazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl,pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azetidinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl,2-oxo-7-aza-[3,5]-spironon-7-yl, cyclopentyl and cyclohexyl areoptionally substituted, independently, with 1-3 substituents of R⁹; eachR⁹, independently, is halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl,—C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,piperazinyl, oxetanyl or dioxolyl, wherein each of the C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl; X is—CH₂— or —O—; and Y is —O—, —S— or —CH₂—, provided that (1) when X is—O—, then Y is —CH₂— or (2) when X is —CH₂—, then Y is —O— or —S—. 3.The compound of claim 1, or a stereoisomer, tautomer or pharmaceuticallyacceptable salt thereof, wherein A¹ is CH or CF; A² is CH or CF; A³ isCH or CF; A⁴ is N; A⁵ is CH, CF or CBr; A⁶ is CH or CF; X is —CH₂— or—O—; Y is —O—, —S— or —CH₂—, provided that (1) when X is —O—, then Y is—CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—; and Z is CH₂, CHF,CF₂, CH(CH₃), C(CH₃)₂ or CH(CF₃).
 4. The compound of claim 1, or astereoisomer or pharmaceutically acceptable salt thereof, wherein eachof R¹, R⁴, R⁵ and R⁸, independently, is H, F, Cl, CF₃, OCF₃, methyl,ethyl, CN, OH, OCH₃, SCH₃, NHCH₃ or C(O)CH₃; one of R² and R⁷,independently, is F, Cl, Br, I, haloalkyl, haloalkoxyl, C₁₋₆-alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl,—N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl, —Si(CH₃)₃ or a ring selectedfrom the group consisting of phenyl, pyridyl, pyrimidyl, pyrazinyl,pyridazinyl, triazinyl, thienyl, pyrazolyl, imidazolyl, oxazolyl,isoxazolyl, thiazolyl, isothiazolyl, diazolyl, triazolyl, tetrazolyl,pyranyl, dihydropyranyl, tetrahydropyranyl, furanyl, dihydrofuranyl,tetrahydrofuranyl, pyrrolyl, dihydropyrrolyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl, azetidinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl,2-oxo-7-aza-[3,5]-spironon-7-yl, cyclopropyl, cyclobutyl, cyclopentyland cyclohexyl, wherein the C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl,—OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl,—NH-benzyl and ring are optionally substituted, independently, with 1-3substituents of R⁹; the other of R² and R⁷, independently, isC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl or —NH-benzyl, phenyl, pyridyl,pyrimidyl or thienyl, wherein the C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl,CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl,—NH-benzyl, phenyl, pyridyl, pyrmidinyl and thienyl are optionallysubstituted, independently, with 1-3 substituents of R⁹; R⁶ is H, halo,haloalkyl, haloalkoxyl, C₁₋₆-alkyl, CN, OH, OC₁₋₆-alkyl, SC₁₋₆-alkyl,NHC₁₋₆-alkyl or C(O)C₁₋₆-alkyl; X is —CH₂— or —O—; Y is —O—, —S— or—CH₂—, provided that (1) when X is —O—, then Y is —CH₂—, or (2) when Xis —CH₂, then Y is —O— or —S—; and Z is CH₂, CF₂ or CH(CH₃).
 5. Thecompound of claim 1 wherein R⁷ is a ring selected from the groupconsisting of phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl,pyrazolyl, isoxazolyl, thiazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl,pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, said ringoptionally substituted, independently, with 1-3 substituents of R⁹. 6.The compound of claim 1, or a stereoisomer or pharmaceuticallyacceptable salt thereof, wherein R² is halo, haloalkyl, haloalkoxyl,C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl,wherein the C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl and C₃₋₈-cycloalkyl areoptionally substituted, independently, with 1-3 substituents of R⁹; eachof R¹, R⁴, R⁵ and R⁸, independently, is H, F, methyl, CN or OH; R⁶ is H,F, Cl, CF₃, methyl, CN, OH, OCH₃, SCH₃ or NHCH₃; R⁷ is a ring selectedfrom the group consisting of phenyl, pyridyl, pyrimidyl, pyridazinyl,pyrazinyl, triazinyl and thienyl, said ring optionally substituted,independently, with 1-3 substituents of R⁹; X is —CH₂— or —O—; Y is —O—,—S— or —CH₂—, provided that (1) when X is —O—, then Y is —CH₂—, or (2)when X is —CH₂, then Y is —O— or —S—; and Z is CH₂.
 7. The compound ofclaim 1, or a stereoisomer or pharmaceutically acceptable salt thereof,selected from A¹ is CH; A² is CH; A³ is CH or CF; A⁴ is N; A⁵ is CH; A⁶is CH; R² is F, Cl, Br, I, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN,—OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl,—NH-benzyl, —Si(CH₃)₃ or a ring selected from the group consisting ofphenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,diazolyl, triazolyl, tetrazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl,dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein theC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl and ring areoptionally substituted, independently, with 1-3 substituents of R⁹; R⁷is a ring selected from the group consisting of phenyl, pyridyl,pyrimidyl, pyridazinyl, pyrazinyl, triazinyl and thienyl, said ringoptionally substituted, independently, with 1-3 substituents of R⁹; eachR⁹, independently, is F, Cl, Br, CH₂F, CHF₂, CF₃, CN, OH, NO₂, NH₂,acetyl, —C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,C₃₋₆cycloalkyl, C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl,C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl,pyrrolidinyl, piperazinyl, oxetanyl or dioxolyl, wherein each of theC₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetanyl or dioxolyl, isoptionally substituted independently with 1-5 substituents of F, Cl, CN,NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,isopropyl, isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl,butoxyl, isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl; X is—CH₂— or —O—; Y is —O—, —S— or —CH₂—, provided that (1) when X is —O—,then Y is —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—; and Z isCH₂.
 8. The compound of claim 7 wherein R² is F, Cl, Br, I, C₁₋₆-alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl,3-methyl-3-oxetanyl-ethynyl, 3-methyl-3-oxetanyl-methoxyl,3,3-dimethyl-butyn-1-yl, 3-methyl-3-butyn-1-yl,2,2-dimethyl-3-cyano-propoxyl, 2-fluoro-2-methyl-propoxyl, or a ringselected from the group consisting of phenyl, 2-pyridyl, 3-pyridyl,4-pyridyl, dihydro-2H-pyran-4-yl, dihydro-2H-pyran-3-yl,tetrahydropyran-4-yl, dihydrofuranyl, tetrahydrofuranyl,pyrrolidin-1-yl, piperidin-1-yl, morpholinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl and2-oxo-7-aza-[3,5]-spironon-7-yl, wherein the C₁₋₆-alkyl, C₂₋₄alkenyl,C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, 3-methyl-3-oxetanyl-ethynyl,3-methyl-3-oxetanyl-methoxyl, 3,3-dimethyl-butyn-1-yl,3-methyl-3-butyn-1-yl, 2,2-dimethyl-3-cyano-propoxyl,2-fluoro-2-methyl-propoxyl and ring are optionally substituted,independently, with 1-3 substituents of R⁹.
 9. The compound of claim 1,or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof,having a general formula I-A

wherein A¹ is CR⁶; A³ is CR⁴; A⁴ is N; each of R¹, R³, R⁴, R⁵, R⁶ andR⁸, independently, is H, F, Cl, CF₃, OCF₃, methyl, ethyl, CN, OH, OCH₃,SCH₃, NHCH₃ or C(O)CH₃; one of R² and R⁷, independently, is F, Cl, Br,I, haloalkyl, haloalkoxyl, C₁₋₆-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, CN,—OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl,—NH-benzyl, —Si(CH₃)₃ or a ring selected from the group consisting ofphenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,diazolyl, triazolyl, tetrazolyl, pyranyl, dihydropyranyl,tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl,dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,azetidinyl, 8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl,aza-bicyclo[2.2.1]hept-5-yl, 2-oxo-7-aza-[3,5]-spironon-7-yl,cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein theC₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl and ring areoptionally substituted, independently, with 1-3 substituents of R⁹; theother of R² and R⁷, independently, is C₁₋₆-alkyl, C₂₋₄alkenyl,C₂₋₄alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, —NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂,—NH-phenyl or —NH-benzyl, phenyl, pyridyl, pyrimidyl or thienyl, whereinthe C₁₋₆-alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl,—NHC₁₋₆alkyl, —N(C₁₋₃alkyl)₂, —NH-phenyl, —NH-benzyl, phenyl, pyridyl,pyrmidinyl and thienyl are optionally substituted, independently, with1-3 substituents of R⁹; each R⁹, independently, is halo, haloalkyl, CN,OH, NO₂, NH₂, acetyl, —C(O)NHCH₃, oxo, C₁₋₆alkyl, C₂₋₆alkenyl,C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-, C₁₋₆dialkylamino-,C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl, isoxazolyl,dihydropyranyl, pyrrolidinyl, piperazinyl, oxetanyl or dioxolyl, whereineach of the C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl,C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl,morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl,oxetanyl or dioxolyl, is optionally substituted independently with 1-5substituents of F, Cl, CN, NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl,ethoxyl, propyl, propoxyl, isopropyl, isopropoxyl, cyclopropyl,cyclopropylmethoxyl, butyl, butoxyl, isobutoxyl, tert-butoxyl, isobutyl,sec-butyl, tert-butyl, C₁₋₃alkylamino-, C₁₋₃dialkylamino,C₁₋₃thioalkoxyl, or oxetanyl; X is —CH₂— or —O—; Y is —O—, —S— or —CH₂—,provided that (1) when X is —O—, then Y is —CH₂—, or (2) when X is —CH₂,then Y is —O— or —S—; and Z is CH₂, CF₂ or CH(CH₃).
 10. The compound ofclaim 9, or a pharmaceutically acceptable salt thereof, wherein A¹ isCR⁶; A³ is CH, CF; A⁴ is N, each of R¹, R⁵, R⁶ and R⁸, independently, isH, F, CF₃, methyl or CN; R² is F, Cl, Br, I, C₁₋₆-alkyl, C₂₋₆alkenyl,C₂₋₆alkynyl, CN, —OC₁₋₆alkyl, —SC₁₋₆alkyl, 3-methyl-3-oxetanyl-ethynyl,3-methyl-3-oxetanyl-methoxyl, 3,3-dimethyl-butyn-1-yl,3-methyl-3-butyn-1-yl, 2,2-dimethyl-3-cyano-propoxyl,2-fluoro-2-methyl-propoxyl, or a ring selected from the group consistingof phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, dihydro-2H-pyran-4-yl,dihydro-2H-pyran-3-yl, tetrahydropyran-4-yl, dihydrofuranyl,tetrahydrofuranyl, pyrrolidin-1-yl, piperidin-1-yl, morpholinyl,8-oxo-3-aza-bicyclo[3.2.1]oct-3-yl, aza-bicyclo[2.2.1]hept-5-yl and2-oxo-7-aza-[3,5]-spironon-7-yl, wherein the C₁₋₆-alkyl, C₂alkenyl,C₂₋₄alkynyl, —OC₁₋₆alkyl, —SC₁₋₆alkyl, 3-methyl-3-oxetanyl-ethynyl,3-methyl-3-oxetanyl-methoxyl, 3,3-dimethyl-butyn-1-yl,3-methyl-3-butyn-1-yl, 2,2-dimethyl-3-cyano-propoxyl,2-fluoro-2-methyl-propoxyl and ring are optionally substituted,independently, with 1-3 substituents of R⁹; R⁷ is a ring selected fromthe group consisting of phenyl, pyridyl, pyrimidyl, pyridazinyl,pyrazinyl, triazinyl and thienyl, said ring optionally substituted,independently, with 1-3 substituents of R⁹; each R⁹, independently, ishalo, haloalkyl, CN, OH, NO₂, NH₂, acetyl, —C(O)NHCH₃, oxo, C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₁₋₆alkylamino-,C₁₋₆dialkylamino-, C₁₋₆alkoxyl, C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl,isoxazolyl, dihydropyranyl, pyrrolidinyl, piperazinyl, oxetanyl ordioxolyl, wherein each of the C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,C₃₋₆cycloalkyl, C₁₋₆alkylamino-, C₁₋₆dialkylamino-, C₁₋₆alkoxyl,C₁₋₆thioalkoxyl, morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl,pyrrolidinyl, oxetanyl or dioxolyl, is optionally substitutedindependently with 1-5 substituents of F, Cl, CN, NO₂, NH₂, OH, oxo,methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl,isopropoxyl, cyclopropyl, cyclopropylmethoxyl, butyl, butoxyl,isobutoxyl, tert-butoxyl, isobutyl, sec-butyl, tert-butyl,C₁₋₃alkylamino-, C₁₋₃dialkylamino, C₁₋₃thioalkoxyl, or oxetanyl; X is—CH₂— or —O—; Y is —O—, —S— or —CH₂—, provided that (1) when X is —O—,then Y is —CH₂—, or (2) when X is —CH₂, then Y is —O— or —S—; and Z isCH₂ or CH(CH₃).
 11. The compound of claim 1, or a stereoisomer orpharmaceutically acceptable salt thereof, selected from(5S)—7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—3-(3,4-difluorophenyl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—3-(3,3-difluoro-1-pyrrolidinyl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—3-(4,4-difluoro-1-piperidinyl)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—3-(2,2-dimethylpropoxy)-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7-(2-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—3-(3,6-dihydro-2H-pyran-4-yl)-7-(2-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—3-(3,4-difluorophenyl)-7-(5-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—3-(3,4-difluorophenyl)-7-(3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—3-(2,2-dimethylpropoxy)-7-(3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—3-(2,2-dimethylpropoxy)-7-(5-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—3-(3,3-difluoro-1-pyrrolidinyl)-7-(5-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine; 3-(((5S)—5′-amino-7-(3-fluorophenyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-3-yl)oxy)-2,2-dimethylpropanenitrile;(5S)—3-(2-fluoro-4-pyridinyl)-7-(5-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—3-(5,6-dihydro-2H-pyran-3-yl)-7-(5-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—7-(2-fluoro-3-pyridinyl)-3-(2-fluoro-4-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—3-(5,6-dihydro-2H-pyran-3-yl)-7-(2-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—3-(3,3-dimethyl-1-butyn-1-yl)-7-(2-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—7-(2-fluoro-3-pyridinyl)-3-(5-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—1-fluoro-3-(2-fluoro-4-pyridinyl)-7-(5-fluoro-3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—1-fluoro-3-(2-fluoro-4-pyridinyl)-7-(3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(3-pyridinyl)-5′,6′-dihydrospiro[chromeno[2,3-c]pyridine-5,4′-[1,3]oxazin]-2′-amine;(5S)—1-fluoro-7-(2-fluoro-3-pyridinyl)-3-(2-methyl-4-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;(5S)—3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine;and(5S)—3-(2,2-dimethylpropoxy)-1-fluoro-7-(2-fluoro-3-pyridinyl)-6′H-spiro[chromeno[2,3-c]pyridine-5,3′-[1,4]oxazin]-5′-amine.12. A pharmaceutical composition comprising a compound according toclaim 1 and a pharmaceutically acceptable excipient.
 13. Apharmaceutical composition comprising a compound according to claim 11and a pharmaceutically acceptable excipient.
 14. A method of reducingthe levels of beta amyloid peptide in the cerebral spinal fluid of asubject, the method comprising administering to the subject an effectivedosage amount of a compound according to claim
 1. 15. A method oftreating Alzheimer's disease, cognitive impairment or a combinationthereof in a subject, the method comprising administering to the subjectan effective dosage amount of a compound of claim
 1. 16. A method oftreating Alzheimer's disease, cognitive impairment or a combinationthereof in a subject, the method comprising administering to the subjectan effective dosage amount of a pharmaceutical composition of claim 12.17. A method of claim treating a neurological disorder selected from thegroup consisting of mild cognitive impairment, Down's syndrome,Hereditary cerebral hemorrhage with dutch-type amyloidosis, cerebralamyloid angiopathy, degenerative dementia, dementia associated withParkinson's disease, dementia associated with supranuclear palsy,dementia associated with cortical basal degeneration, diffuse lewy bodytype of Alzheimer's disease or a combination thereof, in a subject, themethod comprising administering to the subject an effective dosageamount of a compound of claim
 1. 18. A method of slowing the formationof plaque on the brain of a subject, the method comprising administeringto the subject an effective dosage amount of a compound according toclaim
 11. 19. A method of slowing the formation of plaque on the brainof a subject, the method comprising administering to the subject aneffective dosage amount of a pharmaceutical composition according toclaim
 13. 20. A process for preparing a compound of claim 1, the processcomprising the step of reacting a compound 20

wherein A¹, A², A³, A⁴, A⁵, A⁶, R², X, Y and Z of Formula I are asdefined in claim 1, with a compound having the structure

or R⁷-B(OH)₂, wherein R⁷ is as defined in claim 1 to prepare thecompound of claim 1.